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Preface
The experimental work described in this dissertation was carried out in the Department of
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These studies represent original work by the author and have not been submitted in any other
form to another university. Where use has been made of the work of others, it has been duly





Protozoan parasites of the genus Trypanosoma are responsible for chronic and widespread
disease in livestock and humans in Africa. This study describes the purification and
characterisation of a serine oligopeptidase from Trypanosoma brucei brucei and from
T. congolense. Serine peptidase activity has previously been described for T. b. brucei
although the responsible enzyme was not purified to electrophoretic homogeneity. In the
present study this enzyme was purified from bloodstream-form T. b. brucei by a combination
of three-phase partitioning, ion-exchange, affinity and molecular exclusion chromatography.
Characterisation of the enzyme revealed that it closely resembled a bacterial serine
oligopeptidase, Escherichia coli oligopeptidase B, in terms of cleavage-site specificity,
inhibition characteristics and molecular mass. Its overall properties indicate that it is probably
a serine oligopeptidase and we have called it OP-Tb (oligop_eptidase from Trypanosoma
brucei). Antibodies to OP-Tb were prepared in chickens. These antibodies were used in the
purification of a similar enzyme, designated OP-Tc, from T. congolense. OP-Tc closely
resembled OP-Tb in its enzymatic properties.
OP-Tb appears to be monomeric, with an apparent molecular mass of 80 kDa. Activity is
optimal between pH 8.0 and 10.0, and is enhanced in the presence of reducing agents.
Inhibition by 4-(2-aminoethyl)benzenesulfonylfluoride, 3,4-dichloroisocoumarin and
diisopropylfluorophosphate indicates that the enzyme may be classified as a serine protease.
While various natural and synthetic fluorogenic peptide substrates were hydrolysed by OP-Tb,
larger potential substrates (proteins) were not. Studies of the digestion of naturally occurring
bioactive peptides suggested that substrates were restricted to peptides smaller than
approximately 4 or 5 kDa. These peptides were cleaved at the carboxy side of basic amino
acid residues such as arginine and lysine. This is characteristic of a trypsin-like specificity.
Because the enzyme is known to be readily released from the parasites, and because it was
possible to detect OP-Tb-like activity in the blood of T. b. brucei-infected mammalian hosts, it
appears that the enzyme is released into the host bloodstream where it remains uninhibited by
endogenous protease inhibitors. Indeed, OP-Tb was not inhibited by mammalian plasma
serpins or 012-macroglobulin in vitro. This, and the degradation of host peptide regulatory
hormones in vitro, suggests that OP-Tb may have secondary, but important, extracellular roles
in the pathogenesis of African trypanosomiasis.
A variety of serine protease inhibitors, including inhibitors of OP-Tb were tested for their
potential as trypanocidal agents. The results from both in vitro and in vivo studies, suggest
that inhibitors of trypanosome oligopeptidases are promising new lead targets for drug
development. Furthermore, data presented here also shows that OP-Tb is efficiently inhibited
by several of the currently employed trypanocidal drugs. Thus, OP-Tb may already be a
cellular target for trypanocidal drugs. If correct, this may represent an important step towards
understanding the biochemical mechanisms of the trypanocidal activity of these drugs, as well
as providing valuable clues as to how to improve their efficacy.
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Trypanosomiasis is a term applied to a group of acute or chronic infectious diseases of man
and other animals, due to the invasion of the body by unicellular blood parasites of the genus
Trypanosoma (Protozoa: Kinetoplastida). While the first record of a parasitic organism
belonging to this genus was made as early as 1841 (Laveran and Mesnil, 1904), the
significance of these parasites as pathogenic micro-organisms in Africa was not realised until
Bruce (1895) discovered that the notorious "tsetse fly disease" of cattle in Zululand, South
Africa was due to a trypanosome. This organism was subsequently named Trypanosoma
brucei by Plimmer and Bradford (1899), and descriptions of two related organisms from
bovine sources, T. congolense from the Congo (Broden, 1904), and T. vivax, also from West
Africa (Zieman, 1905), followed. During this time, Dutton (1902) described a related parasite,
first discovered in the blood of a human by Forde (1902), and named it T. gambiense, and
eight years later, a second species of human-infective trypansome, T. rhodesiense, was
described by Stephen and Fatham (1910). Subsequently, while trypanosomes infecting all
classes of vertebrates have been described, only those causing disease in man and livestock
appear to have a significant medical and economic impact on the tropical regions of the world
(Ukoli, 1984).
Human African trypanosomiasis has two forms, chronic and acute African trypanosomiasis.
The aetiological agent of chronic African trypanosomiasis is T. brucei gambiense. This disease
occurs widely in the riverine regions of Zaire (recently re-named the Democratic Republic of
the Congo), the Congo and Nigeria, extending westwards along the African coast as far north
as The Gambia (Kuzoe, 1993). The parasite is transmitted by the riverine tsetse fly, Glossina
palpalis (Swellengrebel and Stermann, 1961) and causes chronic disease in human beings,
which initially causes fever and headache (Fripp, 1983). The parasites cross the blood-brain
barrier, and enter the cerebrospinal fluid (CSF), causing meningoencephalomyelitis, fatigue,
emaciation and loss of nervous control, resulting in a comatose condition, followed by death.
Acute African trypanosomiasis is caused by T. b. rhodesiense, which is far more virulent than
its Gambian counterpart, rapidly causing severe febrile illness characterised by high fever,
hepato- and splenomegaly, followed by death within a few weeks of infection (Hall, 1977;
Fripp, 1983). T. b. rhodesiense is transmitted by the savannah tsetse fly, G. morsitans, which
occurs primarily in the open savannah of central east Africa, from as far north as Sudan, and
extending as far south as the Okavango delta of Botswana (Kuzoe, 1993). A variety of
ungulates serve as the natural reservoir of this parasite (Schmidt and Roberts, 1989).
Cattle trypanosomiasis, which is known as nagana, is transmitted by a variety of Glossina
species. The aetiological agents include T. vivax, T. congolense and T. b. brucei. Infection in
cattle is characterised by severe anaemia, elevated pulse-rate, fever, emaciation, impaired
neurological function and finally death. Nagana costs Africa about US$ 5 billion per annum
(International Laboratory for Research on Animal Diseases, 1994).
Broadly speaking, the distribution of African trypanosomiasis parallels that of the tsetse fly.
The tsetse fly and its disease-causing trypanosome parasites currently makes 10 million square
kilometres of Africa - an area larger as the continental United States - inhospitable for live-
stock (International Laboratory for Research on Animal Diseases, 1991). The distribution of
the tsetse fly and the current cattle-producing areas of Africa are illustrated in Fig. 1.
1.1.1 Trypanosome morphology
The generalised morphology of an African trypanosome is illustrated in Fig. 2. Trypanosomes
are typically elongate (30 x 2 um), torpedo-shaped cells. A single flagellum arises from the
flagellar pocket at the posterior end, runs laterally to the anterior, where it extends freely
beyond the anterior end of the body. The kinetoplast is associated with the single tubular
mitochondrion and contains the mitochondrial DNA. The remaining cellular structures are
similar to those found in other eukaryotes (Schmidt and Roberts, 1989).
1.1.2 Classification of African trypanosomes
The classification of the genus Trypanosoma is given in Fig. 3, and this genus, along with
members of the genus Leishmania, are the only members of the family Trypanostomatidae of
medical and veterinary importance. The genus Trypanosoma is divided into two groups on the
basis of the development of the parasite within its insect vector. Kleine (1909) first described
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the development of the flagellate in the alimentary canal of tsetse flies. The "salivarian"
trypanosomes undergo most of their morphological development in the anterior part of the
alimentary system of the vector (i.e. in the salivary glands). In contrast, the development of the
"stercorarial" trypanosomes takes place in the hindgut of the insect vector.
Figure 1. Distribution of disease-carrying tsetse flies in Africa. Tsetse distribution is superimposed on the
cattle-producing regions of the continent (after International Laboratory for Research on Animals Diseases,
1991).
1.1.3 Life cycle of African trypanosomes
The life-cycle of 71 b. brucei is illustrated in Fig. 4. Non-dividing metacyclic forms occur in
the salivary glands of the tsetse fly and are introduced into the mammalian host when the fly
bites the host to take a blood meal. The metacyclic trypanosomes differentiate into the
bloodstream-forms, which rapidly multiply by binary fission once every six to eight hours
(Vickerman, 1976). After a period of rapid division, some of these long, slender (LS)
bloodstream forms of the parasite stop dividing and differentiate into short, stumpy (SS) non-
dividing bloodstream forms (Nelson etal, 1979). It has been hypothesised that these SS
forms have undergone a pre-adaptation for tsetse fly reinfection. When the fly takes a blood
meal from an infected host, bloodstream-form parasites are ingested and enter the midgut of
the tsetse fly where they differentiate into procyclic forms. The organisms are further
transformed into epimastigote forms, and then subsequently into the dormant metacyclic forms,
in the salivary glands of the fly.
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Figure 2. General morphology of an African trypanosome. This figure illustrates the subcellular structures
of a bloodstream-form parasite of the T. brucei group (after Vickerman and Cox, 1978).
1.1.4 Control of trypanosomiasis
EflForts to control trypanosomiasis generally involve the control and elimination of the insect
vector. The most satisfactory means of vector elimination is through spraying pesticides such
as dichlorodiphenyltrichloroethane (DDT), by aircraft (first described by Du Toit, 1949).
However, there are considerable harmful side effects to the environment with this method of
insect control. Elimination of game reservoirs has also enjoyed limited success but is obviously
counter to conservation philosophies (Schmidt and Roberts, 1989). As a result of the
increasing political and economic instability which currently plagues Africa, tsetse-control
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Figure 3. Current classification of the genus Trypanosoma. The phylogenetic tree of both stercorarian and salivarian trypanosomes is illustrated (after Vickermann, 1976).
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Figure 4. The life cycle of an African trypanosome. Most members of the family Trypanosomatidae are
heteroxenous: during one stage of their lives they live in the blood and solid tissues of all classes of vertebrates,
and during the other stages they live in blood-sucking vertebrates (after Read, 1972).
of human and bovine African trypanosomiases, particularly in Zaire and the Congo. For
example, in colonial Zaire, economic interests required healthy, fit labour forces which ensured
that disease control was tight. In 1988 the Bureau Central de la Trypanosomiase (BCT) was
detecting and treating an average of 7 500 patients each year. The political crises in 1990 led
the Belgian government to abandon its support for the BCT, and four years later the case-load
increased to 150 000 per year, with prevalence levels in some villages of over 70% (Walgate,
1994). Similar trends for both the human and bovine forms of the disease have been reported
in 36 African nations (Kuzoe, 1993). Given the considerable agricultural and medical impact
of this disease on the African continent, there should be much interest in developing more
effective means of controlling and treating African trypanosomiasis.
1.1.5 Treatment of African trypanosomiasis
The inability to control the insect vector (Section 1.1.4), together with recent reports of
trypanosome resistance to these drugs (Section 7.1), have prompted considerable interest in
identifying targets for the development of new drugs for the treatment of trypanosomiasis.
There are a number of drugs currently available for the chemotherapy of African
trypanosomiasis. A variety of arsenic-based compounds (e.g. melarsoprol) and the sulfated
naphthylamine, suramin, have been used since the middle of this century for the chemotherapy
of African trypanosomiasis. Recently, an ornithine analogue, a-difluoromethylorninthine
(DFMO) has also been introduced. However, once the disease has progressed to nervous-
system involvement, the prognosis is still very poor. These drugs are discussed in detail in
Section 7.1 and will therefore not be considered further here.
1.1.6 Pathogenesis of African Trypanosomiasis
The pathogenesis of a disease is the pathophysiological changes that occur during that disease,
including the disturbances to the normal physiology, the mechanisms producing these
functional abnormalities and the ways in which they are expressed as symptoms and clinical
signs (Boreham, 1979). An understanding of the mechanisms of disease processes could lead
to better methods of treatment by possibly inhibiting or reversing the important pathological
changes, or by alleviating some of the symptoms of the disease.
The pathogenic mechanisms operating during infection with African trypanosomes are very
poorly understood, and remain a considerable challenge to scientists (Poltera, 1985).
Pathogenic African trypanosomes are loosely divided into two groups: (1) the T. brucei
(humoral) subgroup, which includes those species pathogenic to man and are distributed
throughout the tissues and fluids of the body; and (2) the T. vivax and T. congolense
(haematic) subgroup, which are confined to the blood and are pathogenic to cattle (Losos and
Ikede, 1972). While this separation is not strictly correct it is useful to retain in terms of
pathogenesis. The humoral subgroup causes an inflammatory degenerative disease with
extensive necrosis and central nervous system (CNS) involvement, whereas the haematic
subgroup causes anaemia that is far more severe and pronounced than that of T. brucei
subgroup infections. The salient features of the pathogenesis of the T. brucei and T.
congolense subgroup infections may be summarised as follows:
Altered blood cell function. Both B-cell and T-cell function are altered during infection.
Depression of T-cell responses has been documented in rodents infected with T. brucei
(Pearson et al., 1978), and in cattle infected with T. congolense (Flynn and Sileghem, 1993),
although the mechanisms causing this phenomenon have not been elucidated. This effect is
reversed with the administration of the trypanocidal drug Berenil® (Roelants etal., 1979). A
dominant pathological event is polyclonal activation of B-cells (Greenwood and Whittle,
1980), for which two possible causes have been proposed: deficient T-cell control over B-cells,
or a mitogenic factor for B-cells. Elevated eosinophil levels (500%) have also been
documented (Basson et al., 1977). Platelet counts are reduced in late-stage infection, which is
characterised by disseminated intravascular coagulation (DIC) syndrome (Barrett-Connor et
al., 1973 ) and thrombocytopaenia (Davis, 1980).
Haemolytic anaemia is a consistent feature of human and animal trypanosomiasis and is more
severe in T. congolense and T. vivax infections. This condition is believed to contribute to
fatigue and general loss of condition in infected mammals and is characterised by a decreased
red-cell count (Facer etal., 1982). It has been suggested that the anaemia may have an
immunological basis. Various trypanosome antigens adsorb to the surface of erythrocytes,
where antigen-antibody complexes are subsequently formed, resulting in the lysis of the
erythrocytes in the presence of complement (Murray and Dexter, 1988). Additionally, Tizard
etal. (1978) have described a 10 kDa haemolytic factor from T. b. brucei, but it is not clear if
this operates in infections as such.
Emaciation and nutritional considerations. Within 15 days to 4 months trypanosome
infections result in emaciation, and death may rapidly ensue from malnutrition. The reason for
this malnourished state is not clear (Schmidt and Roberts, 1989). The presence of
trypanosomes of the T. brucei subgroup have been detected in the stomach, small intestine,
abdominal lymphatics and pancreas (Morrison et al. 1981a), and it is possible that toxic
products released from trypanosomes may interfere with normal digestive processes (Tizard et
al, 1978).
Endocrine system dysfunction. The adrenal medulla exhibits sclerosis and diffuse mononuclear
infiltration (Gallais et al, 1953). In the case of T. brucei infections, the interstitial presence of
parasites in the medulla has been observed (Poltera, 1985). Severe lesions of the pituitary have
also been observed, including necrotic foci and trypanosome perivascular cellular infiltrations
(Morrison et al, 1981b). Marked sclerosis and cellular infiltration of the thyroid and pancreas
have also been observed (Gallais et al, 1953).
Blood pressure fluctuations. Hypotension is a common feature of T. brucei subgroup
infections. A drop in blood pressure from 70/65 mm Hg in uninfected control rabbits down to
31/25 mm Hg in infected rabbits has been reported, while the heart-rate remained unchanged
(Boreham and Wright, 1976). These hypotensive responses can be prevented using the
kallikrein inhibitor aprotinin, which led Boreham and Wright (1976) to conclude that
hypotension was a result of the conversion of prekallikrein to active kallikrein, which itself has
hypotensive properties, and will cause the release of hypotensive bradykinin from high
molecular mass kininogen (H-kininogen).
Inflammation. Inflammation incorporates a series of semi-independent reactions. The
inflammatory process is usually divided into a number of stages, including increased vascular
permeability which causes localised oedema, neutrophil exudation, cell proliferation and tissue
repair (Vickerman etal, 1991). T. brucei subgroup infections are characterised by gross
oedema of all tissues (Nagle etal, 1980), as opposed to T. congolense and T. vivax infections,
where the major inflammatory lesions are in the brain as a result of pressure necrosis caused by
an elevated intracranial pressure (ICP). The elevated ICP is caused by oedema resulting from
10
accumulations of trypanosomes in the capillaries and venules (Losos and Ikede, 1972). One of
the major pathological changes that occurs in T. brucei subgroup infections is the increase in
vascular permeability (Boreham, 1979). This has been attributed to a number of
pharmacologically active substances that have been implicated in trypanosomiasis. These
include plasma kinins, fibrinogen degradation products, 5-hydroxytryptamine and histamine
(Boreham, 1979).
Nervous system dysfunction. During the late stages of infection, trypanosomes invade the
central nervous system, in particular the cerebrospinal fluid (Rudin et al., 1983). Neurological
involvement results in lethargy, mental dullness, tremors of the hands and trunk, and
disturbances of coordination. This is usually followed by paralysis, convulsions and death
(Schmidt and Roberts, 1989). The mechanisms producing these symptoms have not been
elucidated, although the release of toxic trypanosome metabolites which produce similar
effects in experimental animals, are thought to be responsible (Schmidt and Roberts, 1989).
Reproductive system dysfunction. A variety of reproductive disorders have been documented
in trypanosome-infected animals, including atrophy of the testes and ovaries, irregular oestrus
cycle, infertility and abortion. This is often attributed to impairment of the pituitary-gonadal
and pituitary-adrenal axes (Mutayoba et al., 1995a). Hublart et al. (1990) reported decreased
levels of testosterone (less than 50% compared to control animals) in rats infected with T. b.
brucei. Furthermore* the administration of trypanosome extracts to uninfected rats reduced
the levels of serum follicle-stimulating hormone (FSH) and serum luteinising hormone (LH) by
more than 50% five-hours post-administration (Hublert etal., 1990). Depression of plasma
progesterone and estradiol-17|3 during infection has also been observed (Mutayoba etal.,
1988a).
Alterations to serum/plasma protein levels. The concentrations of a number of plasma
constituents are altered during T. brucei subgroup infections. Trypanosomes evade the host
immune system by regularly changing their surface antigens, known as variant surface
glycoproteins (VSG). The continual presence of high levels of trypanosmal antigens promotes
high levels of circulating antibodies. Cross-reactivity of these antibodies is thought to cause a
number of autoimmune reactions (Miiller etal., 1993), and autoantibodies directed against
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smooth-muscle (Wolga et al, 1981) and DNA (Daniel-Ribeiro et al, 1983) have been
reported. The depletion of complement levels, in particular Cl (Tizard etal., 1978), C3 and
C4 (Basson et al, 1977) down to less than 50% of normal values, has also been reported.
Fibrinogen concentrations are raised and total serum lipid concentration is elevated up to
400%. Concentrations of serum albumin are decreased (Boreham, 1979), while IgM levels are
elevated (Clarkson and Penhale, 1973).
The nature of most of the above changes cannot be ascribed to any single obvious cause.
Indeed, different systems may be operative in different situations. However, many of the
above changes clearly involve alterations in peptides and/or proteins and therefore any parasite
enzymes that may effect changes in host proteins are obvious targets for examination.
Foremost amongst these are proteases, although there are obviously other candidates such as
kinases and protein phosphatases. Since proteases are the focus of this research, the remainder
of this introduction will focus on proteases and their characteristics.
1.2 Structure and classification of proteolytic enzymes
Proteolytic enzymes (proteases or peptidases), are a broad group of enzymes which hydrolyse
peptide bonds in peptides and proteins. These enzymes are further subdivided into two
groups: the exopeptidases and endopeptidases. The former group catalyses the sequential
removal of amino acid residues from the amino- or carboxy-termini of peptides and proteins.
They are accordingly termed aminopeptidases and carboxypeptidases. The endopeptidases, or
proteinases, catalyse the cleavage of peptide bonds within a protein. These enzymes usually
exhibit a certain degree of specificity, which is often dictated by the nature of the amino acid
residues surrounding the peptide bond that is cleaved (the "scissile bond"). Proteases are
currently classified into one of five groups, depending on the identity of the amino acid
residues that make up the catalytic unit of each group. This classification is given in Table 1.
The active site of an enzyme is divided up into a number of substrate-binding pockets, which
determine the specificity of the enzyme (Fig. 5). Those pockets which bind residues of the
substrate on the N-terminal side of the scissile bond are designated Si, S2, S3,...S«, whereas
those pockets binding substrate residues on the C-terminal side of the scissile bond are
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designated Si', S2', Si',...Sn'. Similarly, the corresponding regions on the peptide substrate are
referred to as F u P:2, P3...P« and Pi', P 2 \ P3'...Pi/ (Schechter and Berger, 1968).
Table 1. The four currently-recognised classes of proteases.
Class" Representative
protease
















"A fifth class of proteease ("proteases of unknown mechanism") are also recognised for proteolytic enzymes for
which the catalstic mechanisms have not been elucidated (after Barrett, 1994).
^Abbreviations: IDFTP, diisopropylfluorophosphate; E-64, L-/ra«5-epoxysuccinyl-leucylamido(4-guanidino)
butane, EDTA. ethyknediaminetetraacetic acid.
Cleavage point
+H3N




Figure 5. SiLbs ite classification of the active site of a protease. This system describes the substrate binding
regions on the enzrme (S) and the corresponding regions on the peptide substrate (P) (after Schechter and
Berger, 1968)_
As only the :seirine proteases are of particular interest in this study, the other classes of
proteases will not be considered further.
1.2.1 Serine prroteases
Serine proteases are the most numerous and diverse group of proteolytic enzymes, being
involved in a wiide range of physiological processes (Barrett and Rawlings, 1992). Apart from
the role placed toy digestive enzymes such as trypsin and chymotrypsin, the serine proteases are
importam jKguDators of enzyme activity, as exemplified by their role in the blood clotting
13
cascade (Davie etal, 1991). Serine proteases are also believed to play an important role in
cell differentiation (Chasan and Anderson, 1989).
Serine proteases are currently divided into about 30 families, which are grouped together into
six "clans" (Barrett and Rawlings, 1995). All these proteases are believed to share a common
catalytic mechanism which involves the hydrolysis of ester and amide bonds, and proceeds via
an acyl transfer mechanism. Michaelis-complex formation is facilitated through the binding of
the P and P' residues of the substrate to the S and S' sites of the enzyme. General base
catalysis by the imidazole of the active-site histidine (His57, Fig 6A) activates the hydroxyl
group of the active site serine (Ser195; Fig 6A).
(A) (B)
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Asp1" \ H N. Jto-j—H O
,H— N \ N X ^ U I ,'H— N
o- : ) I .-' n . . ,
Oxyanion hole R| N C Oi. Oxyanion hole




Asplo2 V H N. . .N O
° I .•'' Q* " \ / - ^ c ^ Q ' Oxyanion hole





«•"* .0 \ _ _ ,So»»
/ Asp« (--- --H N^^N H O
H—N 0- ^ H — N
— ̂ " Oxyanion hole 0^—0^=0^ Oxyanion hole
H k2
 H ~ N
Figure 6. The catalytic mechanism of a serine protease. The catalytic groups of chymotrypsin are shown
interacting with oligopeptides over the Pi to P3 regions. The numbering of chymotrypsin is shown (after Fink,
1987). Ri and R2 represent the C-terminal and N-terminal peptides respectively.
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The active-site aspartic acid (Asp102) may assist by permitting the abstraction of a proton from
His57. The overall effect is to enhance the nucleophilicity of Ser195. A covalent tetrahedral
intermediate is formed after nucleophilic attack by the active-site serine hydroxyl group on the
carbonyl carbon of the scissile bond (Fig. 6B), with concomitant loss of the C-terminal peptide
(Fig. 6C). In the enzyme-catalysed reaction, this transition state is stabilised by the "oxyanion
hole" created by the backbone amino groups of Gly193 and Ser195.
Imidazolium-catalysed proton donation (by His57) to the newly formed alcohol results in the
dissociation of the amine product and formation of a covalent acyl-enzyme intermediate.
Deacylation occurs via the reverse series of events. General base catalysis by the imidazole
group of His57 activates a H2O molecule (Fig. 6D), forming a second tetrahedral intermediate,
which breaks down via imidazolium-catalysed protonation of the serine O? (Fig. 6E) yielding
an acid product (Fig. 6F) (Huber and Bode, 1978; Fink, 1987; Perona and Craik, 1995).
1.2.2 Oligopeptidases
Oligopeptidases form a distinct sub-group of the proteases that are specialised for the
degradation of peptides up to 35 amino acid residues in length. Oligopeptidases have no
activity against proteins (Barrett, 1994) and their natural substrates are believed to include
biologically active peptides. As no three-dimensional structure of any oligopeptidase is
presently available, the structural basis of oligopeptidase specificity is not understood. It is
speculated that oligopeptidases are somehow sensitive to the conformation of their substrates,
and that the active site of oligopeptidases consists of a three-dimensional substrate binding site,-
like a pit, as opposed to the essentially two-dimensional active-site cleft found in other
proteases (Barrett and Rawlings, 1992).
Oligopeptidases are widely distributed amongst eukaryotes and prokaryotes, and are usually
serine or metallo-enzymes. Serine oligopeptidases identified to date are presented in Table 2.
A variety of metallo-oligopeptidases have also been described, such as thimet oligopeptidase
(E.C. 3.4.24.15) from avian (Barrett and Brown, 1990) and mammalian (McKie et al., 1995)
sources.
The term oligopeptidase as used here excludes obligate amino- and carboxy-peptidases such as
angiotensin converting enzyme (ACE) and lysine aminopeptidase that act on small peptide
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substrates. The true oligopeptidases have a defined substrate-size exclusion limit, although this
has only been determined for a small number of oligopeptidases, and is generally between
15-35 amino acid residues (reviewed by Barrett and Rawlings, 1992).















































Kanatani et al. (1993)
Kanatani et al. (1991)
Yoshimoto et al. (1991)
Yoshimoto et al. (1995)
Makinen et al. (1994)
Makinen et al. (1995)
Bagarozzi et al. (1996)
Mathesonefa/. (1995)
This study
Burleigh et al. (1997)
Yoshimoto et al. (1997)
Rennex etal. (1991)
An important characteristic of oligopeptidases that must be of biological significance is their
apparent lack of naturally occurring inhibitors (Barrett and Rawlings, 1992). None of the
known oligopeptidases identified to date have any known natural inhibitors, including a variety
of classical serine proteinase inhibitors (serpins) and the general protease inhibitor,
a2-macroglobulin. This raises the possibility that oligopeptidases released from trypanosomes
into the infected hosts may significantly contribute to the pathogenesis of African
trypanosomiasis.
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1.3 Proteolytic enzymes and disease
Proteolytic enzymes from all four classes of proteases have been implicated in the pathogenesis
of a variety of pathological conditions, including bacterial and protozoan infections,
hypertension, coagulation disorders, viral infection and cancer (Sharpe etai, 1991).
Discussion will be limited here to the proteolytic enzymes of parasitic micro-organisms, and
the potential roles played by these enzymes in the pathogenesis of microbe-induced diseases.
1.3.1 Proteases of parasitic protozoa
Proteolytic enzymes have been identified in a wide variety of pathogenic protozoans (Table 3)
where they have been ascribed a variety of roles. The roles of proteases in the physiology of
these organisms are generally unknown. The lysosomal cysteine and aspartic proteases are
speculated to be involved in protein catabolism for nutritional purposes. This is certainly true
of the aspartic proteases of the malaria plasmodium, Plasmodium falciparum, which are











T. cruzi Chagas' disease J
Leishmania sp. kala-azar J
Plasmodium sp. malaria J
T. brucei sleeping sickness J
Trichomonas vaginalis vaginitis J
Giardia lamblia diarrhoea J
"Members of all four classes of proteases have been identified in pathogenic protozoans (adapted from
McKerrowefa/., 1993).
Unpublished observations from the present study.
A variety of physiological roles have been ascribed to the proteases of these organisms. These
include:
• metabolism of host proteins for nutritional purposes;
• immune system evasion or modulation by degradation of host immune molecules;
• the degradation of host connective tissue to facilitate invasion;
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• parasite remodelling from one morphological stage to another;
• activation or turnover of parasite peptides, enzymes and hormones;
• degradation of host cytoskeletal proteins during invasion or rupture of host cells.
Of particular interest in this study were the proteolytic enzymes of protozoans of the genus
Trypanosoma. The major proteolytic activity of T. b. brucei and T. congolense results from a
cysteine protease, trypanopain, which resembles mammalian cathepsin L (EC 3.4.22.15)
(Lonsdale-Eccles and Mpimbaza, 1986; Robertson et al., 1990; Lonsdale-Eccles, 1991). The
trypanopains have molecular masses in the region of 28-30 kDa and optimum activity against
proteins at pH 5-6. Trypanopain activity is enhanced by reducing agents and is inhibited by the
low-molecular mass cysteine protease inhibitor L-Zrans-epoxysuccinyl-leucylamido-
(4-guanidino)butane (E-64) as well as by the high-molecular mass proteinaceous inhibitors of
cysteine proteases, the cystatins (Troeberg etal., 1996). Trypanopain displays a cathepsin
L-like substrate specificity with a preference for basic residues (arginine > lysine) in Pi, and
bulky hydrophobic residues (phenylalanine) in P2 (Lonsdale-Eccles and Grab, 1987). The
physiological role of trypanopain in T. b. brucei is unknown but the immunolocalisation of
trypanopain in the lysosomal system of T. congolense by Mbawa et al. (1991) suggests a role
in protein catabolism analogous to that of the mammalian lysosomal cathepsins. Inhibition
studies by Russo et al. (1993) also suggest that the enzyme may play a role in assisting the
parasites to evade the immune system.
Serine proteases of African trypanosomes have received little attention in comparison to their
cysteine counterparts. Kornblatt et al. (1992) undertook a preliminary study of a protease that
appeared to be a cytosolic enzyme with optimal activity at pH 8. While this enzyme appeared
to be inactivated by some typical serine protease inhibitors, for instance
diisopropylfluorophosphate (DFP) and 3,4-dichloroisocoumarin (DCI), it was not inhibited by
phenylmethanesulfonylfluoride (PMSF). To confound matters further, the enzyme displayed
thiol-activatable activity and was inhibited by typical low-molecular mass inhibitors of cysteine
proteases, including Hg2+, iodoacetamide and /?ara-chloromercuribenzoic acid (pCMB). Thus,
some ambiguity remained regarding the enzyme's precise classification. It is this enzyme,
designated as an "oligopeptidase from T. b. brucei", or OP-Tb, that will be the subject of the
present study.
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Other proteases are also present in these organisms. Recently, active subunits of the
proteasome from T. b. brucei have recently been purified and characterised (Hua et al, 1996;
Lomo et al, 1997). Also, El-Sayed etal. (1995) showed that the deduced amino acid
sequence from a cDNA expressed sequence tag (EST) from T. b. rhodesiense clone T613
displayed substantial homology to Thimet oligopeptidase (EC 3.4.24.15) (see Section 1.3.2).
While there are no published reports to date of aspartic or metalloproteinase activity from
African trypanosomes, a phenanthroline-sensitive gelatinase activity has been identified in a
crude membrane fraction of T. b. brucei lysates (unpublished data). The gene encoding the
T. b. rhodesiense homologue of the major membrane-bound metalloprotease of Leishmania
has recently been identified (El-Sayed & Donelson, 1997).
The physiological functions of any of these enzymes have not been determined, although
Mbawa etal. (1991) reported changes in the proteolytic activity of various life-cycle stages of
T. brucei, T. congolense and T. vivax. Procyclic forms of T. brucei and T. congolense
typically found in the insect vector demonstrated enhanced activity possibly attributable to
OP-Tb. Conversely, activity attributable to trypanopain was enhanced in LS bloodstream
forms of the trypanosomes. This activity was elevated further after differentiation into SS
bloodstream forms.
As with the African trypanosomes, cysteine and serine protease activities have also been
identified in the South American trypanosome, T. cruzi, the aetiological agent of Chagas'
disease. The major cysteine protease of T. cruzi, cruzipain (also called cruzain), closely
resembles the trypanopains and mammalian cathepsin L (Bontempi et al., 1984; Cazzulo et al,
1990). Again, the serine proteases of the South American trypanosomes are relatively poorly
investigated. Using degenerate oligonucleotide primers and the polymerase chain reaction
(PCR), Sakanari etal. (1989) isolated eight gene fragments from T. cruzi epimastigote
genomic DNA which displayed homology to mammalian serine proteases. Furthermore,
Burleigh etal. (1995) demonstrated the existence of a 120 kDa alkaline peptidase that is
believed to be involved in the generation of a Ca2+-signalling factor in mammalian cells and
with the penetration of T. cruzi into cells. More recently, the gene encoding this enzyme has
been cloned, and homology data suggests that the enzyme belongs to the oligopeptidase B
family of serine peptidases (Burleigh et al, 1997).
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Additional peptidase activities have been identified in South American trypanosomes. A
protease has recently been identified that is secreted by T. cruzi and is able to degrade collagen
types I and IV. However, its precise classification remains to be determined (Santana et al,
1997). In addition, putative membrane-bound metalloproteinase activities in T. dionisii and
T. mega extracts have been detected on gelatin zymograms (Branquinha et al, 1996).
1.3.2 Microbial proteases and disease pathogenesis
Proteases secreted by invading micro-organisms into the host organism exhibit a wide range of
pathogenic effects, either directly, through the digestion of host proteins, or indirectly, through
the inappropriate activation or inactivation of important signalling factors. As one objective of
this investigation was to propose how trypanosome proteases may contribute to disease
pathogenesis, some discussion of the role of microbial proteases in disease pathogenesis is
warranted.
1.3.2.1 Tissue destruction
Direct digestion and liquefaction of tissues at infection foci is the most direct mechanism
whereby the proteases of invading micro-organisms may cause damage to a host. This is
evident in the pathology of penodontal disease, where cysteine and metalloproteases (e.g. from
Porphyromonas gingivalis) cause direct damage to the gum tissues of the mouth (Scott et al.,
1993). Similarly, the keratitis that results from the colonisation of the cornea by Pseudomonas
spp. and Serratia spp. is due to microbial-derived proteases (Holder and Haidaris, 1979).
The secretion of digestive enzymes also appears to be involved in the invasion of host tissues
by invasive pathogenic micro-organisms. The production of cysteine and metalloproteases by
Entamoeba histolytica, the causative agent of amoebiasis, correlates with the virulence and
invasiveness of these parasites. Patients with invasive disease produce antibodies to
amoebapain, the major cysteine protease of the organism, while those with non-invasive
infections do not (Reed etal, 1989). The fascinating parallels between the release of a
cathepsin B-like proteinase from invasive amoebae and similar enzymes found in the
extracellular milieu of invasive cancer cells have been noted by Lushbaugh (1988).
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1.3.2.2 Kinin generation
Bradykinin is an endogenous peptide that exerts a wide range of pharmacological activities,
including hypotension, vasodilation, pain and shock. Bradykinin is usually released from
high-molecular mass kininogen (H-kininogen) by plasma kallikrein, or from kallidin by lysine
aminopeptidase (Bhoola et al., 1993). A number of microbial proteases, particularly those
from Vibrio cholerae and P. gingivalis, are known to activate one or more steps of the
bradykinin-generating cascade (Fig. 7). Additionally, a serine protease from the house-dust
mite Dermatofagoides farinae generates bradykinin from H-kininogen (Maruo etai, 1991).
Significantly, a number of these proteases generate bradykinin in the presence of plasma
protease inhibitors (Maeda and Molla, 1989). The effect on the host of bradykinin generation














Figure 7. Generation of killing by the proteases of invading micro-organisms. Microbial proteases may
activate the bradykinin generating cascade at four different points (after Maeda and Yamamolo, 19%).
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1.3.2.3 Cell and tissue invasion
Plasmodium is an intracellular parasite which invades red blood cells. Serine proteases of
P.falciparum have been implicated in the invasion of host erythrocytes by the parasite
(Rosenthal etal, 1987), and both cysteine and serine proteases have been implicated in the
subsequent merozoite-mediated rupture of erythrocytes (Grellier etal, 1989). This
erythrocyte rupture is thought to contribute to anaemia and shock in these conditions. A
serine protease has also been associated with T. cruzi invasion of host cell. Proteases are also
believed to play a role in cytoadherance of protozoan parasites to mammalian mucus
membranes. Thus, colonisation of the urinogenital tract of women by Trichomonas vaginalis
results in an acute inflammatory response and the production of a purulent vaginal discharge
(Nielsen and Nielsen, 1975). Pre-treatment of parasites with cysteine protease inhibitors
results in a loss of cytoadherance of the parasite, which is restored upon addition of the
proteases. This, together with the cell-surface localisation of a 43 kDa protease, implicates
protease activity in cytoadherance (Arroyo and Alderete, 1989).
1.3.2.4 Inactivation of host protease inhibitors
A variety of pathogen-derived proteases are known to catalytically inactivate host protease
inhibitors. Disturbances in the protease-inhibitor balance of host systems are evident in the
pathogenesis of a number of diseases, including emphysema and possibly also in malignant
cancer (Travis and Salvesen, 1983). Proteases from Candida spp. and Serratia spp. are
known to inactivate antithrombin III (ATIII) leading to uncontrolled thrombus formation
within the host. This causes hypercoaggulation and DIC syndrome (Kaminishi etal, 1994).
Furthermore, Candida spp. and Serratia spp. are known to produce proteases that inactivate
Cl inhibitor, raising the possibility of uncontrolled activation of the complement system.
oti-Protease inhibitor (otiPI) is a serine protease inhibitor that protects the lower respiratory
tract against damage by proteases released during inflammation (Travis etal, 1990).
Bagarozzi etal. (1996) demonstrated that a serine oligopeptidase with a chymotrypsin-like
specificity isolated from the pollen of Ambrosia artemisiifolia (ragweed) was able to
catalytically inactivate ctiPI. As the pollen of A. artemisiifolia is the major cause of late
summer hayfever in the United States, this led to the speculation that the oligopeptidase may
be involved in the degradation of pulmonary neuropeptides and the inactivation on protective
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protease inhibitors during pollen-initiated allergic reactions. Similarly, the faecal pellets of the
house dust mite, D.farinae, contain a cysteine protease designated Der pi. It is inhaled into
the respiratory tract and Der pi has been shown to catalytically inactivate ctiPI (Kalsheker
etal., 1996). Inactivation of the aiPI in the lungs will exacerbate tissue damage and
inflammation and accentuate conditions such as asthma and emphysema.
1.3.2.5 Receptor destruction
Tetanus and botulism toxins are potent neurotoxins that were recently discovered to be
proteases. Both proteases rapidly and specifically degrade the acetylcholine receptors on nerve
cells, blocking the transmission of signals between nerves (Schiavo et al, 1992).
1.3.2.6 Inactivation of immune system components
A number of pathogen-derived proteases are capable of inactivating various components of the
immune system thereby permitting the proliferation of the pathogen. The complement system is
a potent defense mechanism against invading micro-organisms, which is coupled to the
recruitment of phagocytic cells through the generation of a variety of chemotactic components,
including the anaphylatoxins C5a and C3a. Streptococcus spp. are known to produce a
specific protease that inactivates these anaphylatoxins (Cleary etal, 1992). The major
cysteine protease of E. histolytica is also known to rapidly, but non-specifically, degrade C3a
and C5a (Reed etal, 1995). Furthermore, a Pseudomonas-dtnved elastase destroys the
formyl-methionyl-leucyl-phenylalanine (fMLP) peptide, an important bacterial metabolite that
acts as a chemotactic factor for host neutrophils and macrophages. This elastase also destroys
fMLP receptors on neutrophils (Ijiri et al, 1994).
A number of bacteria that specifically colonise mucosal surfaces, Haemophilus influenzae,
Neisseria meningitidis and Streptococcus pneumoniae, produce metalloproteases that
specifically cleave the hinge-region of immunoglobulin A (IgA) (reviewed by Killian etal,
1996). These pathogens are the leading causes of bacterial meningitis and urinogenital-tract
infections. IgA is a class of antibody produced to protect membranous surfaces. The ability of
pathogens to cleave this molecule permits the colonisation of such surfaces. Cleavage in the
hinge-region of IgA results in the loss of the Fc region of the antibody, and thereby prevents
IgA-mediated immune-complex elimination and complement-mediated lysis of opsonised cells.
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Additionally, the surface epitopes on the pathogens are masked by Fab regions of the
antibodies. This prevents their recognition by antibodies of other classes, for example, serum
IgG(Killianefa/., 1996).
Pathogen derived proteases may also be cytotoxic to cells of the immune system. Maeda
etal. (1987) reported that a serine protease from Serratia spp. forms a complex with a2M.
This complex is then internalised by macrophages which possess receptors for the
conformationally altered o^M-protease complex. Once endocytosed, this serratial protease
gradually inactivates o^M and is liberated from the complex within the cell. This free protease
is thought to then disintegrate intracellular structures leading to cell lysis.
1.3.3 Protease inhibitors as drugs
Proteases are important in many aspects of normal physiology and pathology. If the
proteolytic activity is of real clinical importance, the search for a very specific inhibitor is the
next logical step. Proteases have been identified as therapeutic targets in a number of
pathological conditions, including coagulation disorders, hypertension and acquired
immunodeficiency syndrome (AIDS) (reviewed by Sharpe et al., 1991). The use of protease
inhibitors as potential drugs is summarised in Table 4 and is under development for a number
of protozoan diseases, including kala-azar, Chagas' disease and malaria.






































"Modified from Scharpe et al. (1991).
Abbreviations: ACE, angiotensin-converting enzyme; HIV, human immunodeficiency virus; AIDS, acquired
immunodeficiency disease syndrome.
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Rosenthal etal. (1991) identified a cysteine protease from P. falciparum trophozoites called
falcipain that is analogous to human lysosomal cathepsin L. The enzyme is responsible for the
degradation of host haemoglobin. A panel of peptidyl fluoromethylketone (-CH2F) protease
inhibitors were investigated as inhibitors of falcipain. Effectiveness at inhibiting falcipain was
correlated with effectiveness at both blocking haemoglobin degradation and killing of cultured
parasites. The most potent inhibitor, carbobenzoxy-phenylalanyl-arginyl-fluoromethylketone
(Cbz-Phe-ArgCIrbF), blocked haemoglobin degradation and killed parasites at nanomolar
concentrations, far below concentrations which are toxic to cultured mammalian cells,
suggesting that falcipain was a promising target for therapeutic intervention.
The inhibition of intraerythrocytic development of P. falciparum by peptidyl
fluoromethylketones has also been reported (Rockett et al, 1990). Again, inhibitors of
falcipain were employed. These included Cbz-Leu-TyrCFkF and Cbz-Phe-ImNvaCFkF, where
ImNva represents the unnatural amino acid imidazolylnorvaline. These two compounds
inhibited intraerythrocytic development of P. falciparum at nanomolar IC50 concentrations.
Rosenthal et al. (1991) developed these ideas further, and demonstrated that
Mu-Phe-hPheCH2F was a potent inhibitor of the falcipain homologue of P. vinckei, the
aetiological agent of murine malaria. Furthermore, daily administration of Mu-Phe-hPheCHbF
elicited long-term cures in 80% of experimentally-infected animals.
Peptidyl halomethylketones have shown considerable promise in the treatment of other
parasitic diseases. Harth et al. (1993) reported the arrest of intracellular replication and
intercellular transmission of T. cruzi by Cbz-Phe-AlaCHN2 and Cbz-Phe-AlaCFfcF, both of
which are known to be potent inhibitors of cruzipain (IC50 of 2.2 uM for both compounds). In
spite of the better IC50 of Cbz-Phe-ArgCH2F for cruzipain (0.18 uM), this inhibitor was
considerably less effective at inhibiting the intracellular replication of T. cruzi epimastigotes
and amastigotes. This is probably attributable to the diminished cell penetration of
Cbz-Phe-ArgCH2F, which contains a highly charged arginine residue, making this inhibitor less
likely to diffuse across the cell membrane than the less charged alanine-containing analogues.
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Similar observations have been reported by Franke de Cazullo et al. (1994) who reported the
inhibition of T. cruzi growth and differentiation by a peptidyl acyloxymethylketone (AMK),
Cbz-Phe-LysAMK, and additional diazomethylketones, including Cbz-Phe-PheCHN2. Again,
the activity of these protease inhibitors was attributed to the inhibition of cruzipain. This
inhibitor penetrated living parasites, decreased the infection of Vero cells in culture by the
parasites, and abolished differentiation into metacyclics, at a concentration of 5 uM.
McKerrow et al. (1991) built on these ideas to design a peptide-based drug which appears to
have potential in the chemotherapy of Chagas' disease. A high-resolution crystal structure of
cruzipain in a complex with a dipeptide fluoromethylketone, Cbz-Phe-AlaCPfcF was obtained
which provided a structural understanding of how the inhibitor interacted with cruzipain. This
facilitated the development of a dipeptide inhibitor, Mu-Phe-hPheCFbF. This compound
incorporates an unnatural amino acid side-chain, homophenylalanine (hPhe), to minimise
potential cleavage between the two amino acids by mammalian host proteases. A daily dose of
1-2 mg of this novel inhibitor protected mice from experimental infection by T. cruzi.
Two other classes of chemical compounds, the chalcones (l,3-diphenyl-2-propen-l-one, and
its derivatives) (Li et al, 1995) and vinyl sulfones (Rosenthal etal., 1996) have recently shown
promise as potential anti-malarial agents. These compounds exhibit potent anti-malarial
activity at nanomolar concentrations and this activity is attributed to the inhibition of the
malarial trophozoite cysteine protease (Li et al., 1995; Rosenthal et al, 1996).
Attempts have also been made to target the highly glycosylated membrane-bound zinc
metalloprotease, gp63, of Leishmania spp. by synthetic vaccines. Intraperitoneal vaccination
of mice with purified gp63 of L. mexicana emulsified in Freund's complete adjuvant (FCA)
conferred significant protection to the mice upon challenge infection (Russell and Alexander,
1988). Furthermore, synthetic peptides of predicted T-cell epitopes of gp63 protected mice
from challenge infections by L. mexicana and L. major (Jardin et al, 1990).
1.4 Objectives of the current study
Proteases are known to be important virulence factors in parasitic and other diseases (Maeda
and Yamamoto, 1996). While the cysteine proteases of African trypanosomes have been well
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investigated (reviewed by Lonsdale-Eccles, 1991 and Coombs and Mottram, 1997), the serine
proteases have received little attention.
The objectives of this study were to characterise a recently identified oligopeptidase from
African trypanosomes, designated OP-Tb from T. b. brucei and OP-Tc from T. congolense.
This first necessitated the purification of OP-Tb to electrophoretic homogeneity, described in
Chapter 3.
Antibodies were raised against the enzyme, to examine whether such antibodies have any effect
on enzyme activity, whether they kill live parasites in vivo, to provide tools for further
investigation by immunochemical means, and provide a tool for the immunoaffinity purification
of the same enzyme from T. congolense (Chapter 4).
Once purified, comprehensive characterisation of OP-Tb and OP-Tc was undertaken
(Chapter 5). This included detailed substrate specificity, inhibition and activator profiles in
order to determine the precise classification of the protease and determine whether the enzyme
would be active in the extracellular milieu of the host.
In order to investigate whether the enzyme may contribute to disease pathogenesis, attempts
were made to detect the enzyme in the bloodstream of infected mammals and to determine
whether the enzyme is regulated by host plasma protease inhibitors. The interactions of the
enzyme with host regulatory molecules and host peptide hormones were examined in detail, in
the context of disease pathogenesis (Chapter 6).
Trypanosome oligopeptidases were also evaluated as potential targets for currently available
trypanocidal agents, as the mechanism of action of these agents is presently not understood.
Finally, the trypanosome oligopeptidases were evaluated as potential targets for anti-
trypanosome chemotherapy employing serine protease inhibitors (Chapter 7).
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Chapter 2
General materials and methods
A variety of general biochemical techniques which were used throughout this study are
described in this chapter. More specific experiments pertaining to specific chapters of this
dissertation are described in their appropriate sections.
2.1 Materials
HiLoad™ Q-Sepharose columns and protein Mr standards were from Pharmacia LKB
Biotechnology (Lund, Sweden). 2,2'-Azinobis[3-ethyl-2,3-dihydrobenzthiazole-6-sulphonate]
(ABTS), bovine serum albumin (BSA), phenylmethanesulfonylfluoride (PMSF),
4-(2-aminoethyl)benzenesulfonylfluoride (AEBSF), ct2-macroglobulin (0C2M) and papain were
from Boehringer Mannheim (Mannheim, Germany). Human ct2-antiplasmin (CI2AP), human
low-molecular mass kininogen (L-kininogen), high-molecular mass kininogen (H-kininogen),
human a2-HS-glycoprotein (0C2HSGP) and human neutrophil elastase (HNE) were from
Calbiochem (San Deigo, USA). Sephacryl S-100 HR, Sephacryl S-200, benzamidine and
poly-(L-lysine) insolubilised on Sepharose 4B, Percoll, reduced and oxidised glutathione,
pentamidine isethionate, 3,3',5,5'-tetramethylbenzidine (TMB), 5-bromo-4-chloro-3-
indolylphosphate (BCIP), nitroblue tetrazolium (NBT), fibrinogen, ovalbumin, trypsin, poly-(L-
lysine), Freund's complete adjuvant (FCA) and Freund's incomplete adjuvant (FIA) were from
Sigma (St Louis, USA). Nunc Immuno Maxisorp F96 multiwell plates and FluorNunc® 96-
well fluorimetry plates were from Nunc Intermed (Roskilde, Denmark). Sterile disposable
plasticware for cell culture waf from Corning/Costar (Cambridge, USA). Sterivex™-GM 0.22
l̂ m filter units were from Millipore (Bedford, USA). Diethylaminoethyl-Cellulose (DE-52,
DEAE-Cellulose) was from Whatman International (Kent, UK). Diisopropylfluorophosphate
(DFP) and chymotrypsin were from Fluka (Buchs, Switzerland). Peptide aldehydes,
fluorogenic peptide substrates, diazomethylketones and chloromethylketones were from
Bachem (Bubendorf, Switzerland) or Cambridge Research Biochemicals (Cambridge, UK).
Foetal calf serum was from Delta Bioproducts (Kempton Park, South Africa). Penicillin-
streptomycin mixtures were from Gibco (Paisley, UK). Germanin® was from Bayer
(Leverkusen, Germany) and Berenil® was from Hoechst Veterinar (Munich, Germany). 3 ml
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Polystyrene concentrators, containing 10 kDa Mr cut-off membranes, were from Micron
Separations Incorporated (Westboro, USA). Common laboratory chemicals were from BDH
(Poole, England), Merck (Darmstadt, Germany) or Boehringer Mannheim (Mannheim,
Germany) and were of analytical or higher quality.
T. b. brucei strain ILTat 1.1 and T. congolense strain IL3000 were obtained from the
International Laboratory for Research on Animal Diseases (ILRAD), Nairobi, Kenya. Human
cystatin C was a gift from Dr Magnus Abrahamson (Institutionen for Klinik Kemie,
Universitet i Lund, Lund, Sweden). Sheep cystatin B was purified in this department by Dr
Theresa Coetzer. Antithrombin III (ATIII) was a gift from Dr Robert Pike (Department of
Haematology, University of Cambridge, Cambridge, UK). E. coli oligopeptidase B was a gift
from Prof. Tadashi Yoshimoto (Faculty of Pharmacy, University of Nagasaki, Nagasaki,
Japan). Adult male Wistar rats were obtained from the Biomedical Resource Centre
(University of Durban-Westville, Westville, South Africa). Bovine serum, naturally infected
with trypanosomes, was a gift from Dr Olivier Matthee (Department of Protozoology,
Onderstepoort Veterinary Research Institute, Pretoria, South Africa). Sera from N'Dama and
Boran cattle experimentally infected with T. congolense was a gift from Dr Edith Authie
(International Laboratory for Livestock Diseases, Nairobi, Kenya).
DL-a-difluoromethylornithine (DFMO) was a gift from Dr Andrew Peregrine (International
Livestock Research Institute, Nairobi, Kenya). Melarsoprol and melarsen oxide were gifts
from Dr Alan Fairlamb (Department of Medical Parasitology, London School of Hygiene and
Tropical Medicine, London, UK). Suramin analogues were synthesised by Prof. Dr Peter
Nickel (Pharmazeutisches Institut, Universitat Bonn, Bonn, ̂ Germany). Peptidyl phosphonate
diphenyl esters were synthesised by Dr James Powers (School of Chemistry and Biochemistry,
Georgia Institute of Technology, Atlanta, USA).
Distilled water (dH2O) was produced by a Milli-RO® 15 Water Purification System (Millipore,
Marlboro, USA). Distilled, deionised water (ddH2O) was produced by a Milli-Q Plus Ultra-




Protein concentration was determined by one of three methods. The modified method of
Bradford (Read and Northcote, 1981) was routinely used as it is a rapid and sensitive means of
protein determination, that is unaffected by the presence of free thiols. However, in cases
where samples contained detergents or high concentrations of salts, or low concentrations of
proteins, the bicinchoninic acid (BCA) assay (Smith et al, 1985) was employed. In some
cases, protein concentration could be determined directly from the absorbance provided that
the molar extinction coefficients were available (Schultze and Heremans, 1966).
2.2.1 Bradford dye-binding assay
The Bradford dye-binding assay for protein concentration employs the dye Coomassie Brilliant
Blue G-250. The dye is believed to bind chiefly to arginine residues of the protein via the
electrostatic attraction of the dye's sulfonic acid groups (Compton and Jones, 1985). The dye
reagent contains the dye in acid solution, where it exists in its cationic (yellow) form with an
absorbance maximum of 470 nm. Reduction on exposure to protein in solution converts the
dye to an anionic (blue) species with a concomitant shift in absorbance maximum to 595 nm.
The advantage of the Bradford dye-binding assay is that it is compatible with most agents that
interfere with other protein assays, including metal ions and reducing agents. However,
detergents including Triton X-100 and SDS do interfere with this assay (Friedenauer and
Berlet, 1989). Another disadvantage of this assay is the protein-to-protein variation in colour
response. Read and Northcote (1981) modified the original method of Bradford (1976) by
replacing the original dye, Coomassie brilliant Blue G-250, with Serva Blue G, and altering the
dye and phosphoric acid concentrations, at the expense of a loss in sensitivity of the assay.
2.2.1.1 Materials
Dye-reagent. Serva Blue G dye (50 mg) was dissolved in 88% (v/v) phosphoric acid (50 ml)
and added to 99.5% (v/v) ethanol (23.5 ml). The solution was made up to 500 ml with dH2O,
stirred (30 min), filtered through Whatman No. 1 filter paper, and stored in an amber bottle at
RT. Each batch of reagent was calibrated individually.
Standard protein solution (1 mg.ml'1 ovalbumin). Ovalbumin (10 mg) was dissolved in
(10 ml). This stock solution was diluted to 100 lag.ml"1 for the assay and used immediately.
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2.2.1.2 Method
A standard curve was constructed with the protein standard for the range 1-5 ug of protein.
Ovalbumin working solution (10-50 ul of the 1 ug.ml"1 solution) was diluted to a final volume
of 50 ul with dH2O in a 1.5 ml polyethylene microfuge tube. Dye reagent (950 \x\) was added,
the solution mixed by inversion, and incubated at RT for 2 min, after which the absorbance at
595 nm was determined in a 1 ml plastic microcuvette with a Pharmacia LKB Ultraspec III
spectrophotometer, with dH20 serving as a blank. Samples of unknown protein concentration
were diluted to a total volume of 50 ul in buffer before the addition of dye reagent (950 ul).
Buffer (50 |_il) treated in the same way served as a blank. The protein concentration of the
unknown sample was then calculated from equations generated by linear regression of the
standard curve data.
2.2.2 Bicinchoninic acid assay
The bicinchoninic acid (BCA) protein assay relies on the reduction of alkaline Cu2+ to Cu+ by
proteins, biogenic amines and reducing sugars. The cuprous (Cu*) ion is then complexed with
the BCA ion in a 1:2 (Cu+:BCA) ratio. BCA specifically chelates the Cu+ ion, and the
BCA-Cu+ complex has an intense purple colour with a strong absorbance at 562 nm,
permitting the spectrophotometric quantitation of the complex (Smith et al, 1985).
This assay has the advantage over the Bradford dye-binding assay (Section 2.2.1) of
compatibility with ionic and non-ionic detergents and exhibiting less protein-to-protein
variation while retaining high sensitivity. While, reducing agents do interfere with the assay
they may be removed beforehand by precipitation of the protein with trichloroacetic acid
(TCA), and resolubilisation of the protein in alkaline SDS (Brown et al, 1989).
2.2.2.1 Materials
BCA reagent [1% (m/v) sodium bicinchoninate. 2% (Wv) Na7C(X 0.16% (m/v) sodium
tartrate. 0.95% (mM NaHCCh]. Sodium bicinchoninate (1 g), Na2CO3 (2 g), sodium tartrate
(0.16 g), NaOH (0.4 g) and NaHCO3 (0.95 g) were dissolved in dH2O (90 ml), adjusted to pH
11.25 with NaOH and made up to 100 ml with dH2O.
4% (m/v) Copper sulfate. CuSO4.5H2O (0.4g) was dissolved in dH2O (10 ml).
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Standard Working Solution fSWRY BCA reagent (50 ml) and 4% (m/v) CuSO4 (1 ml) were
combined and stored for not longer that 1 week at 4°C.
Standard protein solution (1 mg.ml*1 ovalbumin). Ovalbumin (10 mg) was dissolved in df^O
(10 ml). This stock solution was diluted to 250 iig.ml'1 for the assay and used immediately.
2.2.2.2 Method
A standard curve was constructed with the protein standard for the range 1-5 u,g of protein.
Ovalbumin working solution (4-20 u1 of the 250 ug.ml'1 solution) was diluted to a final volume
of 20 ul with dH2O in a 1.5 ml polyethylene microfuge tube. SWR (1 ml) was added, the
solution mixed by inversion, and incubated at 60°C for 30 min. The absorbance at 562 nm was
determined in a 1 ml plastic microcuvette using a Pharmacia LKB Ultraspec III
spectrophotometer, with dH20 serving as a blank. Samples of unknown protein concentration
were diluted to a total volume of 20 ul in buffer before the addition of SWR. Buffer (20 ul)
treated in the same way, served as a blank. The protein concentration of the unknown sample
was then calculated from equations generated by linear regression of the standard curve data.
2.2.3 Extinction coefficient
The concentration of any pure protein solution is determined provided the molar extinction
coefficient (s) and light-path length (/) are known (Schultze and Heremans, 1966). The molar
extinction coefficient of a compound may be defined as the absorbance of a 1 M solution using
a 1 cm light-path (Dawson et ah, 1968), although this is often replaced with an extinction
coefficient describing the absorbance of a 0.1% (i.e. 1 mg.ml'1) solution using a 1 cm light-
path. Concentration (c) may thus be defined in terms of absorbance at 280 nm (A280) as:
A = e / c (Schultze & Heremans, 1966).
2.3 Synthetic peptide substrate enzyme assays
Synthetic peptide substrates consist of single amino acids or short peptides which are
covalently modified at their amino- (N) and carboxy- (C) termini. The N-terminus may be
blocked with moieties such as benzoyl (Bz), carbobenzoxy (Cbz) or acetyl (Ac) groups. The
C-terminus is usually coupled by_ an amide bond to a fluorogenic or chromogenic leaving
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group, such as 4-methoxy-P-naphthylamine (4Me(3NA), /?ara-nitroaniline (pNA) or 7-amino-
4-methylcoumarin (AMC) (John, 1992; Sarath et al, 1989). Due to their higher sensitivity,
fluorogenic leaving groups are generally preferred to their chromogenic counterparts. These
synthetic substrates have a low intrinsic fluorescence but after hydrolysis of the amide bond, a
highly fluorescent leaving group is released. The intensity of the fluorescence provides a direct
indication of enzyme activity (reviewed by Knight, 1995).
Throughout this investigation the substrate Cbz-Arg-Arg-AMC was used (Barrett and
Kirschke, 1981), as a preliminary survey of the substrate specificity of OP-Tb (Section 5.11.1
Table 9) revealed a preference for cleavage after paired basic residues. OP-Tb activity is
expressed throughout this investigation either as picomoles of AMC released per second
(pmol.sec*1) or change in fluorescence per min (AF.min"1)
The standard synthetic substrate assay (Section 2.3.2) was employed where a high degree of
precision was required. For example, in the determination of kinetic constants and the effects
of drugs on enzyme activity (Section 5.11.1 et seq.). For the simultaneous assay of a large
number of samples, for example, to obtain an enzyme activity profile from chromatography
column fractions, the standard method (Section 2.3.2) was adapted for use in a 96-well
microfluorimeter plate (Section 2.3.3).
2.3.1 Materials
4 x Assay buffer [200 mM Tris-Cl. 40 mM dithiothreitol. 0.02% (m/v) NaN^. pH 8], Tris
(2.422 g), dithiothreitol (0.616 g) and NaN3 (0.02 g) were dissolved in dH2O (75 ml), adjusted
to pH 8, and made up to 100 ml.
Substrate stock solution (\ mM Cbz-Arg-Arg-AMC in DMSOY Cbz-Arg-Arg-AMC (1.1 mg)
was dissolved in DMSO (1.5 ml) and stored at 4°C.
Substrate working solution [20 uM Cbz-Arg-Arg-AMC in 0.02% (v/v) DMSO in dH7Q1.
Stock substrate solution (100 ul) was diluted to 5 ml. This solution was stored at 4°C for no
longer that 2 days.
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0.1% (m/v) Brij 35. Brij 35 (0.1 g) was dissolved in dH2O (80 ml) and made up to a final
volume of 100 ml.
Stop solution [100 mM monochloroacetate. 20 mM sodium acetate. 70 mM sodium acetate.
pH 4.3], Monochloroacetate (9.45 g), CH3COONa.3H2O (4.08 g) and glacial acetic acid (4
ml) were dissolved in dH^O (950 ml), adjusted to pH 4.3 with NaOH, and made up to 1 litre.
1 mM AMC standard. AMC (1.8 mg) was dissolved in DMSO (10 ml), and stored at 4°C.
2.3.2 Standard assay
All reagents were pre-equilibrated to 37°C. For standard continuous assays, samples (1-5 ng
OP-Tb) were diluted in 0.1% (m/v) Brij 35 to 500 \ii before assay buffer (250 ul) was added.
The enzyme was allowed to activate in a temperature-controlled cell (10 min, 37°C) after
which time substrate working solution (250 u,l) was added, and fluorescence monitored
continuously on a Hitachi F-2000 spectrofluorimeter (X.ex370 nm, X^ 460 nm), for 10 min.
Stopped-time assays were performed in the same manner, except that stop solution (1 ml) was
added to the reaction mixture 10 min after the addition of substrate, and a single fluorescence
reading taken.
To facilitate quantitation of product, separate calibration graphs were constructed for the
standard continuous assays and the stopped-time assays. AMC standard was diluted in assay
buffer for calibration of the continuous assay, while for the stopped-time assay, AMC standard
was diluted in a 1:1 mixture of assay buffer and stopping reagent. Linear regression analysis of
the standard data yielded equations from which the AMC concentration in the standard
continuous and stopped-time assays could be determined.
2.3.3 Microplate assay
All reagents were pre-equilibrated to 37°C. Samples (1-5 ng OP-Tb) were diluted in 0.1%
(m/v) Brij 35 to 50 u.1, before assay buffer (25 (il) was added. The enzyme was allowed to
activate on a temperature-controlled heating pad (10 min, 37°C) after which time substrate
working solution (25 jal) was added, and fluorescence monitored continuously in a Cambridge
Technology 7620 Microplate Fluorimeter (kex 370 nm, X.̂  460 nm), for 3 min. Stopped-time
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assays were performed in the same manner, except that stop solution (100 |j.l) was added to the
reaction mixture 3 min after the addition of substrate, and a single fluorescence reading taken.
Separate calibration graphs were constructed for the continuous and the stopped-time
microplate assays, as described in Section 2.3.2 to facilitate quantitation of product.
2.4 Precipitation techniques
A variety of precipitation techniques are used in the purification of proteins, particularly as
crude fractionation steps in the early stages of purifications. These include precipitation with
ammonium sulfate (Melander and Horvath, 1977) or organic solvents (Askonas, 1951), or
combinations thereof such as three-phase partitioning (TPP; Odegaard et al, 1984). In this
investigation three-phase partitioning was employed in the crude fractionation of trypanosome
lysates (Section 3.3).
2.4.1 Three-phase partitioning
Three-phase partitioning is a protein fractionation technique which employs ammonium sulfate,
(NHt^SOa, and tertiary-butanol (/-butanol) to promote the precipitation of proteins in
solution. The technique, first introduced by Odegaard et al. (1984), has been developed by
Pike and Dennison (1989) and by Jacobs et al (1989) for the purification of the lysosomal
proteases cathepsin L and cathepsin D respectively.
The procedure entails the mixing of an aqueous protein sample with a volume of ?-butanol,
which is miscible with water. The aqueous and organic phases are induced to form separate
phases by the introduction of a salt, usually (NH^SC)^ Protein present in solution is
precipitated out at the organic-aqueous interface, thereby concentrating and dehydrating the
sample. The technique is also selective, as different degrees of saturation with (NH4)2SC>4 will
precipitate out different species of proteins. The technique has the advantage of extracting
various contaminants such as lipids and phenolics into the organic phase (Pike and Dennison,
1989). In addition, the technique may be performed at RT, in contrast to the low temperatures
required for alcohol precipitation.
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2.5 Column chromatographic techniques
In order to facilitate the flow of arguments presented in this study, only background and
general chromatographic methods will be introduced in this section, and the specific
procedures will be described in the relevant chapter.
2.5.1 Ion-exchange chromatography
Ion-exchange chromatography (IEC) relies on the reversible electrostatic binding of ions in
solution to an inert support medium to which ionisable functional groups have been covalently
bound (Cooper, 1977). The system is equilibrated with a buffer of a pH at which the
functional groups are ionised, and will attract counter-ions of an opposite charge to satisfy the
requirements of electrical neutrality (Rossomando, 1990). For cation-exchange
chromatography, negatively-charged functional groups, such as sulfonate [SO3"], are attached
to the matrix. Conversely, for anion-exchange chromatography, positively-charged groups
such as quaternary ammonium [CH2N+(CH3)3] are be employed. The pH of the system is
manipulated to alter the charge of the proteins in solution. As protein molecules contain, inter
alia, ionisable amine and carboxylate moieties, the degree of protonation, and hence charge, of
these moieties is dependent on the pH of the solvent in which the protein is dissolved.
Anion-exchange resins, such as the DEAE-cellulose and Q-Sepharose resins employed in this
investigation are positively charged and attract negatively charged counter ions. A mixture of
solutes of various charges is applied to the matrix where anionic solutes displace the
electrostatically-bound counter ions, and themselves act as counter ions to the charged
functional groups. Neutral and cationic solutes do not bind to the cationic matrix and a group
fractionation is thus accomplished. Bound ions of different characteristics may be sequentially
eluted by washing the matrix with a gradient of increasing concentration of a suitable counter-
ion, provided by a salt such as NaCl, which will cause the displacement of bound solutes by
mass action. Alternatively, a pH gradient may replace the salt gradient. This will alter the
charge of the solutes and the matrix, thereby reducing the electrostatic attraction between the
two components of the system. For preparative protein fractionation, a salt gradient is
preferred as adverse pH may irreversibly denature protein molecules.
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1.5.1.i Diethylaminoethyl-cellulose
Cellulose is a linear polymer of D-glucose residues linked by P-D-(l->4)-glycosidic bonds
(Ward and Seib, 1970), and is a popular matrix for IEC involving macromolecules or whole
cells, as cellulose matrices have a very open microstructure providing easy accessibility of cells
or macromolecules to charged fiinctional groups. Additionally, the highly hydrophilic nature of
cellulose minimises the hydrophobic interactions which complicate protein adsorption to EEC
resins (Peterson, 1970).
DEAE-cellulose is a weak anion-exchange resin, containing a tertiary amine in the form of a
diethylaminoethyl (DEAE) functional group covalently linked to the cellulose matrix (Peterson,
1970). DEAE-Cellulose was employed in this investigation for the isolation of live
trypanosomes from infected rat blood (Section 3.2) and in the purification of cti-protease
inhibitor from bovine plasma (Section 6.2.4).
2.5.1.2 Q-Sepharose
Q-Sepharose is a strong anion-exchange chromatography medium, consisting of quaternary
amine groups (Q) covalently attached to Sepharose CL-6B. In contrast to cellulose,
Sepharose has a microreticular structure, imparting to it a high degree of chemical and physical
stability. This prevents the fluctuations in bed volume under conditions of changing ionic
strength and permits the use of high flow rates, in excess of 1 ml.min"1, which results in
enhanced performance in terms of resolution. These reasons, together with the stability of the
matrix to pH, ionic strength and organic solvents, make Sepharose-based ion exchange media
preferable to cellulose-based media for protein fractionation (Cooper, 1977). Q-Sepharose
was employed in this investigation in the isolation of proteolytic enzymes from trypanosome
lysates (Sections 3.4 and 3.6).
2.5.2 Molecular exclusion chromatography
Molecular exclusion chromatography (MEC), also termed gel filtration, gel permeation or
molecular sieving, is a chromatographic technique that exploits differences in the size of
solutes to effect their separation (James and Morris, 1964).
The chromatographic matrix is composed of polymeric particles containing a network of
uniform pores into which solvent and solute may diffuse. The average time spent by a solute in
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the porous network of the matrix is a function of its size. Molecules smaller than the average
pore size penetrate deepest into the pores, and so their passage through the column is
hindered, and they elute from the column last. In contrast, molecules significantly larger than
the average pore size are excluded from the matrix, hence the term molecular exclusion, and
elute from the column with the buffer front.
Thus, MEC serves as a method of preparative protein fractionation, as well as an analytical
tool used to determine the Mr of proteins (Andrews, 1965). For this purpose, an MEC column
is first calibrated by the application of a set of Mr standards. A calibration graph is constructed
relating logioMr to the elution volume (Ve) of each standard. Alternatively, an availability
constant (Kav), may be calculated from the equation,
V - V
K = - S ± (Ackers, 1970),
av V - V
t o
The elution volume (Ve) is given by the volume of buffer required to elute that particular
protein species. The void volume (Vo) is given by the Ve of a standard with a Mr considerably
larger than the exclusion limit of the column and Vt is the volume of the cylindrical gel bed.
A variety of MEC matrices were utilised in this investigation. Sephacryl S-100 HR
(fractionation range 1-100 kDa) was utilised in the purification of OP-Tb from T. b. brucei
lysates (Section 3.8) and for the isolation of ai-antichymotrypsin from bovine plasma
(Section 6.2.3). Additionally, Sephacryl S-200 HR (fractionation range 5-250 kDa) was used
to probe the interaction between OP-Tb and a2-macroglobulin (Section 6.3.2), while
SephadexG-75 (fractionation range 3-80 kDa) was employed in the isolation of ai-protease
inhibitor (Section 6.2.4).
2.5.3 Affinity chromntography
Affinity chromatography relies on the specific, reversible interactions between a protein and a
ligand immobilised on a chromatographic matrix. Such ligands may take the form of enzyme
inhibitors, antibodies, carbohydrate-binding lectins or cofactors (Hermanson et al., 1992).
After application of a sample to such a matrix, only the protein of interest will bind to the
immobilised ligand, allowing the remaining contaminants to be washed off the matrix. The
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bound protein may then be eluted by applying conditions to the matrix that reduce the affinity
between the protein and the ligand. Such conditions include changes in pH, the use of
chaotropic agents (e.g. in the case of immunoaffinity chromatography), increasing ionic
strength, or supplying a compound which will compete with the protein for the ligand and
displace the bound protein by mass action (Cooper, 1977).
2.5.3.1 Para-aminobenzamidine-Sepharose
The ligand /?-aminobenzamidine is an arginine analogue that has been used extensively for the
affinity-purification of proteases that possess an arginine-binding site, including trypsin and
plasminogen activator (Hermanson et al, 1992). In this investigation, /?-aminobenzamidine
coupled to cyanogen bromide-activated Sepharose 4B via a 6-atom spacer, with a binding
capacity of 10 mg trypsin per ml (Sigma, St. Louis, USA), was utilised for the isolation of a
OP-Tb (Section 3.5).
2.5.3.2 Poly-(L-lysine)-Sepharose
Poly-(L-lysine) may be employed as an affinity ligand for proteins which are known to bind
polyamines, and has been successfully used for the isolation of phosphoprotein phosphatases
from rabbit muscle (Gratecos et al, 1977) and Paramecium (Friderich et al, 1992).
Throughout this investigation, commercially available poly-(L-lysine) (70-150 kDa)
immobilised on cyanogen bromide-activated Sepharose 4B (Sigma, St. Louis, USA) was
employed. The poly-(L-lysine) was immobilised, via its e-amino group with a one-atom spacer,
at a concentration of 1-2 mg ligand per ml of gel. Poly-(L-lysine)-Sepharose was utilised in
this investigation for the isolation of a OP-Tb (Section 3.7).
2.5.3.3 Cibacron Blue F3GA-Sepharose
The use of dye molecules as affinity ligands constitutes a pseudo-affinity chromatography
method in which the structure of the dye molecule resembles a biological ligand. Cibacron
Blue F3GA is a triazine dye that contains an anthroquinone region which successfully mimics
the structure of certain enzyme substrates. The dye is thus able to bind enzymes that require
adenylic co-factors and has been used for the purification of a variety of proteins, including
serum albumins and a2-macroglobulin (reviewed in Clonis, 1987). Hydrophobic interactions
are also believed to be involved in the interaction between this dye and its ligands (Hermanson
et al, 1992). In this investigation, chromatography on Cibacron Blue F3GA-Sepharose was
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employed in the isolation of ai-antichymotrypsin (aiACT) and ociPI from bovine plasma
(Sections 6.2.3 and 6.2.4).
2.6 Sample concentration
When necessary, for example, prior to electrophoresis or molecular exclusion chromatography,
samples were concentrated by one of two methods. If the volume of sample was small
(<3 ml), concentration was achieved by ultrafiltration. For larger sample volumes, dialysis
against polyethylene glycol (Mr 20 000) was employed.
2.6.1 Concentration by ultrafiltration
Concentration by ultrafiltration was performed using 3 ml polysulfone concentrators
(Millipore, Bedford, USA) containing a 10 kDa Mr cut-off membrane. Samples were then
centrifuged (7 000 x g, 10°C) in a Beckman J2-HS centrifuge until concentration was
achieved, usually in 1-2 h. Buffer ions and water are forced through the membrane while
macromolecules such as proteins are retained, thus effecting concentration of the protein
sample.
2.6.2 Concentration by dialysis
Concentration by dialysis entails creating a concentration gradient between a dilute sample and
a concentrated solution (usually sucrose or polyethylene glycol), through a semi-permeable
(dialysis) membrane. The concentration gradient causes water and other small molecules to
move by osmosis from the dilute sample into the more concentrated sample, effecting
concentration. Dialysis is usually conducted against sucrose or organic polymers, for example,
polyethylene glycol (PEG), which is a are water-soluble, high molecular mass polymer.
PEG 20 000 has an average Mr of 20 000 (Budavari etal., 1987). PEG 20 000 is the
compound of choice as, in contrast to sucrose, its large molecular mass prevents it from
entering the dialysis tube and contaminating the sample.
Cellulose membrane dialysis tubing (Mr 12 000 cut-off) was soaked in dHbO for 10 min at RT
before use. Dilute protein samples were placed in the dialysis tube, and the tube was placed on
a bed of solid PEG 20 000, with which it was also covered, and the sample allowed to
concentrate at 4°C. Once concentration had been achieved, the dialysis tube was briefly rinsed
with dH2O, and the sample squeezed out of the tube.
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2.7 Electrophoretic techniques
In this investigation reducing and non-reducing polyacrylamide gel electrophoresis in the
presence of sodium dodecyl sulfate (SDS-PAGE) was used to determine the homogeneity of
purified protein preparations, and for the determination of the molecular mass of purified
trypanosome oligopeptidases. In conjunction with western blotting (Section 4.4), SDS-PAGE
was used to evaluate the specificity of antibodies raised against OP-Tb, and their cross-
reactivity with potentially related proteins from other sources. A combination of SDS-PAGE
and protein blotting was also used to detect OP-Tb in trypanosome lysates and purified
preparations by active-site blots (Section 7.4), and for the preparation of material for
N-terminal sequencing (Section 3.10).
The supporting matrix usually take the form of polyacrylamide gels. These are constructed by
the vinyl polymerisation of a synthetic acrylamide monomer, with a cross-linking agent, such as
N,N'-methylenebisacrylamide (Bis). The polymerisation occurs in the presence of a free-radical
catalyst, such as the sulfate radical, S(V, provided by ammonium persulfate. The free-radicals
react with the acrylamide to generate activated acrylamide where the free-radical state is
preserved within the acrylamide molecule. These polymeric chains, which are still in a fluid
state, are then cross-linked in the presence of Bis to form a gel, which is analogous to a "net"
of acrylamide chains. Because of its ability to exist in the free-radical state, the compound
N,N,N',N'-tetramethyl-l,2-diaminoethane (TEMED) is used as an accelerator of
polymerisation. The porosity of these gels may be varied by manipulating the relative amount
of cross-linking agent to acrylamide monomer (described as %C), and the mass of acrylamide
in the total volume of the gel (m/v) (described as %T).
The extent of migration of proteins during native PAGE is a function of the charge-to-mass
ratio of that particular protein species and the size and shape of the protein. However, this
provides little information about the molecular mass of the protein. For this reason, PAGE
conducted in the presence of the anionic detergent, sodium dodecyl sulfate (SDS), using the
discontinuous gel and buffer system of Ornstein (1964) and Davis (1964) was introduced by
Laemmli (1970). Sodium dodecyl sulfate binds to most proteins at a constant ratio of 1.4 gram
SDS per gram of protein (Reynolds and Tanford, 1970). The extensive binding of detergent to
protein is sufficient to negate the intrinsic charge carried by the protein, and imparts to that
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protein a nett negative charge that is directly proportional to the molecular mass of that
protein. To effect complete unfolding of proteins, which may contain tertiary structures that
SDS alone cannot disrupt, samples may be denatured (100°C, 10 min) in the presence of
reducing agents, such as P-mercaptoethanol or dithiothreitol. These agents permit extended
unfolding of the proteins by reducing disulfide bridges which ordinarily restrain the structure,
thereby inhibiting unfolding. Proteins may thus be separated on the basis of size alone. In this
way, the Mr of a protein may be determined by comparing the migration of the protein of
interest with that of a set of standard proteins of known Mr run in parallel (Neville, 1971;
Weber and Osborne, 1969).
As most protein species are colourless, they have to be visualised on the gel. A number of
means exists for this, including protein staining (Syrovy and Hbdny, 1991; Sections 2.7.3 and
2.7.4) and densitometry (Hoffmeister, 1974).
2.7.1 Tris-Tricine SDS-PAGE
Tris-Tricine SDS-PAGE was first described by Schagger and von Jagow (1987) as an
alternative to the Tris-glycine system of Laemmli (1970). In this system, Tricine is used
instead of glycine as the trailing ion in the stacking phase, at a higher pH. This system is
reportedly useful for the resolution of proteins in the range of 5-100 kDa, provides better
resolution of protein samples due to enhanced stacking of protein bands, and can tolerate high
salt concentrations in protein samples.
2.7.1.1 Materials
SDS Solution [10% (m/v) SDS]. SDS (10 g) was dissolved in a total volume of 100 ml dH20.
This process required gentle heating.
Gel buffer [3 M Tris-Cl. 0.3% (m/v) SDS. pH 8.45], Tris (72.7 g) and SDS solution (6 ml)
were dissolved in dH2O (150 ml), adjusted to pH 8.45 with HC1 and made up to 200 ml.
Monomer solution [49.5% (m/v) acrylamide. 3% (m/v) bisacrylamide], Acrylamide (48 g) and
bisacrylamide (3 g) were dissolved and made up a total volume of 100 ml with dtbO, filtered
through Whatman No. 1 filter paper and stored in an amber bottle at RT.
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Initiator [10% (mM ammonium persulfate]. Ammonium persulfate (0.1 g) was dissolved in
ml), just before use.
Anode buffer [200 mM Tris-Cl. pH 8.9]. Tris (24.22 g) was dissolved in dH2O (900 ml),
adjusted to pH 8.9 with HC1 and made up to 1 litre.
Cathode buffer [100 mM Tris-Cl. 100 mM Tricine. 0.1% (m/v) SDS. pH 8.25], Tris (12.2 g),
Tricine (17.9 g) and SDS solution (10 ml) were dissolved in dH2O (900 ml), adjusted to pH
8.25 with HC1, and made up to 1 litre.
Non-reducing sample treatment buffer [100 mM Tris-Cl. 1% (m/v) SDS. 20% fv/v> glvcerol.
pH 8.45]. Tris (0.121 g), SDS solution (1 ml) and glycerol (2 ml) were dissolved in dH2O
(4 ml), adjusted to pH 8.45, made up to 10 ml, divided into aliquots and stored at -20°C.
Reducing sample treatment buffer [100 mM Tris-Cl. 1% (m/v) SDS. 20% fv/v) glvcerol. 10%
(v/v) P-mercaptoethanol. pH 8.45]. Tris (0.121 g), SDS solution (1 ml), glycerol (2 ml) and
(3-mercaptoethanol (1 ml) were dissolved in dH2O (4 ml), adjusted to pH 8.45, made up to
10 ml with, divided into aliquots and stored at -20°C.
Tris-Tricine Mr standards [phosphorylase b (97 kDa) . BSA (68 kDa) . ovalbumin (45 kDa).
carbonic anhydrase (30 kDa). soybean trypsin inhibitor (21.5 kDa). q-lactalbumin (14 kDa:
each protein at 1 ng.nl'1>. in 125 mM Tris-HCl. 4% (m/v) SDS. 25% (m/v) sucrose. pH 8.45 in
non-reducing sample treatment buffer]. Lyophilised protein standards, containing sucrose,
were obtained as a kit from Pharmacia (Lund, Sweden). The standards were reconstituted in
non-reducing sample treatment buffer from which the glycerol had been omitted.
HNCh [20% (v/v) HNCh]. 55% HN03 (36 ml) was diluted to 100 ml with dH20, and stored in
an amber bottle at RT.
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2.7.1.2 Method
Tris-Tricine SDS-PAGE was carried out as described by Schagger and von Jagow (1987)
using a Bio-Rad Mini-Protean® II vertical slab electrophoresis unit assembled as described in
the manufacturer's manual. If gels were intended for silver staining, all glassware was soaked
overnight in 20% (v/v) HNO3. Stacking and separating gels were prepared as described in
Table 7. Separating gels were cast and allowed to polymerise for 1 h. Stacking gels usually
polymerised within 20 min. Gels were cast using 1.5 mm spacers and combs.








"After Schagger and von Jagow (1987).
Protein samples (containing at least 2 ug protein per band for Coomassie Blue staining, or
100 ng per band for silver staining) were combined in a 1:1 ratio with the relevant sample
treatment buffer, and boiled for 10 min. After cooling, bromophenol blue (1 ul), as a marker
dye, was added, and the samples loaded into gel wells with a micropipette (disposable 25 ul
tip). Gels were run at unlimiting current and 70 V, until samples reached the separating gel,
when the voltage was increased to 100 V.
2.7.2 Substrate gel electrophoresis
Proteases may be visualised after electrophoretic separation by the co-polymerisation of
protein substrates (such as fibrinogen or gelatin) with the polyacrylamide gel, as described for
urokinase-type plasminogen activator by Heussen and Dowdle (1980). Upon completion of
electrophoresis, the denaturing, protein-bound SDS is removed from the gels with several
washes of a non-ionic detergent, usually Triton X-100. This is believed to assist in the
















any necessary activators of the protease. Areas of proteolytic activity are evident as clear
bands against a stained background. This technique has the added advantage of providing the
approximate molecular mass at which the proteolytic activity occurs, and is reportedly at least
as sensitive as silver staining.
2.7.2.1 Materials
Amido black stain solution [0.1% (m/v) amido black in methanol:acetic acid:dH?O (30:10:60)].
Amido black (0.1 g) was dissolved in methanol:acetic acid:dH2O (30:10:60; 100 ml) and
filtered through Whatman No. 1 filter paper.
Assay buffer [50 mM Tris-HCl. 10 mM dithiothreitol. 0.02% (m/v> NalSk pH 8]. Tris (3 g),
dithiothreitol (0.77 g) and NaN3 (0.03 g) were dissolved in dH2O (450 ml), adjusted to pH 8,
and made up to 500 ml.
Protein solution [1% (m/v) gelatin in separating gel buffer]. Gelatin (0.1 g) was dissolved in
gel buffer (10 ml, Section 2.5.1.1) with gentle heating. The solution was prepared freshly.
2.5% Triton X-100. Triton X-100 (5 ml) was diluted to 200 ml with dH2O.
2.7.2.2 Method
Separating gels were cast as described in Section 2.7.1.2 but a proportion (3.75 ml) of the
separating gel buffer (Table 5) was replaced with a mixture of 1% (m/v) gelatin (1.5 ml) and
separating gel buffer (2.25 ml). Stacking gels were cast as described in Section 2.5.1.2. Once
the electrophoretic run was complete, gels were incubated in 2.5% (v/v) Triton X-100
(2 x 30 min) to remove SDS. Gels were then incubated in assay buffer (3 h, 37 °C) to permit
the digestion of protein substrates, and stained in amido black for 1 h. Gels were destained
with several changes of methanol:acetic acid:dH2O (30:10:60) until clear bands were visible
against a darkly stained background.
2.7.3 Coomassie Blue R-250 staining of proteins
Coomassie staining is a simple and rapid, yet insensitive, method of protein visualisation. This
technique, which employs the dye Coomassie Brilliant Blue R-250, is able to detect down to 1
(j.g of protein per band (Syrovy and Hodny, 1991). Once the electrophoresis run was
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completed, the gel was briefly incubated in stain solution. Background dye was then removed
by incubating the gel in a destain solution.
2.7.3.1 Materials
Stain stock solution [1% fm/v) Coomassie Blue R-250], Coomassie Blue R-250 (1 g) was
dissolved in dt^O (100 ml) by magnetic stirring for 1 h at RT, and filtered through Whatman
No. 1 filter paper.
Stain working solution [0.125% fm/v) Coomassie Blue R-250. 50% fv/v> methanol. 10% fv/v)
acetic acid]. Stain stock solution (62.5 ml) was diluted with methanol (250 ml) and acetic acid
(50 ml), and made up to 500 ml.
Destaining I [50% (v/v) methanol. 10% (vM acetic acid], Methanol (500 ml) was mixed with
acetic acid (100 ml), and made up to 1 litre with
Destaining II [5% fv/v) methanol. 7% fv/v) acetic acid]. Methanol (50 ml) was mixed with
acetic acid (70 ml), and made up to 1 litre with
2.7.3.2 Method
The gels were removed from the electrophoresis apparatus, and incubated in stain working
solution (4 h) with agitation on a Belly Dancer® agitator (Stovall Life Science, Greenboro,
USA). Following staining, the gels were rinsed with dt^O and placed in destain I overnight.
Finally, the gels were placed in destain II until the background staining was completely
removed. Gels were stored hydrated in polythene zip-seal bags, at 4°C, until photographed.
2.7.4 Silver staining of proteins
Silver staining of proteins is considerably (up to 100-fold) more sensitive than the Coomassie
Blue R-250 stain (Section 2.5.4). This technique relies on the reduction of ionic silver in
solution to its (insoluble) metallic form. This may be accomplished in strongly acidic or basic
solution (Allen and Budowle, 1994). The basic procedure, employing sodium carbonate or
sodium hydroxide are more sensitive but generally have high background staining. The
inclusion of a pre-treatment step with sodium thiosulfate (Blum et al., 1989) considerably
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reduces the intensity of background staining primarily by preventing the precipitation of
insoluble silver complexes on the surface of the gel.
2.7.4.1 Materials
Fixative [50% (v/v) methanol. 12% (v/v) acetic acid. 0.1% (v/v) HCOH], Methanol (100 ml),
acetic acid (24 ml) and 37% (v/v) formaldehyde (0.1 ml) were mixed and made up to 200 ml.
Wash solution [50% (v/v) EtOH]. Ethanol (100 ml) was made up to 200 ml with dH2O.
Pre-treatment solution [0.2 mg.ml'1 Na->S-?O?]. Na2S2O3.5H2O (40 mg) was dissolved in 200 ml
dH2O.
Impregnation solution [0.2% (m/v) AgNCk 0.03% (v/v) HCOH"]. AgNO3 (400 mg) and 37%
formaldehyde (0.15 ml) were dissolved in 200 ml dH2O.
Developer [60% (m/v) Na^CCX 0.02% (v/v) HCOH. 0.004% (m/v) Nfr&OV]. Anhydrous
Na2CO3 (12 g), pre-treatment solution (4 ml) and 37% formaldehyde (0.1 ml) were combined
and made up to a total volume of 200 ml.
Stop solution [50% (m/v) methanol. 12% (m/v) acetic acid]. Methanol (50 ml) and acetic acid
(12 ml) were dissolved and made up to a total volume of 200 ml.
2.7.4.2 Method
Gloves were worn during the developing procedure to prevent fingerprints on the gel.
Development of gels was carried out on a Belly Dancer® agitator (Stovall Life Sciences,
Greensboro, USA), at RT, in glass containers which had been soaked overnight in 20% (v/v)
HNO3 (Section 2.7.1.1). Gels were removed from the electrophoresis apparatus and soaked in
fixative (16 h), followed by wash solution (3 x 25 min), to remove residual fixative. The gels
were treated with pre-treatment solution (2 min), rinsed with dH2O (3 x 25 sec) and soaked in
impregnation solution (25 min, in the dark). Gels were rinsed with dH2O (2 x 25 sec), to
remove excess AgNO3, and immersed in developer until protein bands became evident against
a faintly stained background. The gel was washed with dH2O ( 2 x 2 min), and the reaction
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terminated in stop solution (10 min). The gel was stored hydrated in polythene zip-seal bags, at
4°C, until photographed.
2.7.5 Electroblotting of proteins
Electroblotting of proteins provides a convenient means of transferring proteins that have been
resolved by gel electrophoresis onto membranes. Electroblotting was undertaken in this
investigation for the N-terminal analysis of OP-Tb (Section 3.10), the detection of proteases in
complex samples by active-site labelling (Section 7.4) and for the characterisation of anti-
OP-Tb antibodies by western blotting (Section 4.4).
2.7.5.1 Materials
Electrotransfer buffer [10 mM Caps. 10% (v/v) methanol. pH 11 f. Caps (2.21 g) and
methanol (100 ml) were dissolved in dH2O (800 ml), titrated to pH 11 with NaOH, and made
up to 1 litre.
2.7.5.2 Method
A variety of membranes were employed, depending on the application of the blot. For
N-terminal analysis (Section 3.10) proteins were blotted onto polyvinylidene difluoride
(PVDF) membranes, while for western blots (Section 4.4) and active-site blots (Section 7.4)
proteins were blotted onto nitrocellulose.
The membranes were cut to a suitable size and floated on top of the blotting buffer before
immersion to prevent entrapment of air-bubbles. The membrane was placed on top of the gel,
air-bubbles expelled, and sandwiched between three pieces of Whatman No. 4 filter paper and
two pieces of Scotchbrite® foam. Both the filter paper and the foam were pre-soaked in
blotting buffer. The sandwich was placed into a Hoefer TE Series Transphor western blot
apparatus which was pre-filled with blotting buffer. The apparatus was maintained at 8°C by a
refrigerated circulator. Electrotransfer of the proteins from the gel to the membrane was
accomplished at 30V for 16 h with unlimiting current.
2.8 Cell culture
In contrast to the culture of procyclic salivarian trypanosomes and stercorarian trypanosomes
(Brun and Schonenberger, 1979), the in vitro culture of bloodstream-form salivarian
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trypanosomes was initially highly problematic (Baltz et al., 1985) and only very limited success
had been reported with the cultivation of bloodstream-form salivarian trypanosomes on feeder-
cell layers of NIH 3T3 fibroblasts (Hirumi et al. 1977). Duszenko et al. (1985) observed that
cysteine eliminated the requirements for feeder-cells, and Duszenko et al. (1992) later reported
that cysteine was an essential requirement for the in vitro culture of bloodstream-form
salivarian trypanosomes. However, cysteine is readily oxidised to cystine by Cu2+ ions present
in the culture medium. With this in mind, Hesse et al. (1995) reported a novel cultivation
technique for the long-term maintenance of bloodstream-form trypanosomes in culture,
through the inclusion of bathocuproinedisulfonic acid (BCDSA), in the culture medium.
Bathocuproinedisulfonic acid (2,9-dimethyl-2,4-diphenyl-l,10-phenthrolinedisulfonic acid) was
designed as a highly soluble, specific chelator of divalent copper cations (Zak, 1958). While
the culture medium is not specifically supplemented with copper, it is present in bovine serum
at a concentration of approximately 6 \xM (Altman and Dittmer, 1961), and is probably
introduced with the addition of foetal calf serum, to a final concentration of approximately
0.9 uM in the culture medium.
In vitro culture of African trypanosomes was employed in this investigation to investigate the
effect of antibodies directed against trypanosome proteins on parasite viability (Section 4.6).
Furthermore, cultures were employed to determine the trypanocidal activity of trypanocidal
drugs and their analogues (Section 7.2) and potentially new therapeutic agents (Section 7.3,
7.4, 7.5).
2.8.1 Materials
Penicillin/streptomycin solution [10 000 U.ml'1 penicillin. 10 mg.ml'1 streptomycin. 0.9% fm/v*)
NaCl], Penicillin/streptomycin was reconstituted in autoclaved ddH2O (20 ml).
Cysteine stock solution [25 mM cysteine. 1 mM bathocuproinedisulfonic acid (BCDSA')].
Cysteine.HCl (0.22 g) and BCDSA (0.028 g) were dissolved in dH2O (50 ml) and filter-
sterilised through a 0.22 urn filter.
Foetal calf serum (FCSY If necessary, FCS was heat-treated to inactivate complement
proteins, by incubation at 57°C for 1 h.
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Culture medium [minimal essential medium (MEM), with Earle's salts. 0.3 g.l*1 L-glutamine.
0.25 mM cysteine. 0.01 mM BCDSA. 15% (vM FCS]. Supplemented MEM was prepared
exactly as described by Hesse et al. (1995). Supplemented MEM (9.6 g) and NaHCO3 (2.2 g)
were dissolved in ddHbO (850 ml) and filter-sterilised through a 0.45 jam pre-filter and a
0.22 [xm filter. FCS (150 ml) was added aseptically after filtration. For each 100 ml aliquot of
medium, cysteine stock solution (1 ml) and penicillin/streptomycin solution (1 ml) were added
aseptically.
2.8.2 Method
Cell culture was undertaken exactly as described by Hesse et al. (1995). Culture medium was
pre-warmed to 37°C and divided into 5 ml aliquots in disposable polystyrene tissue culture
flasks (25 cm2 surface area) with a vented-cap containing 0.22 urn filters. Culture medium was
inoculated with parasites thawed from cryo-preserved stabilates prepared from infected rat-
blood. Stabilates had previously been rapidly thawed and diluted in PSG (Section 3.2.1) to an
appropriate cell-number. Cultures were maintained at 37°C in 5% (v/v) CO2.
Cytotoxicity assays were undertaken exactly as described by Kaminsky and Zweygarth (1989).
Cytotoxic agents were dissolved in DMSO and added at various concentrations to
trypanosome cultures, with a final DMSO concentration maintained at 1% (v/v). The cultures
were incubated as described above for 24 h. Control cultures (without inhibitors, but also
containing 1% (v/v) DMSO) were incubated under the same conditions. Cell numbers were
determined with a haemocytometer and the data analysed graphically by plotting growth
inhibition versus drug concentration. The effective concentration which inhibited growth of
trypanosome populations by 50% (EC50) was then obtained from these plots.
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Chapter 3
Isolation of an oligopeptidase from T. b. brucei
3.1 Introduction
The aim of this study was to fully characterise a trypanosome oligopeptidase from T. b. brucei
(OP-Tb) and investigate its potential role in the pathogenesis of African trypanosomiasis. It
was therefore necessary to obtain a pure preparation of this enzyme. While a trypsin-like
proteinase activity from T. b. brucei has been identified (Lonsdale-Eccles and Grab, 1987;
Mbawa et al, 1991) and partially characterised (Kornblatt et al. 1992), the enzyme had not
been purified to electrophoretic homogeneity at the outset of the present study.
Working with partially purified preparations, Kornblatt et al. (1992) demonstrated that activity
against Cbz-Arg-Arg-AMC was the most suitable marker for the enzyme. Therefore, an assay
based on this substrate (Sections 2.3.2 and 2.3.3) was selected to follow the purification of the
enzyme through the isolation procedure. Initial attempts at purification revealed that the
presence of reducing agents was essential to maintain the stability of OP-Tb and consequently
1 mM dithiothreitol was included in all solutions.
Kornblatt et al. (1992) employed a combination of ultracentrifugation, ion-exchange and
molecular exclusion chromatography as well as preparative isoelectric focusing in an attempt
to isolate OP-Tb. In the present investigation, three-phase partitioning (Pike and Dennison,
1989) was used as an initial crude purification step since it has been successfully employed for
the purification of several proteases in our department (Jacobs et al, 1989; Pike et al, 1992;
Troeberg et al, 1996). Subsequent fractionation was achieved by anion-exchange and
molecular exclusion chromatography, and affinity chromatography using para-
aminobenzamidine (Hermanson et al, 1992) and poly-(L-lysine) (Friderich et al, 1992) as





Re-dissolve [10-25% (NH^SC^) cut]
Buffer A (20 mM sodium acetate, 1 mM Na2EDTA, pH 5.5)
I
Q-Sepharose
(100 x 26 mm, flow rate 1 ml.min"1;
pre-equilibrated in buffer A with 100 mM NaCl).
Unbound
Dialyse against buffer B
(50 mM Tris-Cl, 1 mM dithiothreitol, pH 8.0)
p-Aminobenzamidine-Sepharose
(120 x 15 mm, flow rate 0.23 ml.min"1)






(100 x 26 mm, equilibrated in buffer B, 1 ml.min'1)
Linear gradient (5 column volumes; 0.1-1 M NaCl)
Poly-(L-lysine)-Sepharose
(90 x 15 mm, 1 ml.min"1; equilibrated in buffer B)
Linear gradient (5 column volumes; 0.1-1.0 M NaCl in buffer B)
Sephacryl S-100 HR
(900 x 15 mm, flow rate 0.23 ml.min'1; equilibrated in buffer B)
OP-Tb
Figure 8. Flow-diagram depicting the OP-Tb purification procedure.
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3.2 Growth and harvesting of trypanosomes
Throughout this investigation, T. b. brucei clone ILTat 1.1 was used. The first stock was
isolated in 1965 from infected bovine blood at Utembo, Kenya (Young, 1985). Trypanosomes
were purified from infected rat blood by a combination of isopycnic density gradient
centrifugation on a Percoll® gradient (Grab and Bwayo, 1982) and anion-exchange
chromatography on DEAE-cellulose (Lanham and Godfrey, 1970); supplemented with
hypoxanthine (Lonsdale-Eccles and Grab, 1987).
3.2.1 Materials
Phosphate-buffered saline, containing glucose fPSG) [57 mM Na9HP(L. 3 mM NalkPOa. 44
mMNaCl. 56 mM glucose. 0.1 mM hypoxanthine. pH 8.0], Na2HPO4 (8.1 g), NaH2PO4.2H2O
(0.36 g), NaCl (2.5 g), D(+) glucose (10 g) and hypoxanthine (0.02 g) were dissolved in dH2O
(950 ml), the solution adjusted to pH 8 with NaOH, and made up to 1 litre.
Elution buffer [100 mM sodium acetate. 1 MNaCl. pH 5], Glacial acetic acid (5.7 ml) and
NaCl (58.4 g) were dissolved in dH2O (950 ml), adjusted to pH 5 with NaOH, and made up to
1 litre.
Anti-coagulant [2% (m/v) tri-sodium citrate in PSG]. Tri-sodium citrate (2 g) was dissolved in
PSG (100 ml).
Percoll® solution [250 mM sucrose. 2% (m/v) glucose in Percoll® pH 7.4]. Sucrose (8.55 g)
and glucose (2 g) were dissolved in Percoll® (80 ml), adjusted to pH 7.4 by the addition of
solid Hepes, and made up to 100 ml with Percoll®
20% (v/v) glvcerol in PSG. Glycerol (10 ml) was dissolved in PSG (80 ml) and made up to
100 ml with PSG.
1% (v/v) Triton X-100. Triton X-100 (1 ml) was dissolved in dH2O (50 ml) with gentle
heating (37°C) and made up to 100 ml.
m
3.2.2 Methods
Trypanosomes were thawed from cryopreserved stabilates, and viability determined
microscopically. Trypanosome suspensions were diluted to a concentration of 1 x 10 cells per
ml with PSG. Inoculum (1 ml, containing 1 x 106 parasites, per rat) was injected
intraperitoneally into large male (4-5 month old) Wistar rats. Blood parasitaemia was
monitored microscopically from smears taken from the tail vein, and a high level of
parasitaemia was usually attained in less than one week.
Once an acceptable level of parasitaemia was reached (as judged by smears from the tail-vein),
rats were euthanased with ether, and anticoagulant (1 ml) was injected into the heart. The
thoracic cavity was opened and the heart and lungs macerated with scissors. Clotting was
prevented by the addition of more anticoagulant (up to 2 ml). Blood was aspirated out of the
thoracic cavity with a syringe and stored on ice, with regular agitation to ensure mixing of the
anticoagulant and blood. Infected blood was diluted with 1.5 volumes of Percoll® solution and
centrifuged (20 600 x g, 40 min, 4°C). The trypanosome layer was aspirated off and diluted
1:1 with PSG to dilute out the Percoll®, and the trypanosomes pelleted by centrifugation
(3 000 xg, 15 min, 4°C). The pellet was resuspended in PSG (15-20 ml) and evenly layered
onto an equilibrated DEAE-cellulose gel bed contained in a glass funnel with a flat sintered-
glass disk of porosity 1. The DEAE-cellulose was pre-equilibrated with PSG and the
trypanosome preparation washed through the gel with PSG. Platelets and plasma proteins
adsorbed to the gel, while trypanosomes passed through unhindered. The eluant was
continually examined microscopically until trypanosomes were no longer evident in the eluant.
Trypanosomes were concentrated by centrifugation (3 000 xg, 15 min, 4°C). Cell numbers
were determined with a Neubauer haemocytometer after resuspending the trypanosome pellet
in PSG (5 ml), and the remainder of the suspension was frozen at -75°C until required.
Cryopreserved stabilates were prepared as described by Carrington (1993). Stabilate was
prepared directly from freshly collected infected rat blood which was combined with 20% (v/v)
glycerol in PSG, to give a final concentration of 10% (v/v) glycerol as cryoprotectant. The
stabilate was divided into aliquots (1.5 ml), in 2 ml cryopreservation tubes. Stabilate was
slowly frozen by placing the cryotubes in an insulated plastic tube which was then immersed in
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liquid N2. Once the stabilate was completely frozen (30 min), the cryotubes were stored
directly in liquid N2 until used.
DEAE-cellulose was regenerated after trypanosome isolation by washing with PSG containing
1 M NaCl, followed by extensive washing alternately with elution buffer and dtbO. The gel
was finally washed with dH2O (2.5 litres) to remove acetate, suspended in PBS containing
0.02% NaN3 and stored at 4°C. Before use, the gel was rinsed extensively with dH2O
(a 2.5 litres) to remove traces of azide preservative which may harm the trypanosomes during
the isolation. As the pH of the gel was crucially important, it was resuspended in PSG,
allowed to equilibrate, and the pH adjusted to pH 8 with NaOH.
When required for enzyme purification, trypanosome lysates were prepared from frozen or
freshly prepared trypanosome preparations by means of a freeze (-75°C)-thaw (25°C) cycle.
Prior to protein purification, Triton X-100 was added to the lysate to a final concentration of




Buffer A [20 mM acetate. 1 mM Na^EDTA. 0.02% (m/v) NaN^. pH 5.5]. Glacial acetic acid
(1.15 ml), Na2EDTA (0.37 g) and NaN3 (0.2 g) were dissolved in dH2O (950 ml), adjusted to
pH 5.5 with NaOH, made up to 1 litre, and filtered through a 0.22 (im filter.
0.1% fmM Brij 35. Brij 35 (0.1 g) was dissolved in a final volume of 100 ml dH2O.
3.3.2 Optimisation of three-phase partitioning
As this technique has not previously been used for the isolation of this enzyme, it was
necessary to optimise the TPP conditions. For optimisation, trypanosome lysates (3 x 109
cells) were diluted to 25 ml with 0.1% (m/v) Brij 35, and /-butanol (11 ml) added to a final
concentration of 30% (v/v) in a total volume of 36 ml. Solid (NKU)2SO4 (1.8 g) was added to
bring the solution to a concentration of 5% (m/v) (NH4)2SO4 and the suspension was
centrifiiged (10 000 x g, 10 min, 25°C). The precipitate was recovered, and the supernatant
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volume determined. Additional (NtL^SCu was added to bring the solution to 10% (m/v)
(NH4)2SO4. This procedure was repeated, in 5% increments, up to 45% (m/v) (NH^SO* The
precipitate obtained at each step was resuspended in buffer A (Section 3.3.1) (5 ml) and
assayed for activity against Cbz-Arg-Arg-AMC (Section 2.3.3).
3.3.3 Purification using three-phase partitioning
Trypanosome lysates (1.8 x 1010 cells) were diluted to 25 ml with 0.1% (m/v) Brij 35, and a
0-10% (m/v) (NH4)2SO4 cut prepared as described in Section 3.2.2. The solution was
centrifuged (10 000 x g, 10 min, 25°C), the resultant pellet discarded and solid (NH4)2SO4
(5.4 g) added to a concentration of 25% (m/v). The solution was centrifuged (10 000 x g,
10 min, 25°C), the resultant pellet resuspended in buffer A (Section 3.3.1) (10 ml), and the
solution clarified by centrifugation (15 000 xg, 30 min, 4°C). The clarified supernatant was
retained for further fractionation by Q-Sepharose anion-exchange chromatography at pH 5.5
(Section 3.4).
3.4 Q-Sepharose anion-exchange chromatography at pH 5.5
3.4.1 Materials
20% (v/v) Ethanol. Ethanol (20 ml) was dissolved in ddH2O to total volume of 100 ml.
Buffer B [50 mM Tris-Cl. 1 mM dithiothreitol. 0.02% (m/v) NalNk pH 8], Tris (6.1 g),
dithiothreitol (0.15 g) and NaN3 (0.2 g) were dissolved in ddH2O (950 ml), adjusted to pH 8
with HC1, and made up to 1 litre.
3.4.2 Method
Q-Sepharose stored in 20% (v/v) ethanol as preservative was obtained pre-packed as a
HiLoad™ Q column (26 x 100 mm) from Pharmacia (Lund, Sweden). Ethanol was removed
by washing the column with ddH2O (500 ml), and the column was equilibrated with buffer A
containing 100 mM NaCl (100 ml, 1 ml.min'1). Sample [10-25% (m/v) (NH4)2SO4 cut from
TPP] was loaded, and after elution of the unbound protein fraction with buffer A containing
100 mM NaCl, bound material was eluted with a linear gradient of 0.1 to 1 M NaCl in
buffer A, over five column volumes.
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Fractions were assayed for activity against Cbz-Arg-Arg-AMC and Cbz-Phe-Arg-AMC
(Section 2.3.3), and the unbound fractions active against Cbz-Arg-Arg-AMC were pooled and
retained for further fractionation by /?AB-Sepharose affinity chromatography (Section 3.5).
The bound material which had activity against Cbz-Phe-Arg-AMC was used for the
purification of trypanopain-Tb in a parallel study.
Buffer exchange was achieved by dialysis against buffer B (16 h, 4°C), with three buffer
changes (3 x 1 litre).
3.5 />-Aminobenzamidine-Sepharose chromatography
3.5.1 Method
After dialysis into buffer B (Section 3.4.1), the pooled enzyme from Q-Sepharose
chromatography at pH 5.5 (Section 3.4) was loaded onto a p-aminobenzamidine-Sepharose
affinity chromatography column (120 x 15 mm, 1 ml.min*1), which had been pre-equilibrated
with buffer B. After the elution of unbound material with buffer B, elution of bound protein
was achieved in a single step by application of 250 mM NaCl in buffer B. The enzyme-
containing fractions were pooled and retained for further fractionation by Q-Sepharose anion
exchange chromatography at pH 8 (Section 3.6).
3.6 Q-Sepharose anion-exchange chromatography at pH 8
3.6.1 Method
The active pool from the/?-aminobenzamidine-Sepharose column (Section 3.5) was diluted
two-fold with buffer B (Section 3.4.1), to reduce the NaCl concentration in the sample. The
sample was applied to the column and, after elution of the unbound protein fraction with
buffer B, bound material was eluted with a linear gradient of 0.1 to 1 M NaCl in buffer B over
five column volumes, followed by one column volume of buffer B containing 1M NaCl.
Fractions were assayed for activity against Cbz-Arg-Arg-AMC, (Section 2.3.3), and the





The active pool from Q-Sepharose chromatography at pH 8 (Section 3.6) was diluted five-fold
in buffer B (Section 3.4.1), and loaded onto a poly-(L-lysine) affinity chromatography column
(90 x 15 mm, 1 ml.min"1), which had been pre-equilibrated with buffer B. After the elution of
unbound material with buffer B, bound material was eluted with a linear gradient of 0.1 to 1 M
NaCl in buffer B over ten column volumes, followed by 1 column volume of buffer B
containing 1 M NaCl.
Fractions were assayed for activity against Cbz-Arg-Arg-AMC (Section 2.3.3), and the bound,
active fractions pooled and retained for further fractionation by Sephacryl S-100 HR molecular
exclusion chromatography (Section 3.8).
3.8 Sephacryl S-100 HR Chromatography
3.8.1 Method
The active pool from the poly-(L-lysine)-Sepharose column (Section 3.7) was concentrated by
ultrafiltration (Section 2.6.1) to 200 \xl, and applied to a Sephacryl S-100 HR molecular
exclusion chromatography column (900 x 15 mm, 4°C, 0.32 ml.min'1), which had been pre-
equilibrated in buffer B (section 3.4.1). Fractions were assayed for activity against
Cbz-Arg-Arg-AMC (Section 2.3.3), and the eluted active fractions pooled. The active pool
was concentrated by ultrafiltration (Section 2.6.1) and sample purity evaluated by Tris-Tricine
SDS-PAGE (Section 2.7.1).
3.9 Active-site titration of OP-Tb
It is often useful to know the active concentration, [E]o, of a pure enzyme preparation, as a
proportion of the purified enzyme may become irreversibly denatured during purification. A
variety of methods exists for the active-site titration of trypsin-like enzymes. Chase and Shaw
(1970) described the use of the nitrophenyl ester of/?-guanidobenzoate (NPGB) for the active
site titration of trypsin, plasmin and thrombin. This compound has found widespread use in
this regard, where the enzyme is rapidly acylated with a stochiometric release of nitrophenol,
followed by a very slow deacylation of the enzyme due to the instability of p-guanidobenzoyl-
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enzymes (Kezdy and Kaiser, 1981). The limitation of the NPGB method is a lack of
sensitivity. This method has a detection limit of down to 1 nmole of active enzyme, whereas,
for quantitative measurements with an accuracy of above 5%, 0.1 umoles of active enzyme is
required. Jameson et al. (1973) described the use of a fluorogenic analogue of NPGB,
4-methylumbelliferyl-/?-guanidobenzoate (MUGB), which operates on the same principle as
NPGB but extends the sensitivity of the procedure to a detection limit of 1 pmole of active
enzyme. Although this technique theoretically has a detection limit of 1 fmole, MUGB is
subject to base-catalysed hydrolysis and this limits the sensitivity of the procedure, and
underscores the importance of a blank.
3.9.1 Materials
MUGB titrant [1 mM 4-methylumbelliferyl-p-guanidobenzoate in dry DMF], MUGB (3.7 mg)
was dissolved in dry DMF (10 ml). The bottle was wrapped in aluminium foil to protect the
reagent from exposure to light.
Assay buffer [100 mM sodium phosphate. 1 mM dithiothreitol. pH 7]. NaH2PO4.2H2O
(1.56 g) and dithiothreitol (15 mg) were dissolved in dH2O (80 ml), titrated to pH 7 with
NaOH and made up to 100 ml with dH2O.
Dilution buffer [100 mM sodium phosphate. pH 6]. NaH2PO4.2H2O (1.56 g) was dissolved in
dH2O (80 ml), titrated to pH 6 with NaOH and made up to 100 ml with dH2O.
4-methylumbelliferone standard [10 mM 4-methylumbelliferone in dry DMF].
4-methylumbelliferone (17.6 mg) was dissolved in dry DMF (10 ml). The bottle was wrapped
in aluminium foil to protect the reagent from light.
3.9.2 Method
Enzyme (10 jag in 10 (il) was pre-incubated in assay buffer (20 ul) in a 1.5 ml microfuge tube
(10 min, 37°C), after which MUGB titrant (2 u.1) was added. The preparation was centrifuged
in a Hagar HM2 bench-top microfuge to ensure complete mixing of the small volumes, and
incubated (10 min, 37°C). A blank was prepared in the same manner, except the enzyme was
replaced with buffer in the blank. After incubation, dilution buffer (800 ^1) was added to the
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preparation, the solution transferred to a spectrofluorimeter cuvette and fluorescence
determined on a Hitachi F-2000 spectrofluorimeter (Xex 323 nm, X^ 446 nm).
To facilitate quantitation of fluorescence, a calibration graph relating fluorescence units to
picomoles of 4-methylumbelliferone was prepared. The 4-methylumbelliferone standard was
diluted with dilution buffer to the necessary concentrations, and the fluorescence of 800 ul
aliquots determined on a Hitachi F-2000 spectrofluorimeter (A,ex 323 nm, Xem 446 nm).
3.10 N-terminal sequence and amino-acid analysis of OP-Tb
Proteins may be sequenced by Edman degradation from their N-termini. During one cycle of
this reaction, the N-terminal residue is removed from a polypeptide after labelling with
Edman's reagent, phenylisothiocyanate (PITC), and identified by high-performance liquid
chromatography (HPLC). The shortened polypeptide is left with a free N-terminus which can
undergo further labelling and degradation. This procedure is now performed by automated gas-
phase sequenators (Matsudaira, 1993). N-terminal analyses are usually performed on purified
proteins which have been resolved by SDS-PAGE, and electroblotted on to PVDF membranes
(Hulmese/a/., 1989).
Knowledge of the N-terminal sequence of a protein is useful for molecular cloning studies as it
permits the construction of oligonucleotide probes with which full-length clones from gene
libraries can be isolated. Furthermore, a number of protein sequence databases now exist
where an N-terminal sequence may be compared with those held in the database, permitting the
identification and classification of the protein of interest (Lottspeich, 1994).
A number of post-translational modifications of proteins may hinder the sequencing process, in
particular, N-terminal blocking. The N-termini of up to 50% of eukaryotic cytosolic proteins
are believed to be blocked. This may occur by acetylation of N-terminal residues, particularly
serine and threonine residues; formylation of N-terminal methionine residues; or the formation
of pyroglutamyl groups at the N-terminus. Such N-terminally blocked proteins cannot be
sequenced by conventional Edman degradation (LeGendre et ah, 1993), and are either




Stain solution [0.1% (m/v> Coomassie Brilliant Blue G-250 in 50% (v/v) methanol].
Coomassie Brilliant Blue G-250 (O.lg) was dissolved in 50% (v/v) methanol (100 ml).
Destain solution [50% (v/v) methanol]. Methanol (50 ml) was made up to 100 ml.
3.10.2 Methods
Tris-Tricine gels were prepared as described in Section 2.7.1.2 three days in advance, after
which no reactive peroxide radicals should remain in the gel which may catalyse the artifactual
N-terminal blocking of the enzyme (Matsudaira, 1987). Stacking gels were polymerised a day
in advance for the same reason. Electrotransfer was accomplished as described in
Section 2.7.5. Thioglycollic acid (0.1 mM) was added to the electro-transfer buffer
(Section 2.7.5.1) to reduced the possibility of artifactual N-terminal blocking (LeGendre et al,
1993). After completion of electro-blotting, the PVDF membrane was washed in dHbO
(5 min), immersed in stain solution (2 min), destain solution (10 min), then rinsed in dHbO
(2x5 min) and air-dried. N-terminal sequencing and amino-acid analysis were undertaken by
the core sequencing facility of the British Medical Research Council Cambridge Centre,
University of Cambridge, Cambridge, United Kingdom.
3.11 Results
3.11.1 Three-phase partitioning
The results of the optimisation of the three-phase partitioning for OP-Tb isolation are
illustrated in Fig. 9. Activity against Cbz-Arg-Arg-AMC precipitated primarily in the 15-20%
(m/v) (NH^SCu cuts, which contained 54% of the activity (Fig. 9). Additional activity
precipitated in the 10-15% and 20-25% cuts. A 10-25% (NH^SC^ cut was subsequently
used in the purification of OP-Tb to maximise the yield of enzyme. Furthermore, the major
lysosomal cysteine proteinase of T. b. brucei, trypanopain-Tb also precipitated over this range
of (NH4)2SO4. Thus, both enzymes were completely precipitated at this stage, facilitating the
simultaneous purification of both enzymes from the same starting material. About 11% of the
total activity was associated with the membrane and cytoskeletal fractions in the 0-5% cut,




























Figure 9. Optimisation of three-phase partitioning. T. b. brucei lysates were precipitated at various
(NH4)2SO4 concentrations, and assayed for activity against Cbz-Arg-Arg-AMC. Error bars represent the
mean ± SEM (n = 3).
3.11.2 Q-Sepharose chromatography at pH 5.5
Activity against Cbz-Arg-Arg-AMC eluted in the unbound fraction from a Q-Sepharose
column at pH 5.5, while activity against Cbz-Phe-Arg-AMC was retained on the column,
eluting at about 250 mM NaCl (Fig. 10).
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Figure 10. Anion-exchange chromatography of OP-Tb on Q-Sepharose at pH 5.5. Q-Sepharose
(26 x 100 mm, 1 ml.min'1) was equilibrated in buffer A [20 mM acetate, 1 mM Na2EDTA, 0.02% (m/v) NaN3,
pH 5.5] containing 100 mM NaCl. After elution of unbound protein with buffer A, bound protein was eluted
with a linear gradient (•—) of 0.1 to 1 M NaCl in buffer A over 5 column volumes. ( ) A280, ( - • - ) enzyme
activity against Cbz-Arg-Arg-AMC, ( - • - ) enzyme activity against Cbz-Phe-Arg-AMC.
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This reflects the separation of a trypsin-like activity attributable to OP-Tb from a cathepsin L-
like activity attributable to trypanopain-Tb (Mbawa et al., 1992; Troeberg et al, 1996).
3.11.3 /j-Aminobenzamidine-Sepharose chrotnatography
Application of the Q-Sepharose pH 5.5 active fraction (Section 3.4) to a /?-aminobenzamidine
column resulted in the separation of two fractions with activity against Cbz-Arg-Arg-AMC
(Fig. 11). The bulk of the activity (84%) remained weakly bound to the column, eluting with a
single-step salt gradient. A small amount of activity was also evident in the unbound fraction.
This activity did not bind to the matrix, even after repeated passages over a previously unused
batch of jD-aminobenzamidine-Sepharose matrix. This enzyme activity was not characterised







Figure 11. Affinity chromatography of OP-Tb on /j-aminobenzamidine-Sepharose. />-Amino-
benzamidine-Sepharose (120 x 15 mm, 0.32 ml.min'1) was equilibrated in buffer B [50 mM Tris-Cl, 2 mM
dithiothreitol, 0.02% (m/v) NaN3, pH 8]. After elution of unbound protein with buffer B, bound protein was
eluted by application of 250 mM NaCl in buffer B, in a single step, applied at the point indicated by the arrow
(I). (—) A280, (—Q—) enzyme activity against Cbz-Arg-Arg-AMC.
3.11.4 Q-Sepharose chromatography at pH 8
In contrast to chromatography on Q-Sepharose at pH 5.5 (Fig. 10), application of the active,
bound fraction from the/?-aminobenzamidine-Sepharose column (Section 3.5) to Q-Sepharose
at pH 8 resulted in the Cbz-Arg-Arg-AMC activity binding to the column (Fig. 12). This
activity was eluted at approximately 400 mM NaCl.
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3.11.5 Poly-(L-Iysine)-Sepharose chromatography
Application of the active fraction from Q-Sepharose chromatography at pH 8 (Section 3.6) to
a poly-(L-lysine)-Sepharose column resulted in strong binding of the Cbz-Arg-Arg-AMC
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Figure 12. Anion-exchange chromatography of OP-Tb on Q-Sepharose at pH 8. Q-Sepharose (26 x
100 mm, 1 ml.min'1) was equilibrated in buffer B [50 mM Tris-Cl, 1 mM dithiothreitol, 0.02% (m/v) NaN3,
pH 8]. After elution of unbound protein, bound protein was eluted with a linear gradient ( ) of 0.1-1 M NaCl



















Figure 13. Affinity chromatography of OP-Tb on po!y-(L-lysine)-Sepharose. poly-(L-lysine)-Sepharose (90
x 15 mm, 1 ml.min'1) was equilibrated in buffer B [50 mM Tris-Cl, 1 mM dithiothreitol, 0.02% (m/v) NaN3,
pH 8]. After elution of unbound protein, bound protein was eluted with a linear gradient (••••) of 0.1-1 M NaCl
in buffer B over 5 column volumes. (—) A^o, (-D-) enzyme activity against Cbz-Arg-Arg-AMC.
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3.11.6 Sephacryl S-100 HR chromatography
Cbz-Arg-Arg-AMC activity was eluted in a single peak from a Sephacryl S-100 HR molecular
exclusion column (Fig. 14), well resolved from low molecular mass material which eluted at
approximately Vt. Calibration of the column (Section 2.5.2) revealed that the






Figure 14. Molecular exclusion chromatography of OP-Tb on Sephacryl S-100 HR. Sephacryl S-100 HR
(900 x 15 mm, 4°C, 0.32 ml.min"1) was equilibrated in buffer B [50 mM Tris-Cl, 1 mM dithiothreitol, 0.02%
(m/v) NaN3, pH 8], Sample (200 ul) was loaded, and protein eluted with buffer B. ( ) A280, (•••••) enzyme
activity against Cbz-Arg-Arg-AMC.
3.12 Evaluation of purification
Evaluation of sample purity by Tris-Tricine SDS-PAGE is illustrated in Fig. 15, on which the
active enzyme fraction from Sephacryl S-100 HR chromatography (Section 3.11.6; Fig. 14)
gives rise to a single band at approximately 80 kDa. This estimated molecular mass compares
well with that of potentially related enzymes from E. coli (82 kDa; Kanatani et al, 1991) and
T. cruzi (80 kDa; Burleigh et al, 1997). A purification table for the isolation of OP-Tb is
presented as Table 6. OP-Tb was isolated from T. b. brucei lysates in a six-step procedure
with a 28% yield.
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Figure 15. Evaluation of OP-Tb purification by Tris-Tricine SDS-PAGE. (a) molecular mass markers (as
in Section 2.7.1.1); (b) Sephacryl S-100 HR active pool (200 ng). Samples were resolved by reducing Tris-
Tricine SDS-PAGE (Section 2.7.1) and protein visualised by silver staining (Section 2.7.4).
3.12.1 Active-site titration
When a solution of enzyme containing 10 (ig of OP-Tb was incubated with the MUGB,
51 pmoles of 4-methylumbelliferone was liberated. As the number of moles of
4-methylumbelliferone liberated is equivalent to the number of moles of active enzyme, it
follows that there are 51 pmole of active enzyme in 10 |ig of the OP-Tb sample. Assuming a
Mr of 80 kDa, and assuming one active-site per enzyme, 51 pmoles is equivalent to a mass of
4.08 u.g of active OP-Tb. The OP-Tb preparation was therefore 40.8% active.
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3.12.2 N-terminal and amino acid analysis
N-terminal analysis of OP-Tb revealed that the enzyme was N-terminally blocked and it was
therefore not possible to determine the N-terminal sequence. However, an amino acid analysis
was obtained for the enzyme, and is illustrated in Table 7, along with the amino acid analyses
of two other trypsin-like serine oligopeptidases, for comparison. The amino acid composition
of OP-Tb was from the analysis of a protein sample, while the composition of the T. cruzi and
E. coli enzymes was from deduced amino acid sequences obtained from their genes. Hence, no
values for methionine, tryptophan and cysteine were obtained for the OP-Tb enzyme.
















































































"Composition of OP-Tb was from amino acid analysis of a protein sample, while the composition of the T. cruzi
and the E. coli enzymes is from deduced amino acid sequences from their respective genes. Hence, no values
for methionine, tryptophan and cysteine were obtained for the OP-Tb enzyme.
6 After Burleigh et al. (1997).
eAfter Kanatani et al. (1991).
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Internal sequences were obtained for OP-Tb by digestion of the enzyme with endoproteinase
Lys-C (E.C. 3.4.99.30). The resultant OP-Tb-derived peptides were resolved by reverse-phase
high-performance liquid chromatography (RP-HPLC), and the individual peptides subjected to
N-terminal sequencing. Three OP-Tb-derived peptides were obtained from endoproteinase
Lys-C digestion, and the sequences of all three peptides displayed homology to the primary












































































































Figure 16. Sequences of OP-Tb-derived peptides. OP-Tb was cleaved with endoproteinase Lys-C, and the
resultant peptides were resolved by reverse-phase high-performance liquid chromatography. Peptides
sequences were obtained from N-terminal sequencing of the individual peptides. Sequences from the T. b.
brucei enzyme were compared with those from T. cruzi oligopeptidase B (Burleigh et al, 1997), E. coli
oligopeptidase B (Kanatani et al, 1991) and M. lacunata oligopeptidase B (Yoshimoto et al, 1995). The first
residue in each T. b. brucei-derived peptide is assumed to be lysine and is therefore shown in italics.
3.13 Discussion
OP-Tb was purified to electrophoretic homogeneity for the first time in this study from T. b.
brucei lysates in a six-step procedure with a 28% yield. A most useful step in the procedure
was the crude fractionation of trypanosome lysates by TPP. OP-Tb activity was precipitated in
the 10-25% (NH4)2SO4 cut. This activity co-precipitated with that of the major cysteine
proteinase of T. b. brucei, trypanopain-Tb. This was fortuitous as it permitted the simultaneous
purification of the two enzymes studied in our laboratory from the same starting material. Due
to the difficulty in obtaining sufficient starting material, an effort was made to co-purify the
two proteinases from the same limited starting material. For this reason, the first two steps of
the OP-Tb purification were performed at pH 5.5, at which trypanopain-Tb is most stable.
Although this pH had no direct adverse affects on OP-Tb, it was found that trypanopain-Tb
degraded OP-Tb resulting in a lower yield (results not shown). The next step in the
purification was therefore designed to rapidly separate these two proteolytic activities.
The two activities were completely separated by anion-exchange chromatography on
Q-Sepharose at pH 5.5. Trypanopain remained bound to the column while OP-Tb eluted in
the unbound fraction. Despite the fact that there was no evident increase in the specific
activity of OP-Tb (Table 6), this was an essential step as it removed all contaminating
trypanopain-Tb early in the purification scheme with only a small loss in yield (3%). This
behaviour on Q-Sepharose may be explained in terms of the isoelectric point of OP-Tb.
Kornblatt et al. (1992) suggested a pi of 5.1 for this enzyme and OP-Tb is thus not expected
to bind this matrix at pH 5.5. In contrast, trypanopain-Tb was reported to bind quarternary
amine resins at pH 5.5 (Troeberg et al, 1996). Therefore, anion-exchange chromatography at
pH 5.5 provided a convenient means of purifying the two enzymes to be purified from the
same trypanosome preparation.
Due to the trypsin-like specificity of the enzyme, where cleavage occurs preferentially after
arginine and lysine residues, the arginine analogue, /?-aminobenzamidine, was selected as an
affinity ligand for the next step in the purification. OP-Tb bound weakly to
/?-aminobenzamidine-Sepharose, and was eluted at 250 mM NaCl, resulting in a 30-fold
increase in the specific activity of the active fraction. Unfortunately, the weak affinity of
OP-Tb for the matrix did not permit the loading or washing of the column with a high-salt
buffer. Consequently, the /?-aminobenzamidine-Sepharose also acted as an ion-exchange
column, and many protein contaminants were eluted with the bound, active pool. A small
amount of activity against Cbz-Arg-Arg-AMC was evident in the unbound
/7-aminobenzamidine-Sepharose fraction. This activity did not bind the affinity matrix after
repeated passage over the matrix, or over unused matrix, and resulted in a loss of 16% of the
activity. This activity was therefore attributed either to an altered or complexed form of
OP-Tb which could not bind to the matrix, or to another proteinase with activity against
Cbz-Arg-Arg-AMC. The pro-protein convertases (Lazure et al, 1983; reviewed by
Nakayama, 1997) and the proteasome (Hua et al, 1996; Lomo et al, 1997) are potential
candidates.
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A 68 kDa protein proved to be a persistent contaminant throughout the purification. This
contaminant was identified by N-terminal analysis as rat serum albumin. Although
chromatography on Cibacron Blue F3GA-Sepharose is a conventional method of removing
albumin from protein preparations (Travis et al, 1976), this method did not successfully
remove all of the contaminating albumin from OP-Tb preparations (results not shown). This is
explained by the observation of Naval etal. (1982) that while Cibacron Blue F3GA-Sepharose
binds up to 100% of human serum albumin, it will only bind up to 80% of the albumin present
in rat sera. Hydrophobic chromatography on phenyl-Sepharose, another frequently used
method for removing albumin (Belew et al, 1985) could not be employed as OP-Tb eluted
from phenyl-Sepharose at the same salt concentration as albumin (results not shown). The
observation that polyamines influence the activity of OP-Tb (Section 5.11.7, Table 12)
suggested that a polyamine affinity matrix may be useful in the affinity chromatography of OP-
Tb. Therefore, the bound active fraction from Q-Sepharose at pH 8 was applied to a
poly-(L-lysine)-Sepharose affinity matrix. OP-Tb bound relatively strongly to this matrix,
eluting at 450 mM NaCl, successfully separating the enzyme from albumin and a number of
other protein contaminants which were eluted in the unbound fraction. Molecular exclusion
chromatography on Sephacryl S-100 HR successfully removed the remaining protein
contaminants, and desalted the OP-Tb preparation. The resultant protein preparation was
homogenous by SDS-PAGE (Fig. 15), yielding a single band at approximately 80 kDa.
Active-site titration of the purified enzyme with MUGB revealed that the enzyme preparation
was 40.8% active. The addition of dithiothreitol to the chromatography buffers considerably
(10-fold) enhanced the final yield of enzyme, and it is possible that during the isolation
procedure an essential thiol group is oxidised by oxidising agents present in the isolation
reagents or liberated from the trypanosomes when they are ruptured. This may account, in
part, for the reduced activity of the preparation. This hypothesis is supported by enzymatic
studies with OP-Tb, which have revealed that OP-Tb activity is enhanced by reducing agents
(Section 5.11.4, Fig. 31). Furthermore, thiol-blocking reagents irreversibly extinguished the
activity of the enzyme (Section 5.11.6, Table 11), suggesting an essential free thiol group near
the active site which must be maintained in its reduced state if the enzyme is to retain its
activity.
70
N-terminal analysis of OP-Tb revealed that this enzyme had a blocked N-terminus. N-terminal
blocking is a common phenomenon amongst cytosolic proteins (Brown and Roberts, 1976).
Matheson et al. (1995) isolated an oligopepidase from P. velutina pollen which was also
N-terminally blocked. However, the N-terminal sequences of a number of bacterial
oligopeptidases have been obtained, including those from E. coli (Kanatani et al, 1991),
M. lacunata (Yoshimoto et al, 1995) and F. meningicoseptum (Yoshimoto et al, 1991). It
would therefore appear that the N-termini of prokaryotic oligopeptidases are not blocked.
Sequences was obtained, however, for three peptides obtained from OP-Tb, following
incubation with endoproteinase Lys-C. All three peptides displayed homology to the primary
sequences of oligopeptidase B from T. cruzi, and to a lesser degree, to the primary sequences
of oligopeptidase B from E. coli and M. lacunata. These data suggest that OP-Tb is indeed a
member of the prolyl oligopeptidase family of serine proteases, to which the oligopeptidase B
enzymes belong (Barrett and Rawlings, 1995). This can only be confirmed when the entire
OP-Tb sequence is known.
OP-Tb had approximately four-fold less phenylalanine residues, and twice as many valine
residues as potentially related enzymes from T. cruzi and E. coli (Table 7). In contrast, there
was approximately the same number of histidine, lysine and isoleucine residues in all three
enzymes. While amino acid analysis data were not particularly useful on their own, they did
assist in the interpretation of inhibition data for polysulfated naphthylamine inhibitors of OP-
Tb, which bind to basic residues in proteolytic enzymes (Section 7.6.1).
The purification of OP-Tb to electrophoretic homogeneity facilitated the generation of
polyclonal antibodies against OP-Tb which allowed the immunoaffinity purification of a related
enzyme from T. congolense (Chapter 4). Following the purification of these enzymes they
were comprehensively characterised (Chapter 5), which further facilitated investigations into
how the enzyme may contribute to the pathogenesis of African trypanosomiasis through its
interaction with host molecules (Chapter 6). The purification of these enzymes also allowed





As a result of the high degree of specificity of an antibody for its antigen, antibodies are
extremely useful reagents for detection of specific molecules. This lends itself to a variety of
biological applications. Indeed, antibodies are exploited in many situations. In medicine for
sero-diagnostics and immunotherapy, in research for immunoaffinity purification and in
immunocytochemistry for localisation of intracellular compounds. It was thus desirable to
generate antibodies against OP-Tb.
It is generally accepted that parasitaemia is controlled by anti-VSG antibody responses,
stimulated in response to each new VSG variant (reviewed in Roelants and Pinder, 1984).
Following antibody-mediated destruction of parasites, a wide variety of invariant antigens are
released, and it has been suggested that these antigens may be involved in producing the
pathology associated with the disease (discussed in Chapter 6; Mansfield, 1990). It has been
proposed for malaria that immune recognition of such parasite "toxins" could protect the host
against the pathological effects of infection (Playfair et al, 1990). The cysteine proteinases of
parasitic protozoa and helminths are known to be antigenic in human infections. Sera from
patients with chronic Chagas' disease contain anti-cruzipain antibodies (Martinez et al, 1991),
and IgGi and IgG4 antibodies are generated against schistosome cathepsins B and L in
Schistosoma mansoni-infected hosts (Grogan et al, 1997). Such antibodies may have an
immunoprotective function, as immunisation with cruzipain enhanced the percentage survival
of mice subsequently challenged with 103 trypomastigotes (Laderach et al, 1996).
Boran cattle (Bos indicus), which represents the vast majority of cattle in Africa, are highly
susceptible to trypanosomiasis, whilst N'Dama cattle (Bos taunts) are known to be resistant or
"trypanotolerant" (Roelants, 1986). Trypanotolerance is defined as the genetically determined
ability to limit the multiplication of the parasite and to resist the pathogenic effects of infection
(reviewed by Trail et al, 1989). Although the mechanisms of trypanotolerance are not
understood, an effective immune response to invariant trypanosome antigens may be an
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important mechanism of resistance to the disease. In support of this, the antibody response to
two trypanosome invariant antigens, with molecular masses of 69 and 33 kDa, appeared to
correlate with trypanotolerance (reviewed by Authie, 1994; Authie et al, 1994). Gene
sequence analysis revealed that the 69 kDa antigen is homologous to the mammalian
immunoglobulin heavy-chain-binding protein (BiP) (Boulange and Authie, 1994). The 33 kDa
antigen has been identified as congopain, the major lysosomal cysteine proteinase of
T. congolense (Authie et al, 1992; 1993a). N'Dama cattle have a considerably elevated IgGi
response to both antigens as well as other antigens, when compared to Boran cattle, while
there is little difference in the IgM profiles of both species (Authie et al, 1993b). Such
antigens may provide a basis for an anti-trypanosome vaccine, and it was therefore of interest
to determine whether infected bovine hosts generate antibodies to trypanosome
oligopeptidases, and furthermore, whether the generation of anti-oligopeptidase antibodies
correlates with natural resistance to trypanosome infections.
In the present study, antibodies were raised in chickens against OP-Tb (Section 4.2), antibody
production was monitored by enzyme-linked immunosorbent assay (ELISA, Section 4.3), and
antibody specificity was determined by western blotting (Section 4.4). The effects of the
anti-OP-Tb antibodies on the activity of OP-Tb (Section 4.5) and on live T. b. brucei
(Section 4.6) were also investigated, as was their potential use for the purification of a
trypanosome oligopeptidase from T. congolense. Finally, the generation of anti-oligopeptidase
antibodies in T. congolense-infected hosts was investigated (Section 4.7).
4.2 Production of anti-OP-Tb antibodies
Chickens are highly suitable experimental animals for the production of polyclonal antibodies
(Poison et al, 1980a). Chickens are easily handled, have a very accessible immunisation site
on the breast muscle, and conveniently package large quantities of antibodies in their egg-
yolks, from which the antibody fraction is easily isolated (Poison et al, 1980b, 1985).
Generally, the larger the immunogen, the more immunogenic it is (Catty and Raykundalia,
1988), and no problems were therefore anticipated, or encountered, in preparing antibodies
against the 80 kDa OP-Tb.
4.2.1 Materials
100 mM sodium phosphate buffer [100 mM sodium phosphate. 0.02% (m/v) NaN^. pH 7.6],
NaH2PO4.H2O (13.8 g) and NaN3 (0.2 g) were dissolved in dH2O (950 ml), titrated to pH 7.6
with NaOH, and made up to 1 litre.
4.2.2 Method
Chickens were immunised by intramuscular injection, at two sites in the breast muscle, with a
total of 20 |ig OP-Tb emulsified in a 1:1 (v/v) ratio with adjuvant. Chickens were boosted at
3, 7, and 11 weeks after the first immunisation, with 10 ug of OP-Tb per booster. The initial
immunisation was done with OP-Tb emulsified in FCA, and subsequent immunisations with
OP-Tb emulsified in FIA. Chicken eggs were collected on a daily basis.
Chicken egg-yolk antibodies (IgY) were isolated by a method adapted from those of
Poison etal. (1980a) and Poison et al. (1985). Yolks were separated from the egg-white and
washed carefully under running water to remove as much egg-white as possible. The yolk sac
was punctured, and the yolk volume determined in a measuring cylinder. Two volumes of 100
mM sodium phosphate buffer were added to the yolk, and mixed thoroughly. Solid PEG 6 000
was added to 3.5 % (m/v) (i.e. 3.5 g per 100 ml yolk-buffer suspension), and dissolved by
gentle stirring. The precipitated vitellin fraction was removed by centrifugation (4 420 x g,
30 min, RT), and the supernatant filtered through absorbent cotton wool to remove the lipid
fraction. The PEG concentration was brought to 12% (m/v) (i.e. 8.5 g PEG 6 000 was added
per 100 ml supernatant), and dissolved by gentle stirring. The suspension was centrifuged
(12 000xg, 10 min, RT) to pellet the IgY-containing precipitate, and the supernatant was
discarded. The precipitate was redissolved in 100 mM sodium phosphate buffer, in a volume
equal to the volume obtained after filtration, and the IgY fraction was re-precipitated by the
addition of PEG 6 000 to 12% (m/v), which was dissolved by gentle stirring. The IgY fraction
was pelleted by centrifugation (12 000 x g, 10 min, RT), and the supernatant discarded. The
pellet was redissolved in 1/6 of the original egg-yolk volume in 100 mM sodium phosphate
buffer, and stored at 4°C. Antibody concentrations were determined directly from the A280 of
the IgY preparations in 100 mM sodium phosphate buffer, as described in Section 2.2.2.3,
using an IgY extinction coefficient of 1.25 (mg.mr'yVcm'1 (Coetzer, 1985).
4.3 Enzyme-linked immunosorbent assay
Antibody production in experimental animals is conveniently monitored by ELISA, originally
introduced by Engvall and Perlmann (1971), as this assay is highly sensitive and is surpassed
only by radioimmunoassays (Butler, 1980). Briefly, antigen is coated to the plastic surface of
the wells of polystyrene microtitre plates, and the primary antibodies to be quantified are
incubated with the insolubilised antigen, and residual primary antibody washed away. Non-
ionic detergents such as Tween® 20 are usually included in the washing solution to prevent any
non-specific protein interactions. After excess antibody has been washed away, a secondary
antibody, raised against the primary antibody, to which a marker enzyme has been conjugated,
is added to the wells of the microtitre plate (Clarke and Engvall, 1981). This "sandwich" has
the added advantage of amplifying the response, as more than one secondary antibody, and
hence more reporter enzyme, may bind to a single primary antibody. The enzyme reacts with a
substrate which yields a soluble, coloured, reaction product, which can be quantified
spectrophotometrically (Kemeny and Chantler, 1988). In the present study, horseradish
peroxidase (HRPO) (EC 1.11.1.7) was employed as the reporter enzyme, and
2,2'-azinobis[3-ethyl-2,3-dihydrobenzthiazole-6-sulfonate] (ABTS) was used as the substrate.
ELISAs were employed in the present study to evaluate the production of polyclonal
antibodies generated against OP-Tb in chickens during the immunisation programme.
4.3.1 Materials
Phosphate buffered saline fPBSl pH 7.2. NaCl (8 g), KC1 (0.2 g), Na2HPO4.2H2O (1.15 g)
and KH2PO4 were dissolved in dH2O (950 ml), titrated to pH 7.2, and made up to 1 litre.
0.5% (m/v) Bovine serum albumin in PBS fBSA-PBS). BSA (0.5 g) was dissolved in PBS
(100 ml).
0.1% Tween® in PBS (PBS-Tween). Tween® 20 (1 ml) was made up to 1 litre in PBS.
0.15 M citrate-phosphate buffer. pH 5.0. A 0.15 M solution of citric acid.H2O (21.0 g.l'
1) was
titrated with a 0.15 M solution of Na2HPO4.2H2O (35.6 g.l"
1) to pH 5.0.
Substrate solution [0.05% (m/v) ABTS and 0.0015% (v/v) H?O? in citrate-phosphate buffer].
ABTS (7.5 mg) and H2O2 [7.5 jo.1 of a 30% (v/v) solution] were dissolved in citrate-phosphate
buffer, pH 5.0 (15 ml).
Stopping buffer [0.1% (m/v) NaN^ in citrate-phosphate buffer. pH 5.0]. NaN3 (0.1 g) was
made up to 100 ml in citrate-phosphate buffer, pH 5.0.
4.3.2 Method
Nunc Immuno F polystyrene microtitre plates were coated with antigen (1 (J.g.ml"1, 100 (j.1 per
well) in PBS overnight at 4°C. Uncoated areas of wells were blocked with BSA-PBS (200 \x\
per well) for 1 h at 37°C and washed 3 times with PBS-Tween. Appropriate dilutions of
primary chicken antibodies in BSA-PBS (1 mg.ml"1-! ug.ml'1) were added (100 u,l per well),
incubated for 1 h at 37°C and excess antibody removed by rinsing the wells with PBS-Tween
(3 x 200 ul). A 1:5 000 dilution of sheep anti-rabbit IgG-horseradish peroxidase (HRPO)
conjugate in BSA-PBS, was added (120 JJ.1 per well) and incubated for 1 h at 37°C. The
ABTS substrate (150 ul per well) was added and incubated in the dark for optimal colour
development (usually 10-20 min). The enzyme reaction was stopped by the addition of 0.1%
(m/v) NaN3 in citrate-phosphate buffer (50 ul per well) and the absorbance determined at
405 nm in a Bio-Tek EL307 ELISA plate reader.
4.4 Western blotting
Western blotting is a convenient means of determining the specificity of an antibody
preparation. Western blotting entails the electroblotting of a purified protein or a complex
protein mixture, resolved by SDS-PAGE, onto an insoluble matrix such as nitrocellulose
(Towbin et ah, 1979). Unoccupied protein binding sites are blocked non-specifically with low-
fat milk or BSA, after which the blot is probed with antibodies raised against the proteins of
interest (the primary antibody). Antigen-antibody complexes are visualised with a secondary
antibody directed against the primary antibody, and conjugated to a reporter enzyme, which
catalyses a reaction that leads to the deposit of an insoluble, coloured, product at the site of the
reaction (Wilson and Goulding, 1986). In the present study, an alkaline phosphatase (AP)
(EC 3.1.3.1) reporter enzyme was employed, using 5-bromo-4-chloro-3-indolyl phosphate
(BCD5) and nitroblue tetrazolium (NBT) as substrates (Mclnnes and Symons, 1989).
The method used in the present study is essentially the same as that of Towbin et al. (1979),
with the exception that proteins were electroblotted with Caps buffer (pH 11) instead of Tris-
glycine blotting buffer (pH 8.3) (Section 2.7.5). In the present study, western blotting was
employed to determine the specificity of antibodies raised against purified OP-Tb, and to
investigate whether infected hosts generate their own antibodies against trypanosome
oligopeptidases.
4.4.1 Materials
Tris-buffered saline (TBS. 20 mM Tris-Cl. 200 mM NaCl. pH 7.41 Tris (2.42 g) and NaCl
(11.7 g) were dissolved in dH2O (950 ml), adjusted to pH 7.4 with HC1 and made up to 1 litre.
0.5% fm/v) BSA-TBS. BSA (0.5 g) was dissolved in TBS (100 ml).
Substrate [100 mM Tris-Cl. 0.15 mg.mr1 BCIP. 0.3 mg.ml'1 NBT. 5 mM MgClV]. Substrate
was obtained pre-mixed in tablet form from Sigma. One tablet was dissolved in dH2O (10 ml).
0.1% (m/v) Ponceau S. Ponceau S (0.1 g) was dissolved in 1% (v/v) glacial acetic acid.
4.4.2 Method
Purified proteins or complex protein mixtures were resolved by Tris-Tricine SDS-PAGE
(Section 2.5.2) and electroblotted to nitrocellulose membranes (Section 2.5.6). Following
electrotranfer of proteins, the nitrocellulose sheet was briefly rinsed with dlfeO ( 2 x 1 min) air-
dried overnight, transiently stained with Ponceau S (30 sec), and rinsed in dH2O to remove
background stain. Positions of Mr standards were marked on the nitrocellulose in pencil, and
the blot completely destained by the addition of a few drops of 500 mM NaOH to the dH2O.
Unoccupied protein binding sites were blocked by incubating the nitrocellulose strips in 0.5%
(m/v) BSA-TBS (1 h, RT). The blot was washed with TBS ( 3 x 5 min), incubated with an
appropriate dilution of anti-OP-Tb IgY in 0.5% (m/v) BSA-TBS (2 h, RT), rinsed with TBS
( 3 x 5 min) and incubated with a 1:20 000 dilution of rabbit anti-chicken IgY-AP conjugate in
0.5% (m/v) BSA-TBS. Excess conjugate was removed by rinsing with TBS ( 3 x 5 min), after
which the blots were immersed in BCIP/NBT substrate solution and allowed to react in the
dark until dark bands were evident against a lightly-stained background. The reaction was
terminated by washing the blots in dt^O and drying them between sheets of filter-paper.
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4.5 Inhibition of OP-Tb activity by anti-OP-Tb antibodies
4.5.1 Method
Inhibition of the OP-Tb-catalysed hydrolysis of Cbz-Arg-Arg-AMC by anti-OP-Tb antibodies
was evaluated using assays essentially as described in Section 2.3.2. OP-Tb (^20 ng in 10 ul,
0.1 pmole, active concentration) was diluted with Brij 35 to 500 ul, and added to antibody
solution (1 mg.ml"1, 500 ul, yielding a final antibody concentration of 500 ug.ml'1). This
mixture was incubated at 37°C for 10 min, after which an aliquot (500 ul) was removed, and
pre-incubated with 4 x assay buffer (250 ul, 37°C, 10 min), prior to the addition of substrate
(250 ul). Change in fluorescence was monitored continuously for 5 min at 37°C
(Section 2.3.2). Strongly inhibitory antibodies were titrated out in the same way, except that
serial two-fold dilutions of antibody preparations replaced the 1 mg.ml'1 antibody solution.
4.6 Effects of antibodies on trypanosomes in culture
In order to determine whether anti-OP-Tb antibodies had any affect on live trypanosomes,
trypanosomes were cultivated in the presence and absence of the week 13 anti-OP-Tb
antibodies, which demonstrated the greatest effect on OP-Tb activity (Section 4.9.3, Fig. 19).
Cell culture was undertaken in two different media: one containing heat-inactivated FCS, and
another containing native FCS, to explore the effect of active complement components on
parasite health. Cell culture was undertaken and parasite numbers determined essentially as
described in Section 2.8.2.
4.7 Immunoaffinity purification of OP-Tc
The generation of antibodies to OP-Tb (Section 4.9.1), and their demonstrated cross-reactivity
with a related enzyme from T. congolense (Section 4.9.2, Fig. 18) suggested that they may be
useful tools for the immunoaffinity purification of such an enzyme from T. congolense lysates.
The diseases caused by the humoral (T. &rwce/-subgroup) and the haematic (T. congolense-
subgroup) trypanosomes have considerably different pathologies (Section 1.1.6). Since we are
investigating potential roles played by trypanosome oligopeptidases in the pathogenesis of
African trypanosomiasis, it was interesting to compare the enzymatic characteristics of
oligopeptidases from both humoral and haematic trypanosomes. This necessitated the
purification of the related oligopeptidase from T. congolense, which we have called OP-Tc.
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4.7.1 Materials
2 M Na9C(X Na2CO3 (21.19 g) was dissolved in dH2O (100 ml).
1 M ethanolamine-Cl. pH 8.0. Ethanolamine (6.06 ml) was diluted in dH2O (80 ml), titrated to
pH 8.0 with HCl and made up to 100 ml.
Coupling buffer HOP mM NaHCCh. 500 mM NaCl. pH 8.3V Na2CO3 (5.3 g) and NaHCO3
(4.2 g) were each dissolved separately with NaCl (14.61 g) in dH2O (500 ml). The NaHCO3
solution (250 ml) was titrated against the Na2CO3 solution to pH 8.3.
Cyanogen bromide (1 g.ml'1). CNBr (10 g) was dissolved in acetonitrile (10 ml).
Elution buffer [3.5 M NaSCN], NaSCN (7.1 g) was dissolved in loading buffer (25 ml).
Loading buffer [50 mM Tris-Cl. 1 M NaCl. 10 mM CaCk 0.5% (m/v) Brij-35. 0.02% (m/v)
NaN.. pH 7.4]. Tris (6.06 g), NaCl (58.44 g), CaCl2 (1.47 g), Brij-35 (5 g) and NaN3 (0.2 g)
were dissolved in dH2O (950 ml), titrated to pH 7.4 with HCl and made up to 1 litre.
Wash A C200 mM NaHCCk pH 9.6V A 200 mM NaHCO3 solution (100 ml) was titrated
against the a 200 mM Na2CO3 solution to pH 9.6.
Wash B riOO mM NaHCCk pH 9.2V A 100 mM NaHCO3 solution (100 ml) was titrated
against a 100 mM Na2CO3 solution to pH 9.2.
4.7.2 Preparation of immunoaffinity matrix
Wet Sepharose-4B (15 ml, packed gel volume) was washed in a Biichner funnel with dH2O,
allowed to settle in a small (50 ml) beaker and the supernatant solution aspirated off. Distilled
H2O (15 ml) and 2 M Na2CO3 (30 ml) were added to the gel, and the slurry was put on ice
under a fume-hood and slowly mixed with a magnetic stirrer. Once the slurry had cooled, the
rate of stirring was increased and the CNBr solution in acetonitrile (2 ml) added, all at once.
The slurry was stirred quickly (2 min), transferred to a Biichner funnel and washed
successively with 100 ml each of dH2O, wash A and wash B.
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Anti-OP-Tb IgY (15 mg) was dissolved in coupling buffer (10 ml), and dialysed against
coupling buffer (100 ml, 16 h, 4°C). The activated Sepharose-4B (10 ml) was resuspended in
coupling buffer (10 ml) to which the anti-OP-Tb solution (10 ml) was added, and the
suspension was mixed in an end-over-end mixer (24 h, 4°C). To determine coupling efficiency,
the A280 was determined for the solution before and after coupling. After coupling, free
reactive sites on the activated Sepharose were blocked by the addition of 1 M ethanolamine-Cl,
pH 8 (10 ml) for 2 h at RT. Coupling efficiency was estimated at 96.7%. Ethanolamine and
ionically-bound ligand were removed from the affinity matrix with alternate washes of loading
buffer and elution buffer.
4.7.3 Purification procedure
Parasites (T. congolense strain IL3000) were grown in rats and harvested exactly as described
in Section 3.2. For purification purposes, lysates (6.7 x 109 cells) were subjected to three
preliminary clean-up steps before immunoaffinity chromatography. These steps included three-
phase partitioning, ion-exchange chromatography on Q-Sepharose, and affinity
chromatography on p-aminobenzamidine-Sepharose, all performed exactly as described in
Sections 3.3, 3.4 and 3.5 respectively. The resultant active fraction from/?-aminobenzamidine-
Sepharose (22 ml) was dialysed against loading buffer (250 ml, 8 h, 4°C), and loaded onto the
anti-OP-Tb immunoaffinity column (50 x 15 mm, 0.32 ml.min'1). After elution of unbound
proteins, the column was washed with loading buffer, after which bound, active, material was
eluted with elution buffer. Thiocyanate was removed by dialysis against buffer B
(Section 3.4.1), and protein concentrated by ultrafiltration (Section 2.6.1).
4.8 Do trypanosome-infected hosts produce anti-oligopeptidase antibodies?
In order to investigate the vaccine potential of trypanosome oligopeptidases, and whether or
not the immunogenicity of these oligopeptidases is related to trypanotolerance, the sera of
infected trypanosusceptible and trypanotolerant bovine hosts were analysed for anti-
oligopeptidase antibodies. Due to the paucity of the material, only T. congolense-infected
material was screened.
4.8.1 Materials
Extravidin^-AP conjugate working solution. Extravidin®-AP conjugate obtained from Sigma
(St. Louis, USA) was diluted 1:50 000 with 0.5% (m/v) BSA in TBS prior to use.
Primary antibodies. Chronically infected Boran and N'Dama sera were obtained from Dr. Edith
Authie, International Livestock Research Institute, Nairobi, Kenya.
Secondary antibodies. Monoclonal anti-bovine IgM clone BM-23-biotin conjugate and rabbit
anti-bovine IgG-alkaline phosphatase conjugate were obtained from Sigma (St. Louis, USA).
4.8.2 Method
Trypanosome lysates and purified OP-Tb were subjected to western blotting (Section 4.4) and
probed using infected bovine serum as a source of primary antibody. As whole serum was
employed as a source of primary antibody, the precise antibody concentration could not be
determined. Whole bovine serum is estimated to contain 12 mg.ml"1 IgG, and 1 mg.ml'1 IgM
(Altman and Dittmer, 1961). Thus, infected sera was diluted to give an estimated 100 ug.ml'1
when used as a source of primary antibody. As mild increases (10%) in IgG levels (Clarkson
and Penhale, 1973) and considerable increases (400%) in IgM levels (Nielsen et al, 1978) of
T. congolense-'mfected animals have been reported, this is a very approximate estimate. The
IgG antibodies in infected sera were then detected employing rabbit anti-bovine IgG-alkaline
phosphatase conjugate at a 1:30 000 dilution as described in Section 4.4.2. The IgM
antibodies in infected sera were detected in a two-step procedure. Blots were first incubated
with monoclonal mouse IgGi anti-bovine IgM clone BM-23-biotin conjugate (1:30 000
dilution, 2 h, RT), after which the blots were washed with TBS ( 3 x 5 min), incubated with
extravidin-AP conjugate working solution (2 h, RT), rinsed with TBS (3x5 min) and
developed as described in Section 4.4.2.
4.9 Results and discussion
4.9.1 Enzyme-linked immunosorbent assay
Antibody production monitored by ELISA (Section 4.3) showed an increasing antibody
response over the immunisation period. Week 13 antibodies gave the highest response when
compared to the pre-immune antibodies, and the titre was estimated at approximately
75 u-g-ml"1 (Fig. 17). Titre is defined in the present study as the lowest antibody concentration
yielding a significant A^f (~0.3 absorbance units) relative to pre-immune antibodies at the
same concentration. The week 13 antibodies were used in western blots (Section 4.9.2) and
for immunoaffinity purification of the oligopeptidase from T. congolense. Only 50 ug in total
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of the OP-Tb immunogen was used to elicit a very good immune response. This suggests that
the parasite enzyme is highly immunogenic in the avian immune system, resulting in high titre
antibodies suitable for further application (e.g. cross-reactivity studies).
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Figure 17. Monitoring of chicken anti-OP-Tb antibody production by ELISA. Microtitre plates were
coated with OP-Tb at 1 ug.ml'1 and incubated with dilutions of pre-immune IgY (-O-); IgY from week 4
( - • - ) ; 8 (-•—) and 13 ( - • - ) after the start of the immunisation programme. Binding of antibodies was
visualised by incubation with HRPO-linked secondary antibodies, followed by ABTS/H2O2 substrate
(Section 4.3.2). Each point is the mean absorbance at 405 nm of duplicate samples.
4.9.2 Western blotting
Antibody specificity was determined by western blotting (Section 4.4). Week 13 antibodies
targeted single bands in T. b. brucei lysates and in a purified OP-Tb preparation. Furthermore,
a single band was targeted in T. congolense lysate (Fig. 18).
The targeting of a single band in a T. b. brucei lysate on the western blot (Fig. 18a)
demonstrates the specificity of the antibody preparation for OP-Tb. Cross-reactivity of anti-
OP-Tb IgY with a protein in T. congolense lysates suggests the presence of a structurally
related enzyme in T. congolense, and raised the possibility of immunoaffinity purification of
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Figure 18. Characterisation of anti-OP-Tb antibodies by western blotting. Protein samples were resolved
by Tris-Tricine SDS-PAGE (Section 2.5.2) and electroblotted onto nitrocellulose (Section 2.5.6): (a) T. b.
brucei lysates (40 (xg); (b) purified OP-Tb (200 ng); (c) T. congolense lysates (100 ug); each incubated with
week 13 anti-OP-Tb IgY (75 ng.ml"1). (d) T. b. brucei lysates and (e) purified OP-Tb; incubated with pre-
immune IgY (75 \ig.ra\A). Antibody-antigen complexes were detected with an AP-linked secondary antibody
and BCIP/NBT substrate as described in Section 4.4.2.
It is interesting to compare the western blot data with that obtained from the active-site blots
(Section 7.6.3, Fig. 62). Active site blots of T. b. brucei lysates with biotin-ArgCJibCl
revealed three prominent high-molecular mass bands, at approximately 68, 80 and 100 kDa
(Fig. 62a). While the 80 kDa band is most probably attributable to OP-Tb, the identity of the
other two bands is problematic. It has been suggested that the 100 kDa band may represent a
complex of OP-Tb with a regulatory protein, although such complexes are usually non-
covalent and would not be stable to boiling in the presence of SDS. The absence of a
comparable band on the western blot (Fig. 18a) suggests that the protein labelled by biotin-
ArgCH2Cl at 100 kDa is not attributable to OP-Tb, and probably represents a different
protease with a similar substrate specificity. Similarly, no band was visible at 68 kDa on the
western blot (Fig. 18a). It has been suggested that the 68 kDa protein labelled by
biotin-ArgCH2Cl (Fig. 62a) may be due to a processed form of OP-Tb. The lack of
immunological reactivity at 68 kDa suggests that if the 68 kDa band on the active-site blot is
indeed a processed form of OP-Tb, this processing has destroyed the epitopes recognised by
the anti-OP-Tb antibodies. It is quite probable that the 68 kDa protein labelled on the active-
site blot represents a non-specific interaction with rat serum albumin, or a different protease.
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4.9.3 Evaluation of inhibition of OP-Tb activity by anti-OP-Tb antibodies
All antibody preparations from chickens immunised with OP-Tb demonstrated varying degrees
of inhibition of OP-Tb activity (Fig. 19). Inhibitory antibodies initially peaked at week 5, and
then peaked sharply again at week 13, two weeks after the third booster immunisation. Week
13 antibodies were strongly inhibitory, producing 92% inhibition of enzyme activity. By
definition, a polyclonal immune response entails the production of a heterogeneous antibody
population. These antibodies are produced by a population of B-cells, each B-cell clone
producing antibodies to a particular epitope. It is expected that only a proportion of B-cell
epitopes will elicit inhibitory antibodies. The initial fluctuation in inhibitory antibody titre over
the progression of the immunisation schedule may suggest that different B-cell clones are being
stimulated at different stages of the immunisation period. At week 13 there was a dramatic
increase in the level of inhibitory antibodies which may indicate maturation of antibody affinity
for the active-site epitopes as a result of repeated booster injections (Roitt, 1994). Week 13
antibodies were strongly inhibitory, and inhibitory activity was therefore titrated out (Fig. 20).
Half maximal inhibition occurred at approximately 7.5 ug.mr\ Maximal inhibition, producing
about 90% inhibition relative to controls containing pre-immune antibodies, was attained at an
antibody concentration of 250 ug.ml"1.
To date, the only other oligopeptidase for which inhibition by antibodies has been examined is
porcine prolyl oligopeptidase. Moriyama et al (1988) described the production of polyclonal
inhibitory antibodies in rabbits. Half-maximal inhibition of activity against Suc-Gly-Pro-AMC
was observed at rabbit IgG concentrations of 10 ug.ml"1. Maximal inhibition (95% of the
uninhibited controls) was obtained at IgG concentrations of 100 ug.ml"1.
The production of polyclonal inhibitory antibodies has been described for a number of
proteases, including human and ovine cathepsinL (Coetzer et al, 1991, Coetzer, 1992).
However, a much greater excess of antibody over enzyme (based on mass ratios) was required
in comparison to that required for the inhibition of OP-Tb (present study) or porcine prolyl
oligopeptidase (Moriyama et al, 1988). Coetzer (1992) reported that human cathepsin L
(25 ng) was still not fully inhibited in the presence of 1 mg of polyclonal anti-human
cathepsin L IgY.
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Similar results were obtained with polyclonal IgY raised against ovine cathepsin L where half-
maximal inhibition of cathepsin L (25 ng) was obtained in the presence of 250 ug of antibody.
This contrasts sharply with the 7.5 ug required to produce half-maximal inhibition of OP-Tb
for the same mass of protease. It should be stressed, however, that these figures do not
represent the molar ratio of active enzyme to antibody. It was not practical to calculate such a
value as the antibody preparations were not affinity purified, and active concentrations of
enzyme were not considered. Additionally, OP-Tb has a Mr approximately three times greater
than cathepsin L, and the same mass of protein would yield a lower molar concentration of
protease.
The active-sites of oligopeptidases are thought to be deeply buried in an active site "pit", as
opposed to the active site "cleft" for most other proteases (Barrett and Rawlings, 1992). This
introduces steric hindrance access by large peptides and proteins, and consequently, only
oligopeptides can gain access to the active-site and are hydrolysed. It follows therefore that a
single antibody blocking entry to the active-site pit would completely inhibit access to the
active site of the enzyme. For this reason, should the correct B-cell clone be stimulated,
polyclonal antibodies directed against oligopeptidases may be more strongly inhibitory than
antibodies directed against proteases, which have a more exposed active site.
The results of Moriyama et al. (1988) are also interesting as they report the production of
strongly inhibitory antibodies by a mammal, against a mammalian oligopeptidase, raising the
possibility that chronically infected mammalian hosts may produce antibodies, perhaps even
inhibitory antibodies, against OP-Tb. This would be extremely desirable in terms of host
defence, as OP-Tb activity has been detected in the bloodstream of infected animals (Section
6.8.4, Fig. 46), presumably being released into the bloodstream during complement-mediated
trypanosome-lysis. Circulating anti-OP-Tb antibodies could opsonise OP-Tb released into the
bloodstream, thereby hastening its removal from the bloodstream, and possibly inhibiting its
activity in the bloodstream, which would neutralise its contribution to disease pathogenesis.
For these reasons, the effects of anti-OP-Tb antibodies were examined for their effects on live
T. b. brucei in culture (Section 4.9.4) and the serum of infected bovine hosts was examined for
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Figure 19. Inhibitory activity of anti OP-Tb antibodies raised in chickens. OP-Tb (25 ng) was pre-
incubated in the presence of IgY (500 ug.mT1), and then assayed for activity against Cbz-Arg-Arg-AMC.
Percentage inhibition was calculated as the activity in the presence of week 13 IgY relative to the activity in the
presence of pre-immune IgY at the same concentration. Arrows (i) indicate administration of booster
immunisations. Error bars give the mean ± SEM (« = 3).
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Figure 20. Titration of inhibitory week 13 anti-OP-Tb IgY antibodies. OP-Tb (25 ng) was pre-incubated
with an appropriate dilution of IgY (0-1 mg.ml'1, 10 min), and then assayed for activity against
Cbz-Arg-Arg-AMC (Section 2.3.2). Percentage inhibition was calculated as the activity in the presence of
immune IgY relative to the activity in the presence of pre-immune IgY at the same concentration. Standard
deviations for the % inhibition were less than ±5% of the mean value.
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4.9.4 Effects of antibodies on trypanosomes in culture
Anti-OP-Tb antibodies had little effect on trypanosomes in culture. Trypanosomes cultured in
the presence of native (i.e. without prior heat-inactivation) FCS exhibited extremely poor
growth, while growth was satisfactory in the presence of heat inactivated FCS containing pre-
immune IgY. In the presence of the heat inactivated FCS, week 13 anti-OP-Tb IgY caused a
















Figure 21. Effect of anti-OP-Tb IgY antibodies on trypanosomes in culture. Trypanosomes were cultured
for 24 h in the presence of week 13 inhibitory anti-OP-Tb IgY (•) or in the presence of pre-immune IgY (•)
both at a concentration of 1 mg.ml'1. Parallel experiments were conducted in the presence of normal FCS
( ) and heat-inactivated FCS ( ). Error bars represent the mean ±SEM {n = 3).
Antibody-mediated cell-lysis is usually facilitated by an antibody binding to a surface antigen
on a cell, which then activates the classical pathway of complement activation (Joiner et al.,
1984). T. b. brucei and T. congolense are known to activate both the classical (Balber et al.,
1979) and alternative (Kierszenbaum and Weinman, 1977) complement pathways in vivo, and
the activation of the classical pathway, mediated by anti-VSG antibodies, is proposed to be the
primary means of parasite clearance from host tissues.
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It is possible that anti-OP-Tb antibodies may exert a trypanocidal effect in two ways. We have
detected OP-Tb-like activity in a membrane/cytoskeletal fraction of T. b. brucei
(Section 3.11.1, Fig. 9). Furthermore, live T. b. brucei are able to hydrolyse
Cbz-Arg-Arg-AMC (Section 6.8.5, Fig. 47), and this hydrolysis is blocked in the presence of
anti-OP-Tb antibodies (Section 6.8.5, Fig. 47).
Taken together, these data suggest the possibility of surface-membrane bound OP-Tb. Anti-
OP-Tb antibodies may therefore bind to OP-Tb the trypanosome cell-surface and activate the
classical pathway of complement activation. Secondly, if the presence of active OP-Tb on the
cell-surface is necessary for parasite viability, inhibitory anti-OP-Tb antibodies may bind
OP-Tb on the cell-surface and inhibit enzyme function, with deleterious consequences for the
parasite.
However, in this experiment, chicken IgY was employed as the antibody, while bovine native
and heat-inactivated FCS were employed as a serum source. As it is not known whether IgY
can activate the classical pathway of complement activation, and because parasites grew poorly
in the presence of native FCS, only the second hypothesis was tested here. Trypanosome
growth was satisfactory in the presence of heat-inactivated FCS, and in the presence of anti-
OP-Tb antibodies, a small (20%) decrease in viable cell number was observed. As the standard
error bars do not overlap for the 24 h time-point in Fig. 21, it is possible that this 20%
reduction in cell numbers, caused by anti-OP-Tb antibodies, is significant. The reason for poor
parasite growth in the presence of native FCS is probably attributable to the action of
complement proteins. The presence of antibodies or antigen-antibody complexes in the native
FCS would result in the non-specific activation of the complement cascade, and may cause
complement-mediated lysis of trypanosomes. It is for this reason that complement proteins are
usually heat-inactivated for use in cell-culture.
Internalised antibodies would probably enter the lysosomal system of the trypanosome, and as
OP-Tb is probably a cytosolic enzyme, it is unlikely that these internalised antibodies would
encounter OP-Tb. Thus any trypanocidal effect of anti-OP-Tb antibodies must be mediated by
antibody interaction with a surface-bound protein.
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4.9.5 Immunoaffinity purification of OP-Tc
The results of the optimisation of three-phase partitioning for OP-Tc isolation are illustrated in
Fig. 22. The bulk (86%) of the total activity against Cbz-Arg-Arg-AMC precipitated in the
10-25% (m/v) (NH4)2SO4 cuts, with 11% remaining associated with the insoluble fraction
containing membrane and cytoskeletal components. These findings are consistent with the
trends observed with the OP-Tb purification (Section 3.1.1; Fig. 9 et seq.). Thus, a 10-25%
(NH4)2SO4 cut was subsequently used in the purification of OP-Tc to maximise the yield of
enzyme. Furthermore, the major lysosomal cysteine proteinase of T. congolense, congopain,
precipitated over this range of (NH4)2SO4 (results not shown). Thus, both enzymes were
completely precipitated at this stage, again facilitating the simultaneous purification of both

























Figure 22. Optimisation of three-phase partitioning for OP-Tc purification. T. congolense lysates were
precipitated using TPP at various (NH^SC^ concentrations, and the precipitated fractions were assayed for
activity against Cbz-Arg-Arg-AMC. Error bars represent the mean ± SEM (n = 3).
Activity against Cbz-Arg-Arg-AMC eluted in the unbound fraction from a Q-Sepharose
column at pH 5.5, while activity against Cbz-Phe-Arg-AMC was retained on the column,
eluting at about 200 and 600 mM NaCl (Fig. 23). This reflects the separation of a trypsin-like













Figure 23. Anion-exchange chromatography of OP-Tc on Q-Sepharose at pH 5.5. Q-Sepharose
(26 x 100 mm, 1 ml.min"1) was equilibrated in buffer A [20 mM acetate, 1 mM Na2EDTA, 0.02% (m/v) NaN3,
pH 5.5] containing 100 mM NaCl. After elution of unbound protein with buffer A containing 100 mM NaCl,
bound protein was eluted with a linear gradient (••••) of 0.1 to 1 M NaCl in buffer A over 5 column volumes.
( ) A280, (—•-) enzyme activity against Cbz-Arg-Arg-AMC, ( - • - ) enzyme activity against
Cbz-Phe-Arg-AMC.
Application of the Q-Sepharose pH 5.5 active fraction to a /?-aminobenzamidine-Sepharose
column (Section 3.4) resulted in the separation of two fractions with activity against
Cbz-Arg-Arg-AMC (Fig. 24). The bulk of the activity (approximately 85%) remained weakly
bound to the column, eluting with a single-step salt gradient. A small amount of activity was





Figure 24. Affinity chromatography of OP-Tc on />-aminobenzamidine-Sepharose. />-Aminobenzamidine-
Sepharose (120 x 15 mm, 1 ml.min"1) was equilibrated in buffer B [50 mM Tris-Cl, 2 mM dithiothreitol, 0.02%
(m/v) NaN3, pH 8]. After elution of unbound protein with buffer B, bound protein was eluted by application of
250 mM NaCl in buffer B, in a single step, applied at the point indicated by the arrow (I). (-) A280, ( -* - )
enzyme activity against Cbz-Arg-Arg-AMC.
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Cbz-Arg-Arg-AMC-hydrolysing activity was eluted in a single well-resolved peak from an
anti-OP-Tb-Sepharose immunoaffinity column (Fig. 25), while no activity was observed in the
unbound fraction. The purified OP-Tc was homogenous on Tris-Tricine SDS-PAGE, and has





Figure 25. Immunoaffinity chromatography of OP-Tc on anti-OP-Tb-Sepharose. Anti-OP-Tb-Sepharose
(50 x 15 mm, 1 ml.min"1) was equilibrated in loading buffer [50 mM Tris-Cl, 1 M NaCl, 10 mM CaCl2, 0.5%
(m/v) Brij-35, 0.02% (m/v) NaN3, pH 7.4]. After elution of unbound protein with loading buffer, bound protein
was eluted by application of 3.5 M NaSCN in loading buffer, in a single step, applied at the point indicated by
the arrow (I). (—) A280, (-•—) enzyme activity against Cbz-Arg-Arg-AMC.


























































Figure 26. Evaluation of OP-Tc purification (a) Mr markers (as in Section 2.7.1.1); (b) anti-OP-Tb-
Sepharose active pool (300 ng). Samples were resolved by reducing Tris-Tricine SDS-PAGE (Section 2.7.1)
and protein visualised by silver staining (Section 2.7.4).
OP-Tc was purified to electrophoretic homogeneity for the first time in this study from
T. congolense lysates in a four-step procedure with a 34% yield. OP-Tc behaved almost
identically to OP-Tb in the three-phase partitioning, ion-exchange and p-aminobenzamidine-
Sepharose affinity chromatography (Sections 3.11.1, Fig. 9; 3.11.2, Fig. 10, and 3.11.3,
Fig. 11 respectively). Affinity chromatography on anti-OP-Tb-Sepharose replaced three
further column chromatography steps that were used to purify OP-Tb. However, the
shortened procedure only resulted in a 6% improvement in enzyme yield, with 11% being lost
in the immunoaffinity procedure. It is possible that OP-Tc was not stable in the 3.5 M
NaSCN, and this may account for the loss of activity during this procedure. However, elution
of the OP-Tc from the immunoaffinity column with 50 mM Glycine-Cl, pH 2.3, instead of
3.5 M NaSCN (results not shown) resulted in an even lower final yield (24%). It is also
possible that the high-salt binding conditions required for the immunoaffinity step were
unfavourable, however, the stability of trypanosome oligopeptidases under conditions of high
ionic strength has not been determined. Despite only a 6% increase in yield, the
immunoaffinity step, which replaced three column-chromatography procedures, represented a
considerable reduction (approximately 50%) in the duration of the purification procedure.
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4.9.6 Do trypanosome-infected hosts produce anti-oligopeptidase antibodies?
Most of the specific antibodies present in N'Dama and Boran cattle sera were directed against
trypanosome antigens in the range 20-90 kDa. Both Boran and N'Dama cattle appeared to
raise IgG against two primary antigens of approximately 30 and 50 kDa (Fig 27).
Furthermore, a 40 kDa trypanosome protein appeared to be a dominant antigen in infections of
N'Dama, but not of Boran cattle, and it is likely that the responsible antigen is congopain
(L. Troeberg, pers. comtn., Authie et al, 1993b). OP-Tc was not a dominant antigen in
infections of either Boran or N'Dama cattle, as it was not targeted on western blots by IgG
from either source.
In contrast to these results, IgM in both Boran and N'Dama sera primarily targeted antigens at
40 and 80 kDa, although there was a stronger antibody response from the Boran sera, where a
greater number of bands which showed much more pronounced staining, was evident (Fig. 28).
In spite of the band at 80 kDa targeted in T. congolense lysates, purified OP-Tc was not
targeted by IgM from either source, again suggesting that OP-Tc was not a dominant antigen
in either Boran or N'Dama infection.
These data are generally consistent with the findings of Authie et al. (1993b), although no
immunodominant 69 kDa antigen was detected in the present study. A 40 kDa antigen was
detected, and the IgG response to this antigen appeared to correlate with trypanotolerance,
suggesting that the antigen was congopain. Furthermore, Authie et al. (1993b) also reported
that Boran cattle have higher IgM responses, but weaker IgG responses when compared with
N'Dama cattle, which is consistent with the trends observed here. This has been attributed to
an impairment in the class-switching from IgM to IgG during infection in trypanosusceptible
cattle (Authie et al., 1993b; Musoke et al, 1981), since isotype switching involves Th-cell
participation (Kishimoto and Hirano, 1988), and depression of Th-cell has been documented in
T. b. brucei (Pearson et al, 1978) and T. congolense (Flynn and Sileghem, 1993).
No inhibitory activity was detected when N'Dama and Boran sera were tested for their ability
to inhibit the OP-Tc catalysed hydrolysis of Cbz-Arg-Arg-AMC, even at serum dilutions of











Figure 27. Characterisation of IgG response to trypanosome infection in cattle. Purified OP-Tb (200 ng)
(a) and T. congoleme lysates (50 ng) (b) were resolved by Tris-Tricine SDS-PAGE (Section 2.7.1) and
electroblotted onto nitrocellulose (Section 2.7.5). Nitrocellulose strips were then incubated with T. congolense-
infected N'Dama (A) and Boran (B) serum (1:100 dilution). Antibody-antigen complexes were detected with









Figure 28. Characterisation of IgM response to trypanosome infection in cattle. Purified OP-Tb (200 ng)
(a) and T. congoleme lysates (50 ug) (b) were resolved by Tris-Tricine SDS-PAGE (Section 2.7.1) and
electroblotted onto nitrocellulose (Section 2.7.5). Nitrocellulose strips were then incubated with T. congolense-
infected N'Dama (A) and Boran (B) serum (1:100 dilution). Antibody-antigen complexes were detected with a
monoclonal anti-bovine IgM clone BM-23-biotin conjugate, followed by an extravidin-AP conjugate as
described in Section 4.4.
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In conclusion, these preliminary data illustrate that OP-Tc is not differentially recognised by
the immune system of trypanotolerant versus trypanosusceptible cattle, and inhibitory
antibodies are not generated by T. congolense-infected hosts. However, whether or not OP-Tc
may be a suitable candidate as a target in a vaccine regimen remains to be determined. The
fact that trypanosome oligopeptidases are released into infection serum and remain active there
suggests that these oligopeptidases may be suitable candidate targets for a vaccine.
4.10 Concluding remarks
Antibodies were raised against OP-Tb in chickens, and antibody production was monitored by
ELISA. These antibodies were highly specific for OP-Tb, targeting a single band at 80 kDa in
T. b. brucei lysates on a western blot. Anti-OP-Tb IgY strongly inhibited enzyme activity,
producing half-maximal inhibition of OP-Tb activity at 7.5 ug.mT1. This appears to be far
more potent than antibodies raised against other proteases by other investigators. This raises
the possibility that chronically infected mammalian hosts may produce antibodies against
OP-Tb, which would be highly desirable in terms of host defence. Such antibodies would
inhibit the activity and hasten the removal of circulating OP-Tb, released by lysed
trypanosomes, from the host bloodstream.
Inhibitory antibodies had no major effect on live trypanosomes in culture, but it is not yet
known whether they may influence the course of parasitaemia during natural infections. It
would be interesting to see if a prior immunisation of mice with OP-Tb had any affect on
parasitaemia after a subsequent challenge infection.
The generation of anti-OP-Tb antibodies facilitated the purification of a related enzyme from
T. congolense by immunoaffinity chromatography. Although this procedure did not result in a
greatly improved enzyme yield, it did reduce the duration of the purification procedure
by 50%. In addition, the cross-reactivity of the antibody with both T. brucei and
T. congolense derived enzymes raises the possibility that the antibody may prove to be a useful
diagnostic probe for trypanosome infections.
The intracellular distribution of eukaryotic oligopeptidases has not been conclusively
demonstrated, although subcellular fractionation has suggested that porcine prolyl
oligopeptidase is both soluble and membrane bound (O'Leary et al, 1996). Oligopeptidase B
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from T. cruzi has recently been localised to the parasite cytoplasm by immunoelectron
microscopy, with no evidence of surface-membrane association (Burleigh etal., 1997). Similar
observations have been made with OP-Tb (Lonsdale-Eccles and Mpimbaza, preliminary
unpublished observations). Live T. b. brucei do hydrolyse Cbz-Arg-Arg-AMC, and this
activity is inhibited in the presence of anti-OP-Tb antibodies. This raised the possibility that
OP-Tb is membrane bound, or is released extracellularly by trypanosomes. Furthermore,
OP-Tb activity has been detected in the plasma of infected rats and cattle (Section 6.8.4,
Fig. 46). It is not known whether the protease is actively or constitutively secreted, present in
an active form on the trypanosome cell surface, or simply released into the host bloodstream
upon complement-mediated trypanosome lysis. It would thus be useful to determine the
precise intracellular localisation of trypanosome oligopeptidases. Should trypanosome
oligopeptidases be membrane-bound, anti-oligopeptidase antibodies raised by the host may
abrogate any hydrolytic activity of these membrane-bound oligopeptidases. Furthermore,
attachment of such anti-oligopeptidase antibodies to the cell surface would facilitate
complement-mediated cell-lysis of the parasites. Preliminary investigations suggest that in the
case of T. congolense infections, anti-OP-Tc antibodies are not elicited in chronically infected
bovine hosts.
The diseases caused by T. congolense and T. b. brucei in infected hosts vary considerably in
their pathology (Section 1.1.6), and since proteases are known to be important pathogenic
factors in microbial infections (Section 1.3.2), we have proposed that trypanosome
oligopeptidases play a role in the pathogenesis of African trypanosomiasis. To explore this




Enzymatic characterisation of trypanosome oligopeptidases
Serine proteases from African trypanosomes have only recently been identified, and have not
previously been purified to electrophoretic homogeneity. For this reason, no thorough
enzymatic characterisation has been undertaken of these enzymes. Thus, the aim of this aspect
of the present study was to conduct a thorough enzymatic characterisation of two trypanosome
proteases: OP-Tb, from T. b. brucei and OP-Tc from T. congolense. This characterisation
included determination of the substrate specificity and sensitivity to pH and ionic strength.
Furthermore, the effect of a variety of potential activators and inhibitors on the activity of these
trypanosome oligopeptidases was examined, to further probe the substrate specificity and
catalytic mechanism of these enzymes.
5.1 Fluorogenic peptide specificity
The Michaelis constant, Km, and the maximum velocity of an enzyme-catalysed reaction, Fmax,
are important kinetic constants which reflect the specificity and activity of an enzyme. The
Vm*. represents the maximum turnover-rate of an enzyme, a point at which all active sites are
occupied by the substrate. It is often useful to express Fjnax in terms of the number of moles of
enzyme present, known as the turnover number, or
[ E ]
(Salvesen and Nagase, 1986)
where [E]o represents active enzyme concentration. The Km represents the amount of substrate
required to produce ViV^. In many cases it is an indication of the affinity between enzyme
and substrate; the lower the Km, the more preferred the substrate (Michal, 1983).
Determination of these constants is accomplished for single-substrate reactions by the
determination of the initial steady-state velocity (vo) at various substrate concentrations. A
direct plot of vo versus substrate concentration ([S]) permits an estimation of Km and Fmax.
These four factors are related by the Briggs-Haldane revision of the Michaelis-Menten
equation:
Vo =
 Fmax t S 3 (Briggs and Haldane, 1925)
[S] + Km
The inherent uncertainty in evaluating the F^K, and hence, Km, from a direct plot prompted a
number of investigators to devise alternative plots in which such data is fitted to a straight line,
including the Lineweaver-Burk plot (Lineweaver and Burk, 1934), the Eadie-Hofstee plot
(Eadie, 1942; Hofstee, 1952), the Hanes plot (Hanes, 1932) and the direct linear plot of
Eisenthal and Cornish-Bowden (Eisenthal and Cornish-Bowden, 1974).
Knowledge of the precise substrate specificity of trypanosome oligopeptidases would provide
the groundwork for the design of highly specific inhibitors which would be useful to explore
the physiological functions of these enzymes both within the trypanosome, and in the
pathogenesis of African trypanosomiasis. Such inhibitors could also be used to explore the
potential of these enzymes as therapeutic targets. A knowledge of the substrate specificity may
also assist in the identification of the in vivo substrates of these enzymes. For these reasons, it
was desirable to determine the P4-P1 subsite specificity of OP-Tb and OP-Tc, and this was
undertaken by examining the hydrolysis of a panel of aminomethylcoumaryl peptide substrates
by these two proteases.
5.1.1 Materials
1 mM Substrate stock solutions. Cbz-Arg-Arg-AMC (0.9 mg), Boc-Leu-Lys-Arg-AMC
(1.1 mg), Cbz-Gly-Gly-Arg-AMC (0.9 mg), Cbz-Phe-Arg-AMC (1 mg), Boc-Leu-Arg-Arg-
AMC (1.2 mg), Boc-Leu-Gly-Arg-AMC (0.9 mg), Boc-Gly-Arg-Arg-AMC (1 mg), Cbz-Ala-
Arg-Arg-AMC (1.1 mg), Boc-Val-Gly-Arg-AMC (0.9 mg), Cbz-Arg-AMC (0.7 mg), Boc-
Gly-Lys-Arg-AMC (1 mg), H-Ala-Phe-Lys-AMC (0.8 mg), Boc-Val-Leu-Lys-AMC (0.9 mg),
Boc-Ala-Gly-Pro-Arg-AMC (1 mg), Boc-Val-Pro-Arg-AMC (0.9 mg), Glt-Gly-Arg-AMC
(0.8 mg), Ac-Ala-Ala-Pro-Ala-AMC (0.8 mg), H-Gly-AMC (0.3 mg); H-Leu-AMC (0.4 mg);
MeoSuc-Gly-Trp-Met-AMC (1 mg); Suc-Leu-Tyr-AMC (1 mg); Cbz-Glt-Gly-Gly-Phe-AMC
(0.8 mg) or Gly-Pro-AMC (0.7 mg) were dissolved separately in DMSO (1.5 ml). H-Arg-
AMC (0.5 mg) was dissolved in dH2O (1.5 ml).
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5.1.2 Method
The hydrolysis of fluorogenic peptide substrates is discussed in Section 2.3. Oligopeptidase
activity against fluorogenic peptide substrates was determined by preincubation of OP-Tb or
OP-Tc (1.5 ng, representing ^18.75 frnol of active enzyme, 5 min) in assay buffer (Section
2.3.2), followed by addition of substrate. The initial steady-state velocity (v0) was determined
by continuous assay over a range of substrate concentrations (usually 45 nM-75 \xM but forXm
values above 20 uM, the upper limit was extended to &Km). Km and V^ were determined by
hyperbolic regression of the kinetic data using the software package Hyper 1.01 (obtained
from Dr. J.S. Easterby, University of Liverpool, UK).
5.2 Effect of pH on oligopeptidase activity and stability
A pH activity profile permits the determination of the pH at which an enzyme is most active,
and the pH at which the enzyme no longer functions. It is useful to determine these parameters
for the optimisation of an enzyme assay, and as a clue to the in vivo localisation of an enzyme.
Cytosolic enzymes frequently have alkaline pH optima, as opposed to lysosomal enzymes,
which are usually optimally active at acidic pH. This rule has its exceptions, however. For
example, the lysosomal enzyme cathepsin B has an alkaline pH optimum (Dehrmann et al,
1996). It was of interest to determine whether oligopeptidases were active and stable at the
physiological pH of the mammalian host-organism, as activity and stability at physiological pH
(taken as pH 7.4) would suggest that the enzyme may remain active in the host bloodstream,
where it may contribute to disease pathogenesis, until eliminated from the host.
As variations in ionic strength (I) may affect enzyme activity independently of pH, it is
important to maintain a constant ionic strength over the pH range utilised
(Dehrmann et al, 1995). For this reason, pH activity and stability studies were conducted
using the constant ionic strength acetate-Mes-Tris (AMT) buffers of Ellis and Morrison
(1982).
5.2.1 Materials
AMT buffers HOP mM acetate. 200 mM Tris. 100 mM Mes. 1 mM dithiothreitol. 4 mM
Na->EDTA: IaQ.l). Glacial acetic acid (1.72 ml), Mes (5.86 g), Tris (7.27 g) and
Na2EDTA.2H2O (0.45 g) were dissolved in <fflb0n(200 ml). This solution was divided into 12
aliquots (20 ml each) which were titrated to pH values in the range 4.0 to 9.0 using HC1 or
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NaOH, and then made up to 25 ml with dH2O. Dithiothreitol (4 mg) was added to each 25 ml
aliquot on the day of use, and the pH re-adjusted if necessary.
5.2.2 Method
The hydrolysis of Cbz-Arg-Arg-AMC by OP-Tb or OP-Tc (1.5 ng, =±18.75 finol active
enzyme) was conducted exactly as described for the standard continuous assay (Section 2.3.2),
except that AMT buffers replaced the standard assay buffer. OP-Tb or Op-Tc (10 ng, =±0.125
pmol active enzyme, in 5 u,l) was incubated (1 h, 37°C) in the relevant AMT buffer (25 ul).
AMT buffer (1=0.1, pH 8.5, 0.72 ml) was then added to bring all samples to pH 8.5, and
residual activity against Cbz-Arg-Arg-AMC determined as described in Section 2.3.2.
5.3 Effect of ionic strength on OP-Tb activity
Ionic strength is known to influence the activity of the proteolytic enzymes cathepsin B and
cathepsin L (Dehrmann et al., 1995, 1996; Dennison et al, 1992). It was important to
determine whether oligopeptidases were active at the ionic strength of the host extracellular
milieu, as this would indicate whether the enzyme could possibly be active at the ionic strength
of the host bloodstream.
5.3.1 Materials
AMT buffers. AMT buffers were prepared exactly as described in Section 5.2.1, with the
exception that they were prepared at 1.33 x nominal ionic strength in the assay, to allow for
dilution of the buffer.
5.3.2 Method
The effect of ionic strength on OP-Tb activity was investigated exactly as described by
Dehrmann et al. (1995), employing constant ionic strength AMT buffers. OP-Tb (1.5 ng,
— 18.75 fmol active enzyme) was pre-incubated in AMT buffer (750 ul) for 2 min, after which
substrate solution (250 ul) was added, and fluorescence monitored as described in Section
2.3.2. To facilitate comparison with the work of others, the effect of ionic strength was also
investigated by addition of NaCl to 50 mM Hepes, pH 8.0 (used in place of AMT buffers).
5.4 Reductive activation of oligopeptidases
Trypanosome oligopeptidases are sensitive to the presence of reducing agents. The presence
of reducing agents was necessary to maintain the stability of the enzyme throughout a
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purification protocol (discussed in Section 3.13), and enzyme activity was enhanced in the
presence of reducing agents. The effects of various reducing agents on oligopeptidase activity
were therefore determined.
5.4.1 Materials
Assay buffer (50 mM Tris-Cl. pH 81 Tris (3 g) was dissolved in dH2O (450 ml), titrated to
pH 8 with HC1, and made up to 500 ml with dH2O.
Stock 25 mM reduced glutathione. Reduced glutathione (0.77 g) was dissolved in assay buffer
(100 ml), and the pH re-adjusted if necessary.
Stock 25 mM dithiothreitol. Dithiothreitol (0.38 g) was dissolved in assay buffer (100 ml), and
the pH re-adjusted if necessary.
Stock 25 mM L-cysteine-HCl. L-cysteine-HCl (0.3 g) was dissolved in assay buffer (100 ml)
and the pH re-adjusted if necessary.
5.4.2 Method
OP-Tb and OP-Tc activity against Cbz-Arg-Arg-AMC were determined as described in
Section 2.3.2, except that various reducing agents, either cysteine-HCl, reduced glutathione, or
dithiothreitol were included in the assay buffer at various concentrations. Stock reducing
agent solutions were diluted to the necessary concentration with assay buffer. Enzyme
(1.5 ng, —18.75 fmol active enzyme) was pre-incubated with the respective reducing agents
(37°C, 10 min) before addition of substrate.
5.5 Rate of activation with dithiothreitol
As dithiothreitol proved to be the most effective reducing agent for enzyme activation, this was
the reagent of choice for the standard enzyme assay. For the standard assay to yield accurate
results, particularly for the calculation of kinetic constants, it is necessary to have the enzyme
fully activated before the addition of substrate. It was therefore important to know the
optimum time of activation of these enzymes by dithiothreitol.
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5.5.1 Method
Enzyme (1.5 ng, ^18.75 finol active enzyme) was pre-incubated in assay buffer containing 10
mM dithiothreitol (Section 2.3.2) for various lengths of time (0-15 min), and activity against
Cbz-Arg-Arg-AMC determined as described in Section 2.3.2.
5.6 Inhibitor profile of trypanosome oligopeptidases
Testing the effect of a broad spectrum of inhibitors on the activity of a protease often permits
its classification into one of the four currently recognised classes of proteases (Table 1).
Additionally, inhibition data may provide insight into the substrate specificity of the protease by
providing information about the binding site specificity.
5.6.1 Materials
2 x Assay buffer flOO mM Tris-Cl. 20 mM dithiothreitol. pH 8). Tris (3 g) and dithiothreitol
(0.4 g) were dissolved in dH2O (200 ml), titrated to pH 8 with HC1 and made up to 250 ml
with dthO. Due to the relative instability of dithiothreitol, the solution was prepared on the
day of use.
10 x Inhibitor stock solutions. Inhibitor stock solutions were prepared at 10 x their working
concentration in the final assay mixture and stored at -75°C. AEBSF (31.8 mg, 100 mM),
benzamidine-HCl (4.2 mg, 10 mM), chymostatin (12.1 mg, 10 mM), EDTA (74.4 mg, 100
mM), EGTA (38 mg, 100 mM), iodoacetate (37.2 mg, 100 mM), iodoacetamide (37 mg, 100
mM), leupeptin (8.6 mg, 10 mM), pepstatin A (13.7 mg, 10 mM), soybean trypsin inhibitor
(1 mg, 50 uM), lima bean trypsin inhibitor (1 mg, 0.11 mM) and aprotinin (1 mg, 0.16 mM)
were each dissolved separately in dEbO (1 ml). Antipain (12.1 mg, 10 mM),
N-ethylmaleimide (25 mg, 100 mM), E-64 (7.2 mg, 100 mM), 1,10-phenanthroline (39.6 mg,
100 mM) andpCMB (35.7 mg, 100 mM) were each dissolved separately in 1 ml volumes of
DMSO. PMSF (34.8 mg, 10 mM) was dissolved in ethanol (1 ml).
100 mM DFP. Pure DFP (5.43 M) was diluted in assay buffer to a concentration of 100 mM
and used immediately. These experiments were performed in a fume hood, and residual DFP
was neutralised with 2 M NaOH when necessary.
102
5.6.2 Method
Enzymes were pre-incubated with the respective compounds (10 min, 37°C) in assay buffer,
before assaying residual activity against Cbz-Arg-Arg-AMC over a range of substrate
concentrations (45 nM-75 uM). Km and Vmax were determined by hyperbolic regression of the
kinetic data. The inhibition mechanism was diagnosed from the effect of the inhibitor on the
Km and Fmax obtained in the presence and the absence of the inhibitor. Where inhibitors were
dissolved in inorganic solvents, control experiments were performed in the presence of
comparable concentrations of solvent, without the inhibitor.
For competitive reversible inhibitors, the inhibition constant (K\) was determined by the
method of Salvesen and Nagase (1989). The enzyme-catalysed hydrolysis of
Cbz-Arg-Arg-AMC was monitored continuously (Section 2.3.2) to establish an uninhibited
rate of substrate hydrolysis (vo), after which a twenty-fold molar excess of inhibitor over
enzyme was added (in less than 5% of the total assay volume), and the new steady-state
velocity in the presence of the inhibitor (v;) determined. The apparent inhibition constant in the
presence of substrate (K^pp)) was calculated from the equation
— = 1 + - ^ - (Salvesen and Nagase, 1989).
Vi Kifrm)
The true K\. was calculated for reversible competitive inhibitors, catering for the presence of
substrate, from the relationship
(Salvesen and Nagase, 1989).
The rate constant for complex formation (k^) between the enzyme and reversible inhibitors
was determined by the methods of Lenarcic et al. (1996) which is based on methods described
by Nicklin and Barrett (1984) and Salvesen and Nagase (1989), where the inhibitor is added to
a steady-state enzyme-substrate reaction, and the^cnange in reaction velocity monitored
continuously. The pseudo-first-order inhibitijem rate constant (kohs) was obtained from the
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linear section of plots of In vt/v0 versus time, which has a slope of -Act*. The apparent second-
order inhibition rate constant (k^) was obtained from the relationship
/ihss = — 1 + -—- (modified from Salvesen and Nagase, 1989).
[ I ] V KIT. J
The rate constant for complex dissociation, Adiss, was determined from the relationship
— (Bieth, 1980).
/Cass
As non-competitive and irreversible inhibition are difficult to differentiate from simple kinetic
data alone, attempts were made to dilute the inhibitory effect of compounds exhibiting either
mode of inhibition. This was achieved with a succession of dilution/concentration cycles
where enzyme-inhibitor samples were diluted with assay buffer and concentrated to the original
volume in 3 ml polysulfone concentrators (7 000 x g, 10°C) (Section 2.6.1).
The effects of irreversible protease inhibitors were investigated under pseudo first-order
conditions ([I] > 5O[E]o), as described by described by Salvesen and Nagase (1989) by adding
an aliquot of inhibitor (10 ul) to a buffered enzyme solution (140 \xl, containing 50 ng OP-Tb
or OP-Tc in 50 mM Tris-Cl, pH 8.0) to initiate the inactivation. Aliquots were removed at
timed intervals and residual activity determined against 5 uM Cbz-Arg-Arg-AMC (vt). Again,
£ot>s was obtained from plots of In vt/v0 versus time, which have a slope of -£obs, facilitating the
calculation of k^ from the relationship
kobs
= — (Salvesen and Nagase, 1989)
where [I] represents the inhibitor concentration. The time required for the free enzyme
concentration to decrease by 50% (half-life, tvs) is given by
t a = — (Salvesen and Nagase, 1989).
kass [ I J
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5.7 Potential activators of oligopeptidase activity
A variety of effector molecules are known to be involved in the regulation of enzyme activity
in vivo. Some serine proteases, such as the Clp protease of E. coli are known to be ATP-
dependent (Barrett and Rawlings, 1992), while others such as kexin are strongly calcium-
dependent (Fuller et al, 1986). Polyamines are also known to regulate the activity of enzymes
in vitro (Lim Tung et al, 1985). The effect of these molecules on the activity of OP-Tb and
OP-Tc was therefore investigated.
5.7.1 Materials
10 mM Stock solutions. Putrescine.2HCl (16 mg), spermine.4HCl (35 mg), spermidine.3HCl
(25.4 mg), ornithine.HCl (17 mg), ATP (55 mg) and GTP (52 mg) were each dissolved
separately in dH2O (10 ml). As heparin does not have a well-defined molecular mass, it was
made up as a stock solution of 1 mg.ml'1.
5.7.2 Method
Assays were performed exactly as described in Section 2.3.2, with the exception that the
activator was included in the assay buffer at 1.33 x final concentration, to allow for dilution
following addition of substrate.
5.8 Influence of metal ions on oligopeptidase activity
The influence of metal ions on the activity of an enzyme may give an indication of the catalytic
mechanism of the enzyme. Enhancement of protease activity by metal ions, in particular by
Zn2+ often suggests the action of a metalloprotease, such as a carboxypeptidase or matrix
metalloprotease (Matrisian, 1992), while a number of serine proteases are activated by Ca2+
(Fuller et al., 1986). Similarly, most cysteine proteases are reversibly inactivated in the
presence of Hg2+(Barron, 1951).
5.8.1 Materials
10 mM metal ion stock solutions. MgCl2.6H20 (20 mg), CaCl2.2H2O (15 mg), ZnCl2
anhydrous (14 mg), MnCl2.4H2O (20 mg), HgCl2 anhydrous (27 mg), CuCl2.2H2O (17 mg),
FeCl2.4H2O (12 mg), NiCl2.2H2O (23 mg), CdCl2.2'/2H2O (23 mg) and BaCl2.2H2O (24 mg)
were each dissolved in assay buffer (10 ml). Because of the potential formation of complexes
between dithiothreitol and heavy-metal ions, dithiothreitol was omitted from the assay buffers.
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As dithiothreitol is a non-essential activator of OP-Tb and OP-Tc activity (Sections 5.11.4 and
5.11.5), there was sufficient enzyme activity in its absence to conduct these experiments.
5.8.2 Method
Assays were performed as described in Section 5.7.2, with the exception that activator was
replaced with the relevant metal ion, in the absence of dithiothreitol.
5.9 Hydrolysis of protein substrates
OP-Tb was incubated with a number of mammalian host plasma proteins in order to determine
whether protein substrates were hydrolysed. For this investigation, four of the most prominent
mammalian plasma proteins were selected as potential substrates. Bovine pancreatic trypsin
was employed as a positive control as it has a similar cleavage specificity to OP-Tb.
5.9.1 Materials
Protein stock solutions (1 nig.ml'1), BSA (1 mg), bovine fibrinogen (1 mg), human
012-HS-glycoprotein (1 mg) were each dissolved separately in dt^O (1 ml). Bovine IgG stock
solution (11.2 mg.ml"1) and the 1 mg.ml"1 protein stock solutions were diluted further with
when required.
Trypsin stock solution (1 mg.ml"1). Bovine pancreatic trypsin (1 mg) was dissolved in 1 mM
HC1 (1 ml).
5.9.2 Methods
OP-Tb (60 ng, ^0.75 pmol) was incubated (37°C) in separate experiments with 100-fold
molar excesses of BSA (5.1 ug, =̂ 75 pmol), fibrinogen (3.75 ug, ^75 pmol), bovine IgG
(12 ug, ^75 pmol) or a2-HS-glycoprotein (3.6 ug, ^75 pmol). Aliquots were removed at 0
min, 60 min, 120 min and 180 min, and proteolytic activity terminated by the addition of
reducing treatment buffer and boiling (10 min). Positive controls were conducted in the same
manner using bovine pancreatic trypsin at a 1:100 molar ratio. Samples were resolved by
reducing Tris-Tricine SDS-PAGE (Section 2.7.1), and proteins visualised by Coomassie-blue
staining (Section 2.7.3).
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5.10 Digestion of gelatin in substrate SDS-PAGE
Substrate SDS-PAGE provides a sensitive and convenient means of detecting proteolytic
activity on polyacrylamide gels. This technique is discussed fully in Section 2.7.2.
5.10.1 Methods
Purified OP-Tb (100-500 ng) and T. b. brucei lysates (2-10 ug) were subjected to
electrophoresis on gelatin-containing SDS-PAGE gels (Section 2.5.3) and the gels developed
as described in Section 2.7.2.2.
5.11 Results and discussion
5.11.1 Fluorogenic substrate specificity
Peptide hydrolysis by OP-Tb indicated that the presence of basic amino acid residues in the Pj
position was obligatory, thereby suggesting that OP-Tb has a trypsin-like specificity (Table 9).
A variety of residues were acceptable in the P2 position, including Phe, Leu, Gly, Pro, Lys and
Arg. A comparison of the hydrolyses of Cbz-Arg-Arg-AMC and Cbz-Phe-Arg-AMC indicates
that Arg is preferred over Phe in P2, with a 6.5-fold decrease in ka*.IKm compared to the
Phe-containing substrate. A comparison of the hydrolysis of Boc-Val-_GLv-Arg-AMC. versus
Bj}C=Yal-Pro-Arg-AMC illustrates that substitution of Pro with Gly in P2 is accompanied by a
8.5-fold increase in kcat/Km (i.e. Gly is preferred over Pro in the P2 position). Substitution of
Gly with Arg in Boc-Leu-Gly-Arg-AMC (to give Boc-Leu-Arg-Arg-AMC) caused a 20%
increase in k^lKm, indicating that Arg is preferred over Gly in P2. However, substitution of
this P2-Arg with Lys in this substrate (to give Boc-Leu-Lys-Arg-AMC) has little (0.01%
increase) effect on k^ilKm, indicating that Lys and Arg are equally acceptable in P2. In
contrast, substitution of Lys with Arg in Boc-Gly-Lys-Arg-AMC (to give Boc-Gly-Arg-Arg-
AMC) resulted in a four-fold increase in kat/Km, suggesting that Arg is preferred over Lys in P2
in this case.
The poor U ^ m for H-Arg-AMC (0.07 s^.uM"1) and lack of activity against H-Gly-AMC and
H-Leu-AMC suggests that OP-Tb has poor aminopeptidase activity. In contrast, blocking of
the N-terminus with a Cbz group (i.e. Cbz-Arg-AMC) elevated the k^/Km approximately
150-fold. This may indicate that substrate binding is more successful when both Pi and P2 are
occupied. This is further supported by the results obtained with reversible competitive
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inhibitors (Section 5.11.6, Table 10) and trypanocidal drugs (Section 7.6.1, Table 16). Thus,
the P2 preference appears to be (Arg/Lys) > Gly > Phe > Pro. There appears to be little
specificity in P3, as substitution of Val for Leu in Boc-Leu-Gly-Arg-AMC (to give
Boc-Val-Gly-Arg-AMC) and Gly for Leu in Boc-Leu-Arg-Arg-AMC (to give
Boc-Gly-Arg-Arg-AMC) has little (<0.001%) effect on W ^ m .







































































































































"No activity was detected against Ac-Ala-Ala-Pro-AIa-AMC, H-Gly-AMC; H-Leu-AMC; MeoSuc-Gly-Trp-Met-
AMC; Suc-Leu-Tyr-AMC; Glt-Gly-Gly-Phe-AMC or H-Gly-Pro-AMC after 1 h.
The kat was consistently lower for OP-Tc activity against fluorogenic peptides, and this
suggests that OP-Tc may be catalytically less efficient than OP-Tb. It also cannot be
discounted that errors in the determination of the [E]o for OP-Tb and OP-Tc may be
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responsible for this apparent difference. Similar trends in substrate-specificity were observed
for OP-Tc, suggesting that the substrate specificities of these two enzymes are very similar.
The indistinguishable values of Km observed for many of the substrates also points to this
conclusion. However, the 3.4-fold difference in Km observed between OP-Tb and OP-Tc with
their best substrate (Cbz-Arg-Arg-AMC) indicates that the enzymes are not identical.
The Km values for the hydrolysis of Cbz-Arg-Arg-AMC by OP-Tb and OP-Tc compare well
with those obtained for potentially analogous enzymes from other sources, including an
"alkaline peptidase" from Crithidia fasciculata (1 uM; Ashall et al., 1990a) and a trypsin-like
proteinase from soybeans, with a Km of 2.2 (xM against Cbz-Arg-Arg-pNa (Nishikata, 1984).
Furthermore, an enzyme resembling the oligopeptidases of African trypanosomes has recently
been isolated and cloned from Trypanosoma cruzi (Burleigh and Andrews, 1995; Burleigh
et al, 1996) for which the recombinant enzyme has a Km of 5 uM for Cbz-Arg-Arg-AMC. As
the Km is not an absolute constant and depends on pH, temperature, presence of effector
molecules and buffer composition (Michal, 1983), these small variations in Km values may be
attributable to different reaction conditions.
5.11.2 Effect of pH on oligopeptidase activity
OP-Tb activity against Cbz-Arg-Arg-AMC peaked at pH 9 (Fig. 29A), and the enzyme was
still considerably active (75% of maximal activity) at physiological pH (pH 7.4). At pH 6, OP-
Tb activity was less than 20% of that obtained at pH 9, although at pH 10 the enzyme still
remained about 40% active. Almost identical results were obtained for OP-Tc.
The effect of pH on Km and kat respectively was only investigated for OP-Tb, as these studies
are expensive in terms of enzyme and substrate. The Km appeared to be relatively unaffected
by pH with a 1.6-fold variation in Km over the pH range 4 to 12 (Fig. 29B). The shape of the
curve suggested pKa values of approximately 6 and 10. This is probably due to ionisation of
the imidazole group of an active-site histidine, and the hydroxyl group of an active-site serine,
respectively. These data are consistent with the pH-dependence trends observed for serine
proteinases (Dunn, 1989). In contrast, changes in pH exerted a dramatic effect (100-fold























Figure 29. Effect of pH on the activity and stability of trypanosome oligopeptidases. (A) OP-Tb (—) and
OP-Tc ( ) (1.5 ng) was assayed in AMT buffers (I = 0.1) over the pH range 4.0 to 12.0, containing 10 mM
dithiothreitol. (B) Effect of pH on the Km (A) and A^ (O) of OP-Tb, constructed from the data presented in (A).
(C) pH stability of OP-Tb was determined by incubating OP-Tb (10 ng) for 1 h at 37°C in AMT buffers (I =
0.1) over the pH range 4.0 to 12.0 in the absence (D) and presence (•) of 10 mM dithiothreitol. Residual
enzyme activity against Cbz-Arg-Arg-AMC was then determined in the pH 8 AMT buffer.
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This suggests that the enzyme will bind substrates over the pH-range tested, but can only
hydrolyse them at neutral or alkaline pH. Thus, the arrangement of the catalytic residues (Asp-
His-Ser triad, or oxyanion hole) is being disrupted, possibly through the titration of one or
more of the residues.
Both in the presence and absence of the reducing agent dithiothreitol, OP-Tb was stable over a
wide pH range, between pH 6 and 10 (Fig. 29C). In the absence of dithiothreitol, pH stability
peaked at approximately pH 7, while in the presence of 10 mM dithiothreitol, OP-Tb was
optimally stable at approximately pH 8.5. OP-Tb was nearly 100% irreversibly inactivated
below pH 4, both in the absence and presence of dithiothreitol. However, OP-Tb appeared to
be more stable in alkaline solution, retaining up to 40% of its activity at pH 12, in the presence
of 10 mM dithiothreitol.
5.11.3 Effect of ionic strength on OP-Tb activity
OP-Tb activity was sensitive to ionic strength (Fig. 30), where increasing ionic strength resulted in
a decrease in OP-Tb activity irrespective of the buffer system employed. OP-Tb activity was
optimal at low ionic strength (1^0.025) and about half-maximally active at physiological ionic
strength (1^0.1) at pH 7. At 1=^0.2, OP-Tb was less than 20% active, and activity was completely
abolished at 1^0.5.
Ionic strength
Figure 30. Effect of ionic strength on OP-Tb activity against Cbz-Arg-Arg-AMC. OP-Tb (1.5 ng) activity
was assayed in the absence (D) an presence (•) of 10 mM dithiothreitol in constant-ionic-strength AMT
buffers. Inset, Activity assayed in the absence (O) an presence (•) of 10 mM dithiothreitol in 50 mM Hepes,
pH 8, containing sodium chloride as indicated on the abscissa. Standard deviations were less that ±10%.
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While similar trends have been observed for the lysosomal cysteine proteinases (Dehrmann
etal, 1995; 1996, Dennison et al, 1992), these observations contrast with the finding that
increasing the sodium chloride concentrations of up to 2 M NaCl enhances the activity of
prolyl oligopeptidase from porcine brain (Polgar, 1982) and Treponema denticola (Makinen et
al, 1994). Turk et al (1994) have proposed a mechanism for the destabilisation of the
tertiary structure, and hence active-site, of cathepsin B by elevated ionic strength. However, in
the absence of a three-dimensional structure for OP-Tb, it is not possible to comment further at
present on the extent to which this model may apply to OP-Tb.
5.11.4 Effect of reducing agents on oligopeptidase activity
Dithiothreitol, cysteine and reduced glutathione (GSH) all enhanced OP-Tb activity (Fig. 31),
and a parallel situation was observed for OP-Tc (results not shown). At all concentrations
tested, dithiothreitol proved to be the best reducing agent, with maximal activation occurring
at approximately 10 mM. Cysteine and GSH were comparatively poor activators of OP-Tb
and OP-Tc, with maximal activation occurring between 5 and 10 mM. Above these
concentrations, cysteine and GSH became inhibitory. Therefore lOmM dithiothreitol was






Figure 31. Effect of reducing agents on OP-Tb activity against Cbz-Arg-Arg-AMC. OP-Tb (1.5 ng) was
assayed as described in Section 2.3.2 except that dithiothreitol (-O-), GSH ( - • - ) or cysteine-HCl ( - • - ) were
used as reducing agents at various concentrations. Standard deviations for the activities were less than ±10%.
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The activation of serine protease activity by reducing agents suggests that an essential cysteine
residue, which must be maintained in its reduced state for catalysis to proceed, may occur in
the vicinity of the active site. The enhancement of oligopeptidase activity by reducing agents
has also been observed for prolyl oligopeptidase (EC 3.4.21.26), a serine oligopeptidase from
mammalian and porcine brain tissue, which exhibits 150% enhancement of activity in the
presence of 50 uM dithiothreitol or 50 uM p-mercaptoethanol. However, these reducing
agents became inhibitory at concentrations above 0.5 mM (Moriyama et al. 1988). Prolyl
oligopeptidase possesses two cysteine residues in the immediate vicinity of the catalytic
aspartic acid residue (Rennex et al, 1991). However, as the amino acid sequences of OP-Tb
and OP-Tc are not yet known, it is not possible to investigate this hypothesis further.
Furthermore, essential cysteine residues that are far removed from the catalytic apparatus in
the primary structure of the enzyme may be brought into close proximity to the catalytic site by
the tertiary structure of the enzyme. As the cytosol is a reducing environment, this introduces
the possibility that intracellular reducing agents such as glutathione and trypanothione may act
as in vivo regulators of OP-Tb activity within trypanosomes.
5.11.5 Rate of activation with dithiothreitol
OP-Tb was rapidly activated (approximately two-fold increase in activity) in the presence of
10 mM dithiothreitol after 1 min (Fig. 32). The rate of activation then slowed down
considerably, and plateaued after about 10 min. In all subsequent assays, OP-Tb was activated
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Figure 32. Optimum time of OP-Tb activation with dithiothreitol. OP-Tb (1.5 ng) was assayed as
described in Section 2.3.2, except that the enzyme was pre-incubated with dithiothreitol (10 mM) for 0-15 min
before the addition of Cbz-Arg-Arg-AMC. Standard deviations for the activities were less than ±10%.
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5.11.6 Inhibitor profile of trypanosome oligopeptidases
The inhibition of trypanosome oligopeptidases by reversible, competitive inhibitors is
illustrated in Table 10. Both OP-Tb and OP-Tc were inhibited by the peptide aldehydes
antipain and leupeptin, which contain the aldehyde on the Pi-Arg residue. The lower K\ and
higher k^ of antipain are probably attributable to the comparatively more basic nature of
antipain, whose tripeptide contains two arginine residues, compared to leupeptin that has only
one arginine residue (Umezawa, 1976). No inhibition was observed for chymostatin, where
the aldehyde is present on the Pi-Phe residue. This further supports the findings with
fluorogenic peptide substrates that phenylalanine is not acceptable in Pi (Table 9). Similar
trends in inhibitory potency of tripeptide argininals (antipain > leupeptin) have also been
reported for oligopeptidase B fromM lacunata (Kanatani et al., 1991), a trypsin-like protease
from soybeans (Nishikata, 1984), and by a related oligopeptidase from T. cruzi (Burleigh et al,
1996). As the argininals (arginine aldehydes) probably exist primarily as inactive cyclic
carbinolamines in aqueous solution (Schultz et al, 1989), the actual [I] is probably below the
predicted [I], resulting in an observed K\ that is higher and an observed km that is lower than
the real values.





























































"No inhibition was observed with amastatin, bestatin, chicken ovomucoid, chymostatin, EDTA, EGTA,
elastinal, lima bean tiypsin inhibitor, pepstatin, 1,10-phenanthroline or soybean trypsin inhibitor.
*n.d., not determined. In these cases, the &», was too fast to be measured experimentally.
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Both OP-Tb and OP-Tc were inhibited competitively by E-64, with K[ values of 62.5 uM and
73.7 uM respectively. This contrasts with the widely-held view that E-64 is a class-specific
inhibitor of cysteine proteinases (Barrett et al, 1982), although the inhibition of bovine (3-
trypsin by E-64, by a reversible competitive mechanism with a K\ of 36 uM, has recently been
reported (Sreedharan et al, 1996). These K\ values are, however, considerably higher than
those reported for the inhibition of cathepsin L-like cysteine proteinases by E-64, which are
generally below 10 uM (Barrett et al, 1982).
Benzamidine, a low molecular mass inhibitor of trypsin-like proteases, was a comparatively
poor inhibitor of OP-Tb and OP-Tc, with a K\ of 254 uM and 247 uM respectively, compared
to a K\ of 36 uM for bovine P-trypsin and 12 uM for mast-cell tryptase (Caughey et al, 1993).
In contrast to these proteinases, oligopeptidase B from microbial sources is relatively
unaffected by benzamidine (Kanatani et al, 1991; Yoshimoto et al, 1995). The poor K\ for
benzamidine may account for the relatively weak binding of OP-Tb and OP-Tc to
p-aminobenzamidine-Sepharose, from which they eluted at about 250 mM NaCl. In contrast,
trypsin requires much harsher conditions for elution from this matrix (e.g. 100 mM
CH3COOH) (Hermanson etal, 1992).
Classical reversible aspartic and metalloprotease inhibitors had no affect on the activity of
OP-Tb or OP-Tc (Table 10).
Aprotinin (bovine pancreatic trypsin inhibitor) is a competitive inhibitor of OP-Tb and OP-Tc
with sub-nanomolar K\ values, indicating that it was a better inhibitor of OP-Tb than plasma
kallikrein (K[ = 30 nM) and plasmin (Kt = 1 nM) (Fritz and Wunderer, 1983). While
oligopeptidase B from soybeans is inhibited by aprotinin (Nishikata, 1984), recombinant
oligopeptidase B from T. cruzi is apparently not (Burleigh et al, 1997). Neither OP-Tb nor
OP-Tc were inhibited by any other protein inhibitors of serine and cysteine proteases, including
soybean trypsin inhibitor (SBTI), lima bean trypsin inhibitor, chicken ovomucoid (Table 10), or
the mammalian plasma serpins, kininogens and cystatins (Section 6.8.3, Table 15), supporting
the hypothesis that these enzymes are oligopeptidases with considerable size constraints on
their ability to bind substrates and/or inhibitors.
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If indeed the catalytic-site of oligopeptidases is buried in an "active-site pit" as has been
proposed by Barrett and Rawlings (1992), the differential effects of aprotinin and SBTI may be
explained in terms of the size and tertiary structure of these two inhibitors. Aprotinin has a
highly cross-linked, very compact pear-shaped tertiary structure, about 29A in length and 19A
in diameter at its widest and about 10A at its narrowest point (Huber et al., 1971; Deisenhofer
and Steigmann, 1974) (Figs 33 A and 33B). The region of interaction of aprotinin with its
target protease, containing the Lys15-Ala16 reactive-site bond, is located in this narrow region,
at the "top" of the pear (see arrows in Fig. 33B).
In contrast, SBTI (Fig. 33C) has a far more globular structure, and the overall structure of this
inhibitor is that of a sphere of about 35 A in diameter (Sweet et al., 1974). Here the reactive-
site Arg^-Phe66 bond is located on a curved loop slightly protruding from the bulk of the
molecule (see arrow in Fig 33C). It is evident from the structures presented in Fig. 33 that the
reactive-site region of SBTI would have greater difficulty gaining access to a catalytic site
buried in an active-site "pit" than would be the case for the almost rod-shaped aprotinin
molecule. Furthermore, the regions of contact between aprotinin and trypsin span a single
domain of aprotinin, all located in the "top" of the pear-shaped molecule (shading, in
Fig. 33A). In contrast, the interaction of SBTI with trypsin involves interactions within and
outside the reactive-site region, which are located in two separate domains of SBTI. In
addition to the Pro^-Phe66 region containing the reactive-site bond, the N-terminal Asp'-Phe2
region is believed to form an important interaction with trypsin, where the carboxyl group of
Asp1 forms an ion-pair with Lys60 of trypsin (Sweet et al, 1974). Again, it is unlikely that the
proposed active-site "pit" of oligopeptidases could accommodate two separate domains of a
protein inhibitor. It seems likely that the dimensions of this "pit" in OP-Tb and OP-Tc may lie
somewhere between 10A and 3 5A.
OP-Tb and OP-Tc were inactivated by irreversible organophosphate, sulfonylfluoride and
isocoumarin inhibitors of serine proteinases (Table 11). 3.4-dichloroisocoumarin (DCI) was
the most effective of the non-peptide irreversible inhibitors, with jtass-values of 142.1 ivTVs"1 for
OP-Tb and 167 NfVs"1 for OP-Tc. These k^ values approximate those reported by Harper et




Figure 33. Tertiary structure of protein inhibitors of scrine proteases. (A) Ca-skeletal model of aprotinin.
Shaded region indicates regions in close contact in the trypsin-aprotinin complex (Deisenhofer and Steigmann,
1974). Ribbon-diagrams illustrating the tertiary structure of aprotinin (B) and SBTI (C). Arrows indicate the
reactive-site bond (after Richardson, 1981).



















































"Data reflect the mean k^ ± SD (n = 3).
*ty, at 250 uM inhibitor concentration.
'Assays conducted in the absence of dithiothreitol. In the presence
inhibitor! of OP-Tb by thiol-reactive agents was elevated as follows:
(2559 s). yV-ethylmaleimide (1900 s) andpCMB (1854 s).
of 10 mM dithiothreitol, the ty, for the
iodoacetamide (2520 s), iodoacetic acid
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AEBSF is an irreversible inhibitor of serine proteases, inactivating trypsin and chymotrypsin at
a rate comparable to that of DFP. Both OP-Tb and OP-Tc were more rapidly inactivated by
AEBSF than is serum kallikrein (tass = 0.68 JVTVS'1). Similarly, both oligopeptidases were
inactivated more rapidly by DFP and PMSF than is serum kallikrein, which has k^ values of
0.3 M"\s'' and 0.07 M^.s'1 for these inhibitors respectively (Markwardt et al, 1974).
As AEBSF has enhanced stability at physiological pH values (t̂ 2 = 2 h, compared with 20 min
for DCI, and 1 h for DFP and PMSF) and much lower toxicity [LD50 = 2.8 g.kg'1, oral dose in
mice, as opposed to 3.7 mg.kg"1 for DFP (Markwardt et al., 1974)], AEBSF was routinely
employed in this investigation to inhibit trypanosome oligopeptidases, and in conjunction with
SBTI, to distinguish oligopeptidase activity from trypsin-like serine protease activity, primarily
of plasma kallikrein (see later).
The inhibition of OP-Tb activity by thiol-reactive agents (iodoacetate, iodoacetamide,
TV-ethylmaleimide and pCMB) supports the reductive activation data, suggesting that an
essential cysteine residue is either implicated in catalytic activity or located in close proximity
to the active site. Alkylating reagents attached to this residue could either create an
unfavourable charge environment at the catalytic site or block access of the substrate to the
catalytic apparatus.
In order to test this hypothesis, a variety of thiol-reactive agents with differing physico-
chemical properties were examined for inhibitory potency. 7V-ethylmaleimide andpCMB would
both introduce relatively large bulky groups at the site of covalent attachment which may sterically
interfere with the binding of substrates in the active site. In contrast, iodoacetamide and iodoacetate
are both small molecules which carry opposite charges. Their presence in the active-site may either
electrostatically interfere with substrate binding, or may interfere with the catalytic mechanism of the
enzyme. Iodoacetamide would introduce a neutral amide group at the site of covalent attachment,
whereas iodoacetate would introduce a negatively-charged acetate group (Fig. 34).
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Protein-SH + ICH2CONH2 ^ Protein-SCH2CONH2 + H* + Y
Protein- SH + ICH2COO' ^ Protein-SCH2COO' + H* + I"
Figure 34. Alkylation of free thiol groups in proteins by iodoacetate and iodoacetamide. Alkylation of OP-
Tb by iodoacetamide (ICH2COONH2) introduces a neutral amide, whereas iodoacetate (1CH2COCT) introduces a
negatively charged acetate group (after Benesch and Benesch, 1962).
All four thiol-reactive agents demonstrated inhibitory activity, albeit with different rates of
association with the enzyme. The fact that these compounds do inhibit oligopeptidase activity
may suggest that both steric hindrance, or an unfavourable charge environment at the catalytic
site may interfere with substrate binding and/or catalysis. The presence of competing thiols
such as dithiothreitol elevated the t%, probably by mopping up the inhibitor in solution. In the
absence of a three-dimensional structure of OP-Tb, it is not possible to predict where these
inhibitors may bind to the enzyme, and thus impirair its activity.
These findings parallel those of Polgar (1991) who reported a similar trend (pCMB >
Af-ethylmaleimide > iodoacetamide) in the inhibition of porcine prolyl oligopeptidase by thiol-
reactive agents. Prokaryotic members of the prolyl oligopeptidase family including
oligopeptidase B from E. coli (Kanatani et al, 1991), F. meningosepticum (Yoshimoto et al,
1991) and M. lacunata (Yoshimoto et al, 1995) also display sensitivity to these thiol-reactive
agents, albeit to a lesser extent than their eukaryotic counterparts.
5.11.7 Potential activators of oligopeptidase activity
Oligopeptidase activity was enhanced in the presence of the polyamines spermine and
spermidine, and to a lesser degree, putrescine (Table 12). Polyamines are known to influence
the activity of various enzymes, for example, the serine/threonine protein phosphatases where
micromolar concentrations of spermine enhance activity, but higher concentrations (10 mM)
abolish the activity (Lim Tung et al, 1985).
In contrast to the results reported here, Ashall (1990) reported the inhibition of alkaline
peptidase activity from T. cruzi and C. fasciculata by spermine and spermidine. These
investigators possibly did not use the polyamines at sufficiently low concentrations to
recognise the enhancing effects of these compounds. In this investigation, both spermine and
spermidine (50 uM) enhanced the activity of OP-Tb against Cbz-Arg-Arg-AMC. This
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introduces a possible in vivo mechanism of regulation of oligopeptidase activity within
trypanosomes as trypanosomes contain micromolar concentrations of a number of polyamines,
including spermine and spermidine (Fairlamb et al, 1987).
Neither ATP nor GTP had any effect on the activity of OP-Tb which suggested that it was not
related to the ATP-dependent serine proteases. Heparin was also shown to enhance OP-Tb
activity, raising the possibility that any heparin circulating in the host bloodstream may also
enhance the activity of OP-Tb when released by trypanosomes into the bloodstream.

























"No effect on activity was observed in the presence of ornithine, ATP or GTP.
A number of ATP-dependent serine proteases from E. coli are currently recognised, including the
Clp endopeptidase and endopeptidase La (reviewed by Gottesman and Maurizi, 1992). However,
neither ATP nor GTP had any effect on the activity of OP-Tb or OP-Tc (Table 12), which
suggested that trypanosome oligopeptidases are not related to the ATP-dependent serine proteases.
5.11.8 Influence of divalent metal ions
The influence of divalent metal ions on OP-Tb activity is illustrated in Table 13. None of the
metal ions tested had an activating effect on the activity of OP-Tb. Heavy metal ions, in
particular, iron, zinc, cadmium and mercury were strongly inhibitory, abolishing between 90%
and 100% of the activity. Copper and nickel were also inhibitory, albeit to a lesser extent.
The divalent metal ions of heavy metals and some metalloids can combine with free thiols to
form mercaptides. Zn2+, Hg2+, Cd2* and Fe2+ all completely inhibited oligopeptidase activity at
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1 mM, and each of these metals are known to form mercaptides of varying degrees of
reversibility (Barron, 1951). Furthermore, Cu2+, which partially extinguished oligopeptidase
activity, is known to catalyse the oxidation of free thiols (Barron, 1951).
It would therefore appear that OP-Tb contains a cysteine residue which must be maintained in
its free and reduced state to preserve the activity of the enzyme. The lack of activation by
divalent metal ions (Table 13), together with the lack of inhibition of oligopeptidase activity by
EDTA, EGTA and 1,10-phenanthroline (Table 10), suggests that these oligopeptidases do not
posses metal ion requirements.
































"No effect on activity was observed in the presence of BaCl2.2H2O, CaCI2.2H2O, MgCl2.2H2O or
MnCl2.2H2O.
5.11.9 Hydrolysis of protein substrates
OP-Tb did not hydrolyse a number of major plasma proteins, including BSA, IgG, fibrinogen or
a^HS-glycoprotein at 1:100 (enzyme: substrate) molar ratios (Figs 35A-35D), despite their rapid
hydrolysis by trypsin, a serine protease with some substrate specificity similarities to OP-Tb.
Furthermore, OP-Tb was not inhibited by high molecular mass inhibitors of trypsin-like serine
proteases, including SBTI (reviewed in Birk, 1976a) and lima bean trypsin inhibitor (reviewed in
Birk, 1976b) (Table 10). All these data together suggested that OP-Tb was in fact an
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Figure 35. Digestion of protein substrates by OP-Tb. BSA (A), fibrinogen (B), rabbit IgG (C) and a2-HS-glycoprotein (D) (1:100 molar ratio) were incubated with
OP-Tb and aliquots were removed at 0 min (a), 60 min (b), 120 min (c) and 180 min (d). Lane (e) contains H markers as in Section 2.7.1.1. Similarly, each protein (1:100
enzyme:substrate molar ratio) was incubated with bovine pancreatic trypsin and aliquots were removed at 0 min (f), 60 min (g), 120 min (h) and 180 min (i). Samples were
resolved by reducing Tris-Tricine SDS-PAGE as described in Section 2.7.1.
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5.11.10 Digestion of gelatin in substrate SDS-PAGE
OP-Tb did not degrade gelatin in substrate SDS-PAGE (Fig. 36). T. b. brucei lysates gave rise to
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Figure 36. Digestion of gelatin by OP-Tb on a substrate gel. Gelatin-containing SDS-PAGE of OP-Tb-
containing preparations was performed at pH 8 as described in Section 5.10. Mr markers as in Section 2.7.1.1
(lanes a and h); OP-Tb (100 ng) (b); OP-Tb (200 ng) (c); T. b. brucei lysate (2 jig) (d); T. b. brucei lysate (10 ng)
(e); OP-Tb (400 ng) (f) and OP-Tb (500 ng) (g).
A number of bands of activity are evident between 30 and 45 kDa, with a major band of activity at
30 kDa. These activities are probably attributable to the major cysteine protease of T. b. brucei,
trypanopain-Tb. This enzyme yields multiple bands of activity in samples which have not been boiled
or reduced prior to electrophoresis (L. Troeberg, pers. comm.), as was the case with substrate
SDS-PAGE. Furthermore, additional bands of activity are evident at approximately 85 and 100 kDa.
Despite the activity at 85 kDa in T. b. brucei lysates, no activity was observed in lanes containing
purified OP-Tb. This high molecular mass activity may be attributable to enzymatically active
trypanopain-Tb-L-kininogen complexes. The formation of such complexes has been reported for T. b.
brucei, T. congolense and Leishmania sp (Lonsdale-Eccles et al, 1995) and for T. cruzi (Wiser et al,




Enzymatic characterisation of the trypanosome oligopeptidases OP-Tb and OP-Tc revealed that
they exhibited a preference for basic amino acid residues in the Pi and P2 positions. While only
basic residues were acceptable in Pi, a variety of residues were tolerated in the P2 position. These
included basic residues (arginine and lysine); small, uncharged residues (glycine); hydrophobic
residues (phenylalanine and leucine) and bulky residues (proline), in that order of preference.
There was little preference exhibited at the P3 position, and only a very weak arginine
aminopeptidase activity was detected. These observations were supported by data obtained for
the inhibition of OP-Tb activity by reversible, competitive inhibitors such as peptide aldehydes.
OP-Tb was optimally active at neutral to basic pH, and displayed a similar pH stability profile.
The effects of varying pH on the Km and kat were consistent with those observed for other serine
proteases. As OP-Tb and OP-Tc were active and stable at the pH and ionic strength of the host
bloodstream, the possibility was raised that the enzyme may contribute to disease pathogenesis
through the digestion of host peptide hormones if it is released into the host bloodstream.
OP-Tb and OP-Tc were sensitive to the presence of reducing agents (dithiothreitol >
p-mercaptoethanol > cysteine-HCl), and were inhibited by a number of thiol-reactive agents.
Taken together, these data suggest that an essential cysteine residue within the oligopeptidase
molecule must be maintained in its reduced state for substrate binding and/or catalysis to proceed.
The activation of OP-Tb and OP-Tc by reducing agents and polyamines may constitute two
mechanisms of in vivo regulation of the activity of these enzymes.
In spite of the weak inhibition of OP-Tb and OP-Tc by E-64 and their activation by reducing
agents (which would normally suggest the activity of a cysteine protease) OP-Tb was also
inhibited by mechanism-based inhibitors of serine proteases, including DCI, AEBSF and PMSF.
This led us to conclude that OP-Tb and OP-Tc were thiol-sensitive serine oligopeptidases.
No activity was evident against a variety of protein substrates tested, and these data, together
with the apparent lack of inhibition by high-molecular-mass serine protease inhibitors suggested
that these enzymes were oligopeptidases, and without activity against large protein molecules.
Furthermore, the sensitivity of OP-Tb and OP-Tb to reducing agents, and the inhibition of these
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two enzymes by thiol-reactive agents, together with their apparent lack of activity against
proteins, strongly suggests that OP-Tb and OP-Tc are members of the prolyl oligopeptidase
family of serine proteases (the "S9" family of serine proteases in the nomenclature of Barrett and
Rawlings, 1995).
The results of a detailed study of the interactions of OP-Tb with host system molecules are
presented in Chapter 6. Furthermore, determination of the substrate specificity of these
oligopeptidases facilitated the identification of various inhibitors which were used to evaluate the
potential of trypanosome oligopeptidases as therapeutic targets (Chapter 7).
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Chapter 6
Interaction of OP-Tb with host molecules
6.1 Introduction
There are no known endogenous inhibitors of oligopeptidases (Barrett and Rawlings, 1992).
Furthermore, trypanosome oligopeptidases are active at the physiological pH and ionic strength of
the mammalian host bloodstream (Sections 5.11.2, Fig. 29 and 5.11.3, Fig. 30). This raises the
possibility that if trypanosome-derived oligopeptidases enter the host bloodstream or cerebrospinal
fluid (CSF), the enzyme may remain active and thereby contribute to disease pathogenesis through
the digestion of host peptides. It was therefore decided to investigate whether trypanosome
oligopeptidases were inhibited by endogenous host serine protease inhibitors, and whether
oligopeptidase activity could be detected in the bloodstream of infected hosts.
Host plasma proteases are usually regulated in vivo by host plasma protease inhibitors, which are
generally high molecular mass proteins (50-750 kDa) (Travis and Salvesen, 1983). However, due
to the restricted substrate size accommodated by oligopeptidases, it was not certain whether these
inhibitors would exhibit any inhibitory activity against oligopeptidases.
Protease inhibitors represent more than 10% of the total protein in human plasma. The majority of
these inhibitors are involved in the regulation of serine protease activity, and are collectively referred
to as serpins (serine protease inhibitors) (Travis and Salvesen, 1983) (Table 14). In vivo, these
serpins regulate a variety of physiological processes including blood coagulation, fibrinolysis and
complement activation (Travis et al, 1990). A disturbance of the balance between proteases and
their endogenous inhibitors is frequently implicated in the pathogenesis of disease. Such conditions
have been described for asthma, inflammation and possibly cancer (Section 1.4.2.4).
The most abundant plasma serpin is ai-protease inhibitor (ociPI), also known as cti-antitrypsin.
The most extensively studied target protease of this serpin is the enzyme elastase which is involved
in the degradation of the extracellular matrix. Two other serpins, arantiplasmin (o^AP) and
antithrombin m (ATIII) have a similar specificity for trypsin-like proteases. The physiological
target of 012AP is plasmin, and this inhibitor is therefore involved in regulating fibrinolysis (Travis
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and Salvesen, 1983). Similarly, ATIII regulates the activity of thrombin, and hence the blood
clotting cascade (Travis and Salvesen, 1983). In contrast, oci-antichymotrypsin (aiACT)
specifically inhibits proteases with a chymotrypsin-like specificity (Travis and Salvesen, 1983). In
spite of its name, the physiological target of aiACT is neutrophil cathepsin G, which is released
during inflammatory processes (Travis et al, 1990).
Additionally, a2-macroglobulin (a2M), which is a general inhibitor of all classes of proteases, occurs
in the plasma. Its mechanism of inhibition is distinct from that of typical serpins (Barrett and
Starkey, 1973), and it will thus be dealt with separately from them.
An important structural feature of serpins is the presence of a reactive-site loop which is exposed on
the surface of these proteins. Serpins react irreversibly with their target enzymes in a 1:1 molar
ratio. The formation of enzyme-inhibitor complexes occurs at the reactive-site loop, where the
protease hydrolyses, or attempts to hydrolyse, a peptide bond within the reactive-site loop. The
specificity of the serpin is determined by the amino acid sequence of the reactive-site loop, as it is
this region of the serpin that mimics the substrate. Consequently, it is useful to designate the amino
acid sequence of the reactive-site loop in the same way as that of proteinase substrates by the
method of Schechter and Berger (1967) (Section 1.2, Fig. 5). The reactive site sequences for a
number of serpins and their concentrations in plasma are provided in Table 14.
Interestingly, oligopeptidases are known to catalytically inactivate serpins (Bagarozzi et al, 1996).
While it may initially seem counter-intuitive that an oligopeptidase is able to digest part of a large,
globular, intact protein, it is believed that the reactive-site loop may protrude far enough from the
bulk of the globular protein for the loop to be treated as an isolated peptide. Examination of the
three-dimensional structures of aiACT and ATin reveal that the reactive-site loop does indeed
protrude from the bulk of the protein (Fig. 37). Bagarozzi et al. (1996) reported the
characterisation of a chymotrypsin-like serine oligopeptidase which did not display hydrolytic
activity against any protein substrates, but catalytically inactivated aiPI in the reactive-site loop.
This raised the possibility that OP-Tb may catalytically inactivate host plasma serpins in a sinular
manner.
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"After Carrell and Stein (1995).
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Figure 37. Three-dimensional structures of plasma serpins. Ribbon diagrams of (A) o^-antichymotrypsin
and (B) antithrombin III, illustrating the exposed reactive-site loop containing the Pi residue (after Carrell and
Stein, 1995).
The fact that trypanosome oligopeptidases are without activity against protein substrates suggests
that such oligopeptidases cannot contribute to disease pathogenesis through the digestion of host
proteins. However, mammalian peptide hormones are distributed throughout the body in the blood
plasma and CSF. This raised the possibility that OP-Tb may contribute to disease pathogenesis
through the hydrolysis of host peptide hormones, thereby disrupting their hormonal activity.
Peptide hormones are a diverse group of biologically active peptides, usually with a Mr of between
1 and 6 kDa and approximately 2-60 amino acid residues in length (Carraway and Reinecke, 1989).
The primary function of these peptides is intercellular communication.
128
Unfortunately, there are few reports of the levels of hormonal regulatory peptides in African
trypanosomiasis. The exceptions include adrenocorticotropic hormone (ACTH) in T. congolense
infection (Mutayoba et al., 1995a, 1995b), and atrial natriuretic factor (ANF) in T. brucei infections
(Ndung'u et al, 1992). Both are depleted. The biochemical mechanisms promoting these changes
have not been elucidated. The detection of an amidolytic activity in infected host sera (Section
6.8.4, Fig. 46) and the demonstration that live parasites hydrolyse Cbz-Arg-Arg-AMC (Section
6.8.5, Fig. 47) raised the possibility that oligopeptidase activity in the host bloodstream could
hydrolyse circulating regulatory peptides, resulting the depleted levels of these peptides. The small
size of these peptides makes them ideal substrates for oligopeptidases, and the depletion of peptide
hormone levels in the host bloodstream and CSF may have serious consequences for the metabolic
homeostasis of the host.
It was therefore of interest to determine whether OP-Tb activity is indeed present in the host
bloodstream, and whether or not it was regulated by host plasma serpins in vitro. This necessitated
the purification of two plasma protease inhibitors, cti-protease inhibitor (ociPI) (Section 6.2.4) and
ai-antichymotrypsin (aiACT) (Section 6.2.3) as the purchase of these compounds was beyond the
means of our limited research budget. Furthermore, should plasma protease inhibitors be without
activity against OP-Tb (Section 6.3), it would be of further interest to determine whether OP-Tb
could proteolytically inactivate host plasma serpins (Section 6.6), and whether OP-Tb has any effect
on the peptide hormones that are present in the host bloodstream and CSF (Section 6.7). As no
major kinetic differences were observed between OP-Tb and OP-Tc (Section 5.11.1), only OP-Tb
was employed in these investigations.
6.2 Serpin Purification
6.2.1 Antichymotrypsin activity assay
Plasma aiACT is a serpin which specifically inactivates serine proteases with a chymotrypsin-like
specificity. Therefore, the inhibition of a-chymotrypsin was used to follow aiACT inhibitory
activity throughout the purification. The chymotrypsin-inhibition assay used in the present study is a
fluorometric assay, based on the calorimetric assay of Travis and Morii (1981), employing the
fluorogenic substrate for chymotrypsin, Suc-Leu-Tyr-AMC.
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6.2.1.1 Materials
Assay buffer [50 mM Tris-Cl. pH 8]. Tris (0.3 g) was dissolved in dH2O (40 ml), titrated with HC1
to pH 8, and made up to 50 ml.
Substrate stock solution [1 mM Suc-Leu-Tyr-AMC in DMSO], Suc-Leu-Tyr-AMC (1 mg) was
dissolved in DMSO (1.5 ml), and stored at 4°C.
Substrate working solution [20 uM Suc-Leu-Tyr-AMC in dH?O]. Substrate stock solution
(100 ul) was added to dH2O (4.9 ml).
Enzvme diluent [1 mM HC1. 50 mM CaQ>]. HC1 (32% (v/v), p = 1.16 g.ml'1) (9.8 ul) and
CaCl2.2H2O (0.7 g) were dissolved in dH2O (100 ml).
Chymotrypsin stock solution [1 mg.ml"1 in 1 mM HC1. 50 mM CaCl?], Bovine a-chymotrypsin
(1 mg) was dissolved in enzyme diluent (1 ml) and used immediately.
6.2.1.2 Method
To facilitate screening of a large number of fractions for antichymotrypsin activity, activity assays
were conducted in 96 well fluorimeter plates. Assays were conducted essentially as described in
Section 2.3.3. An appropriate dilution of enzyme (25 ul) was incubated (lOmin, 37°C) in assay
buffer (50 ul) with the sample of interest (25 ul), after which substrate solution (25 ul) was added,
and fluorescence monitored as described in Section 2.3.3.
6.2.2 Antitrypsin activity assay
Inhibition of trypsin was used to follow aiPI inhibitory activity during the purification. Trypsin was
employed as it is available in high purity and is easily detected using synthetic substrates. The
trypsin-inhibition assay is a fluorometric assay, based on the calorimetric assay of Travis and
Johnson (1981), employing the fluorogenic substrate for trypsin Cbz-Arg-AMC.
6.2.2.1 Materials
Assay buffer [10 mM Tris-Ci pH 8] Tris (0.061 g) was dissolved in dH2O (40 ml), titrated with
HC1 to pH 8, and made up to 50 ml.
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Substrate stock solution [1 mM Cbz-Arg-AMC in DMSO], Cbz-Arg-AMC (0.9 mg) was
dissolved in DMSO (1.5 ml), and stored at 4°C.
Substrate working solution [20 uM Cbz-Arg-AMC in dUbO], Substrate stock solution (100 ul)
was added to dH2O (4.9 ml).
Enzyme diluent [2 mM HO], HC1 (32% (v/v); p = 1.16 g.ml"1) (19.6 ul) was dissolved in dH2O
(100 ml).
Trypsin stock solution [0.2 mg.ml'1 in 2 mM HC1], Porcine pancreatic trypsin (1 mg) was dissolved
in enzyme diluent (5 ml) and stored at 4°C for not more than 2 weeks.
6.2.2.2 Method
The assay method was exactly the same as that described for aiACT activity (Section 5.2.12).
6.2.3 ai-Antichymotrypsin purification
ai-Antichymotrypsin (c^ACT) was purified as described by Travis and Morii (1981) with the
exception of an additional molecular exclusion chromatography step on Sephacryl S-100 HR.
6.2.3.1 Materials
10 x Anticoagulant [109 mM trisodium citrate in dHbO]. Trisodium citrate.2H2O (6.4 g) was
dissolved in dH2O (200 ml) and used immediately.
Bovine plasma. Bovine plasma was harvested from freshly slaughtered cattle (Abakor abbatoir,
Cato Ridge). Plasma (1.8 litres) was harvested into two-litre plastic vessels containing
anticoagulant at ten times the nominal concentration (200 ml).
Saturated (NHASOa [4.2 M fNHdbSO*]. (NHO2SO4 (110.88 g) was dissolved in a final volume of
200 ml of dH2O.
Buffer A f30 mM NaHoPO^. 0.02% fm/v) NaNk pH 6.8] NaH2PO4 (4.7 g) and NaN3 (0.2 g) were
dissolved in dH2O (950 ml), adjusted to pH 6.8 with NaOH, and made up to 1 litre.
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Buffer B [50 mM Tris-CL 0.02% fmM NaEk pH 8.0]. Tris (6.05 g) and NaN3 (0.2 g) were
dissolved in dl^O (950 ml) adjusted to pH 8, and made up to 1 litre.
6.2.3.2 Methods
Step 1. Ammonium sulfate fractionation. Pooled plasma (100 ml) was brought to 50% saturation
(NH4)2SO4 by the addition of an equal volume (100 ml) of saturated (4.2 M) (NrLt^SO^ with
constant stirring. The mixture was allowed to settle (2 h, 4°C), centrifuged (25 000 x g, 30 min,
4°C) and the supernatant was retained and dialysed against buffer A (5 x 2 litres, 4°C).
Step 2. Cibacron Blue-Sepharose fractionation. The dialysed fraction from step 1 was applied to a
column of Cibacron Blue F3GA-Sepharose (200 x 25 mm, 4°C, 0.8 ml.min"1) equilibrated with
buffer A. The column was washed extensively with buffer A and once all unbound contaminants
had been eluted, bound protein, including aiACT, albumin and other contaminants, was eluted in a
single step by application of 100 mM NaCl in buffer A. The flow-through fraction from this step
was retained for the purification of aiPI (Section 5.2.4).
Step 3. Rechromatography on Cibacron Blue Sepharose. Fractions from step 2 exhibiting
inhibition of chymotrypsin activity were extensively dialysed against buffer B (5 x 2 litres) and re-
chromatographed on the same column of Cibacron Blue F3GA-Sepharose (200 x 25 mm, 4°C,
0.8 ml.min'1) equilibrated in buffer B. The column was washed extensively with buffer B. Once all
unbound contaminants had been eluted, bound aiACT was eluted in a single step by application of
200 mM NaCl in buffer B.
Step 4. Chromatography on Sephacryl S-100 HR Fractions from step 3 exhibiting chymotrypsin-
inhibitory activity were concentrated by ultrafiltration (Section 2.6.1) to 1 ml and applied to a
Sephacryl S-100 HR column (900 x 15 mm, 4°C, 0.32 ml.min'1), previously equilibrated with
buffer B. Protein was eluted with buffer B. Sample purity was evaluated by Tris-Tricine SDS-
PAGE (Section 2.7.1), and purified aiACT was stored in aliquots at 1 mg.ml'1 in buffer B at -75°C.
6.2.4 ai-Protease inhibitor purification




1 M Tris. Tris (12.1 g) was dissolved in dH2O (100 ml, final volume).
6.2.4.2 Methods
Step 1. Fractionation on DEAE-cellulose. The flow-through fraction from the Cibacron Blue
F3GA-Sepharose column (Section 6.2.3.2) was brought to pH 6.8 with 20 mM HC1, and applied to
a column of DEAE-cellulose (2.5 x 30 cm, 0.8 ml.min"1, 4°C), equilibrated with buffer A. The
column was washed with buffer A until protein was no longer evident in the effluent, and bound
protein was eluted with a linear gradient of 0 to 0.2 M NaCl in buffer A over 14 column volumes.
Step 2. Fractionation on Sephadex G-75. The bound, active fractions from Step 1 were pooled
and adjusted to pH 8 by the addition of 1 M Tris (unbuffered). The sample was concentrated by
dialysis to 5 ml, and applied to a Sephadex G-75 column (2.5 x 100 cm, 0.8 ml.min'1, 4°C)
previously equilibrated with buffer B. Protein was eluted with buffer B. Sample purity was
evaluated by Tris-Tricine SDS-PAGE (Section 2.7.1), and aiPI was stored in aliquots at 1 mg.ml'1
in buffer B at-75°C.
6.3 Inhibition of OP-Tb by serpins
6.3.1 Classical serpins
Inhibition of OP-Tb activity by classical serpins (aiPI, aiACT, 0C2AP, ATDI) was examined by pre-
incubation of OP-Tb (5 min) with a molar excess (at least 50-fold) of each serpin, followed by
addition of a fluorogenic substrate. Control experiments in which the inhibitor was omitted were
performed in parallel.
6.3.1.1 Method
Enzyme activity was assayed as described in Section 2.3.3, except that enzyme (6.25 nM final
concentration, 5 ng, in 25 ul Brij 35), was pre-incubated with assay buffer (50 ul), and either
inhibitor solution (10 ul, 1 uM final concentration) or bovine serum or plasma (10 ul) for 10
min at 37°C, after which substrate (25 ul) was added, and the fluorescence recorded after 3
min. Activity was expressed as percentage activity relative to a control, in which the inhibitor
solution was replaced with
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6.3.2 a2-Macroglobulin
Inhibition of proteases by 012M occurs by a different mechanism to that employed by classical
serpins. The nett effect is the entrapment of an active protease within the (X2M cage. After
entrapment of the protease, the closed 012M cage remains permeable to peptides and small proteins
of molecular masses up to 10 kDa (Barrett, 1981; Barrett and Starkey, 1973). This phenomenon is
exploited in testing for protease entrapment by CX2M.
To investigate whether 012M does indeed entrap a protease, (X2M is incubated with active protease in
approximately equimolar active concentrations. After incubation, the protease-c^M mixture is
resolved by MEC (Section 2.5.2). The exclusion limit of the MEC gel is selected so that the gel
would include the protease but exclude the 012M and o^M-protease complex (Barrett and Starkey,
1973; Mason, 1989). The eluted protein fractions are then examined for protease activity using
small fluorogenic peptide substrates, which are small enough to diffuse into the (X2M cage and are
acted upon by the entrapped protease. If a protease is entrapped by the 012M, there would be an
apparent shift of enzyme activity on the MEC profile, from a point corresponding to the molecular
mass of the native protease to the void volume. While it is conventional to use dithiothreitol in
chromatography buffers when working with OP-Tb, these had to be omitted from all investigations
involving oc2M, as a2M is inactivated by free thiols at concentrations above 1 mM (Barrett, 1981).
6.3.2.1 Materials
MEC buffer T50 mM Tris-Cl. 0.02% (mM NaNy pH 7.4]. Tris (6.05 g) and NaN3 (0.2 g) were
dissolved in dH2O (950 ml), adjusted to pH 7.4 with HC1, and made up to 1 litre.
6.3.2.2 Method
OP-Tb (0.16 pmoles, 20 ul of an 80 nM solution) was combined with a2M (0.16 pmoles, 8 ul of a
193 nM solution, active concentration) in MEC buffer (50 ul). The sample was incubated (1 h,
37°C) and applied to a Sephacryl S-200 MEC column (320 x 15 mm, 0.29 ml.min'1, 4°C).
Fractions (1 ml) were collected and assayed for activity against Cbz-Arg-Arg-AMC as described in
Section 2.3.2. At this point, dithiothreitol could be incorporated into the assay buffer as the 012M-
OP-Tb complexes, and native OP-Tb had already been resolved from one another.
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6.4 Detection of OP-Tb activity in host plasma
OP-Tb activity was determined in the plasma of infected rats by a method adapted from that of
Coleman and Bagdesarian (1976). SBTI, AEBSF and E-64 were used in combinations that
permitted discrimination between OP-Tb activity and that of trypanosome cysteine proteases such
as trypanopain-Tb, and of rat plasma kallikrein, which also digests the peptide substrates employed.
6.4.1 Materials
Assay buffer [50 mM Tris-Cl. 150 mM NaCl. 10 mM dithiothreitol. 0.02% (m/v) NaNV|. Tris
(0.6 g), NaCl (0.9 g), dithiothreitol (0.154 g) and NaN3 (0.02 g) were dissolved in dH2O (80 ml),
titrated to pH 8 with HC1, and made up to 100 ml.
SBTI stock solution [120 uM SBTI in dH-?O]. SBTI (3.6 mg) was dissolved in dH2O (1.5 ml).
This yielded a final assay concentration of 20 uM.
AEBSF stock solution [11 mM AEBSF in dHbO]. AEBSF (4 mg) was dissolved in dH2O (1.5 ml).
This yielded a final assay concentration of 1.85 mM.
E-64 stock solution [10 mM E-64 in dfrkO]. E-64 (5.3 mg) was dissolved in DMSO (50 ul) and
made up to 1.5 ml with dH2O. This yielded a final assay concentration of 1.67 mM.
Substrate stock and working solutions were prepared as described in Section 2.3.1.
6.4.2 Method
The blood of trypanosome-infected rats was harvested at peak parasitaemia by cardiac puncture.
Plasma was obtained by centrifiigation (3 000 x g, 25 min, 40°C) to pellet red blood cells and
trypanosomes. The resultant plasma was examined microscopically to confirm the absence of
parasites and red blood cells. Infected blood (25 ul) was preincubated with assay buffer (50 ul) and
inhibitor stock solution (25 ul per inhibitor, 10 min). If inhibitors were omitted, dH2O (25 ul)
replaced the inhibitor solution. Final assay volume was 150 ul. Substrate working solution (25 ul)
was added after preincubation, and fluorescence determined as described in Section 2.3.2.
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6.5 Hydrolysis of Cbz-Arg-Arg-AMC by live trypanosomes
Live trypanosomes hydrolyse Cbz-Phe-Arg-AMC (Lonsdale-Eccles et al, 1995), a substrate
that is also hydrolysed by purified OP-Tb (Section 5.11.1, Table 9). Leupeptin, a potent
inhibitor of OP-Tb activity (Section 5.11.6, Table 10), completely inhibits this hydrolysis of
Cbz-Phe-Arg-AMC by live parasites, while in the presence of E-64 only 50% of the activity is
inhibited (Lonsdale-Eccles et al., 1995). This, together with the association of a
Cbz-Arg-Arg-AMC hydrolysing activity with the trypanosome cell membrane (Section 3.11.1,
Fig. 9) and the partial labelling of the surface of trypanosomes by anti-OP-Tb antibody
(Mpimbaza, Lonsdale-Eccles and Wells, unpublished studies) raises the possibility that OP-Tb
may also be a membrane-bound surface enzyme. To explore this possibility further, the
hydrolysis of Cbz-Arg-Arg-AMC by live trypanosomes in the presence of serine protease
inhibitors was investigated.
6.5.1 Materials
As per Sections 2.3.1, 3.2.1. and 6.4.1.
6.5.2 Method
T. b. brucei (8.325 x 106 cells) were resuspended in PSG (75 ul) in a 96-well fluorescent
microplate, and pre-incubated (37°C, 10 min) either in the absence of inhibitors, or in the presence
of AEBSF (1 mM, final concentration) or inhibitory anti-OP-Tb IgY (1 mg.ml'1) (Section 4.9.3).
Substrate was then added and fluorescence monitored (Section 2.3.2) at timed intervals for 10 min.
6.6 lnactivation of serpins by OP-Tb
Serpin inactivation by OP-Tb was investigated as described by Mast et al. (1991). OP-Tb and
serpins were incubated with the serpin in 30-fold molar excess. The mixture was then resolved by
Tris-Tricine SDS-PAGE (Section 2.7.1), and the electrophoretic pattern compared with that of a
control serpin sample which had not been pre-incubated with OP-Tb. Serpins inactivated by
cleavage within their reactive-site loop are characterised by release of a C-terminal peptide of
approximately 4 kDa. While this 4 kDa band is often not visible on SDS-PAGE gels, the
inactivation of serpins by cleavage in the reactive-site loop induces a conformational change in the
serpin, causing it to migrate to a noticeably different position on an SDS-PAGE gel, relative to the
intact serpin (Kalsheker et al, 1996; Mast et al, 1991).
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6.6.1 Materials
2 x OP-Tb assay buffer [100 mM Tris-Cl. 2 mM dithiothreitol. pH 8], Tris (1.21 g) and
dithiothreitol (0.031 g) were dissolved in dH20 (90 ml), adjusted to pH 8, and made up to 100 ml.
2 x Papain assay buffer [340 mM sodium acetate. 60 mM acetic acid. 4 mM EDTA, 8 mM
dithiothreitol. pH 5.51. CH3COONa.3H2O (4.6 g), glacial acetic acid (34 ul) and
Na2EDTA.2H2O (0.15 g) were dissolved in dH2O (90 ml), adjusted to pH 5.5 with NaOH, and
made up to 100 ml.
6.6.2 Methods
Serpin digests were performed as described by Mast et al. (1991). Serpin (50 ul) and OP-Tb
(50 ul) were combined in a 1:30 (enzyme:serpin) molar ratio in assay buffer (100 ul) and
incubated at 37°C for 2 h. The reaction was terminated by the addition of non-reducing
sample treatment buffer (200 ul) and boiling (10 min). Samples were resolved by non-
reducing Tris-Tricine SDS-PAGE (Section 2.7.1) and protein visualised by Coomassie Blue
staining (Section 2.7.3).
Positive controls were conducted as follows: bovine ociPI was cleaved with S. aureus V8
proteinase (1:20 molar) ratio in OP-Tb assay buffer, and separately with papain or sheep
cathepsin L (1:30 molar ratio) in papain assay buffer. Bovine ctiACT and human a2AP and
ATIII were incubated with human neutrophil elastase (1:20 molar ratio), and separately papain
or sheep cathepsin L (1:30 molar ratio) in papain assay buffer.
6.7 Interaction with regulatory peptides
Reversed-phase high-performance liquid chromatography (RP-HPLC) provides a convenient
method for the rapid separation and sensitive resolution of mixtures of low Mr peptides (Krstulovil
and Brown, 1982). RP-HPLC was used in this investigation to monitor the hydrolysis of
mammalian regulatory peptides by OP-Tb.
6.7.1 Materials
2 x Non-reducing assay buffer [100 mM Tris-Cl. pH 8] Tris (1.21 g) was dissolved in ddH2O
(90 ml), adjusted to pH 8, and made up to 100 ml.
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2 x Reducing assay buffer flOO mM Tris-Cl. 20 mM dithiothreitol. pH 8], Tris (1.21 g) and
dithiothreitol (0.308 g) was dissolved in ddH2O (90 ml), adjusted to pH 8, and made up to 100 ml.
Peptide substrate solution (1 ug.uT1). Peptide (100 ug) was dissolved in ddH2O (100 ul),
aliquotted, and stored at -20°C.
Stopping reagent [5% (v/v) TFA in ddFkO]. TFA (500 ul) was made up to 10 ml with ddH2O.
Solution A [0.1% fv/v) TFA in ddH>O]. TFA (1 ml) was made up to 1 litre with ddH2O. The
solution was degassed by sonication prior to use.
Solution B [0.1% (y/v) TFA in acetonitrile]. TFA (1 ml) was made to 1 litre with acetonitrile. The
solution was degassed by sonication prior to use.
6.7.2 Methods
HPLC was performed as described by Tetaert et al. (1994). Peptide (10 ug, 10 ul of a 1 ug.ul'1
solution) was pre-incubated (10 min, 37°C) in a solution of assay buffer (25 ul) and ddH2O (10 ul),
after which enzyme solution (5 ul) was added, and the reaction mixture incubated at 37°C.
Stopping reagent (50 ul) was added at 0,1,4 and 16 hours. Products were resolved by RP-HPLC.
HPLC was carried out on a Waters Associated apparatus, equipped with a Waters 994 DAD
detector. The acidified reaction mixtures (50 ul) were applied to a Vydac Cig protein and peptide
column (150 x 3.9 mm, 1 ml.min"1), previously equilibrated in solution A. Elution of bound material
was achieved with an isocratic gradient of 10-80% solution B over 20 min (3.5% per min,
1 ml.min"1). Absorbance was monitored at 214 nm.
6.8 Results and Discussion
6.8.1 Purification of di-antichymotrypsin
The chymotrypsin-inhibitory activity present in the ammonium sulfate supernatant was resolved
from trypsin-inhibitory activity by chromatography on Cibacron Blue F3GA-Sepharose
(Fig. 38). A large peak of chymotrypsin-inhibitory activity was bound by the Cibacron Blue
F3GA Sepharose at pH 6.8, whilst trypsin-inhibitory activity and some chymotrypsin-inhibitory
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activity were present in the unbound fraction. Chymotrypsin-inhibitory activity present in the
flow-through fraction was probably attributable to aiPI (Travis and Morii, 1981). The trypsin-
inhibitory pool was retained for the purification of otiPI, while aiACT was purified from the
chymotrypsin-inhibitory fraction that was retained by Cibacron Blue F3GA at pH 8.
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Figure 38. Chromatography of c^ACT on Cibacron Blue F3GA-Sepharose at pH 6.8. Cibacron Blue
F3GA-Sepharose (200 x 25 mm, 0.8 ml.min"1) was equilibrated in buffer A [30 mM Nal^PO^ 0.02% (m/v)
NaN3, pH 6.8]. After elution of unbound protein with buffer A, bound protein was eluted in a single step with 100
mM NaCl in buffer A, applied at point I. (—) A28&; (-D-) % inhibition of chymotrypsin activity; (•••••) %
inhibition of trypsin activity.
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Figure 39. Rechromatography of atACT on Cibacron Blue F3GA-Sepharose at pH 8. Cibacron Blue
F3GA-Sepharose (200 x 25 mm, 0.8 ml.min'1) was equilibrated in buffer B [50 mM Tris-Cl, 0.02% (m/v) NaN3,
pH 8.0]. After elution of unbound protein with buffer B, bound protein was eluted in a single step with 100 mM NaCl
in buffer B, applied at point i. (—) A280, (•••••) % inhibition of chymotrypsin activity.
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Rechromatography at pH 8 of the bound, chymotrypsin-inhibitory fraction from Cibacron-Blue
F3GA at pH 6.8 caused retention of chymotrypsin-inhibitory activity by the matrix (Fig. 39).
The bound, chymotrypsin-inhibitory fraction contained protein contaminants at approximately
27 and 50 kDa (Fig. 41, lane e). These contaminants were successfully removed by MEC on
Sephacryl S-100 HR (Fig. 40). The resultant chymotrypsin-inhibitory fraction was
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Figure 40. Chromatography of diACT on Sephacryl S-100 HR Sephacryl S-100 HR (900 x 15 mm, 4°C,
0.32 ml.min"1) was equilibrated in buffer B [50 mM Tris-Cl, 1 mM dithiothreitol, 0.02% (m/v) NaN3, pH 8].
After loading the column with sample (500 (xl), protein was eluted with buffer B. (—) A^o, (•••••) % inhibition
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Figure 41. Evaluation of aiACT purification by Tris-Tricine SDS-PAGE. (a) H markers (as in
Section 2.7.1.1); (b) bovine plasma (25 ug); (c) (NH^SC^ supernatant (25 ng); (d) Cibacron Blue F3GA-Sepharose
bound fiaction (15 ng); (e) second Cibacron Blue F3GA-Sepharose bound fraction (15 ng); (f) Sephacryl S-100 HR
inhibitory fraction (5 ng). Samples were resolved by non-reducing Tris-Tricine SDS-PAGE (Section 2.7.1) and
proteins visualised with silver staining (Section 2.7.4).
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6.8.2 Purification of di-protease inhibitor
The unbound peak from Cibacron Blue F3GA-Sepharose chromatography at pH 6.8 exhibiting
trypsin-inhibitory activity was applied to a DEAE-cellulose resin, and bound proteins eluted with a
gradient of 0-0.2 M NaCl (Fig. 42). The o^PI eluted at approximately 40 mM NaCl, and the active
fractions were pooled and further resolved by molecular exclusion chromatography on Sephadex
G-75 Fig. 43). The resultant inhibitory fraction was homogeneous by Tris-Tricine SDS-PAGE
(Fig. 44), giving a single band at about 68 kDa..
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Figure 42. Chromatography of ctiPI on DEAE-cellulose. DEAE-cellulose (300 x 25 mm, 4°C,
0.49 ml.min"1) was equilibrated in buffer B [50 mM Tris-Cl, 1 mM dithiothreitol, 0.02% (m/v) NaN3, pH 8].
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Figure 43. Chromatography of aiPI on Sephadex G-75. Sephadex G-75 (1000 x 25 mm, 4°C,
0.49 ml.min'1) was equilibrated in buffer B [50 mM Tris-Cl, 1 mM dithiothreitol, 0.02% (m/v) NaN3> pH 8].
After loading the column with sample (500 ul), protein was eluted with buffer B. (—) A280, ("D-) % inhibition
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Figure 44. Evaluation of cciPI purification by Tris-Tricine SDS-PAGE. (a) Mr markers (as in Section
2.7.1.1); (b) bovine plasma (25 ^g); (c) (NRO2SO4 supernatant (25 ng); (d) Cibacron Blue F3GA-Sepharose unbound
fraction (15 )ig); (e) DEAE<ellulose bound fraction (10 ng); (f) Sephadex G-75 inhibitory fraction (7.5 ng). Samples
were resolved by non-reducing Tris-Tricine SDS-PAGE (Section 2.7.1) and proteins visualised with silver staining
(Section 2.7.4).
6.8.3 Inhibition of OP-Tb by host protease inhibitors
OP-Tb activity was not inhibited by any host plasma protease inhibitors, including general serine
protease inhibitors (aj-protease inhibitor, ai-antichymotrypsin, a^antiplasmin and antithrombin HI)
and the two major cysteine protease inhibitors of mammalian plasma and cerebrospinal fluid,
kininogen and cystatin C (Abrahamson et ai, 1986; Barrett et al, 1984; Table 15). No inhibition
was observed by either bovine serum or plasma (results not shown). OP-Tb was incubated with
bovine plasma and bovine serum in case these fluids contained an as-yet-undescribed protease
inhibitor that may have inhibitory activity against OP-Tb.
No shift in the elution profile of OP-Tb and OP-Tb-o^M mixtures was observed, and it was
therefore concluded that no complex formation occurred between (X2M and OP-Tb (Fig. 45).
This suggests that CI2M is not eflfective in controlling OP-Tb activity in the host bloodstream, as was
observed for the other classical host plasma serpins (Section Table 15). There are a number of
potential reasons for this. It is possible that OP-Tb is incapable of cleaving the CC2M bait region.
This is plausible as it has been demonstrated that OP-Tb is incapable of cleaving any of the protein
substrates tested (Section 5.11.9, Fig. 35 and Section 6.8.6, Fig. 48). Additionally, Barrett (1981)
suggested that (X2M does not entrap proteases larger than 75 kDa. As native OP-Tb has a H- of
approximately 80 kDa, it is possible that it is simply too large to fit into the CI2M trap.
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"Inhibitors at 1 \iM final concentration.
*Data reflect mean % ± S.D. (n=3).
Tn 50 raM Tris-Cl, 1 mM dithiothreitol, pH 8.
'in 50 mM Tris-Cl, pH 7.5.
In 50 mM Tris-Cl, 1 mM CaCl2) pH 7.5.
4n 270 mM sodium acetate, 30 mM acetic acid, 2 mM EDTA, 4 mM dithiothreitol, pH 5.5.
*n.d., not determined.
These data together suggest that OP-Tb, if released into the host bloodstream, would not be
regulated by any of the host plasma protease inhibitors. The enzyme would therefore remain active
in the host bloodstream, where it could contribute to disease pathogenesis through the digestion of
host peptides. With this in mind, acutely infected murine plasma and chronically infected bovine































Figure 45. Interaction of OP-Tb with a2M. a2M, OP-Tb and potential complexes of a2M and OP-Tb were
resolved by MEC in equilibration buffer [50 mM Tris-Cl, 1 mM dithiothreitol, 0.02% (m/v) NaN3, pH 8] on a
Sephacryl S-200 column (320 x 15 mm, 0.32 ml.min'1). (A) Elution profile for a2M alone, (B) elution profile
for OP-Tb alone, (C) elution profile for ct2M after incubation with OP-Tb. (-) A^o, ("•) activity against
Cbz-Arg-Arg-AMC.
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6.8.4 Detection of activity in host plasma
Activity against Cbz-Arg-Arg-AMC was detected in the plasma of infected rodents. This activity
was not inhibited by E-64 suggesting that it was not attributable to host or trypanosome cysteine
proteases such as cathepsin L or trypanopain-Tb. Inhibition of the activity by AEBSF suggested
that a trypsin-like serine protease was responsible for the observed activity, whilst a lack of
inhibition by SBTI suggested that this protease was in fact a serine oligopeptidase rather than a
blood-derived protease such as kallikrein or thrombin. The activity was not detected in the plasma
of uninfected rodents. The same AEBSF-sensitive, SBTI-insensitive activity against
Cbz-Arg-Arg-AMC was also observed in chronically infected bovine serum, albeit to a lesser
degree (approximately 500 AF.min"\25 pi serum'1). Again, this activity was not observed in the
sera of uninfected cattle (results not shown).










Figure 46. Detection of serine oligopeptidase activity in infected rat plasma. Enzyme assays were conducted
exactly as described in Section 5.4.2 on the plasma of infected (shaded bars) and uninfected (unshaded bars) rat
plasma. The inhibitors E-64, SBTI and AEBSF were used to discriminated between serine and cysteine protease
activity, and between protease and oligopeptidase activity.
Peptidase activity has been described in the plasma of mice infected with T. b. brucei (Knowles et
al, 1987), and Tetaert et al. (1993) reported the unusual cleavage of peptide hormones in the
serum of rats infected with T. b. brucei, concluding that the activity was attributable to a serine
endopeptidase. The present study demonstrated a serine oligopeptidase activity in the plasma of
rats infected with T. b. brucei, and it is quite likely that this is the same activity identified by Tetaert
et al. (1993). However, Tetaert et al. (1993) also reported that the activity observed in infected rat
serum was inhibited by 5 mM DFMO and 3.5 mM EDTA. OP-Tb is not inhibited by either DFMO
(Section 7.6.1, Table 16) or EDTA (Section 5.11.6, Table 10), and it is possible that Tataert's
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group was working with more than one protease, although exactly how DFMO, a highly specific
suicide inhibitor of ornithine decarboxylase, could inhibit a proteolytic enzyme is not obvious.
6.8.5 Cbz-Arg-Arg-AMC hydrolysis by live trypanosomes
The hydrolysis of Cbz-Arg-Arg-AMC by live trypanosomes (Fig. 47) was almost completely
abolished in the presence of AEBSF, a potent inhibitor of serine proteases, including OP-Tb.
Furthermore, this activity was inhibited by approximately 50% in the presence of inhibitory
anti-OP-Tb antibodies (Section 4.9.3, Figs 18 and 19). Taken together, these data suggest that
OP-Tb may be present on the trypanosome cell-surface or may be released by a type III









Figure 47. Hydrolysis of Cbz-Arg-Arg-AMC by live trypanosomes. Live T. b. brucei (8.325 x 106 cells) were
resuspended in PSG (75 nl) containing no inhibitors (-O-), AEBSF (1 mM, - D - ) or anti-OP-Tb IgY (1 mg-inl"1,
- A - ) . After pre-equilibration (10 min), activity against Cbz-Arg-Arg-AMC was determined as described in
Section 2.3.3. The S.D. for each data point was less than ±10%.
Metalloproteinases are known to be present on the cell surface of related Leishmania parasites
(Etges and Bouvier 1993), and the gene encoding the T. brucei homologue of this enzyme has
been isolated (El-Sayed & Donelson, 1997). However, the metalloproteinase does not have
activity against Cbz-Arg-Arg-AMC (Bouvier et al, 1990). Furthermore, although the
Cbz-Arg Arg-AMC hydrolysing activity was only inhibited by 50% in the presence of
inhibitory antibodies, AEBSF caused almost 100% inhibition, suggesting that this activity is
entirely attributable to a serine protease. Thus, either an additional surface-bound serine
protease is responsible for the remaining 50% of the activity, or the antibodies are not able to
inhibit all of the surface-bound enzyme. The trypanosome cell-surface is known to be coated
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with variable surface glycoproteins (VSG; Donelson and Turner, 1985), and it is possible that
such antibodies may experience some steric hindrance during antibody-antigen interaction at
the cell surface, accounting for this partial inhibition.
6.8.6 Inactivation of serpins by OP-Tb
No inactivation of a2AP, aiPI, otiACT or ATIH by OP-Tb was observed. However, all these
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Figure 48. Proteolytic digestion of serpins. Digestion of (A) oc2AP, (B) a,PI, (C) a] ACT, (D) ATIII by
proteolytic enzymes. Serpins were incubated with proteases for 2 h in assay buffer (Section 5.5). Lane (a) Mr
markers (Section 2.7.1.1); (b) intact serpin; (c) serpin incubated with OP-Tb; (d) serpin incubated with either
S. aureus V8 proteinase (B) or human neutrophil elastase (HNE) (A, C, D); (e) serpin incubated with ovine
cathepsin L; (f) serpin incubated with papain. Reaction mixtures were resolved by non-reducing Tris-Tricine
SDS-PAGE (Section 2.7.1).
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Native oc2AP, and a2AP incubated in the presence of OP-Tb exhibited the same electrophoretic
mobility (Fig. 48), suggesting that OP-Tb did not hydrolyse this serpin. However, a2AP incubated
in the presence of human neutrophil elastase resulted in a mixture of cleaved and uncleaved o^AP,
producing bands at approximately 60 and 70 kDa. Human a2AP incubated in the presence of
cathepsin L and papain was completely cleaved, producing a major band at 60 kDa (Fig. 48A).
Similar results were obtained for aiPI (Fig. 48B) and ctiACT (Fig. 48C).
Similarly, native ATIII and ATIII incubated in the presence of OP-Tb did not exhibit any shift in
electrophoretic mobility, suggesting that ATIII is not hydrolysed by OP-Tb (Fig. 48D). In contrast
to a2AP, aiPI and aiACT, incubation of ATIII with human neutrophil elastase, cathepsin L or
papain resulted in a band at a slightly higher molecular mass than the native enzyme. This
phenomenon has also been observed for cleaved ATIII by Mast et al. (1991). The cleavage points













Figure 49. Reactive-site loop cleavage sites of serpins. Some reactive-site loop cleavage sites on serpins by
papain, S. aureus V8 proteinase (SV8) and human neutrophil elastase (HNE) have been determined (after Mast et al.,
1991). P| residues are given in bold type. In the case of <x2AP, Pi for plasmin is Arg, while Pi for chymotrypsin is
Met. Cathepsin L cleavage sites have not been determined for these serpins.
Pathogen-derived proteases are known to catalytically inactivate host protease inhibitors, and
disturbances in the protease-inhibitor levels in the bloodstream and CSF may have serious
implications for the host (section 1.3.2.4). Bagarozzi et al. (1996) described the inactivation of
aiPI in the reactive-site loop by a an oligopeptidase which otherwise had no activity against any
other protein substrates. Therefore, OP-Tb was examined for activity against mammalian serpins.
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None of the plasma serpins tested, including aiPI, aiACT, a2AP and ATin were hydrolysed by
OP-Tb. However, all serpins were cleaved by cathepsin L, papain, and either human neutrophil
elastase or S. aureus V8 proteinase. This suggests that OP-Tb present in the host bloodstream does
not contribute to pathogenesis through the digestion of host plasma serpins.
6.8.7 Interaction with regulatory peptides
Hydrolysis of peptide hormones was monitored by RP-HPLC. OP-Tb degraded neurotensin,
reduced [Arg8]vasopressin (AVP), ANF and glucagon. The degradation of neurotensin by OP-Tb
is illustrated in Fig. 50. The gradual disappearance of the intact neurotensin peak at approximately
14min is evident, as is the gradual appearance of peaks at 9 min and 13 min, attributable to







Figure 50. Degradation of neurotensin by OP-Tb. Neurotensin (10 ug) was incubated with OP-Tb (10 ng) for
various time intervals and the reaction mixtures resolved by RP-HPLC as described in Section 6.7.1.
The amino acid sequences and putative cleavage sites of the peptide hormones hydrolysed by
OP-Tb are illustrated in Fig. 51. Similar data for peptides not degraded by OP-Tb are illustrated in
Fig. 52. The cleavage of mammalian peptide hormones was undertaken for two reasons, (1) to
determine the possible substrate size-exclusion limit for OP-Tb, and (2) to determine whether
OP-Tb was able to degrade host peptide hormones, thereby suggesting a potential role for OP-Tb in
the pathogenesis of African trypanosomiasis.
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Preliminary studies with a variety of peptides containing suitable cleavage sites suggested that
molecules that were larger than 4 kDa were not cleaved by OP-Tb, indicating that this may
represent an approximate substrate-size exclusion limit.
1





1 I I I
ANF S-L-R-R-S-S-C-F-G-G-R-M-D-R-I-G-A-Q-S-G-L-G-C-N-S-F-R-Y
I I
Figure 51. Peptide hormones cleaved by OP-Tb. Potential cleavage sites are indicated by arrows (1), paired
basic residues are indicated in bold type. Disulfide bridges are indicated by a solid line. This putative cleavage point
in neurotensin (1673 Da) has been confirmed by amino acid analysis. Abbreviations: AVP ([Arg8]vasopressin, 1084
Da), ANF (atrial natriuretic factor, 3080 Da).
Neurotensin is a peptide hormone present in the blood and CSF of mammals, where it regulates a
number of metabolic processes by up-regulating the secretion of a number of protein hormones.
Neurotensin enhances the secretion of growth hormone, prolactin and thyrotropin (Aronin et al.,
1986). Rivier et al. (1977) demonstrated that while the integrity of the eight N-terminal residues of
neurotensin was unrelated to its biological activity, any cleavage in the six C-terminal residues
abolished its biological activity. As OP-Tb would most likely cleave neurotensin in this region, it is
reasonable to assume that neurotensin cleavage by OP-Tb would destroy its biological activity.
OP-Tb may therefore be responsible for the depletion of neurotensin in infected hosts. The nett
effect would be a reduction in the secretion of growth hormone, prolactin and thyrotropin. The
general state of emaciation, compromised immune system and thyroid dysfunction observed in
trypanosome-infected animals (Section 1.2.1) may be attributable, at least in part, to the depletion of
host neurotensin, and the down-stream effects that such cleavage would have.
Intact ANF was cleaved into multiple peptides by OP-Tb, as revealed by RP-HPLC (result not
shown). This suggests that OP-Tb may also cleave ANF in the host bloodstream, and depleted
levels of this hormone have been reported by Ndung'u et al. (1992). ANF plays an important role
in the regulation of blood volume, blood pressure, diuresis and natriuresis (deBold, 1985).
Cleavage of ANF, particularly in the five residue C-terminal region, is known to abolish the
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biological activity of ANF (Kangawa et al, 1984). As OP-Tb can cleave ANF in vitro, possible at
the putative cleavage site in the five residue C-terminal region, it is possible that OP-Tb may reduce
circulating levels of ANF in the host bloodstream thereby effecting alterations in blood pressure and
blood volume. This is consistent with the symptoms of African trypanosomiasis (Section 1.2.1).
Glucagon (3483 Da), which is also cleaved by OP-Tb in vitro (Fig. 51), plays an important role in
glucose homeostasis, where it mobilises glucose from carbohydrate stores in response to
hypoglycaemia. The fact that OP-Tb is active in the bloodstream, and that OP-Tb hydrolysed
glucagon in vitro suggests that OP-Tb may degrade circulating glucagon in the bloodstream of
infected hosts, thereby reducing blood-glucagon levels. Clinical manifestation of depressed
glucagon levels would include hypoglycaemia and anaemia (Walsh, 1987), and both symptoms are
not inconsistent with those observed in African trypanosomiasis (Section 1.2.1).
[Arg8]vasopressin was only cleaved by OP-Tb after reduction of the disulfide bridge (Fig. 51),
and intact vasopressin was not cleaved (Fig. 52). As only intact vasopressin has biological
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Figure 52. Peptide hormones not cleaved by OP-Tb. Potential cleavage sites are indicated by arrows (1), paired
basic residues are indicated in bold type. Disulfide bridges are indicated by a solid line. Abbreviations: SP (substance
P, 1348 Da), ANG1 (angiotensin 1, 1296 Da), INSP (insulin oxidised f$ chain, 3496 Da), PP (pancreatic polypeptide,
4182 Da), ACTH (adrenocorticotrophic hormone, 4541 Da) and GHRF (growth-hormone releasing factor, 5040 Da).
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6.9 Concluding remarks
OP-Tb is not effectively inhibited in the mammalian host bloodstream and OP-Tb activity was
not inhibited in the presence of host plasma protease inhibitors of cysteine and serine proteases,
or the general protease inhibitor (X2M. Furthermore, an enzyme activity attributable to OP-Tb
was detected in the plasma of infected rodents and cattle, and live parasites were able to
hydrolyse Cbz-Arg-Arg-AMC. The inhibition of this hydrolysis by anti-OP-Tb antibodies
suggested the presence of OP-Tb on the cell surface. It would therefore appear that OP-Tb is
exposed to the extracellular milieu of the host bloodstream, either bound to the cell-surface of
the trypanosome, or released by the parasite into the host bloodstream.
OP-Tb was unable to catalytically inactivate host plasma serpins, although this phenomenon
has been reported for a pollen-derived oligopeptidase (Bagarozzi et ai, 1996). However,
OP-Tb was found to degrade a number of host peptide hormones, and it is suggested that
OP-Tb may contribute to the pathogenesis of African trypanosomiasis through the digestion of
peptide hormones in the host bloodstream, thereby interfering with the normal metabolic
homeostasis of the host animal.
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Chapter 7
OP-Tb as a therapeutic target
7.1 Introduction
The chemotherapy of African trypanosomiasis currently involves five major trypanocidal drugs
(Pentacarinate® Berenil®, Germanin®, Arsobal® and Ornidyl™), the chemical structures of which
are illustrated in Fig. 53. However, currently-employed chemotherapeutic strategies are plagued
by several problems, including toxic side-effects, increasing drug resistance, and high cost.
Pentamidine. Pentamidine is an aromatic diamidine, most commonly marketed as the isethionate
salt (Mr 593), known as Pentacarinate® (May & Baker, United Kingdom). While the biochemical
mechanism of the anti-trypanosome activity of pentamidine is not understood (Pepin & Milford,
1994), pentamidine has been shown to be a reversible inhibitor of trypanosome
S-adenosyl-L-methionine decarboxylase, and thus it has been suggested that it may down-regulate
the synthesis of trypanosome polyamines (Bitonti et al. 1986). Pentamidine has also been proposed
as an inhibitor of glycolysis, DNA and RNA synthesis, and amino acid transport within
trypanosomes (Sands et al., 1985). During therapeutic regimens, pentamidine typically reaches
concentrations of up to 13 uM in the host bloodstream (Sands et al., 1985), and is actively
concentrated by bloodstream-form trypanosomes which possess pentamidine transporters, and
is present at intracellular concentrations of approximately 80 uM (Damper and Patton, 1976).
Pentamidine administration has frequent and severe side-effects, including thrombocytopaenia,
arrhythmias and chronic liver and renal failure, which are exacerbated in HIV-co-infection, a
common complication of human African trypanosomiasis (Goa and Campoli-Richards, 1987).
The new-found application for pentamidine in the treatment of Pneumocystis carinii
pneumonia in AIDS patients has created a new and very lucrative market for pentamidine, and
has resulted in an increase in the cost of the drug, from US$1 to US$30 per 300 mg vial (Pepin
and Milford, 1994).
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Diminazene. Diminazene, marketed in the form of diminazene aceturate (Mr 587) as Berenil
(Hoechst Veterinar, Munich, Germany) is only employed in veterinary chemotherapy. The mode of
action of diminazene is not understood but it is known to irreversibly inhibit trypanosome
S-adenosyl-L-methionine decarboxylase (Bitonti et al, 1986) and to selectively block kinetoplast















Figure S3. Chemical structures of trypanocidal drugs (after Wang, 1995).
Hoechst has never been interested in marketing diminazene for human trypanosomiasis because
the limited market does not justify the high cost of the required toxicological studies. Thus,
while Berenil® costs only US$1.50 per treatment, this drug is restricted to veterinary use
(Pepin and Milford, 1994). Nevertheless, due to its effectiveness and low cost, it has been
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used effectively in endemic countries to treat human trypanosomiasis, where it has a low
(typically 5-15%) relapse rate (Abaru and Matova, 1984). With the exception of two cases of
fatal reactive encephalopathy (De Raadt, 1967) there seem to be few toxic side-effects.
Suramin. Suramin has been used since 1923 for the chemotherapy of human trypanosomiasis
(Kleine and Fischer, 1923). Suramin, the symmetrical urea of the sodium salt of/w-aminobenzoyl-
/w-amino-/7-methylbenzoyl-l-naphthylamino-4,6,8-trisulfonic acid, is a sulfated naphthylamine
(Mr 1429), usually marketed as Germanin® or Bayer 205® (Bayer, Leverkusen, Germany). The
biochemical mechanism of the anti-trypanosome activity of suramin is not known. However, it is
known to inhibit numerous enzymes in vitro, including L-a-glycerophosphate oxidase (Fairlamb
and Bowman, 1977), RNA polymerase, fumarase, hexokinase, urease and trypsin (Hawking, 1978).
Suramin reaches a plasma concentration of 100 uM (Collins et al, 1986), and similar intracellular
concentrations within trypanosomes (Wang, 1995). In addition to its trypanocidal activity, it is also
known to be an inhibitor of viral reverse transcriptase (De Clercq, 1979), and has been investigated
as a potential lead-compound for the design of new anti-viral (De Clercq, 1987), anti-tumour (Le
Rocca et al, 1990) and anti-fertility (Jones et al, 1996) agents.
Suramin, which costs approximately US$35 per treatment, is regarded as a most effective drug
for the treatment of early-stage trypanosomiasis (Apted, 1980). While few side effects apart
from moderate renal toxicity have been documented, patients who are moribund on admission
are reported to die immediately after the administration of suramin (Pepin et al, 1989).
Concomitant onchocerciasis, another common co-infection with African trypanosomiasis,
introduces the risk of hypersensitivity reactions, and the use of suramin is not recommended in
these cases (Pepin and Milford, 1994). Due to the poor CNS penetration of pentamidine,
diminazene and suramin, these drugs are not effective in treating late-stage trypanosomiasis,
and melarsoprol and DFMO are generally used in this instance.
Melarsoprol and melarsen oxide. Melarsoprol is a trivalent arsenical (Mr 398) marketed as
Arsobal® by Rhone Poulenc (Paris, France). The cellular target of melarsoprol is generally regarded
as trypanothione (Fairlamb et al, 1989) but this compound is also known to be an inhibitor of
trypanosome phosphofructokinase (K[ = 1 uM) and fructose-2,6-bisphosphatase (K\ = 2 uM) (Flynn
and Bowman, 1969). Trypanothione [NI,N8-bis(glutathionyl)spermidine] is a conjugate of
155
glutathione and spermidine which is believed to be a major factor involved in the thiol-disulfide
redox balance of trypanosomes. Fairlamb et al. (1987) showed that melarsoprol and melarsen oxide
forms stable adducts with trypanothione. This melarsen-trypanothione adduct inhibits T. b. brucei
trypanothione reductase (K{ = 18 uM) which is thought to be a key enzyme in the regulation of the
thiol-disulfide state of trypanothione.
Common and severe adverse effects of melarsoprol therapy are reactive and haemorrhagic
encephalopathy, tremors and polyneuropathy (Pepin et al, 1989). These are probably direct
toxic effects of arsenic deposition in the spinal cord (Gherardi et al, 1990). In spite of being
the most effective drug on the market, it is also one of the more expensive drugs, costing
around US$45 per course.
Difliioromethylomithine. DL-a-difluoromethylornithine (DFMO) is an omithine analogue marketed
as Ornidyl™ by Marion-Merrell-Dow (Cincinnati, USA). Unlike most other trypanocidal drugs,
DFMO crosses the blood-brain barrier, and has an excellent CSF penetration. A mean CSF/plasma
ratio of 0.91 has been reported for adults, with a CSF drug concentration of 50 nM (Milord et al,
1993). Melarsoprol and DFMO are therefore the only means of treating trypanosomiasis once it
has reached the stage of CNS involvement. DFMO has the added advantage of oral administration,
which is useful as other treatments are usually administered by intramuscular injection, and the
injection sites are known to be extremely sensitive (Pepin and Milford, 1994). DFMO is a selective
and irreversible inhibitor of omithine decarboxylase (McCann et al, 1986), for which it has a K\ of
130 uM. Omithine decarboxylase catalyses the conversion of omithine to putrescine, the first and
rate-limiting step in the synthesis of putrescine and the polyamines spermine and spermidine (Bacchi
et al, 1980). Polyamines are essential for the growth and multiplication of all eukaryotic cells,
where they contribute to the regulation of protein and nucleic acid synthesis (Pegg and McCann,
1982). DFMO is thus the only trypanocidal drug whose mechanism of action is understood (Pepin
and Milford, 1994).
The only alternative to melarsoprol for late-stage infections is DFMO. However, serious toxic
side-effects have been reported for DFMO, and some researchers have reported that between
5 and 20 % of patients die during therapy (Pepin et al, 1987; Milford et al, 1992). This
appears particularly common in children under two years of age, and is highly problematic in
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HIV co-infections (Pepin et al, 1987; Milford et al, 1992). Side-effects include bone marrow
suppression, convulsions, abortion and leucopenia (Milford et al, 1992, 1993). Furthermore,
this is the most expensive treatment available, costing US$150 per course, well beyond the
means of most people likely to be afflicted. In 1993, Marion-Merrell-Dow ceased production
of DFMO (Pepin and Milford, 1994).
Thus, with the single exception of DFMO, the biochemical basis for the trypanocidal action of the
remaining drugs is unknown. Suramin is known to inhibit a number of trypsin-like serine proteases
(Fong and Good, 1972; Eisen and Loveday, 1973), and the two diamidines (pentamidine and
diminazene) have structural similarities to the side-chains of basic amino acids, suggesting that these
compounds may have inhibitory activity against trypanosome oligopeptidases, which are trypsin-like
serine proteases. Furthermore, melarsoprol is known to react with free thiols, and given the
sensitivity of trypanosome serine oligopeptidases to thiol-reactive agents (Section 5.11.6, Table 11),
investigation of the reaction between these oligopeptidases and melarsoprol was also warranted.
For these reasons, the effects of these trypanocidal agents on OP-Tb activity was investigated
(Section 7.2), in an attempt to elucidate potential trypanocidal mechanisms involving the
trypanosome serine oligopeptidases.
These serious side-effects of the currently used therapeutic agents, their high costs and the
increasing incidence of drug-resistance exhibited by African trypanosomes (Pepin and Milford,
1994), strongly suggests that alternative, more effective chemotherapeutic strategies need to be
developed. While the use of protease inhibitors in the treatment of protozoan diseases is not
without precedent, previous efforts have generally targeted the lysosomal cysteine proteases of
parasitic protozoans. Therefore, one of the aims of the present study was to explore the
potential of the recently identified serine oligopeptidases of African trypanosomes as
therapeutic targets. This chapter reports the effects of general protease inhibitors on
trypanosomes in culture (Section 7.3), and extends these findings to more specific inhibitors of
OP-Tb, including peptidyl chloromethylketones and diazomethylketones (Section 7.4) and
peptidyl phosphonate diphenyl esters (Section 7.5).
7.2 Interaction of trypanocidal drugs with OP-Tb
As OP-Tb may have a regulatory role within trypanosomes, and since the mechanism of anti-
trypanosome action is unknown for many trypanocidal drugs, the effect of the five major
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trypanocidal drugs on OP-Tb activity was investigated. The interaction of suramin with OP-Tb
was further investigated with a series of suramin analogues which were custom synthesised
(these are illustrated in Figs 59 and 60), in which various moieties, such as the length of the
spacer-arm connecting the sulfonated naphthylamine groups, and the number of sulfonic acid
groups, were varied. These analogues were then examined for their ability to inhibit OP-Tb,
and for their trypanocidal activity. The structure of suramin is illustrated in Fig. 54, and
follows the nomenclature devised by Jentsch et al. (1987). Suramin is a symmetrical molecule
that can be sub-divided into three regions: an acidic naphthalene residue; an aminobenzoyl
residue; and a central urea group. For compounds with symmetrical structures it is sufficient to
describe only half the molecule, thus the code for suramin is Aa-Bb-Ba-Cc (as opposed to
Aa-Bb-Ba-Cc-Ba-Bb-Aa). This system describes the different structural elements of the
synthesised analogues listed in Table 17. Further derivatives are found as footnotes to
Table 17.
NaO3S SO3Na
Figure 54. Chemical formula of suramin and designated nomenclature for suramin analogues. Analogue
nomenclature follows that of Jentsch et al. (1987).
7.2.1 Materials
10 mM Stock drug solutions. Suramin hexasodium salt (0.142 g), Berenil® (58.2 mg),
pentamidine isethionate (59.3 mg) and DFMO (16.8 mg) were dissolved in dH2O (10 ml).
Melarsoprol® (3.9 mg) and melarsen oxide (2.4 mg) were dissolved in DMF (1 ml).
158
Suramin analogues. NF-037 (2.80 mg), NF-031 (2.80 mg), NF-065 (2.26 mg), NF-013
(2.32 mg), NF-058 (2.38 mg), NF-023 (2.32 mg), NF-078 (0.92 mg), NF-035 (1.2 mg),
NF-036 (1.2 mg), NF-064 (3.08 mg) and NF-226 (1.2 mg) were each dissolved separately in
dH2O (100 ul).
7.2.2 Method
Fmax and Km were determined in the absence and presence of trypanocidal drugs exactly as
described in Section 5.1. If altered values for these factors [denoted Vn«x apparent (V'max) and
Km apparent (K'm), respectively] were obtained in the presence of trypanocidal drugs, these
data were used to diagnose the mechanisms of inhibition. For competitive inhibitors, The K\
was determined as described in Section 5.6.2. For non-competitive inhibition, the K\ was
determined from the relationship
(Michal, 1983).
F'max I K
In the case of the arsenicals, melarsoprol and melarsen oxide, an uninhibited Km was
determined in the presence of an appropriate concentration of DMF, in order to negate the
effect of this solvent on the Km and Fmax. In the case of hyperbolic non-competitive inhibition,
the K{ was determined from the complex steady-state rate equation described by Baici (1987)
as modified by Szedlacsek et al. (1988) and Cadene et al. (1997),
l + g o£, [I]
a + a [ E ] 0 [E]o
where a = [S]/Km and v(J0 = 0 kat [E]o[S]/[S]+o^m. The parameters a and 0 are dimensionless
factors representing the change in the Km and kat respectively in the presence of an inhibitor
and v^ is the rate extrapolated at infinite [I]. Once Km, kat, a and J3 had been determined
separately, the K\ was calculated by non-linear regression analysis, fitting (v;, [I]) pairs to the
above equation in which all other parameters were fixed.
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7.3 Trypanocidal activity of general protease inhibitors
The trypanocidal activity of a variety of general protease inhibitors was explored to determine
whether exposure of T. b. brucei to protease inhibitors in culture had any affect on cell viability
and growth.
7.3.1 Materials
Stock inhibitor solutions. Inhibitors (required mass to prepare 100 mM solutions) were
dissolved in the specified volume of DMSO: antipain (6.8 mg, 100 ul); iodoacetate (10 mg,
500 ul); DCI (5.3 mg, 250 ul); Iodoacetamide (18 mg, 1 ml); leupeptin (5.8 mg, 120 ul); E-64
(8mg, 122 ul); Pepstatin A (3.4 mg, 50 ul); 1,10-phenanthroline (19.8 mg, 1 ml); PMSF
(17.4 mg, 1 ml). Similarly, the following masses of inhibitor were dissolved in the
corresponding volume of dHbO: AEBSF (100 mM, 12 mg, 500 ul); aprotinin (13.6 mM,
8.8 mg, 100 ul); SBTI (20 mM, 43 mg, 100 ul).
7.3.2 Method
Cell culture was undertaken exactly as described in Section 2.8. T. b. brucei was cultured in
MEM (2.5 ml) to which inhibitor solutions (25 ul, 100 mM) had been added to give a final
inhibitor concentration of 1 mM. Final concentrations of SBTI and aprotonin were 200 uM
and 140 uM respectively. Control experiments were performed in parallel, which contained
either 25 ul of DMSO or dFkO only, without inhibitors. The number of motile trypanosomes
was determined after 24 h, using a haemocytometer.
7.4 Trypanocidal activity of peptidyl methylketones
Peptidyl chloromethylketones (peptidyl-CH2Cl) and diazomethylketones (peptidyl-CHN2) are
irreversible inhibitors of cysteine and serine proteases. These inhibitors are widely used as
irreversible inhibitors of cysteine proteinases such as cathepsin L and cathepsin B (Kirschke
and Shaw, 1981) where they bind covalently to the catalytic cysteine residue. They are also
employed as inhibitors of serine proteases, where they bind to the active-site serine and

























Figure 55. Mechanism of inhibition of a serine protease by a peptidyl chloromethylketone. An enzyme-
inhibitor complex (A) is formed when the inhibitor binds to the enzyme active-site. The active-site serine then
reacts with the carbonyl of the chloromethylketone (B) to give a tetrahedral structure, after which the Nx
nitrogen of the active-site histidine imidazole ring is alkylated (C, D) (after Powers and Harper, 1986).
In the present study, various peptidyl chloromethylketones and diazomethylketones, containing
an arginine residue in the Pi site, were tested for their ability to inactivate OP-Tb, the only
serine protease described from T. b. brucei to date. These inhibitors were also tested for their
ability of kill trypanosomes in culture.
In addition, a biotinylated chloromethylketone analogue in combination with protein blotting
("active-site blotting") was employed in an effort to determine which trypanosome proteases
are targeted by these inhibitors in live trypanosomes. The synthesis and characterisation of
biotinylated affinity labels for trypsin-like (biotin-ArgCtkCl) and chymotrypsin-like
(biotin-PheCrtCl) enzymes have been described by Kay et al. (1992). Enzymes which have
been covalently labelled with biotin by such probes are denatured by boiling and/or reduction
and subjected to SDS-PAGE and electroblotted to nitrocellulose membranes. The labelled
protein is then detected using an avidin-reporter-enzyme conjugate.
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7.4.1 Materials
10 mM Synthetic inhibitor stock solutions. D-Val-Phe-LysCH2Cl (0.7 mg),
Leu-Glu-Gly-ArgCH2Cl (0.5 mg), Ac-Ala-Ala-AJa-AlaCH2Cl (0.4 mg), MeSuc-Ala-Ala-Pro-
ValCH2Cl (0.5 mg), D-Phe-Pro-ArgCH2Cl (0.5 mg), Cbz-Phe-PheCH2Cl (0.5 mg),
Cbz-Gly-Gly-PheCH2Cl (0.5 mg), Cbz-Gly-Leu-PheCH2Cl (0.5 mg), D-Val-Leu-LysCH2Cl
(0.6 mg), Cbz-Phe-LysCH2Cl (0.6 mg), Cbz-Phe-PheCHN2 (0.5 mg), Cbz-Phe-AlaCHN2
(0.4 mg), Cbz-Phe-Gly-TyrCHN2 (0.5 mg), Cbz-Ala-AlaCHN2 (0.3 mg),
Cbz-Phe-Tyr(OBut)CHN2 (0.5 mg), Cbz-Ile-LeuCHN2 (0.4 mg), Boc-Val-Leu-Gly-LysCHN2
(0.6 mg) and Z-Phe-AlaCHN2 (0.5 mg) were each dissolved separately in DMSO (100 ul).
Stock biotin-Arg-CH?Cl (100 \M). Biotin-ArgCH2Cl (10 mg) was dissolved in DMSO
(230 (j.1) and stored at -20°C.
All other reagents as per Sections 2.7.1.1., 2.8.1 and 3.2.
7.4.2 Method
The ability of peptidyl chloromethylketones and diazomethylketones to inactivate OP-Tb was
investigated through the determination of the k^, exactly as described in Section 5.6.2, and the
EC 50 for these inhibitors, acting on T. b. brucei in culture, were determined exactly as
described in Section 2.8.2.
For active-site labelling, OP-Tb (1 jig, 12.5 pmol, 20 ul) or T. b. brucei lysates (100 ug, 20 ul)
were incubated (1 h, 37°C) in assay buffer (20 ul) with a 20-fold molar excess of
biotin-ArgCH2Cl (0.25 nmol, 2.5 ul of stock solution), after which non-reducing sample
treatment buffer (20 ul) was added, and samples boiled for 10 min. Additionally, T. b. brucei
was cultured (5 x 106 cells.ml'1) in the presence of biotin-ArgCH2Cl (100 uM) for 24 h as
described in Section 5.8.2. Cells were then pelleted by centrifugation (3000 x g, 10 min, 4°C)
and resuspended in PSG. Non-covalently-bound probe was removed by three successive
cycles of pelleting by centrifugation followed by resuspension in PSG. Cells were then lysed
by the addition of non-reducing sample treatment buffer (20 ul) and boiled for 10 min.
Samples were subjected to Tris-Tricine SDS-PAGE (Section 2.7.1) and electroblotted onto
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nitrocellulose (Section 2.7.5). Blots were then developed with an avidin-AP conjugate as
described for the monoclonal bovine anti-IgM-biotin conjugate (Section 4.4).
7.5 Trypanocidal activity of peptidyl phosphonate diphenyl esters
Peptidyl a-aminoalkyl phosphonate diphenyl esters [peptidylp(OPh)2] represent a further class
of irreversible protease inhibitors, which are specific for serine proteases, without documented
activity against cysteine proteases (reviewed by Oleksyszyn and Powers, 1994). The
mechanism of inhibition of serine proteases by peptidylp(OPh)2 inhibitors is illustrated in
Fig. 56.
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Figure 56. Mechanism of inhibition of a serine protease by a peptidyl a-aminoalkyl phosphonate
diphenyl ester derivative. An enzyme-inhibitor complex (A) is formed when the inhibitor binds to the enzyme
active-site. Phosphonylation of the active-site serine residue occurs (6) to form a covalent phosphonate diester,
which then ages (C) to a monoester (after Oleksyszyn and Powers, 1994).
After initial complex formation, the active-site serine of the protease attacks the phosphorus
atom of the peptidylp(0Ph)2 and phosphonylation of the serine proceeds via a pentacoordinate
intermediate, forming a tetrahedral inhibition product, with the loss of one of the phenoxy
groups from the peptidylp(0Ph)2. This complex subsequently ages to a mature complex with
the loss of the second phenoxy group from the inhibitor (Oleksyszyn and Powers, 1994).
While the peptidylp(OPh)2 inhibitors are generally much slower inactivators of serine proteases
than are, for example peptidyl-CH2Cl inhibitors, the peptidylp(OPh)2 inhibitors exhibit
remarkable stability under physiological conditions. The ty, > 4 days at pH 7.5 and ty, >24 h in
plasma (Oleksyszyn and Powers, 1994). As with the peptidyl methylketones, inhibitor
specificity towards a particular protease can be enhanced by changing the amino acid sequence
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of the peptidyl portion to suit the P4-P1 substrate specificity of the inhibitor of interest. Thus,
peptidylp(OPh)2 inhibitors may represent an excellent compromise between chemical stability
and inhibitory potency.
Oleksyszyn et al. (1994) reported the synthesis of novel amidine-containing peptidyl (OPh)2
inhibitors, in which the arginine phosphonate derivatives have been replaced with
4-amidinophenylglycine (4AmPhGly). These 4AmPhGly derivatives are more easily
synthesised and are more potent inhibitors than their arginine phosphonate counterparts.
Furthermore, these inhibitors are extremely stable under physiological conditions and form
extremely stable enzyme-inhibitor complexes, making them suitable for in vivo studies.
In the present study, peptidylp(OPh)2 inhibitors containing a 4AmPhGly analogue in the Pi
position were evaluated for inhibitory potency against OP-Tb, and for trypanocidal activity
against trypanosomes in culture. An attempt was also made to identify the proteases targeted
in living trypanosomes. Finally, the effect of peptidylp(OPh)2 administration on disease
progression in infected mice was evaluated.
7.5.1 Materials
Stock inhibitor solutions. Suc-(4AmPhGly)p(OPh)2 (6.58 mg; 127 mM),
Cbz-Phe-(4AmPhGly)p(OPh)2 (2.8 mg, 40.1 mM), Cbz-Ala-(4AmPhGly)
P(OPh)2 (5.8 mg,
93 mM), Cbz-Pro-(4AmPhGly)p(OPh)2 (9.3, 143 mg), Cbz-Lys-(4AmPhGly)
P(OPh)2
(14.1 mg, 207 mM), Cbz-Gly-(4AmPhGly)p(OPh)2 (3.83 mg, 60.6 mM),
Cbz Glu-Gly-(4AmPhGly)p(OPh)2 (2.16 mg, 27.8 mM) were dissolved in DMSO (100 ul).
1 mM Fla-Adp-Lys-r4AmPhGMprOPh^ stock solution. Fla-Adp-Lys-(4AmPhGly)p(OPh)2
(1.11 mg) was dissolved in DMSO (1 ml).
All other reagents as per Sections 2.7.1.1., 2.8.1 and 3.2.
7.5.2 Method
The ability of peptidylp(OPh)2 inhibitors to inactivate OP-Tb was investigated through the
determination of the k^, as described in Section 5.6.2. The EC50 for these inhibitors acting on
T. b. brucei in culture, were determined exactly as described in Section 2.8.2.
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For active-site labelling, a fluorescent-labelled probe, [Fla-Adp-Lys-(4AmPhGly)p(OPh)2] was
employed (Abulyeman et al, 1997). OP-Tb (100 ng, ±1.25 pmol, 20 ul) was incubated (1 h,
37°C) in assay buffer (20 ul) with a vast molar excess of probe (58 uM final concentration,
2.5 ul of stock solution), after which non-reducing sample treatment buffer (20 ul) was added,
and samples boiled for 10 min. Additionally, T. b. brucei (5 x 106 cells.ml'1) were cultured in
the presence of this inhibitor (100 uM, 2 h) and then prepared for analysis by Tris-Tricine
SDS-PAGE as described in Section 2.7.1.1. Fluorescent-labelled proteins were visualised on a
Fotodyne Foto UV transilluminator (Fotodyne, New Berlin, USA).
The administration of peptidylp(OPh)2 inhibitors to infected mice, and the effect on disease
progression was investigated in two ways. Due to the limited amount of material available,
only Cbz-Gly-(4AmPhGly)p(OPh)2 was tested in mice.
The effect of Cbz-Gly-(4AmPhGly)p(OPh)2 on experimental T. b. brucei infection was initially
examined by injecting BALB/c mice intraperitoneally with T. b. brucei (6 x 103 cells per
mouse, in 100 ul PSG) and Cbz-Gly-(4AmPhGly)p(OPh)2 (either 1 mg, 0.1 mg or 0.01 mg per
mouse, in 25 ul DMSO). Two groups of control mice were set up. One group received
T. b. brucei (6 x 103 cells per mouse, in 100 ul PSG) and DMSO (25 ul) alone (i.e. only
trypanosomes and no inhibitors). The second control group received PSG (100 ul) and DMSO
(25 ul) alone (i.e. no trypanosomes or inhibitors).
The effect of delayed, repeated administration on Cbz-Gly-(4AmPhGly)p(OPh)2 on disease
progression in mice was also examined. Again, BALB/c mice were injected intraperitoneally
with T. b. brucei (6 x 103 cells per mouse, in 100 ul PSG). Three hours later,
Cbz-Gly-(4AmPhGly)p(OPh)2 in DMSO (25 ul) was administered at three different
concentrations (0.25, 0.1 or 0.005 mg per mouse). Cbz-Gly-(4AmPhGly)p(OPh)2 in DMSO
(25 ul) was thereafter administered daily at these three concentrations. Two groups of control
mice were set up. One group received T. b. brucei (6 x 103 cells per mouse, in 100 ul PSG),
and DMSO (25 ul) alone three hours later (i.e. only trypanosomes and no inhibitors). The
second control group received PSG (100 ul) and DMSO (25 ul) alone three hours later (i.e. no
trypanosomes or inhibitors). DMSO (25 ul) was administered to both control groups daily.
7.6 Results and discussion
7.6.1 Interactions with trypanocidal drugs
No inhibition of OP-Tb activity against Cbz-Arg-Arg-AMC was observed in the case of
DFMO, melarsoprol or melarsen oxide (Table 16). However, pentamidine, diminazene and
suramin all inhibited OP-Tb activity against Cbz-Arg-Arg-AMC. The various K[ values for the
inhibition of OP-Tb by trypanocidal drugs, and the diagnosed mechanisms of inhibition are
illustrated in Table 16.



























"Data for suramin and its analogues are presented in Table 17.
*n.d., not determined
Pentamidine isethionate is the active principle of the trypanocidal drug Pentacarinate®. The
mechanism of action of this drug is not understood (Pepin and Milford, 1994), although it has
been proposed that it intercalates with trypanosome DNA, obstructing transcription. The
pentamidine molecule represents two benzamidine groups joined together (Fig. 53), and
therefore resembles the paired basic cleavage sites in peptide substrates of OP-Tb. OP-Tb was
competitively inhibited by pentamidine with a K{ of 3.4 uM (Table 16; Fig. 57A), which
compares well with the K\ for bovine (3-trypsin (2.3 uM) and bovine mast-cell tryptase
(1.2 uM) (Fiorucci et ai, 1997). During therapeutic regimens, pentamidine typically reaches
concentrations of up to 13 uM in the host bloodstream (Sands et al, 1985), and is actively
concentrated by bloodstream-form trypanosomes which possess pentamidine transporters,
where it is present at intracellular concentrations of approximately 80 uM (Damper and Patton,
1976). For an inhibitor to be considered physiologically relevant, its in vivo concentration must
be >\0K[ (Bieth, 1980). As the intracellular concentration of pentamidine in bloodstream-form
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trypanosomes is approximately 2AK[, this introduces the possibility that pentamidine may exert
part of its trypanocidal activity through the inhibition of OP-Tb.
Berenil® exhibited mixed inhibition of OP-Tb (Fig. 57B). The active component of this
trypanocidal drug is diminazene aceturate, which, like pentamidine, resembles two benzamidine
groups joined together, although with a shorter spacer-region (Fig. 53). Thus diminazene also
mimics the paired basic cleavage site of OP-Tb substrates. The commercially available
Berenil® preparations contain 45% (m/m) diminazene aceturate, and the remaining mass is
made up of phenyldimethyl pyrazolone, (Leach and Roberts, 1981). This raises the possibility
that the diminazene aceturate competitively inhibits OP-Tb activity, while the phenyldimethyl
pyrazolone contributes to the inhibition of OP-Tb by Berenil in a non-competitive manner.
Purified diminazene aceturate is not commercially available, therefore this hypothesis could not
be investigated further, and the K\ was not determined. Bloodstream-form trypanosomes also
posses transporters which concentrate diminazene, raising the intracellular concentration of the
drug relative to the concentration in the bloodstream (Pepin and Milford, 1994), and the
possibility of diminazene aceturate inhibiting OP-Tb with serious physiological consequences
for the trypanosome, can not be ruled out.
Suramin is known to inhibit a number of proteolytic enzymes with a trypsin-like specificity,
including Cl esterase (Fong and Good, 1972), trypsin (Hawking, 1978) and kallikrein,
thrombin and plasmin (Eisen and Loveday, 1973). The mechanism of this inhibition is by an
unknown mechanism. Kinetic analysis of kallikrein inhibition by suramin revealed that it was
not of a competitive nature (Eisen and Loveday, 1973). More recently, Cadene et al. (1997)
reported the inhibition of neutrophil elastase, cathepsin G and proteinase 3 by suramin, by a
hyperbolic non-competitive mechanism. Suramin was shown to inhibit OP-Tb activity in a non-
competitive manner (Fig. 57C), and the clustering of the V^ data points at high [I] in Fig. 54C




















Figure 57. Diagnosis of inhibition mechanisms by trypanocidal drugs. Lineweaver-Burk plots of kinetic
data obtained for the inhibition of Cbz-Arg-Arg-AMC hydrolysis by OP-Tb over a range of inhibitor
concentrations for (A) pentamidine, (B) Berenil® and (C) suramin.
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As is evident from Fig. 58A, the inhibition of OP-Tb activity against Cbz-Arg-Arg-AMC by
suramin was maximal at 7.5 (xM suramin. At this concentration, OP-Tb retained about 25% of
its hydrolytic activity. Doubling the suramin concentration to 15 uM did not result in any
further increase in inhibitory activity (Fig 5 8A), suggesting that the inhibition was indeed of a
hyperbolic nature, with a K[ of 6.7 uM (Table 17). Furthermore, the \E\olK\ ratio was <0.01,
indicating that there was no tight binding of inhibitor to enzyme (Bieth, 1995). This parallels
the situation observed for the inhibition of neutrophil proteinase 3 by suramin, which also
exhibited non-tight-binding hyperbolic inhibition by suramin (Cadene et al. 1997).
There is generally a good relationship between the basicity of a protease and its affinity for
suramin. For example, the basic neutrophil proteases (pi > 9.1) have much higher affinities for
suramin than do less basic proteases such as trypsin. In contrast to these findings, OP-Tb has a
pi of 5.1 (Kornblatt et al, 1992). In order to further explore the interaction of suramin with
OP-Tb, The inhibition of OP-Tb activity by suramin was investigated in the presence of NaCl.
The presence of NaCl abolished the inhibition of OP-Tb by suramin, suggesting that
electrostatic effects were involved in the OP-Tb-suramin interaction (Fig. 58B). Despite its
low pi, OP-Tb has 24 lysine residues and 59 arginine residues (Table 7), and we propose that
the sulfonic acid groups of suramin interact with these basic residues of OP-Tb. However,
additional specific interactions appear to also be involved, as polysulfated glycosaminoglycans
such as heparin do not inhibit OP-Tb (Table 12), suggesting that the inhibition is not due to a
non-specific electrostatic interaction with polysulfated compounds. As shown later, the
interactions appear to be quite specific in nature.
During trypanosomiasis treatment regimens suramin reaches concentrations of approximately
100 uM within the host bloodstream (Fairlamb and Bowman, 1980). Suramin is not actively
concentrated in the parasite where it also reaches intracellular concentrations of approximately
100 uM (Wang, 1995). As these concentrations are approximately \SK\, the inhibition of
OP-Tb by suramin may be physiologically relevant, and this may explain at least in part, the
trypanocidal action of suramin which, to date, remains unelucidated (Wang, 1995). Despite
being in use for over 70 years, trypanosome resistance to suramin has not been reported,
indirectly suggesting that suramin may act on multiple targets within trypanosomes. Given the
low K[ of suramin for OP-Tb , and its cytosolic location, it is likely that OP-Tb is one of these
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targets. Because we suspect that OP-Tb released into the host bloodstream may to contribute
to disease pathogenesis through the digestion of host peptide hormones (Section 6.8.7), the
administration of suramin to infected hosts may help to abrogate the effects of the enzyme in
the host bloodstream. Indeed therapeutic concentrations of suramin abolished over 80% of the
OP-Tb activity in the blood of infected rats (results not shown), thereby lending credence to
this idea.




100 200 300 400
NaCl concentration (mM)
500
Figure 58. Effect of suramin on substrate hydrolysis by serine proteases. (A) Effect of increasing
concentrations of suramin on the activity of OP-Tb (20 nM) against Cbz-Arg-Arg-AMC (D), chymotrypsin
(25 nM) against Suc-Leu-Tyr-AMC ( • ) and trypsin (25 nM) against Cbz-Arg-AMC (O). Ordinates (vi/v0),
initial rate in the presence of suramin/initial rate in the absence of suramin. (B) Effect of NaCl on the inhibition
of OP-Tb (20 nM) activity against Cbz-Arg-Arg-AMC by suramin (•). Error bars represent the mean v;/v0 ±
SD (n = 3). All substrates at 5 uM.
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It is evident from Table 17 that both suramin, and its demethylated analogue (NF-037;
Fig. 59), in which the methyl groups of the methylbenzoyl (Bb) moiety have been removed,
were potent inhibitors of OP-Tb activity, and were highly trypanocidal when compared with
the other analogues. This suggests that these methyl groups do not contribute to either the
inhibition of OP-Tb activity or the trypanocidal activity. In fact, the absence of these groups is
desirable, as it resulted in a 19% decrease in the Ku and a 16% increase in the EC50.
These findings contrast with those of Fourneau et al. (1924) who reported that demethylation
of suramin resulted in a complete loss of its trypanocidal activity. It is significant, however,
that the EC50 values determined here were determined in vitro, whereas Forneau et al. (1924)
investigated the ability of suramin and its analogues to cure trypanosome infection in vivo, in
mice. Taken together, these data suggest that, while the methyl groups are not important for
the inhibition of OP-Tb activity or for the trypanocidal activity of suramin, they may be
extremely important for the metabolism and/or transport of suramin in mice.























































"Analogue nomenclature is detailed in Jentsch et al. (1987).
* Additional structural elements are: Ab, l-aminonaphthalene-4,6,8-trisulfonic acid; Ac, aniline-3-sulfonic acid;
Ae. aniline-2,4-disulfonic acid; Bk, 4-C-benzoyl; Cf, -NH-CO-l^-CeHe-CO-NH; Cl, -NH-(7-chloro-4-quinolinyl);
Cm, -NH-CO-(5-nitro-2-furyl).
cn.d., not determined. In these cases, no inhibition of OP-Tb activity against Cbz-Arg-Arg-AMC was detected.
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Both the number and spatial arrangement of the sulfonate groups on the aminonaphthyl (Aa)
moiety were important for inhibitory and trypanocidal activity. Replacing each of the
l-naphthylamino-4,6,8-trisulfonic acid (Aa) moieties of suramin with aniline-2,4-disulfonic acid
(to generate NF-065; Fig. 59) resulted in a 12-fold increase in Kh but only a 15% increase in EC50.
Removal of a second sulfonate group from each of the aniline moieties in NF-065 (i.e. replacement
of both the aniline-2,4-disulfonic acid moeities of NF-064 with aniline-3-sulfonic acid to give
NF-078; Fig. 59) further elevated the K\ 25-fold when compared with suramin, and this analogue
possessed no trypanocidal activity at the concentrations tested.
It is immediately apparent from Table 17 that the length of the molecule is also very important
for both inhibitory potency and trypanocidal activity. Removal of the aminobenzoyl (Ba)
group of suramin (to generate NF-058; Fig. 59) resulted in a 24-fold increase in Ku and a two-
fold increase in EC50. Alternatively, removal of the aminomethylbenzoyl (Bb) groups from
suramin (to generate NF-023; Fig. 59) had little effect on K{ or EC50 when compared with
NF-058; which is in agreement with our previous findings (compare NF-037 and suramin) that
these methyl groups are not important for inhibitory or trypanocidal activity.
Replacement of both the aminobenzoyl (Ba) and aminomethylbenzoyl (Bb) groups of suramin
with 4-C-benzoyl groups (to give NF-031; Fig. 59) elevated the Kx nine-fold, with a small
(10%) increase in ECso- Removal of two of these 4-C-benzoyl groups (one from each half of
the molecule, to give NF-013; Fig. 59) further elevated the K{ to 19-fold when compared with
suramin, and increased the EC50 by 31% when compared to that of suramin. This indicated
that a reduction in the length of the molecule was accompanied by a reduction in inhibitory and
trypanocidal activity.
The importance of the length and symmetry of the molecule is also illustrated by the lack of
inhibitory or trypanocidal activity of the "half-suramin" analogue, NF-036 (Fig. 60).
Rearrangement of one of the sulfonate groups on the naphthylene ring (NF-035; Fig. 60), or
attachment of the 4,6,8-substituted aminonaphthylsulfonate to a 5-nitro-2-fiiryl group
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Figure 59. Symmetrical analogues of suramin (P.D. Nickel, unpublished).
No inhibitory activity was seen when the molecule was lengthened by the introduction of an
additional benzene ring into the urea linker-region, and when one the of the
aminonaphthyltrisulfonic acid groups was rotated 180% with respect to the same group on the
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other half of the molecule (NF-064; Fig. 60). This once again points to the importance of the
spatial arrangement of the various substituents.
There was a significant correlation (P = 0.03; by paired student's f-test) between the inhibitory
potency and trypanocidal activity of suramin analogues, which strongly suggests that OP-Tb
represents an important intracellular target for suramin. In the absence of a three-dimensional
structure of OP-Tb, it is difficult to predict how suramin may interact, in such a specific
fashion, with OP-Tb. While the OP-Tb-suramin interaction appears to be electrostatic, due to
the reversing effect of NaCl, it is unlikely that it represents a non-specific electrostatic
association between OP-Tb and the negatively charged sulfonic acid groups of suramin, as
polysulfated glycosaminoglycans like heparin do not inhibit OP-Tb activity (Table 13).
Hart et al. (1989) examined the interactions of suramin and trypanosome phosphoglycerate
kinase (PGK). A striking feature of this enzyme is the presence of two clusters of positively-
charged amino acids on the surface, separated by a distance of 4 nm, one on each of the two
domains of PGK. Individual charges within each cluster are separated by a distance of 0.7 nm.
This disposition of charges suggested to Hart et al. (1989) that there was a possible
complementarity between PGK and the negative charges of suramin. Computer modelling of a
putative PGK-suramin complex confirmed that electrostatic interactions between PGK and
suramin would bridge the PGK active-site and block the mechanism of action of the enzyme.
With the PGK-suramin model in mind, if the active site of OP-Tb is buried in an active-site
"pit" as has been suggested for oligopeptidases (Section 1.22), it is possible that a suramin
molecule spanning the entrance to such a pit, may block access of substrate to such a pit.
OP-Tb contains a total of 83 basic amino acid residues (Table 7). Whether or not some of
these residues are clustered together to form suramin-binding sites will only be established
once a three-dimensional structure of the molecule is available.
Both of the trivalent arsenicals (melarsoprol and melarsen oxide) and DFMO were without
effect on OP-Tb activity. The sensitivity of OP-Tb to reducing agents (Fig. 31), and its
inactivation by thiol-reactive agents (Table 11) and heavy-metal ions (Table 13) suggested that
trivalent arsenicals may inactivate OP-Tb by covalent attachment to an essential cysteine
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residue located at the catalytic site, as is the case with iodoacetate, iodoacetamide, pCMB and
TV-ethylmaleimide. The lack of inhibitory activity may be explained by the observations of
Cunningham et al (1994) that melarsoprol and melarsen oxide generally form adducts with
djthiols, and not free thiols. Both compounds, however, form stable adducts with a unique
trypanosome metabolite, trypanothione, effectively reducing trypanothione concentrations
within the parasite during therapy with these drugs (Fairlamb et al, 1992). Trypanothione is
thought to maintain the correct intracellular redox state (Fairlamb et al, 1987).















Fig 60. Asymmetrical analogues of suramin (P.D. Nickel, unpublished).
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Considering that OP-Tb is activated by reducing agents, which may serve as in vivo regulators
of OP-Tb activity, the depletion of intracellular trypanothione concentrations that result from
melarsoprol and melarsen oxide therapy may down-regulate OP-Tb activity indirectly.
DFMO is an irreversible inhibitor of trypanosome ornithine decarboxylase, an enzyme which
catalyses the rate-limiting step of polyamine biosynthesis. While no direct effect was observed
on OP-Tb activity, therapeutic levels of DFMO are reported to decrease trypanosome
intracellular spermidine levels by 76% after 48 h (Fairlamb et al, 1987). The present study
revealed that OP-Tb activity is enhanced in the presence of spermidine (Table 13), suggesting
that OP-Tb activity is possibly regulated by polyamines in vivo. Depletion of intracellular
polyamine levels by DFMO therapy may down-regulate OP-Tb activity within the
trypanosome, possibly contributing to the trypanocidal action of DFMO. Furthermore,
trypanothione is a glutathione-spermidine conjugate. DFMO, which reduces intracellular
spermidine concentrations, also decreases intracellular trypanothione levels by up to 50%
(Fairlamb et al, 1987). Thus, DFMO may promote the down-regulation of OP-Tb activity not
only directly through the reduction of intracellular polyamine levels, but also through the
depletion of intracellular trypanothione, which would activate OP-Tb.
7.6.2 Trypanocidal activity of general protease inhibitors
With the exception of the proteinacious protease inhibitors (SBTI and aprotinin), all classes of
protease inhibitors were trypanocidal to varying degrees (Fig. 61). However, there was no
correlation between the trypanocidal activity of reversible inhibitors (E-64, leupeptin and
antipain) and their K{ for OP-Tb. Nor was there a correlation between the trypanocidal activity
of irreversible inhibitors (AEBSF, PMSF and DCI) and their k^ for OP-Tb. Thus it seems
likely that inhibitors acted on multiple targets within the trypanosomes. Alternatively, while
such compounds may be powerful inhibitors of the purified enzyme, they may have variable
abilities to actually enter the cell.
Proteinacious inhibitors of trypsin-like serine proteases (SBTI and aprotinin) were without
trypanocidal activity. As it is unlikely that these inhibitors would enter trypanosomes, other
than by internalisation into lysosomes, which have not been reported to contain trypsin-like
serine proteases, their lack of trypanocidal activity is not surprising. In contrast, low molecular
mass serine protease inhibitors were trypanocidal (DCI > AEBSF > PMSF). As these
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inhibitors are specific inhibitors of serine proteases, it appears that the inhibition of parasite
serine proteases is indeed detrimental to parasite viability.
The peptide aldehydes, antipain and leupeptin, which are non-class specific inhibitors of
trypsin-like proteases, were both trypanocidal. However, peptide aldehyde data must be
treated with caution. Wilcox and Mason (1992) demonstrated that leupeptin has very poor
cell-penetration properties and does not enter the lysosomes of mammalian cells in culture.
This was attributed to the inability of this inhibitor to diffuse across membranes, probably due
to the charged guanido group in the molecule. Antipain, which contains two guanido groups
(Umezawa et al. 1976), is probably even less likely to diffuse across the plasma membrane for
the same reason. Furthermore, as the argininals probably exist primarily as inactive cyclic
carbinolamines in aqueous solution (Schultz et al, 1989), the actual [I] is probably below the
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Figure 61. Trypanocidal activity of protease inhibitors. Bars indicate the fraction of viable cells after 24 h
relative to uninhibited controls. Numbers in parentheses indicate the K[ of reversible inhibitors for OP-Tb
inhibition (units of concentration; Table 10) or the k^ of irreversible inhibitors for OP-Tb inhibition (NT'.s"1;
Table 11). All inhibitors were at 1 mM, with the exception of aprotinin (140 uM) SBTI (200 uM).
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The metal chelators, 1,10-phenanthroline and EDTA were weakly trypanocidal. Jones et al.
(1996) reported the inhibition of growth and multiplication of T. cruzi epimastigotes in vitro by
iron chelating agents, although this was not attributed to the inhibition of parasite proteases,
but rather the chelation of iron where it interfered with the iron requirements of the parasites.
African trypanosomes contain a gene encoding a putative membrane-bound metalloproteinase
(El-Sayed and Donelson, 1997), and a phenanthroline-sensitive membrane-associated protease
has been observed on gelatin zymograms (Section 1.3.1). However, it is clearly not possible to
say yet whether the inhibition of this protease by metal-ion chelators is responsible for this
growth inhibition. Additionally, Kawabata and Ichishima (1997) reported the inhibition of
miltpain, a cysteine protease from salmon milt, by 1,10-phenanthroline, raising the possibility
that trypanosome cysteine proteases may also be targets for the metal-ion chelators. However,
neither phenanthroline nor EDTA have activity against trypanopain-Tb, the major lysosomal
cysteine protease of T. b. brucei (Troeberg et al, 1996).
E-64 appeared to have some trypanocidal properties, although it also exhibits poor cell
penetration in mammalian cell-lines (Wilcox and Mason, 1992). E-64 is a weak reversible
inhibitor of OP-Tb {K\ 63 uM) and is also known to inhibit trypanopain-Tb (Troeberg et al,
1996). Whether the inhibition of either of these enzymes by E-64 is of significance to parasite
viability remains to be determined.
Thiol-reactive agents, including /?CMB, iodoacetamide, iodoacetate and iV-ethylmaleimide
were all strongly trypanocidal, killing 100% of the parasites in culture at an inhibitor
concentration of 1 mM. These compounds non-specifically alkylate both thiol, and to a lesser
degree, amino groups on proteins (Barron, 1955). Their inhibitory activity therefore cannot be
attributed exclusively to the inhibition of parasite proteases, although both trypanopain-Tb
(Troeberg et al, 1996) and OP-Tb (Section 5.11.6, Table 11) are known to be inhibited by
these compounds.
Thus, protease inhibitors, including serine protease inhibitors, have trypanocidal properties. It
was therefore of interest to further explore the therapeutic potential of serine protease
inhibitors. As a starting point, the trypanocidal activity of a variety of chloromethylketones
and diazomethylketones was investigated. While these compounds are known to inhibit both
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cysteine and serine proteases, the incorporation of the peptide portion permits a measure of
selectivity, based upon the P3-P1 specificities of the proteases under investigation.
7.6.3 Trypanocidal activity of peptidyl methylketones
Chloromethylketones and diazomethylketones are irreversible inhibitors of cysteine and serine
proteases, generally binding covalently to the catalytic cysteine and histidine residues
respectively (Shaw 1994). The effect of peptidyl-CH2Cl and peptidyl-CHN2 inhibitors on
OP-Tb activity against Cbz-Arg-Arg-AMC is illustrated in Table 18. OP-Tb was rapidly
inhibited by synthetic covalent inhibitors that had basic residues (arginine and lysine) in P r
Both hydrophobic (phenylalanine) and small, uncharged (glycine) residues, as well as basic
residues, were acceptable in P2, which is consistent with the trends observed for the hydrolysis
of fluorogenic peptide substrates by OP-Tb (Section 5.11.1, Table 9).













































32 ± 1 4
>100
>100
67 ± 2 7
"No inhibition was detected after 30 min pre-incubation with Ac-Ala-AIa-Ala-AlaCHjCI; Cbz-Gly-Gly-PheCH2Cl;
Cbz-Gly-Leu-PheCH2Cl; Cbz-Leu-Leu-MetCHN2; biotin-PheCH2Cl; Tos-PheCH2Cl; Cbz-Ala-AlaCHN2; Cbz-Ile-
LeuCHN2; Cbz-Phe-AlaCH2Cl; Cbz-Phe-AlaCHN2; Cbz-Phe-Gly-TyrCHN2; Cbz-Phe-PheCH2Cl; Cbz-Phe-
PheCHN2; Cbz-Phe-Tyr(OBut)CHN2 orMeoSuc-Ala-Ala-Pro-ValCHp.
*Data reflect the mean k^ ± SD (n = 3)
%/, and "delay time" at 10 nM inhibitor concentration
The rate of inactivation of OP-Tb by peptidyl-CH2Cl inhibitors was comparable to that
observed for a variety of other trypsin-like proteases, which also had k^ values in the order of
105 NT's"1 (Kettner and Shaw, 1981). The inhibition of members of the prolyl oligopeptidase
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family of serine proteases (the "S9" family of Barrett and Rawlings, 1995) by peptidyl-CH2Cl
inhibitors has also been described (Stone et aL, 1991). It was found that
[3H]Ac-Ala-Ala-ProCH2Cl irreversibly inactivated prolyl oligopeptidase with covalent
modification apparent in four cysteine residues and the active-site histidine residue.
Eukaryotic serine proteinases are generally not inhibited by diazomethylketones, which are
widely regarded as specific inhibitors of cysteine proteinases (Green and Shaw, 1980).
However, OP-Tb was rapidly inactivated by Boc-Val-Leu-Gly-LysCHN2 at a rate that was
comparable (k^ - 3.26 x 105 MfVs"1) to that with which some lysosomal cysteine proteinases
are inhibited by peptidyl-CHN2 inhibitors (Crawford et al, 1988; Angliker et aL, 1991). This
acute sensitivity to peptidyl-CHN2 inhibitors has also been observed for members of the prolyl
oligopeptidase family of serine proteinases. Stone et al. (1992) described the inhibition of
prolyl oligopeptidase by Cbz-Ala-Ala-PheCKNb. However, this inhibitor acted as a
competitive reversible inhibitor of prolyl oligopeptidase with a K\ of 16 nM. Covalent
modification of the enzyme, employing [3H]Ac-Ala-AJa-ProCHN2, was only demonstrable
after denaturation of the enzyme, and the tritiated inhibitor was found on the active-site serine
residue. In contrast, Cbz-Ala-Ala-PheCHNb inactivates prokaryotic chymotrypsin-like serine
proteinases including subtilisin (£*» = 714 VTVS'1) and thermitase (JiiSS> 2.6 x 10
5 Mf'.s'1) by
alkylation of the active-site histidine (reviewed in Shaw, 1994). The mechanism by which
Boc-Val-Leu-Gly-LysCHN2 inhibits OP-Tb remains to be established.
There was no correlation between the k^ of the inhibitors for OP-Tb and the EC50 for
trypanosomes in culture (Table 18). This suggested either that the trypanocidal activity of
these inhibitors was not related to the ability of the inhibitors to inactivate OP-Tb within the
parasites, or that the different inhibitors had different cell permeability properties. Generally
those inhibitors that contained more than one charged amino acid residue (for example, those
containing aspartic or glutamic acid, in addition to a basic residue in Pi) were poorly
trypanocidal, or not trypanocidal at all at the concentrations tested. This probably reflects the
poor membrane-permeability of these highly charged peptides. It would be interesting to test
these peptides after which the acidic group has been either esterified or amidated.
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Peptidyl-CHN2 inhibitors, including Cbz-[
125I]iodo-Tyr-AlaCHN2 and Cbz-Phe-AlaCHN2 are
known to penetrate into mammalian cells in culture (Wilcox and Mason, 1992) and
Cbz-Ala-Ala-ProCHN2 is known to inactivate prolyl oligopeptidase in intact macrophages
(reviewed in Shaw, 1994). Furthermore, the trypanocidal properties of Cbz-Ala-PheCHN2 and
Cbz-Phe-ImNvaCHN2 have been documented, where they were shown to promote the lysis of
T. b. brucei in culture at inhibitor concentrations of 100 uM. Indeed, incubation of live
trypanosomes in the presence of the affinity label Cbz-Ala-[3H]PheCH2F resulted in the
radiolabelling of a 68 kDa trypanosome protein (Ashall et al, 1990b). This suggested to these
investigators that the parasites contained a 68 kDa protease which was essential for parasite
viability. Using the affinity label biotin-ArgCHaCl, three bands at approximately 68, 80 and
100 kDa were targeted in T. b. brucei lysates (Fig. 62, lane a), and a single band at 80 kDa was
evident in the purified OP-Tb lane (Fig. 62, lane b). Live trypanosomes incubated in the
presence of biotin-ArgCtbCl gave rise to a major band at 80 kDa, and a very faint band at









Figure 62. Active-site blots of T. b. brucei lysates and purified OP-Tb. Labelling of (a) T. b. brucei lysates
(100 ng); (b) purified OP-Tb (1 ug) and (c) live trypanosomes with biotin-ArgCH2Cl as described in Section
7.4.2.
The 80 kDa band evident in all three samples is probably attributable to OP-Tb. The low molecular
mass band at 68 kDa may be due either to an active, processed form of OP-Tb, or to another
cysteine or serine protease with a preference for basic residues in Pi. The pro-hormone convertases
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(Lazure et al., 1983) and the catalytic subunits of the proteasome (Hua et al., 1996; Lomo et al,
1997) are potential candidates. Albumin is known to be an extremely "sticky" protein as it is a
carrier of a large number of non-proteinaceous compounds in the bloodstream. This raises the
possibility that biotin-ArgCtkCl reacted in a non-specific fashion with residual rat serum albumin in
the trypanosome lysates, generating a band at 68 kDa. Trypanopain-Tb, and its complexes with
L-kininogen which are evident on substrate SDS-PAGE gels (Section 5.11.10; Fig. 36), also have a
preference for basic residues in Pi. The 105 kDa trypanopain-Tb-L-kininogen complex may be
responsible for the band evident at about 100 kD on the active-site blot, despite the absence of a
30 kDa band due to trypanopain-Tb alone. Alternatively this band may be due to OP-Tb in a
complex with a regulatory protein, although such complexes are usually non-covalent and would
not normally be expected to be stable to boiling in the presence of SDS. Alternatively, this band
may be attributable to any one of a number of other proteases still awaiting discovery.
While both peptidyl-CH^Cl and peptidyl-CHN2 were potent inhibitors of OP-Tb and were also
strongly trypanocidal, these inhibitors are not class-specific; they inactivate both cysteine and
serine proteases at comparable rates. Therefore, the trypanocidal properties of a second class
of inhibitors, the peptidyl phosphonate diphenyl esters, which are class-specific inhibitors of
serine proteases, were also investigated (Section 7.6.4).
7.6.4 Trypanocidal activity of peptidyl phosphonate diphenyl esters
The peptidyl-(4AmPhGly)p(OPh)2 inhibitors were considerably slower irreversible inhibitors of
OP-Tb activity when compared to peptidyl-CHbCl and peptidyl-CHN2 inhibitors. This is
consistent with the slower inhibition of other enzymes (Oleksyszyn and Powers, 1994). It is
possible that 4AmPhGly is not a good substitute for arginine or lysine in the Pi position for
OP-Tb. While the series of inhibitors tested all contained the arginine analogue 4AmPhGly in
the Pi position, a variety of residues were present in the P2 positions. There was little
difference between the k^ values obtained for the dipeptide inhibitors, irrespective of the
residue in the P2 position. This is consistent with the observations made using fluorogenic
peptide substrates (Section 5.11.1, Table 9) which suggested that OP-Tb has little P2
specificity, although the inclusion of a succinyl blocking group in the P2 region appeared
unfavourable. Lengthening of the peptide from a dipeptide to a tripeptide elevated the k^
when compared with all the dipeptide inhibitors, perhaps suggesting that a contact between the
enzyme and peptide portion of the inhibitor over the P3-P1 region is preferable to only P2-P1
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interaction, and may help to "dock" the inhibitor for a longer period of time, or in a better
position, for phosphonylation of the active-site serine residue.
In spite of the considerably lower k^ values for the peptidyl-(4AmPhGly)P(OPh)2 inhibitors
when compared with the efficacy of OP-Tb inhibition by peptidyl-CH2Cl and peptidyl-CHN2
inhibitors, the peptidyl-(4AmPhGly)p(OPh)2 inhibitors had comparable trypanocidal properties.
This is possibly attributed to the considerable stability of the peptidyl-(4AmPhGly)P(OPh)2
inhibitors at physiological pH (t% > 4 days; Oleksyszyn and Powers, 1994) when compared
with peptidyl-CH2Cl inhibitors, which are unstable above pH 6 (Shaw, 1965). There was no
direct correlation between OP-Tb inhibition and EC5o, again suggesting the possibility of
multiple target proteases within the trypanosome, or that the inhibitors were not all equally
membrane-permeable.
In support of the latter, the highly charged peptides like Suc-(4AmPhGly)p(OPh)2 and Cbz-
Glu-Gly-(4AmPhGly)p(OPh)2 did not exhibit any trypanocidal activity at the concentrations
tested, perhaps indicating that these inhibitors could not diffuse well across the cell membrane.
Table 19. Peptidyl diphenyl phosphonate ester inhibitors of OP-Tba.
Inhibitor 1^ t* [if EC5o





































"No kinetic data were obtained for Fla-Adp-Lys-(4AmPhGly)p(OPh)2 due to the intense fluorescence of this
compound at the Cbz-Arg-Arg-AMC excitation and emission wavelengths.
*Data reflect the mean k^ ± SD (n = 3).
c[l] at which ty, was calculated.
1&3
To determine which trypanosome proteases were targeted in live trypanosomes by the
peptidyl-(4AmPhGly)p(OPh)2 inhibitors, a fluorescein-derivatised inhibitor was employed in a
similar manner to the biotinylated peptidyl-CFbCl in Section 7.5.2.
T. b. brucei cultured in the presence of Fla-Adp-Lys-(4AmPhGly)p(OPh)2 yielded two
fluorescein-labelled proteins (Fig. 63). One of these proteins migrated on SDS-PAGE gels to a
position corresponding to that of purified OP-Tb incubated with the same affinity label,
suggesting that this band also represents OP-Tb. A second trypanosome protein of
approximately 30 kDa was also labelled by Fla-Adp-Lys-(4AmPhGly)p(OPh)2. The identity of
this protein remains unknown but may be trypanopain which would cast some doubt upon the
claimed group specificity of this inhibitor series. Alternatively, there may be at least two
trypanosome proteases that are targeted by peptidyl-(4AmPhGly)P(OPh)2 inhibitors, and the
inhibition of either or both of these proteases may be responsible for the trypanocidal activity









Fig 63. Active-site labelling with fluorescent peptidyl phosphonate diphenyl ester derivatives. OP-Tb (A)
and live T. b. brucei (B) and were labelled with Fla-Adp-Lys-(4AmPhGly)p(OPh)2 as described in Section 7.5.2.
In order to examine the effect of administration of peptidyl-(4AmPhGly)p(OPh)2 inhibitors on
disease progression in mice, these inhibitors were administered in two different regimens to
experimentally-infected BALB/c mice.
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Studies in mice suggested that Cbz-Gly-(4AmPhGly)p(OPh)2 had trypanocidal properties in
vivo as this compound was able to completely clear parasites from infected mice when
administered daily at a dose of 5 mg per kilogram body mass (Table 20). All the surviving
animals completely cleared the infection, as determined by thick blood-films taken from the tail
vein, and were still alive 20 days post-infection. Daily administration of higher quantities
(12.5 mg per kilogram body mass) did not improve the proportion of mice that cleared
infection, but rather prematurely led to the death of 66% of the experimental group. This is
possibly attributed to the toxicity of the reagent. Due to paucity of material, the toxicity of
these compounds in mice could not be investigated further. However, it is known that
peptidyl-(4AmPhGly)p(OPh)2 prolong the prothrombin time and activated partial
thromboplastin time (Oleksyszyn et al, 1994), and it is possible that these compounds
interfered with the haematological homeostasis of the mice with lethal consequences. At
50-fold lower concentrations, administration of Cbz-Gly-(4AmPhGly)p(OPh)2 had no
observable effect on disease progression, and all experimental animals died at a similar time to
control animals that did not receive the inhibitor.
Table 20. Effect of administration of Cbz-Gly-(4AmPhGly)p(OPh)2 on the progression of
trypanosomiasis in BALB/c mice.
Treatment regimen and dose
Control 1 (+ parasites - inhibitor)
Control 2 (- parasites - inhibitor)








Survival up to day 6










"All the surviving animals were still alive, and apparently free of parasites (as determined from a thick blood-
film prepared from a tail-vein blood sample), twenty days post infection.
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7.7 Concluding statements
The biochemical mechanisms by which trypanocidal drugs exert their cytotoxic effects is not
understood. Inhibition data indicate that pentamidine and suramin both inhibit OP-Tb with a K\
low enough to make such inhibition of potential in vivo significance, and it is possible that the
trypanocidal activity of both drugs is due, at least in part, to the inhibition of OP-Tb within the
trypanosome. The correlation between the in vivo trypanocidal properties of various suramin
analogues and the Ki of such analogues for OP-Tb, suggested that OP-Tb may be essential for
parasite viability. Should this be the case, OP-Tb may provide a potentially interesting target
for therapeutic intervention.
A variety of general protease inhibitors exhibited either trypanocidal or trypanostatic properties
when tested against T. b. brucei in culture. Such compounds included a number of specific
inhibitors of serine proteases, suggesting that these enzymes were potential targets for drug
design. To explore this possibility further, a variety of serine protease inhibitors were tested
for (a) inhibitory activity against OP-Tb, the only serine protease isolated from African
trypanosomes to date, and (b) for trypanocidal activity against T. b. brucei in culture.
Peptidyl-CH2C1 were very fast (>10
5 NT'.s"1), irreversible inhibitors of OP-Tb, and
demonstrated potent trypanocidal activity, with EC50 values in the low millimolar range. A
biotinylated peptidyl-CH2Cl labelled three bands in trypanosome lysates, one of which
appeared to be OP-Tb, based on identical migration on SDS-PAGE. A band corresponding to
the molecular mass of OP-Tb was also labelled in live trypanosomes incubated in the presence
of this biotinylated inhibitor. These data suggested that OP-Tb was indeed a target for these
inhibitors in live cells, and that the trypanocidal activity may be due, at least in part, to the
inhibition of this enzyme within live parasites.
A peptidyl-CHN2 inhibitor also inhibited OP-Tb at a rate comparable to the peptidyl-CEbCl
inhibitors. Considering the observations of Stone et al. (1992), it remains to be determined
whether peptidyl-CHN2 inhibitors are reversible inhibitors of OP-Tb, as described for members
of the prolyl oligopeptidase (S9) family of serine proteases, or irreversible inhibitors of OP-Tb,
as has been described for prokaryotic chymotrypsin-like serine proteases (reviewed in Shaw,
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1994). Whatever the case may be, Boc-Val-Leu-Gly-LysCHN2 had comparable trypanocidal
properties to peptidyl-CJtCl inhibitors.
As peptidyl-CHbCl and peptidyl-CHN2 inhibitors will inhibit both serine and cysteine proteases,
another group of inhibitors, peptidyl-(4AmPhGly)p(OPh)2 inhibitors were examined for the
inhibitory and trypanocidal efficacy, as this group of inhibitors is claimed to be class-specific
for serine proteases. Despite being slower inhibitors of OP-Tb when compared with peptidyl-
CH2C1 and peptidyl-CHN2 inhibitors, a variety of peptidyl-(4AmPhGly)
p(OPh)2 inhibitors
exhibited comparable activity against T. b. brucei in culture. Active-site labelling revealed that
a protein with a molecular mass comparable to that of OP-Tb was the major protein labelled in
live trypanosomes, although a second, unidentified protein was also labelled, suggesting that
OP-Tb was indeed a cellular target of these inhibitors, and that their trypanocidal activity may
be mediated, at least in part, through the inhibition of OP-Tb. The observation that the only
common band labelled by the different trypanocidal reagents had a molecule mass of 80 kDa
suggests that the enzyme OP-Tb may be the trypanocidal target of the inhibitors.
Even if OP-Tb is not the target, because daily administration of one of these inhibitors,
Cbz-Gly-(4AmPhGly)p(OPh)2, effected complete clearance of parasites from experimentally
infected animals in 83% of the experimental group, it is clear that trypanosome serine proteases




It has been proposed that proteases may be important mediators of pathogenesis in
trypanosomiasis (McKerrow et ah, 1993), but to date, the lysosomal cysteine proteases are the
only proteolytic enzymes from African trypanosomes that have been extensively characterised
(reviewed by Lonsdale-Eccles, 1991; Coombs and Mottram, 1997). Upon release into the
host, however, these trypanosome-derived cysteine proteases are rapidly inactivated by
endogenous host cysteine protease inhibitors, in particular, the kininogens and cystatins of the
host serum (Troeberg et ah, 1996). This suggests that these enzymes are not major
contributors to the disease pathology (although they remain essential for parasite viability).
For this reason, other classes of parasite proteases are now under investigation as potential
contributors to pathogenic mechanisms. The serine proteases of African trypanosomes are one
such group of proteases, and while serine protease activity has been identified in African
trypanosomes (Kornblatt et ah, 1992) the enzymes responsible for this activity have not been
purified or extensively characterised. Thus, one of the aims of this investigation was to purify,
to electrophoretic homogeneity, the serine protease from African trypanosomes responsible for
this activity.
There are two major groups of African trypanosomes that are pathogenic for mammals, and
members of the two groups of parasites cause very different disease in their host animals. It
was therefore important to purify serine proteases from a representative member of each of
these two groups of African trypanosomes, in order to investigate whether these enzymes
differed in their enzymatic properties, which would perhaps account for the different
pathologies observed (Boreham, 1979). For these reasons, enzyme purification was attempted
from T. b. brucei, a representative of the "humoral" sub-group of African trypanosomes, and
from T. congolense, a representative of the "haematic" sub-group of African trypanosomes.
Once purified, a comprehensive enzymatic characterisation of these two enzymes was
undertaken, to gain information about the substrate specificity, the mechanisms of regulation
and the optimum conditions for activity of these enzymes. These investigations served the
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important dual function of providing some much-needed basic kinetic information about a
member of the prolyl oligopeptidase family of serine proteases, which currently represents one
of the less well understood groups of proteolytic enzymes. Having characterised the enzymatic
properties of these trypanosome oligopeptidases, the potential role that these oligopeptidases
may play in disease pathogenesis, and in the immune response of host animals to these enzymes
was investigated. Additionally, the potential therapeutic value of inhibiting trypanosome
oligopeptidases was investigated.
8.1 The structure and enzymatic properties of trypanosome oligopeptidases
A serine protease, designated OP-Tb, was isolated from T. b. brucei lysates by a combination
of precipitation and column chromatography. This is the first time that this enzyme has been
purified to electrophoretic homogeneity. A particularly useful step in the isolation of OP-Tb
was the crude fractionation of trypanosome lysates by three-phase partitioning, a relatively new
protein fractionation technique developed in our department (Jacobs et al., 1989). OP-Tb
activity co-precipitated with that of the major cysteine protease of T. b. brucei,
trypanopain-Tb. This was fortuitous as it permitted the simultaneous purification of the two
enzymes studied in our laboratory from the same, highly limited, starting material. These two
proteases were easily resolved from one another by anion-exchange chromatography.
Antibodies generated against OP-Tb cross-reacted with a related enzyme in T. congolense
lysates, and these antibodies provided a useful tool for the immunoaffinity isolation of a related
oligopeptidase, designated OP-Tc, from T. congolense.
These trypanosome oligopeptidases rapidly (kat >100 s"
1) hydrolysed a number of low-
molecular mass fluorogenic peptide substrates which contained the basic residues arginine and
lysine in the Pi position, indicating a trypsin-like specificity. Hydrophobic and small uncharged
residues were tolerated in P2, although the enzyme exhibited the lowest Km (260 nM) for
substrates in which basic residues occupied both the Pi and P2 positions, and there appeared to
be little specificity in the P3 region. However, OP-Tb did not hydrolyse any protein substrates,
and this information, together with the apparent lack of inhibition by high molecular-mass
protease inhibitors, suggested that OP-Tb was an oligopeptidase rather than a proteinase.
It remains desirable to active-site map the P' regions of the enzyme to obtain information on
the amino-acid residue specificity, if any, in this region. For this purpose, an internally
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quenched octapeptide, blocked at the N-terminus with an o-aminobenzoyl (Abz) group and at
the C-terminus with a 7V-(2,4-dinitrophenyl)ethylenediamine (EDDnp) group was designed as
described by Del Nery et al. (1997). The peptide, Abz-Ala-Gly-Gly-Arg-Gly-Ala-Gly-Gln-
EDDnp, contains a single arginine residue, Arg4, which acts as the Pi residue. Syntheses of
peptides containing a single amino acid substitution at Gly5, holding all other residues constant,
is now underway. A comparison of the kaJKm. ratios for the OP-Tb catalysed hydrolysis of
each of these peptides will give an indication of the Pi' specificity of the enzyme, and similar
technology can be extended to exploring preference at other P' sites.
The inhibition of OP-Tb by low molecular mass, irreversible inhibitors of serine proteases, in
particular the mechanism-based 3,4-dichloroisocoumarin, suggested that the enzyme is a serine
protease. However, the apparent stimulation of OP-Tb activity by reducing agents, and its
inhibition by thiol-reactive agents have resulted in investigators mistakenly attributing such
activity to a cysteine protease (Ashall, 1990; Ashall et al, 1990b).
The non-essential activation of serine proteases by reducing agents, and their inhibition by
thiol-reactive agents is not without precedent. A number of proteases belonging to the
subtilisin family (the "S8" family in the nomenclature of Barrett and Rawlings, 1995) of serine
proteases exhibit sensitivity to reducing agents, including the pro-hormone convertases kexin
and furin (Van den Ouweland et al, 1991), as well as cerevisin (Moehle et al, 1987),
thermitase (Kominami et al, 1986) and protease K (Jany et al, 1986). Although all of these
enzymes are inhibited by bulky thiol-reactive agents, none display thiol-activatable activity.
However, other serine proteases that also belong to the same subtilisin family of serine
proteases do not demonstrate any sensitivity to thiol-reactive agents. These include subtilisin
BPN', an artificially mutated subtilisin from B. amyloliquefascians (Wells et al, 1983) and
subtilisin derived from B. subtilis Carlsberg (Smith et al, 1986). Examination of the amino
acid sequences surrounding the catalytic histidine, serine and aspartic acid residues of these
proteases reveals why this may be the case (Fig. 64). All serine proteases of the subtilisin
family that are inhibited by thiol-reactive agents possess a conserved cysteine residue four
residues C-terminal to the catalytic histidine residue. This cysteine residue is replaced by a










Figure 64. Alignment of sequences surrounding the catalytic triad of members of the subtilisin family of
serine proteases. Aspartic acid (D), histidine (H) and serine (S) residues of the catalytic triad are presented in
bold type. Conserved cysteine residues are underlined (C). A dash (-) indicates a break in the primary
sequence. Refer to text for information sources.
It was therefore of interest to determine whether a parallel situation existed for members of the
prolyl oligopeptidase (S9) family of serine proteases, as porcine prolyl oligopeptidase
(EC 3.4.21.26) displays acute sensitivity to thiol-blocking reagents, and is activated in the
presence of reducing agents (Moriyama et al., 1988). Three analogous enzymes from
microbial sources, including E. coli (Kanatani et al., 1991), F. meningosepticum (Yoshimoto
etal. 1991) andM lacunata (Yoshimoto etal, 1995) demonstrate similar sensitivity, albeit to
a lesser degree. While it is not known if the analogous enzyme from T. cruzi is activated by
reducing agents, pCMB is known to inhibit the enzyme at nanomolar concentrations (Burleigh
and Andrews, 1997). The amino acid sequences surrounding the catalytic triad of these
proteases are illustrated in Fig. 65.
-QN£FDDFQ£AAEY-LTINGGSNGGLL-KAGHGAGK- prolyl oligopeptidase
-KNTFNDYLDA£DA-£YAMGGSAGGML-DSGHGGKS- E. coli oligopeptidase B
-KNVFNDFIAAGEY-MALSGRSNGGLL-NAGHGAGR- F meningosepticum oligopeptidase B
-RNTFTDFIAAAKH-MAARGGSAGGLL-GAGHFGKS- M. lacunata oligopeptidase B
-QAGLHDPRVAYWE-LACJIGRSAGGLL-ESGHFSPS- T. cruzi oligopeptidase B
Figure 65. Alignment of sequences surrounding the catalytic triad of members of the prolyl
oligopeptidase subclass of serine proteases. Aspartic acid (D), histidine (H) and serine (S) residues of the
catalytic triad are presented in bold type. Unconserved cysteine residues are double-underlined (£). A dash (-)
indicates a break in the primary sequence. Refer to text for information sources.
All members of the prolyl oligopeptidase family of serine proteases which display sensitivity to
thiol-reactive agents contain at least one cysteine residue in close proximity to at least one of
the three catalytic residues. Covalent attachment of bulky thiol-reactive groups to these
cysteine residues may cause steric hindrance that interferes either with substrate binding or
with the charge-relay system of the catalytic residues (Craik et al., 1987). It is also possible
that essential cysteine residues that are far removed from the catalytic apparatus in the primary
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structure of the enzyme are brought into close proximity to the catalytic site by the folding
(tertiary structure) of the enzyme. This situation will only be clarified once X-ray
crystallographic data reveal the precise position of all the residues in the intact enzyme. Thus,
the presence of reducing agents may ensure that these cysteine residues are maintained in a
reduced state, which perhaps maintains an ideal charge environment for catalysis, and this may
explain, at least in part, the activating effects of reducing agents on enzyme activity.
An interesting mechanism of thiol-activation has recently been proposed for the metallo-
oligopeptidase called "Endopeptidase 3.4.24.15" (EC 3.4.24.15), a thermolysin-like
oligopeptidase (Shrimpton et al, 1997). This protease forms an inactive homodimer under
non-reducing conditions. The covalent dimer is formed by any one of three cysteine residues
on one molecule forming a disulfide bridge with any one of these residues on another molecule.
The disulfide bridge is broken by low concentrations (up to 100 uM) of dithiothreitol, with
concomitant regain of activity. It has been hypothesised that access to the catalytic site is
blocked in the dimer, preventing substrate hydrolysis (Shrimpton et al. 1997). Whether a
similar mechanism is in operation for OP-Tb and OP-Tc remains to be determined.
The molecular mass, sensitivity to reducing agents and substrate specificity strongly suggest
that OP-Tb and OP-Tc belong to the prolyl oligopeptidase (S9) family of serine proteases
(Barrett and Rawlings, 1995). This hypothesis is supported by the homology observed
between the primary OP-Tb sequence (as determined from OP-Tb-derived peptides) and
T. cruzi oligopeptidase B, which is a member of this family of serine proteases - as determined
from the primary sequence of the gene encoding this enzyme, which has been cloned (Burleigh
et al, 1997). This hypothesis can only be confirmed once the 71 b. brucei and T. congolense
enzymes have been cloned, and their gene sequences known.
8.2 The physiology and pathophysiology of trypanosome oligopeptidases
The in vivo role of trypanosome oligopeptidases within the trypanosome is not known.
Protease variations among different life-cycle stages of African trypanosomes have been
observed (Mbawa et al, 1991), possibly implicating these proteases in regulatory roles within
the trypanosome. Soluble Cbz-Gly-Gly-Arg-AMC hydrolysing activity of T. congolense strain
IL 3000 was considerably elevated in epimastigote forms of the parasite (specific activity
156 pmor'.s'Vmg"1) relative to metacyclic forms of the parasite where the specific activity was
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reduced by 50% (70 pmol'Vs'Vmg"1; Mbawa et al, 1991). Activity was further reduced five-
fold in bloodstream forms of the parasite (specific activity of 24 pmorVs'Vmg"1). Similar trends
in soluble Cbz-Gly-Gly-Arg-AMC activity were also observed in T. vivax (Mbawa et al,
1997). While the enzyme responsible for this activity was not identified, its activity against
Cbz-Gly-Gly-Arg-AMC, soluble nature, inhibition by both DFP and organomercurial
compounds and its alkaline pH optimum (Lonsdale-Eccles and Grab, 1987) strongly suggest
that it may be OP-Tc, and a related enzyme in T. vivax. The differential expression of this
activity suggests that the enzyme may play a regulatory role in the parasite life cycle, such as
the differentiation into different life-cycle stages.
This is supported further by the observations of Kato et al. (1992), who reported the
purification of an oligopeptidase, designated "protease In", with a trypsin-like specificity, from
E. coll This protease momentarily appears immediately before DNA synthesis in the cell cycle
of E. coli. This suggests that such a cytosolic oligopeptidase may have a regulatory function
within the cell, perhaps through the degradation of intracellular peptide hormones.
The in vitro degradation of peptide hormones by OP-Tb and OP-Tc, demonstrated in the
present study, raises the possibility that these enzymes may function to process or degrade
peptide hormones in the trypanosomes themselves. While peptide hormones were initially
believed to be unique to vertebrate organisms, subsequent research has revealed that similar
molecules exist in a number of invertebrates, including insects, helminths, coelenterates,
molluscs, as well as bacteria, yeasts and protozoans (reviewed in LeRoith et al, 1986). Of
particular interest to this investigation was the detection of such peptide hormones in
protozoans. Molecules resembling peptide hormones including insulin (LeRoith et al, 1980),
ACTH, P-endorphin, calcitonin (Deftos et al, 1985) and neurotensin (Bhatnager and
Carraway, 1981) have been identified in unicellular organisms.
It appears therefore that unicellular protozoans and other invertebrates also possess peptide
hormones, and it seems reasonable that they would also possess enzymes capable of
metabolising such hormones. OP-Tb may be one such enzyme. The identification of peptide
hormone substrates within trypanosomes, and the design of trypanosomes in which the
oligopeptidase gene has been "knocked out", may provide keys to the physiological function of
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this enzyme. Targeted gene disruption technology, while still in its infancy, has been
performed in L. mexicana (Mottram et al, 1997) and in T. cruzi (Norma Andrews,
Department of Cell Biology, Yale Univesrity School of Medicine, New Haven, U.S.A., pers.
comm.) and so opens up the potential for exploring these aspects further.
The biochemical mechanisms of the pathogenesis of African trypanosomiasis are poorly
understood. An understanding of the mechanisms of the disease processes could lead to better
methods of treatment, possibly by inhibiting or reversing the important pathological changes,
or by alleviating some of the symptoms of the disease. It was shown in the present study that
OP-Tb was highly active and stable at physiological pH and ionic strength. Further to this,
OP-Tb was not inhibited by any high molecular mass inhibitors of serine or cysteine proteases
in the mammalian host bloodstream, including cystatins, kininogens, serpins and (X2M. Neither
was OP-Tb activity inhibited in the presence of bovine serum or plasma. This raised the
possibility that should OP-Tb enter the host bloodstream, it would retain its activity and may
contribute to disease pathogenesis through the digestion of host proteins.
The presence of peptidase activity in infected murine plasma (Knowles et al, 1987), and the
unusual cleavage of peptide hormones in the blood of infected rats (Tetaert et al, 1993)
strongly suggests that a peptide-degrading enzyme is present and active in the bloodstream of
infected animals. As OP-Tb was shown to hydrolyse neurotensin, ANF and glucagon in vitro,
it is not unreasonable to assume that a similar situation may exist in vivo, in the bloodstream of
infected hosts. The degradation of these peptides in the bloodstream of the host would have
profound implications in terms of disease pathogenesis.
While some peptide hormones have been shown in the present study to be degraded by OP-Tb
in vitro, most still remain to be tested. An indication of some potential peptide hormone
substrates for OP-Tb present in the mammalian bloodstream and CSF are presented in
Table 21. This list is by no means comprehensive.
To illustrate how the anomalous degradation of these hormones could play a role in the
pathogenesis of trypanosomiasis, the example will be taken of (3-melanoctye stimulating
hormone (P-MSH). (3-MSH acts directly on the thyroid gland in mice to release the thyroid
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hormones 3,5,3',5'-tetraiodo-L-thyronine (thyroxine, T4) and 3,5,3'-triiodo-L-thyronine (T3)
(Schally et al, 1967). Depressed levels of both T3 and T4 have been observed in humans
infected with T. brucei gambiense (Boersma et al, 1989) and in goats infected with
T. congolense (Mutayoba etal, 1988a, 1988b; Section 1.2.1). As we have demonstrated that
OP-Tb is active the host bloodstream, which also serves as the vehicle for P-MSH distribution
in the body, it is quite possible that P-MSH is degraded by OP-Tb in the host bloodstream.
The nett effect of this would be, inter alia, depleted levels of T3 and T4 in infected animals.












"All peptides have a molecular mass of less than 4 kDa, contain paired basic residues, and lack disulfide
bridges. Paired basic residues are indicated in bold-type.
The gastrointestinal tract peptide hormones (neuropeptide K and kinetensin; Walsh, 1987) and
dynorphins A and B (Koob et al, 1982) have important functions in gut motility, behaviour
and appetite-modulating functions; and neuromedin U-25 is a potent hypertensive polypeptide
of the central nervous system (Minamino et al, 1985). In a similar manner described for
p-MSH, the anomalous degradation of any or all of the peptide hormones presented in
Table 20 could give rise to the confusing clinical picture presented by trypanosome-infected
hosts.
The cytokines are known to function as important effector molecules against parasitic
infections (Liew etal, 1997). OP-Tb may also function in trypanosome infections to
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inactivate such cytokines, e.g. P-endorphin. P-Endorphins are peptide hormones that elicit
several biological reactions including analgesia, behavioural changes and growth-hormone
release. P-Endorphins are known to modulate T-lymphocyte activation, with the N- and
C-terminal domains having antagonistic effects. C-terminal peptides (p-endorphini8-3i) are
involved in both CD4+ and CD8+ T-cell activation, whilst the N-terminal peptides
(p-endorphinM6) abrogate this activity (van den Berg et al, 1993). T-lymphocytes secrete a
metalloprotease (T-cell peptidase) involved in the cleavage of P-endorphin into these discrete
peptides between Leu17 and Phe18, and this phenomenon is thought to have important
immunoregulatory activity (Miller et al, 1996). The activating C-terminal peptide possesses a
putative cleavage site for OP-Tb (between Lys29 and Glu30) in the intact P-endorphin peptide
and in the p-endorphinis-3i peptide that is generated by T-cell peptidase. This introduces the
possibility that OP-Tb may degrade T-cell activating peptides in the host bloodstream. Such
effects are consistent with the reports of depression of T-cell responses in African
trypanosomiasis for both rodents infected with T. b. brucei (Pearson et al, 1978), and
T. congolense infection in cattle (Flynn and Sileghem, 1993).
It therefore appears highly probable that OP-Tb, which is released into the host bloodstream,
and possibly the CSF, remains unregulated in host body fluids. It may then interfere with
metabolic homeostasis through the inactivation of host peptide hormones, contributing
significantly to the pathogenesis of African trypanosomiasis. This possibility needs to be
explored further. The determination of the Km and ken for the degradation of peptide hormones
by OP-Tb would indicate whether the reaction is of in vivo significance, and such data may be
supported by the demonstration that the levels of prospective peptide-hormone substrates is
diminished in infected hosts. Furthermore, should trypanosomes in which the OP-Tb gene has
been eliminated, or knocked out, remain viable, it would be interesting to observe whether
there was any effect on the pathogenesis and disease progression caused by such genetically
altered parasites.
8.3 Are trypanosome oligopeptidases potential compounds for vaccine development?
The production of anti-oligopeptidase antibodies by infected hosts would be desirable for two
reasons. Oligopeptidase activity released into the host bloodstream may be abolished should
the host generate antibodies to oligopeptidases, and this would abrogate any contribution of
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this released oligopeptidase to disease pathology. Secondly, these antibodies would promote
complement-mediated trypanosome-lysis by binding to any oligopeptidase on the surface of the
parasites. The latter seems particularly promising since the present study has shown some
evidence for the presence of surface-bound OP-Tb.
Inhibitory anti-OP-Tb antibodies were produced in chickens in the present study and Moriyama
etal. (1988) reported the generation of inhibitory anti-porcine prolyl endopeptidase antibodies
in rabbits. This suggests that infected mammalian hosts may generate their own antibodies,
perhaps even inhibitory antibodies, against trypanosome oligopeptidases, which would be
extremely desirable in terms of host defence. In spite of this, both chronically infected bovine
serum and acutely infected murine serum exhibited OP-Tb-like activity, suggesting that if such
antibodies were produced, they were ineffective at abolishing this activity in the bloodstream of
infected animals.
The generation of antibodies to parasite invariant antigens is known to provide a measure of
protective immunity. The immunoprotective potential of antibody generation to trypanosome
cysteine proteases has been reported (reviewed by Authie, 1994). Such immunprotective
phenomena have also been described for antibodies generated against the surface-bound
metalloprotease of Leishmania (Russell and Alexander, 1988; Jardin etal, 1990) and a serine
protease from Schistosoma (Darani et ah, 1997).
Preliminary investigations in the present study, employing sera from experimentally infected
trypanotolerant N'Dama and trypanosusceptible Boran cattle suggest that antibodies are not
generated to OP-Tc during chronic infection, and there is therefore no correlation between
trypanotolerance and anti-OP-Tc antibody production. Taken together, these data suggest that
neither OP-Tb nor OP-Tb-derived synthetic peptides are useful antigens for vaccine
development. However, active immunisation with purified OP-Tb or OP-Tb, followed by a
challenge infection will be required to conclusively establish this.
8.4 Are trypanosome oligopeptidases potential chemotherapeutic targets?
Current therapeutic strategies employed for the treatment of African trypanosomiasis are
plagued by high costs, ever-increasing drug resistance by the parasites, and unpleasant (and
often fatal) side-effects. Furthermore, the biochemical basis of the trypanocidal activity of
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these drugs is largely not understood. The present study thus addressed two questions. (1) To
determine whether trypanosome oligopeptidases may be targets for the currently employed
drugs, which would improve our understanding of the biochemical mechanisms of how these
drugs work; and (2) to determine whether serine protease inhibitors may serve as useful lead-
compounds for the development of novel therapeutic strategies.
The trypanocidal drugs suramin, pentamidine isethionate and Berenil® were shown in the
present study to inhibit OP-Tb activity in vitro. Suramin, a sulfated naphthylamine was a non-
competitive inhibitor of OP-Tb activity. Additionally, structure-function studies with suramin
analogues, in particular the correlation between inhibitory potency and trypanocidal efficacy,
strongly suggest that OP-Tb is a target for this drug. Pentamidine, the active principle of
Pentacarinate® acted as a competitive inhibitor of OP-Tb, and again, the kinetics of the
reaction suggested that the inhibition of OP-Tb by pentamidine was of in vivo significance.
Both of these findings introduce a hitherto undescribed potential mechanism of action of these
drugs.
Other trypanocidal drugs, including DFMO, melarsoprol and melarsen oxide did not inhibit
OP-Tb activity in vitro. However, it remains possible that they do indirectly down-regulate
OP-Tb activity within the trypanosome. DFMO is an irreversible inhibitor of trypanosome
ornithine decarboxylase, and therapeutic levels of DFMO typically decrease trypanosome
intracellular spermidine levels by 76% after 48 h (Fairlamb et al, 1987). The present study
revealed that OP-Tb activity is enhanced in the presence of spermidine suggesting that OP-Tb
activity is possibly regulated by polyamines in vivo. The depletion of polyamine levels by
DFMO may therefore down-regulate OP-Tb activity within the trypanosome, possibly
contributing to the trypanocidal action of DFMO.
OP-Tb is also sensitive to the presence of reducing agents, and the thiol-disulfide redox
balance within trypanosomes may also regulate OP-Tb activity within the parasites.
Melarsoprol and melarsen oxide effectively reduce trypanothione concentrations within the
parasite during therapy with these drugs. Trypanothione is thought to maintain the correct
intracellular redox state (Fairlamb et al, 1987). This suggests that the depletion of
intracellular trypanothione concentrations that result from melarsoprol and melarsen oxide
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therapy may down-regulate OP-Tb activity. Furthermore, trypanothione is a glutathione-
spermidine conjugate. DFMO, which reduces intracellular spermidine concentrations also
decreases intracellular trypanothione levels by up to 50% during treatment regimens (Fairlamb
et al, 1987). Thus, DFMO may promote the down-regulation of OP-Tb activity not only
directly through the reduction of intracellular polyamine levels, but also through the depletion
of intracellular trypanothione.
To date, the possibility of exploiting parasite proteases in anti-parasite chemotherapy has been
restricted to the cysteine proteases of parasite protozoa (reviewed by Coombs and Mottram,
1997). The trypanocidal activity of the OP-Tb inhibitors, including peptidyl methylketones and
phosphonate diphenyl esters, demonstrated for the first time in the present study, suggest that
these compounds have exciting potential as lead-structures for the development of novel drugs.
For example, administration of peptidyl phosphonate diphenyl esters resulted in an 83%
survival of experimentally infected mice. In contrast, no untreated animals survived.
Regardless of the mode of action, these results point to a new and exciting potential series of
trypanocidal agents.
There is currently considerable interest in the development of novel serine protease inhibitors,
and it would be prudent to examine a variety of classes of these inhibitors for trypanocidal
activity. Alternative inhibitors include novel thiazolidine derivatives (Sudo et al, 1997),
including those incorporating a novel amino-acid-derived heterocyclic scaffold (Groutas et al,
1997). Additionally, the synthesis and anti-metastatic activity of boro-amino acid analogues
has been described (Kinder et al, 1992), as well as anticoagulant candidates such as novel
Pi-argininal derivatives featuring a conformationally constrained P2-P3 bicyclic lactam moiety
(Tamura et al, 1997); and P2-P4 azapeptidomimetic Pi-argininal and Pi-ketoargininamide
derivatives (Semple et al, 1997). This list is by no means comprehensive. Also, older
inhibitors, such as fluoromethylketones have recently been modified to enhance their oral
bioavailability (Veale etal, 1997).
The most immediate problem likely to be encountered in targeting trypsin-like serine proteases
of blood parasites is that the major proteolytic activity in the bloodstream is also attributable to
trypsin-like serine proteases such as plasmin, thrombin, kallikrein and complement proteases.
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There are, however, two possible ways around this. Active site mapping of these proteases has
already revealed some differences in the sub-site specificities of these proteases. The
incorporation of a peptide moiety into inhibitors may enhance the specificity of the inhibitor for
the tiypanosome enzymes, without interfering with normal plasma processes such as
coagulation and complement activation. A subtle but very significant difference between the
trypanosome oligopeptidases and plasma trypsin-like proteases is the sensitivity of the
trypanosome enzymes to thiol-reactive agents, and it would be very useful to exploit this
difference in the design of novel inhibitors which react with the trypanosome enzyme.
The identification of a peptidolytic activity in P. berghei (Schrevel et al., 1984) that closely
resembles OP-Tb suggests that novel inhibitors directed at OP-Tb may also inactivate a related
enzyme in the malaria parasite, opening up an opportunity to extend this work to the
development of novel antimalarial strategies. Similarly, an enzyme similar to the
oligopeptidases of African trypanosomes has been described from the South American
trypanosome, T. cruzi (Burleigh and Andrews, 1996; Burleigh et al, 1997). The reported
resistance of South American trypanosomes to drugs currently employed to treat Chagas'
disease (Filardi and Brener, 1987) underscores the necessity of developing novel drugs for the
treatment of this disease as well. Again, the trypanocidal activity of oligopeptidase inhibitors
may introduce exciting possibilities here.
8.5 Cloning and hyperexpression of OP-Tb
The cloning of trypanosome oligopeptidases is the next logical step in the characterisation of
this enzyme, the determination of its role in disease pathogenesis and to aid drug design
research. Current studies are hindered by the extremely small yields of enzyme (approximately
70 ug from 1010 parasites), and the difficulty in producing adequate quantities of source
material. Cloning of potentially similar enzymes from bacterial sources has already been
achieved, suggesting that the necessary oligonucleotide primers and cell lines are available.
Furthermore, a number of T. b. brucei gene libraries already exist, and enzyme assays for
screening colonies have already been developed. The cloning of the oligopeptidase gene
would conclusively illustrate to which class of serine proteases this enzyme belongs.
Furthermore, obtaining a gene sequence would lay necessary groundwork for the generation of
a null-mutant, in which the oligopeptidase gene was inactivated. Such a mutant would be
invaluable in elucidating the pathological and pathophysiological roles of these enzymes.
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Placing the gene under the control of a high-expression vector would generate sufficient
material for further study, including crystallisation of the enzyme. Despite considerable effort,
the crystallisation of E. coli oligopeptidase B has met with no success (Yoshimoto et al,
1991). To date, no three-dimensional structure of any oligopeptidase is available. Knowledge
of the three-dimensional structure obtained from X-ray crystallography may answer a number
of questions regarding the sensitivity of OP-Tb to reducing agents, and the physical mechanism
by which the enzyme restricts the size of substrates. Furthermore, computer-modelling of
inhibitor structures to the oligopeptidase active site, in conjunction with active-site mapping of
the P' region of the oligopeptidases, may facilitate the design of extremely specific inhibitors of
this enzyme for therapeutic use.
8.6 Conclusion
The objectives of the present study were to characterise a recently identified oligopeptidase
from African trypanosomes and to ascertain whether these oligopeptidases may contribute to
the pathogenesis of African trypanosomiasis. In the present study, oligopeptidases were
isolated from representative members of two distinct groups of African trypanosomes, namely
T. b. brucei and T. congolense. This represents the first time that these oligopeptidases have
been purified to electrophoretic homogeneity, permitting the first enzymatic characterisation of
these enzymes. While there were no differences in the specificity trends of these two enzymes,
the Km values for the hydrolysis of peptides by OP-Tb were consistently lower than those
observed for OP-Tc.
The present study also contributed to the understanding of the potential mechanisms of
pathogenesis by demonstrating that OP-Tb was active in the bloodstream of infected hosts,
where it was not regulated by any endogenous inhibitory molecules. The demonstration that
OP-Tb degrades host peptide hormones in vitro suggests that it may also do so in the host
bloodstream. This opens up a multitude of potential mechanisms by which circulating OP-Tb,
released by trypanosomes into the bloodstream, may contribute significantly to the disruption
of the metabolic homeostasis of the host animals. Preliminary data also suggest that these
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Proteases from Trypanosoma brucei brucei
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African trypanosomes contain proteases that may be released into the bloodstream of their infected
hosts. This paper describes a novel, combined isolation of a cysteine proteinase (called trypanopain-Tb)
and a serine oligopeptidase (which we call oligopeptidase-Tb) from Trypanosoma brucei brucei, as well
as a comparison of the activities of these two enzymes against several host regulatory molecules.
The enzymes differed in various respects. Firstly, purified trypanopain-Tb was shown to readily cleave
proteins such as gelatin maximally at acidic pH. In contrast, oligopeptidase-Tb, which is optimally active
at alkaline pH, did not hydrolyse proteins larger than 4 kDa. However, it readily hydrolysed various
polypeptides, including neurotensin and atrial natriuretic factor.
The interaction of the two enzymes with mammalian protease inhibitors also differed. Cystatins and
os-macroglobulin effectively inhibited trypanopain-Tb, with the K, values for cystatin C and low-molecu-
lar-mass kininogen (=10"" M) predicting that trypanopain-Tb is likely to be effectively controlled by
these inhibitors if released into the host bloodstream. In contrast, oligopeptidase-Tb was not inhibited by
serpins or os-macroglobulin, suggesting that it may remain active if released into the host bloodstream.
In support of these in vitro results, the blood of trypanosome-infected rats displayed no trypanopain-Tb-
like activity, but exhibited high oligopeptidase-Tb-like activity. Thus, while trypanopain-Tb seems likely
to be confined to an intracellular role within the parasite, oligopeptidase-Tb has the potential to remain
active in the host bloodstream and so contribute directly to pathogenesis.
Keywords: Trypanosoma brucei; cysteine proteinase; oligopeptidase; cystatin.
African trypanosomes are protozoan parasites which cause
the diseases nagana and sleeping sickness in cattle and humans,
respectively. These diseases are characterised by intermittent fe-
ver, progressive anaemia, general loss of condition and, ulti-
mately, the death of the infected host. Nagana is still of great
economic importance in Africa, where it prevents livestock
farming in many areas, and certain parts of Africa are experienc-
ing a large resurgence in human trypanosomiasis (Walgate,
1994). While the parasite's major lysosomal cysteine proteinase
(trypanopain) is considered a potentially important factor in the
development of the disease (Authie et al., 1993; Russo et al.,
1994), the role of a cytoplasmic serine oligopeptidase (which we
call oligopeptidase-Tb, OP-Tb) has not yet been explored.
Trypanopain is lysosomally located (Mbawa et al., 1991)
and, as such, is likely to be centrally involved in intracellular
digestive and catabolic proteolysis. Additionally, the enzyme is
proposed to help the parasite escape opsonisation by degrading
internalised antibody-variant surface glycoprotein complexes
(Russo et al., 1994). Enzyme released into the host bloodstream
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rTM, rat trypanopain modulator; Sue, succinyl; SBTI. soybean trypsin
inhibitor: TosLysCH,Cl, tosyllysylchloromethane; TosPheCH,Cl, tosyl-
phenylalanylchloromethane; Z, benzyloxycarbonyl.
has also been proposed to contribute to pathogenesis more di-
rectly by degrading various host proteins. Also, since trypanotol-
erant cattle infected with Trypanosoma congolense produce anti-
bodies to trypanopain-Tc, while susceptible cattle do not, im-
mune targeting of the enzyme may help protect infected hosts
(Authie et al., 1993). While the cDNA of trypanopain-Tb from
Trypanosoma brucei brucei has been sequenced (Mottram et al.,
1989), no purification of the enzyme to electrophoretic homo-
geneity, or characterisation of its basic enzymatic properties, has
been reported. The interactions of trypanopain-Tb with mamma-
lian cysteine proteinase inhibitors and other host regulatory mol-
ecules also have not been reported before.
While OP-Tb has previously been partially purified from T.
b. brucei (Huet et al., 1992; Kornblatt et al., 1992) and Trypano-
soma cruzi (Ashall, 1990), the role of this enzyme in pathogene-
sis has not been investigated. Previous data indicates that the
enzyme is a serine protease, but its sensitivity to reagents which
modify cysteine residues suggests that reduction of a cysteine
residue is required for full enzyme activity (Kornblatt et al.,
1992). The enzyme also appears to be restricted in its action,
cleaving only small peptide substrates. Both these facets of the
enzyme's activity require further investigation.
Here we report the joint purification of trypanopain-Tb and
OP-Tb from T. b. brucei, the effects of various potential in vivo
inhibitors on the enzymes and the action of the enzymes on po-
tentially relevant host peptide and protein substrates.
MATERIALS AND METHODS
Materials. HiLoad™ Q-Sepharose and HiTrap™ Blue Se-
pharose were from Pharmacia. DEAE-cellulose was from What-
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man. 4-(2-Aminoethyl)-benzenesulfonyl fluoride (H:NEtPh-
SO2F), BSA and a,-macroglobulin (a2-M) were from Boehringer
Mannheim. Chymostatin, leupeptin and antipain were from
Cambridge Research Chemicals (UK) and di-isopropyl
fluorophosphate (iPr2P-F) was from Fluka. [l-
l4C|Acetic anhy-
dride was from Amersham. All other inhibitors, benzyloxycar-
bonyl phenylanlanyl-arginyl-aminomethyl coumarin (Z-Phe-
Arg-NHMec), Z-Arg-Arg-NHMec, pepstatin-A-Sepharose,
poly-(L-lysine)-Sepharose, fibrinogen, rabbit IgG, Percoll™ and
Sephacryl S-100 HR were from Sigma. The C18 HPLC column
was from Vydac. Sheep stefin B was purified as described by
Pike et al. (1992). Human recombinant stefin A was from Cal-
Biochem and human low-molecular-mass kininogen (L-kinino-
gen) was purified from human plasma as described by Gounaris
et al. (1984). Recombinant human L-kininogen domain 3 was a
gift from Dr Ennes Auerswald (Ludwig-Maximilians-Universitat
Munchen) human cystatin C was a gift from Dr Magnus Abra-
hamson (University of Lund, Malmo General Hospital) and ser-
pins were a gift from Dr Jan Potempa (Jagiel Ionian University,
Cracow).
Growth and purification of trypanosomes. T. b. brucei
(clone ILTat 1.1) was grown in rats and purified from the in-
fected blood by a combination of Percoll™ gradient centrifuga-
tion (Grab and Bwayo, 1982) and anion-exchange chromatogra-
phy on DEAE-cellulose (Lanham and Godfrey, 1970). Purified
trypanosomes were stored at — 70 °C until used.
Enzyme and protein assays. Trypanopain-Tb activity against
5 uM Z-Phe-Arg-NHMec at 37 °C was initially measured as de-
scribed by Barrett and Kirschke (1981) using an assay buffer of
170 mM sodium acetate, 30 mM acetic acid, 2 mM Na:EDTA,
3 mM dithiothreitol, pH 5.5. Following enzyme characterisation,
the assay buffer was amended to 200 mM sodium phosphate
pH 7.0 containing 30 mM cysteine and 2 mM Na,EDTA. OP-
Tb was similarly assayed against 5 uM Z-Arg-Arg-NHMec in
100 mM Tris/HCl, 10 mM dithiothreitol, pH 8.0 (Kornblatt et
al., 1992).
Protein assays were conducted according to the methods of
Bradford as modified by Read and Northcote (1981) and Smith
et al. (1985).
Isolation of trypanopain-Tb and OP-Tb. Trypanosomes
(=5.5X10 9 parasites) were thawed and lysed by addition of
0.1% (by vol.) Triton X-100 (final concentration). Three-phase
partitioning (Pike and Dennison, 1989) was performed on the
lysate, with all enzyme activity precipitating between 10—25%
(mass/vol. of the total volume) ammonium sulfate (results not
shown). The pellet was redissolved in buffer A (20 mM sodium
acetate, 1 mM Na2EDTA, pH 5.5) and loaded onto HiLoad™ Q-
Sepharose (26X110 mm, flow rate 1 ml • min"1) equilibrated in
buffer A with 100 mM NaCl. After elution of the unbound mate-
rial (which contained OP-Tb and was retained for OP-Tb purifi-
cation), a linear gradient of 0.1-1 M NaCl in buffer A was ap-
plied over five column volumes. Fractions active against Z-Phe-
Arg-NHMec, but inactive against Z-Arg-Arg-NHMec and there-
fore identified as containing trypanopain-Tb, were pooled and
dialysed against buffer A. Since preliminary studies had iden-
tified pepstatin A as a weak inhibitor of trypanopain-Tb, this
inhibitor was considered to be a potential affinity chromatogra-
phy Iigand. Active samples were therefore loaded onto pep-
statin-A—Sepharose (13X10 mm, flow rate 0.26 ml • min'"1)
equilibrated in buffer A containing 500 mM NaCl. Following
elution of the unbound material, trypanopain-Tb was eluted with
5% (mass/vol.) Brij-35 in buffer A with 500 mM NaCl. Frac-
tions active against Z-Phe-Arg-NHMec were applied to Hi-
Trap™ Blue Sepharose (9X23 mm. flow rate I ml • min ')
equilibrated in 50 mM Tris/HCl pH 8.0 to remove suspected al-
bumin contamination. Active fractions were concentrated and
stored at -20°C mixed with glycerol (1:1). The purity of the
enzyme was analysed by tricine/SDS/PAGE (Shagger and von
Jagow, 1987).
The unbound material from HiLoad™ Q-Sepharose was
active against Z-Arg-Arg-NHMec and Z-Phe-Arg-NHMec, but
insensitive to L-fra/is-epoxysuccinyl-leucylamido (4-guanidino)
butane (E-64), indicating that it contained OP-Tb (Kornblatt et
al., 1992). This fraction was dialysed against buffer B (50 mM
Tris/HCl, 1 mM dithiothreitol, pH 8.0) and applied to p-amino-
benzamidine-Sepharose (15X50 mm, flow rate 0.3 ml • min"').
After the elution of unbound material, bound OP-Tb was eluted
with a step gradient of 250 mM NaCl in buffer B. Following
dialysis against buffer B, the sample was applied to HiLoad™
Q-Sepharose equilibrated in buffer B containing 100 mM NaCl,
and a five-column-volume gradient of 0.1 —1 M NaCl applied.
The active fractions were diluted four-fold in buffer B and ap-
plied to poly-(L-lysine)-Sepharose (55X15 mm, flow rate 1 ml
• min"1) equilibrated in buffer B containing 100 mM NaCl. A
10-column-volume gradient of 0.1-1.5 M NaCl in buffer B was
applied to elute the bound material. Active fractions were con-
centrated and applied in buffer B to a Sephacryl S-100 HR gel
filtration column (15X850 mm, flow rate lOml-h"1) .
Following analysis of enzyme purity by tricine/SDS/PAGE, the
purified enzyme was concentrated and stored at
-20°C mixed with glycerol (1:1).
Characterisation of enzymes. The activity of trypanopain-
Tb and OP-Tb in the presence of various inhibitors was investi-
gated by incubating the enzymes with each inhibitor for 15 min
at 37 °C before assaying residual activity against Z-Phe-Arg-
NHMec or Z-Arg-Arg-NHMec, respectively, as described above.
OP-Tb experiments were conducted in the presence of either
10 mM dithiothreitol (indicated as + dithiothreitol in Table 2) or
in residual dithiothreitol remaining from purification (=40 uM
dithiothreitol, indicated as — dithiothreitol in Table 2). Since
chloromethanes and alkylating agents are inactivated by reduc-
ing agents, care was taken to minimise the relative amount of
reducing agents used with these inhibitors. Concentrated en-
zymes were thus activated (10 min at 37°C in 30 mM cysteine
for trypanopain-Tb; 10 mM dithiothreitol for OP-Tb), before be-
• ing diluted to the required working concentration in assay buffer
containing inhibitor (final reducing agent concentrations of
3 mM cysteine for trypanopain-Tb, 1 mM dithiothreitol for
OP-Tb).
The effects of various reducing agents on trypanopain-Tb
and OP-Tb activity were investigated by adding dithiothreitol,
cysteine • HC1, reduced glutathione or 2-mercaptoethanol (1 —
100 mM for trypanopain-Tb and 1-25 mM for OP-Tb) to the
relevant assay buffer. The pH profile of each enzyme against
synthetic substrates was investigated by substituting assay buffer
with constant-ionic-strength acetate/Mes/Tris buffers (100 mM
acetate, 200 mM Tris, 100 mM Mes, 4 mM Na.EDTA) of
pH 4.0-9.0 (Ellis and Morrison, 1982). Trypanopain-Tb hydrol-
ysis of [l4C]gelatin at various pH values was assessed using ace-
tate/Mes/Tris buffers as described above, with the [uC]gelatin
prepared using [l-uC]acetic anhydride as described by Cawston
and Barrett (1979). The pH stability of the enzymes was deter-
mined by incubating the enzymes in acetate/Mes/Tris buffers
(25 mM acetate, 50 mM Tris, 25 mM Mes, 1 mM Na,EDTA) for
1 h at 37°C before addition of a pH-7.0 assay buffer and Z-Phe-
Arg-NHMec for trypanopain-Tb, or pH-8.0 assay buffer and Z-
Arg-Arg-NHMec for OP-Tb. The initial incubation was done
either in the presence or absence of reducing agents (30 mM
cysteine for trypanopain-Tb and 10 mM dithiothreitol for OP-
Tb).
Following determination of the concentration of active trypa-
nopain-Tb by titration with E-64 (Barrett and Kirschke, 1981),
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trypanopain-Tb (0.05 pmol) was incubated with readily hy-
drolysed synthetic substrates (25-100 uM) for 10 min at 37°C
in continuous assays, or with poorly hydrolysed synthetic sub-
strates for 4 h at 37°C in stopped time assays. Km, Vm,,x and k^M
were determined from the direct linear plot (Eisenthal and Cor-
nish-Bowden, 1974) using the software package Hyper 1.01 (©
1992-1993, J. S. Easterby, UK).
Digestion of protein and peptide substrates by trypano-
pain-Tb and OP-Tb. Fibrinogen, BSA and rabbit IgG were di-
gested with trypanopain-Tb at 37 °C over 1 h at various molar
ratios of enzyme/substrate in 100 mM Tris/HCl, 30 mM cyste-
ine, pH 7.4. After the reactions were stopped by the addition of
1 mM E-64, samples were boiled in reducing treatment buffer
and analysed by electrophoresis on 10% tricine gels (Shagger
and von Jagow, 1987). Trypanopain-Tb digestion of serpins was
analysed at 37°C at 1:100 and 1:10 molar ratios of enzyme/
inhibitor in 25 mM Tris, 10 mM cysteine, pH 7.4. Reactions
were stopped by the addition of 20 uM E-64. To determine the
extent of serpin degradation, remaining inhibition of trypsin or
chymotrypsin was determined (Potempa et al., 1986) and the
degradation products analysed by tricine/SDS/PAGE.
OP-Tb was incubated with oligopeptide substrates at various
molar ratios of enzyme/substrate in 0.1 M Tris/HCl, 10 mM di-
thiothreitol, pH 8.0 for 1 - 1 6 h at 37°C, after which the reaction
was stopped by acidification with an equal volume of 5 % (by
vol.) trifluoroacetic acid. The samples were placed on ice until
analysed by HPLC on a C18 column (flow rate 1 ml •
min"1) using a gradient of 10—90% (by vol.) acetonitrile in
water containing 0.1 % (by vol.) trifluoroacetic acid.
Association with cystatins and «2-M. The kinetics of trypa-
nopain-Tb inhibition by various cystatins were determined as
described by Salvesen and Nagase (1992) with data treatment
as described by Henderson (1972). Trypanopain-Tb and OP-Tb
association with as-M was assessed by comparing the elution
volumes from Sephacryl S-100 (for trypanopain-Tb) and Seph-
acryl S-200 (for OP-Tb) (both 15X300 mm, flow rate 10 cm •
h"1, equilibrated with 50 mM Tris/HCl pH 8.0 containing 1 mM
dithiothreitol for OP-Tb only) of each enzyme alone with that
for each enzyme previously incubated with bovine as-M ( = 1 : 1
molar ratio, Mason, 1989).
Measurement of enzyme activity in the blood of infected
rats. The blood of trypanosome-infected rats was harvested by
cardiac puncture at peak parasitaemia, and centrifuged (3000Xg,
25 min, 4°C). The supernatant was microscopically confirmed
to be free of both parasites and blood cells, and then assayed
against Z-Phe-Arg-NHMec and Z-Arg-Arg-NHMec in the pres-
ence of various inhibitors. Since OP-Tb, rat plasma kallikrein
and trypanopain-Tb all hydrolyse Z-Phe-Arg-NHMec, soybean
trypsin inhibitor (SBTI, 20 uM), H2NEtPhSO2F (1.85 mM) and
E-64 (1.7 mM) were used to discriminate between the activities
of the three enzymes. SBTI inhibits blood plasma kallikrein
(Coleman and Bagdasarian, 1976) but not OP-Tb, while
H,NEtPhSO2F inhibits both kallikrein and OP-Tb, so these in-
hibitors were used to discriminate between the two activities.
Hydrolysis of Z-Arg-Arg-NHMec in the presence of these inhib-
itors was additionally investigated to confirm the presence of
OP-Tb.
RESULTS
Proteinase isolation. As far as we are aware, this is the first
time trypanopain-Tb and OP-Tb have been completely and de-
monstrably purified from T. b. brucei (Fig. 1). Three-phase parti-
tioning proved to be a very efficient crude purification method,






















Fig. 1. Silver-stained tricine/SDS/PAGE of trypanopain-Tb and OP-
Tb. OP-Tb (lane B, 250 ng) and trypanopain-Tb (lane C, 250 ng) were
treated with non-reducing buffer and electrophoresed on a 10% tricine/
SDS/PAGE gel prior to silver staining (Blum et al., 1987). Molecular
mass markers, shown in lanes A and D, are phosphorylase b (94 kDa),
BSA (68 kDa), ovalbumin (43 kDa), carbonic anhydrase (30 kDa), SBTI
(20 kDa) and a-lactalbumin (14.4 kDa).
(Table 1). Additionally, the salt remaining from this procedure
reduced the amount of protein binding to HiLoad™ Q-Sepharose
at pH 5.5, and thus increased the efficiency of this step for trypa-
nopain-Tb purification. This initial chromatography step on Hi-
Load™ Q-Sepharose also separated OP-Tb from trypanopain-Tb
(Fig. 2), taking advantage of the unusual affinity of trypanopain-
Tb for this anion exchanger at pH 5.5 and making it possible
for the two enzymes to be purified from the same trypanosome
preparation. The current method is thus more economical and
convenient than previously reported approaches.
Various affinity chromatography resins were tested for the
purification of trypanopain-Tb. The high affinity with which in-
hibitors, such as stefin B and chicken egg white cystatin, bound
trypanopain-Tb rendered these ligands unsuitable for affinity
chromatography purposes. While pepstatin A typically inhibits
aspartic proteinases, it surprisingly also inhibits trypanopain-Tb
weakly (Pamer et al., 1989) and was thus considered a poten-
tially suitable affinity chromatography ligand. Pepstatin-A-
Sepharose chromatography proved to be a very successful purifi-
cation step, with electrophoresis of the column eluate showing
that trypanopain-Tb was contaminated only by a 68-kDa protein,
suspected to be rat serum albumin. This contaminant was suc-
cessfully removed by HiTrap™ Blue Sepharose. The speed of
the trypanopain-Tb purification procedure was found to be criti-
cal for maintenance of enzyme activity, with activity irreversibly
lost if more than one day was taken for purification.
Two affinity chromatography steps were used in the purifica-
tion of OP-Tb, namely p-aminobenzamidine—Sepharose and
poly-(L-lysine) —Sepharose chromatography. Since benzamidine
is a fairly weak inhibitor of OP-Tb (62% inhibition, Table 2),
OP-Tb could be eluted from this column using fairly low salt
concentrations (250 mM NaCl). Poly-(L-lysine)-Sepharose, on
the other hand, bound OP-Tb more strongly, with approximately
450 mM NaCl required to elute the enzyme. While />amino-
benzamidine—Sepharose was particularly effective in removing
large quantities of contaminating protein (increasing the specific
activity 30-fold, Table 1), poly-(L-lysine)—Sepharose was essen-
tial for removing persistent contamination by a 68-kDa protein,
shown by amino acid analysis to be rat albumin, as well as other
minor contaminants.
Trypanopain-Tb characterisation. Trypanopain-Tb activity
against Z-Phe-Arg-NHMec was optimal across a plateau be-
tween pH 5.5 and 8.0 (Fig. 3). The enzyme was optimally stable
between pH 4.0 and 7.0 in the presence of cysteine, and between
pH 4.0 and 8.0 in the absence of cysteine. At all pH values
tested, more trypanopain-Tb activity was maintained after a 1-h
Troeberg et al. {Eur. J. Biochem. 238) 731
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Fig. 2. Elution profile of HiLoad™ Q-Sepharose showing separation
of trypanopain-Tb and OP-Tb. HiLoad™ Q-Sepharose (26 X110 mm,
flow rate 1 ml • min~') was equilibrated in loading buffer (100 mM NaCl
in 20 mM sodium acetate, 1 mM Na2EDTA, 100 mM NaCl, 0.027c
(mass/vol.) NaN,, pH 5.5). The 10 -25% (NH4),SO4 fraction of the
three-phase partitioning was loaded onto the column and the bound ma-
terial eluted with a five-column-volume gradient of 0.1-1 M NaCl.
While OP-Tb fractions (unbound) were active against both Z-Phe-Arg-
NHMec and Z-Arg-Arg-NHMec, trypanopain-Tb-containing fractions
(bound) were active against only Z-Phe-Arg-NHMec.
incubation in the absence of cysteine than in its presence, indi-
cating that the active enzyme undergoes some autocatalysis. Try-
panopain-Tb was active against [l4C]gelatin over a far narrower
and more acidic pH range than against Z-Phe-Arg-NHMec, with
hydrolysis being optimal at pH 5.7 (Fig. 3). While activity de-
creased sharply on either side of this pH, trypanopain-Tb was
still 44% active at pH 7.4, suggesting that it would be active
under physiological pH conditions.
Trypanopain-Tb was only active in the presence of reducing
agents, thus displaying typical cysteine proteinase latency. Cys-
teine • HC1 was the most effective of the reducing agents tested,
with an optimal final concentration of 30 mM. Dithiothreitol was
maximally effective at 20 mM, with 2-mercaptoethanol reaching
optimum efficiency at much higher concentrations (250 mM).
Reduced glutathione was a comparatively poor activator. All
subsequent trypanopain-Tb assays against Z-Phe-Arg-NHMec
were thus performed at pH 7.0 (in the middle of the optimal
Table 2. Effects of various inhibitors on trypanopain-Tb activity
against Z-Phe-Arg-NHMec and OP-Tb activity against Z-Arg-Arg-
NHMec at 37 °C. Enzymes were incubated with each inhibitor for
15 min at 37°C and then assayed as usual. OP-Tb experiments were
conducted in the presence of either 10 mM dithiothreitol (indicated as
+ dithiothreitol) or in residual dithiothreitol remaining from purification
(= 40 u,M dithiothreitol. indicated as - dithiothreitol). Where different
concentrations of inhibitor were used for OP-Tb and trypanopain-Tb, the
concentrations for trypanopain-Tb are given first. 1AA, iodoacetate;






































































































pH range) using 200 mM sodium phosphate containing 30 mM
cysteine and 2 mM Na:EDTA (final concentrations).
Typical cysteine proteinase inhibitors (including E-64 and
iodoacetate) inhibited trypanopain-Tb completely, while typical
serine and metalloproteinases inhibitors such as iPr2P-F and
EDTA, respectively, had no effect on enzyme activity (Table 2).
Leupeptin, antipain and chymostatin were all effective inhibitors
of the enzyme (99-100% inhibition). Interestingly, pepstatin A
(22% inhibition) also inhibited trypanopain-Tb.
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Fig. 3. pH profile of trypanopain-Tb and OP-Tb activity at 37 °C.
Enzyme activity at various pH values was assessed using constant-ionic-
strength acetate/Mes/Tris buffers (Ellis and Morrison, 1982) of pH 4 . 0 -
9.0. (A) Trypanopain-Tb (1.5 ng) activity against 5 uM Z-Phe-Arg-
NHMec ( - • - ) and [l4C]-gelatin ( - • - ) : (B) OP-Tb (2 ng) activity
against 5 uM Z-Arg-Arg-NHMec in the presence ( • ) or absence (T) of
10 mM dithiothreitol.
Table 3. Kinetic constants for trypanopain-Tb hydrolysis of various
NHMec substrates. Values are calculated from 10-min or 4-h stopped-
time assays. Constants were calculated at 37 °C using the direct linear
plot (Eisenthal and Corntsh-Bowden, 1974). No hydrolysis occurred in
4h with Suc-Ala-Ala-Phe-NHMec, Glu-Gly-Gly-Phe-NHMec, Z-Gly-
Pro-NHMec, Gly-NHMec, Leu-NHMec, Ac-Ala-Ala-Tyr-NHMec, Ac-
Ala-Ala-Pro-Ala-NHMec, Z-Pro-Arg-NHMec, Glu-Gly-Arg-NHMec, Z-
Gly-Gly-Arg-NHMec, Boc-Val-Gly-Arg-NHMec, Boc-Leu-Gly-Arg-


























































Trypanopain-Tb degradation of synthetic substrates and
proteins. Of the synthetic substrates tested, Z-Phe-Arg-NHMec
was most readily cleaved by trypanopain-Tb, with a Km of
1.2 u.M and kCM of 13.4 s"
1 (Table 3). Pro-Phe-Arg-NHMec was
also readily hydrolysed. All other substrates tested, including Z-
Arg-Arg-NHMec used to monitor OP-Tb isolation, were com-
paratively poorly hydrolysed.
Trypanopain-Tb hydrolysed fibrinogen, BSA and rabbit IgG
at physiological pH. At a 1:100 molar ratio of enzyme/substrate,
both the « and /? chains of fibrinogen were substantially de-
graded within 15 min at pH 7.4, while the y chain remained re-
sistant over the test period (1 h). However, at a 1:1000 molar
ratio of enzyme/substrate, no degradation occurred. Trypano-
pain-Tb also readily degraded BSA (1:500 and 1:1000 molar
ratio) and IgG (1:100 and 1:1 000 molar ratio) within 15 min,
hydrolysing the latter predominantly in the heavy-chain region.
Characterisation of OP-Tb. OP-Tb activity was substantially
increased by the presence of reducing agents; dithiothreitol was
the most effective, increasing activity 10-fold at 25 mM and 6-
fold at 1 mM. Cysteine was almost as effective as dithiothreitol
at lower concentrations, but activity was lowered at concentra-
tions above 5 mM. Glutathione was about half as effective as
dithiothreitol.
Irrespective of the presence or absence of reducing agents,
OP-Tb was found to be most active between pH 8 and 9.5 at
25 °C (Fig. 3). In contrast, the pH stability of the purified en-
zyme was slightly affected by the presence of a reducing agent,
with the enzyme being most stable in the absence of dithiothrei-
tol in the pH range 6-7.5 and in the presence of dithiothreitol
at pH 8—9. These differences, however, were all ranged between
80-100% activity and it was only below pH 6 and above pH 9
that stability decreased significantly.
The serine proteinase inhibitors iPr2P-F and H2NEtPhSO2F
completely inhibited OP-Tb, supporting the hypothesis that OP-
Tb is a serine protease (Table 2). Leupeptin and antipain were
very effective inhibitors of OP-Tb, as was tosyllysylchlorometh-
ane (TosLysCH2Cl). However, a basic residue was required for
the chloromethane to be active, as shown by the lack of inhibi-
tion tosylphenylalanylchloromethane (TosPheCH:Cl). The en-
zyme was not inhibited by phenylmethylsulfonyl fluoride
(PhMeSO2F) or Z-Phe-Phe-CHN2. Benzamidine was found to be
a weak inhibitor of the enzyme, possibly explaining the success
of/7-aminobenzamidine—Sepharose affinity chromatography as
a step in the isolation of OP-Tb. EDTA increased OP-Tb activ-
ity, indicating that the enzyme is not stabilised by divalent cat-
ions. While E-64 had no effect on activity, iodoacetate,
iodoacetamide and W-ethylmaleimide, which modify cysteine
residues, all reduced OP-Tb activity to various degrees (Ta-
ble 2).
Cleavage of protein and peptide substrates by OP-Tb. OP-
Tb did not hydrolyse fibrinogen, BSA, ovalbumin, carbonic an-
hydrase, SBTI, lysozyme, cystatin C or cytochrome c at pH 8.0.
Therefore, as speculated by Komblatt et al. (1992), the enzyme
appears to be an oligopeptidase rather than a proteinase. We thus
examined a range of substrates of increasing molecular mass in
order to characterise the minimum size of substrates excluded
from the active site of the enzyme. Since OP-Tb cleaves most
efficiently after arginine residues (Kornblatt et al., 1992), only
peptides containing such residues were tested. Where possible,
peptides containing two consecutive basic residues were chosen
to increase the likelihood of hydrolysis. Additionally, peptides
with regulatory roles in the host system were chosen in order to
shed light on the potential physiological relevance of OP-Tb.
OP-Tb was found to completely cleave reduced [Arg8]vaso-
pressin (1084.2 Da, CYFQNCPRG) and [Lyss]vasopressin
(1056.2 Da; CYFQNCPKG; 1:100 molar ratios) in 4 h, while
the oxidised forms of these peptides remained uncleaved after
16 h. Neurotensin (1672.9 Da, ELYENKPRRPYIL) was also
completely hydrolysed in 4 h at a 1:500 molar ratio of enzyme/
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Table 4. Equilibrium constant for inhibition, association and dissoci-
ation rate constants for cystatin inhibition of trypanopain-Tb
(0.05 nM) at 30C. Note that the associations of cystatin C and L-kinino-
gen domain 3 with trypanopain-Tb was too rapid for accurate measure-
ment and the value given is an estimate.
Table 5. Effect of inhibitors on Z-Phe-Arg-NHMec and Z-Arg-Arg-
NHMcc activity in the blood of rats infected with T. b. brucei. The
blood of infected rats was assayed against synthetic substrates in the












































































peptide. The point of cleavage in this instance was determined
to be after the second arginine residue in the sequence, reinforc-
ing the specificity of OP-Tb for two consecutive basic residues
in a given sequence. Atrial natriuretic factor (3080.5 Da,
SLRRSSCFGGRMDRIGAQSGLGCNSFRY) was effectively
cleaved at a 1:100 molar ratio, with the reduced form of the
peptide undergoing more cleavage than the oxidised form. The
importance of the state of substrate reduction suggests that sub-
strate conformation is critical for OP-Tb activity. Peptides such
as angiotensin I (1296.5 Da, DRVYIHPFHL), substance P
(1347.6 Da, RPKPQQFFGLM) and oxidised insulin B chain
(3495.9 Da, FVNQHLCGSHLVEALYLVCGERGFFYTPKA;
1:100 molar ratios) were not cleaved after 16 h, possibly due to
the particular amino acid residues surrounding the basic residues
present in these peptides (Kornblatt et al., 1992), although it is
possible that a size restriction was the reason for non-cleavage
of the insulin B chain. Pancreatic polypeptide (4181.7 Da) and
growth-hormone-releasing factor (5039.7 Da) were also not
cleaved, possibly due to the sizes of these peptides. OP-Tb thus
does not appear to cleave peptides larger than 4 kDa. Further
investigation of peptides between 3—4 kDa which contain suit-
able consecutive basic residues is needed to clarify the exclusion
limit more finely.
Interaction of trypanopain-Tb and OP-Tb with host protein-
ase inhibitors. k,m and predicted kafl values for trypanopain-Tb
association with various cystatins were in the 107—108M"' • s~'
and 10~4 s"1 range, respectively, while K, values were in the
10"" M range (Table 4). Cystatin C and L-kininogen were the
most effective inhibitors. Interestingly, very little difference was
observed between the inhibition by whole L-kininogen and by
domain 3 of the molecule, suggesting that this domain is likely
to be predominantly responsible for the inhibition observed with
the whole molecule. Assuming a plasma concentration of
7.5 uM for L-kininogen and 80 nM for cystatin C (Abrahamson,
1993), trypanopain-Tb would be expected to associate very
rapidly with these inhibitors: the half-life (Bieth, 1980) of the
enzyme in the presence of L-kininogen can be calculated as
0.006 s and with cystatin C, 0.08 s. The inhibitor-enzyme com-
plexes can also be predicted to dissociate slowly, with a half-life
of 131 min for L-kininogen and 67 min for cystatin C. Trypano-
pain-Tb is thus likely to be inhibited effectively by cystatin C
and (especially) L-kininogen in vivo. Additionally, trypanopain-
Tb bound to «,-M ( = 1 : 1 molar ratio) and is thus also likely to
be effectively controlled by this inhibitor in vivo.
Trypanopain-Tb was found to cleave the serpin inhibitor
antithrombin III, but only at enzyme/inhibitor ratios of 1:10, so
it is unlikely that such hydrolysis would occur in vivo. Trypano-
pain-Tb did not cleave other serpins, such as a,-proteinase inhib-
itor, a|-antichymotrypsin and os-antiplasmin.
OP-Tb did not interact with any of the tested host system
inhibitors, including serpins, cystatins and «2-M, presumably due
to the limited interaction of the active site with higher-molecu-
lar-mass proteins in general.
Measurement of enzyme activity in infected rat blood. High
levels of activity against both Z-Phe-Arg-NHMec and Z-Arg-
Arg-NHMec were detected in the blood of infected rats, while
little activity was detectable in the blood of control, uninfected
animals (Table 5). This activity was insensitive to E-64 and
SBTI, but entirely eliminated by H,NEtPhSO:F. OP-Tb is thus
likely to be predominantly responsible for the hydrolysis ob-
served, suggesting that OP-Tb may be released into the blood-
stream of infected rats. Secondly, this study supports the conclu-
sion arrived at from in vitro studies with the purified enzymes,
namely that while trypanopain-Tb is likely to be effectively con-
trolled in the bloodstream, OP-Tb seems to remain active.
DISCUSSION
Isolation of trypanopain-Tb and OP-Tb. A cysteine protein-
ase has previously been isolated from T. congolense (Mbawa et
al., 1992) but we have now purified one from T. b. brucei. OP-
Tb from T. b. brucei has been partially purified and characterised
(Kornblatt et al., 1992), but here we report the purification of
the enzyme to homogeneity as well as a more complete charac-
terisation of certain aspects of its activity. The linked isolation
of these proteinases as reported here has the added advantage of
maximising the yield of both enzymes from a single parasite
preparation.
Characterisation of trypanopain-Tb. Trypanopain-Tb was
shown to be a fairly typical cysteine proteinase, similar to trypa-
nopain-Tc from T. congolense (Mbawa et al., 1992) and cruzi-
pain from T. crttzi (Cazzulo et al., 1989). Interestingly, the aspar-
tic proteinase inhibitor pepstatin A inhibits trypanopain-Tb
slightly (Table 2; Pamer et al., 1989). In contrast, pepstatin A
inhibits trypanopain-Tc by only 9.7% (Mbawa et al., 1992) and
does not affect cruzipain (Murta et al., 1990; Cazzulo et al.,
1989). Pepstatin A appears to be a competitive inhibitor of try-
panopain-Tb (data not shown), and may act as a substrate ana-
logue. This unusual inhibition was successfully exploited in the
purification of trypanopain-Tb, using pepstatin-A-Sepharose.
Trypanopain-Tb was only active in the presence of reducing
agents, and appeared to be quite similar to cathepsin L (Den-
nison et al., 1992) in its requirement of fairly high concentra-
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tions of reducing agent for optimal activity. It was shown to
have cathepsin-L-like specificity for synthetic substrates, hy-
drolysing Z-Phe-Arg-NHMec and Pro-Phe-Arg-NHMec most
rapidly of the substrates tested. Generally, only substrates with
basic residues such as Arg or Lys in P, and hydrophobic residues
such as Phe or Leu in P2 were hydrolysed (Table 3). The pres-
ence of an acidic residue in P4 appeared to be unacceptable.
Similar specificity has been reported for trypanopain-Tc (Mbawa
et al., 1992), cruzipain (Cazzulo et al., 1990) and mammalian
cathepsin L (Barrett and Kirschke, 1981; Dufour and Ribadeau-
Dumas, 1988). Minimal hydrolysis of Z-Arg-Arg-NHMec was
observed in the current study (4-h incubation required to demon-
strate hydrolysis), allowing this substrate to be used for monitor-
ing OP-Tb isolation. This contradicts a previous report by Pamer
et al. (1991) that trypanopain-Tb cleaves Z-Arg-Arg-NHMec
readily, with a Km of 3.2 |iM, although it must be noted that
only partially purified trypanopain-Tb was used in their study.
Trypanopain-Tc does not hydrolyse Z-Arg-Arg-NHMec (Mbawa
et al., 1992), while cruzipain cleaves it poorly (Km 41 uM; Lima
et al., 1992).
Of the serpins tested, only antithrombin III was cleaved by
trypanopain-Tb. Interestingly, cathepsin L, which has been
found to be one of the closest mammalian analogues to trypano-
pain-Tb (Mottram et al., 1989), cleaves «,-proteinase inhibitor
very effectively (Johnson et al., 1986). Cathepsin L also cleaved
antithrombin III and os-antiplasmin very effectively at much
lower enzyme/substrate ratios than did trypanopain-Tb (data not
shown). This indicates that these two enzymes, while very simi-
lar in substrate specificity, are not always comparable.
Effect of host proteinase inhibitors on trypanopain-Tb. It has
been postulated that if released into the host bloodstream, trypa-
nopain-Tb could contribute to pathogenesis by degrading vari-
ous host proteins. For this to occur, the enzyme would have to
remain active in the presence of host proteinase inhibitors such
as cystatins, kininogens and a2-M. Trypanopain-Tb is, however,
effectively inhibited by kininogens, various cystatins and a,-M
in vitro (Table 4). The physiological concentrations of cystatin
C and L-kininogen are more than 10 times Kit so these inhibitors
are likely to inhibit any trypanopain-Tb secreted or released by
trypanosomes in vivo (Bieth, 1980). Interestingly, the most abun-
dant cysteine proteinase inhibitors in blood are also the most
effective in vitro inhibitors of the purified enzyme. Since cysta-
tins are relatively conserved between species (Barrett et al.,
1986) and the trypanosomal cysteine proteinases sequenced to
date are highly similar to each other (Mottram et al., 1989;
Pamer et al., 1990; Eakin et al., 1992; Fish et al., 1995), this in
vitro approach implies that trypanopains from various trypano-
some species are likely to be effectively inhibited by cystatins
in the bloodstream of a variety of mammalian hosts. This con-
clusion is supported by Nwagwu et al. (1988), who showed that
addition of rat serum to isolated parasites inhibited a trypano-
pain-Tb-like activity. Additionally, the Z-Phe-Arg-NHMec ac-
tivity detected in the blood of infected rats in the present study
was not E-64-inhibitable (Table 5), suggesting that there are not
significant concentrations of active trypanopain-Tb in the blood
of infected animals. Thus while trypanopain-Tb readily degrades
IgG and BSA in vitro, it appears that this is unlikely to occur in
the host bloodstream.
In apparent conflict with this conclusion, Lonsdale-Eccles et
al. (1995) reported that a kininogen-like molecule from rat se-
rum enhances trypanopain-Tb activity in fibrinogen zymograms
of T. b. brucei lysates. This molecule (called rat trypanopain
modulator, rTM) cross-reacts to some extent with anti-(human
kininogen) antibodies and has many other features in common
with kininogens, such as its size (68 kDa), its acid and heat sta-
bility, and the presence of 15-kDa proteinase-sensitive domains.
Additionally, L-kininogen was shown to enhance trypanopain
activity on fibrinogen zymograms in a similar manner to rTM.
The current study, however, clearly indicates that purified human
L-kininogen is an effective inhibitor of purified trypanopain-Tb
with a Kt of 0.0035 nM. Pike et al. (1992) reported a similar
apparent contradiction in the interaction between a cysteine pro-
teinase and its putative inhibitor. While purified stefin B inhib-
ited purified cathepsin L as expected, active covalent complexes
of the enzyme and inhibitor were shown to form under certain
circumstances. An unidentified factor, which may be absent in
vitro studies using purified components, may contribute to the
formation of these active complexes in vivo. It is possible that
this putative factor modifies the interaction between trypano-
pain-Tb and L-kininogen in vivo, resulting in the formation of
active complexes as reported by Lonsdale-Eccles et al. (1995).
Such an interaction may therefore interfere with effective control
of trypanopain in the host bloodstream.
Effect of reducing agents and cysteine proteinase inhibitors
on OP-Tb. Because OP-Tb is inhibited by iPr2/>-F and
H,NEtPhSO2F, it is likely to be a serine protease. However, the
enzyme is not inhibited by some other serine protease inhibitors,
namely PhMeSO2F and SBTI. The lack of inhibition by PhMe-
SO2F is not entirely unexpected in view of the subsite specificity
of the enzyme as discussed by Kornblatt et al. (1992). SBTI
(20.1 kDa), on the other hand, is probably ineffective because it
is too large to gain complete access to the active site of the
enzyme.
Additionally, previous work on this enzyme (Kornblatt et al.,
1992) and a similar enzyme from T. cruzi (Ashall, 1990; Ashall
et al., 1990) indicated that some compounds which are generally
considered to be cysteine protease inhibitors reduce OP-Tb ac-
tivity. Here we have been able to delineate more clearly the
effect of various cysteine protease inhibitors on this enzyme.
While OP-Tb is unaffected by the common cysteine protease
inhibitor E-64, the enzyme is inactivated by compounds such as
iodoacetate, iodoacetamide and /V-ethylmaleimide, that cova-
lently modify cysteine residues. It is interesting to note that these
three compounds act in rather contrasting manners, depending
on the presence or absence of dithiothreitol, possibly reflecting
the particular micro-environment of the cysteine residue in-
volved (Table 2). This data, together with the fact that OP-Tb is
activated by reducing agents, suggests that the enzyme contains
a cysteine residue which must be reduced and available for max-
imum activity and thus involved in the control of OP-Tb activity.
This may provide an alternative means of controlling this en-
zyme in vivo, which would be of particular importance in light
of the insensitivity of OP-Tb to more typical means of control
by host inhibitors, including serpins and a,-M.
Hydrolysis of peptides by OP-Tb. OP-Tb successfully cleaved
reduced [Arg"]vasopressin, [Lys"]vasopressin, neurotensin and
atrial natriuretic factor, but was found to be inactive against sub-
strates of more than 4 kDa. The enzyme is likely to cleave only
small peptides in vivo. The fact that atrial natriuretic factor,
[Args]vasopressin and [LysK]vasopressin were more readily
cleaved when reduced suggests that access to the OP-Tb active
site is probably dependent on conformation as well as size. A
similar enzyme from T. cruzi was found to be vital for the infec-
tivity of this organism, since it cleaves and activates a cyto-
plasmic factor involved in a calcium signalling mechanism
which mediates the entry of trypanosomes into cells (Burleigh
and Andrews, 1995). While a similar function for OP-Tb is un-
likely since African trypanosomes are not intracellular parasites,
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OP-Tb may play a role in the activation of other hormone-like
peptides in T. b. bnicei.
OP-Tb was not inhibited by any mammalian protein protein-
ase inhibitor used in this study. In view of the restricted access
to the active site of the proteinase, this is not entirely unex-
pected. Upon release of this enzyme from the parasite, as we
have shown is likely to occur during infections, the enzyme will
thus be free to act upon small regulatory molecules in its imme-
diate environment. The demonstration here that the enzyme is
able to cleave native neurotensin and atrial natriuretic factor,
which have diverse roles in the complex mechanisms of control
over bodily functions, means that this enzyme has the potential
to seriously disrupt control mechanisms of the host system.
Symptoms of sleeping sickness are difficult to define in general
terms, but altered blood volume, and eventual disruption of neu-
rological systems, is not inconsistent with the general symptoms
found (Tizard et al., 1978); thus inappropriate cleavage of regu-
latory molecules by OP-Tb may have profound implications for
the host. It will be of interest to determine the levels of various
hormones in hosts infected by T. b. bnicei in order to investigate
this possibility more directly.
In conclusion, this study suggests that OP-Tb is more likely
than trypanopain-Tb to have an extracellular, pathological role
in African trypanosomiasis, making OP-Tb an attractive target
for future studies in drug design.
This work was supported by grants from the Foundation for Re-
search Development and the University of Natal Research Fund. The
authors are particularly grateful to Dr Ennes Auerswald for human L-
kininogen domain 3, Dr Magnus Abrahamson for recombinant human
cystatin C and to Dr Jan Potempa for serpins.
REFERENCES
Abrahamson, M. (1993) Cystatins-protein inhibitors of papain-Iike cys-
teine proteinases, Cienc. Cult. Soc. Bras. Progr. Cienc. 445, 299-
304.
Ashall, F. (1990) Characterisation of an alkaline peptidase of Trypano-
sonia cruzi and other trypanosomatids, Mol. Biochem. Parasitol. 38,
77-88.
Ashall, F., Harris. D., Roberts, H., Healy, N. & Shaw, E. (1990) Substrate
specificity and inhibitor sensitivity of a trypanosomatid alkaline pep-
tidase, Biochim. Biophvs. Ada 1035, 293-299.
Authie, E., Duvallet, G., Robertson, C. & Williams, D. J. L. (1993)
Antibody response to a 33 kDa cysteine protease of Trypanosoma
congolen.se: relationship to 'trypanotolerance' in cattle, Parasite Im-
munol. 15, 465-474.
Barrett, A. J. & Kirschke, H. (1981) Cathepsin B. cathepsin H and ca-
thepsin L, Methods Enzymol. 80C, 535-561.
Barrett, A. J., Rawlings, N. D., Davies, M. E., Machleidt, W., Salvesen,
G. & Turk, V. (1986) Cysteine proteinase inhibitors of the cystatin
superfamily, in Proteinase inhibitors (Barrett, A. J. & Salvesen, G.,
eds) pp. 515-569, Elsevier, Amsterdam.
Bieth. J. G. (1980) Pathophysiological interpretation of kinetic constants
of protease inhibitors, Bull. Eur. Physiopathol. Respir. 16, 183-195.
Blum, H., Beier, H. & Gross, H. J. (1987) Improved silver staining of
plant proteins, RNA and DNA in polyacrylamide gels, Electwphore-
sis 8. 93-99.
Burleigh, B. A. & Andrews, N. W. (1995) A 120-kDa alkaline peptidase
from Trypanosoma cruzi is involved in the generation of a novel
Ca:*-signalling factor for mammalian cells, J. Biol. Chew. 270,
5172-5180.
Cawston, T. E. & Barrett. A. J. (1979) A rapid and reproducible assay
for collagenase using [l-'4C]acetylated collagen. Anal. Biochem. 99,
340-345.
Cazzulo. J. J., Couso, R., Raimondi, A., Wernstedt. C. & Hellman. U.
(1989) Further characterization and partial amino acid sequence of a
cysteine proteinase from Trypanosoma cruzi. Mol. Biochem. Parasi-
tol. 33, 33-42.
Cazzulo, J. J., Cazzulo Franke, M. C, Martinez, J. & Franke de Cazzulo,
B. M. (1990) Some kinetic properties of a cysteine proteinase (cruzi-
pain) from Trxpanosoma cruzi, Biochim. Biophvs. Ada 1037, 186—
191.
Coleman, R. W. & Bagdasarian, A. (1976) Human kallikrein and prekal-
likrein, in Methods Enzymol. 45B, 303-322.
Dennison, C , Pike, R., Coetzer, T. & Kirk, K. (1992) Characterisation
of the activity and stability of single-chain cathepsin L and of proteo-
lytically active cathepsin L/cystatin complexes, Biol. Chem. Hoppe-
Seyler 373, 419-425.
Dufour, E. & Ribadeau-Dumas, B. (1988) Proteolytic specificity of
chicken cathepsin L on bovine /f-casein, Biosci. Rep. 8, 185 — 191.
Eakin, A. E., Mills, A. A., Harth, G., McKerrow, J. H. & Craik, C. S.
(1992) The sequence, organisation and expression of the major cyste-
ine protease (cruzipain) from Trxpanosoma cruzi, J. Biol. Chem. 267,
7411-7420.
Eisenthal, R. & Cornish-Bowden, A. (1974) The direct linear plot. A
new graphical procedure for estimating enzyme kinetic parameters,
Biochem. J. 139, 715-720.
Ellis, K. J. & Morrison. J. F. (1982) Buffers of constant ionic strength
for studying pH-dependent processes. Methods Enzymol. 87C, 4 0 5 -
426.
Fish, W. R., Nkhungulu. Z. M., Muriuki, C. W., Ndegwa, D. M., Lons-
dale-Eccles, J. D. & Steyaert, J. (1995) The cDNA and deduced
amino acid sequence of a cysteine protease from Trypanosoma (Nan-
nomonas) congolense metacyclic forms. Gene 161, 125—128.
Gounaris, A. D., Brown, M. A. & Barrett, A. J. (1984) Human plasma
c-cysteine proteinase inhibitor, Biochem. J. 221, 445-452.
Grab, D. J. & Bwayo, J. J. (1982) Isopycnic isolation of African trypano-
somes on Percoll gradients formed in situ, Ada Trop. 39, 363 -
366.
Henderson, P. J. F. (1972) A linear equation that describes the steady-
state kinetics of enzymes and subcellular particles interacting with
tightly bound inhibitors, Biochem. J. 102, 193-202.
Huet, G., Richet, C , Demeyer, D., Bisiau, H.. Soudan, B., Tetaert, D., Ki
Han, K. & Degand, P. (1992) Characterisation of different proteolytic
activities in Trypanosoma brucei brucei, Biochim. Biophys. Ada
1138, 213-221'
Johnson, D. A., Barrett, A. J. & Mason, R. W. (1986) Cathepsin L inacti-
vates -proteinase inhibitor by cleavage in the active site region, J.
Biol. Chem. 261, 14748-14751.
Kornblatt, M. J., Mpimbaza, G. W. N. & Lonsdale-Eccles, J. D. (1992)
Characterisation of an endopeptidase of Trypanosoma brucei brucei.
Arch. Biochem. Biophys. 293, 25-31 .
Lanham, S. M. & Godfrey, D. G (1970) Isolation of salivarian trypano-
somes from man and other mammals using DEAE-cellulose, Exp.
Parasitol. 25,521-534.
Lima, A. P. C. A., Scharfstein, J., Storer, A. C. & Menard, R. (1992)
Temperature-dependent substrate inhibition of the cysteine protein-
ase (GP57/51) from Trypanosoma cruzi, Mol. Biochem. Parasitol.
56, 335-338.
Lonsdale-Eccles, J. D., Mpimbaza, G. W. N., Nkhungulu, Z. R. M.,
Olobo, J., Smith, L., Tosomba, O. M. & Grab, D. J. (1995) Trypano-
somatid cysteine protease activity may be enhanced by a kininogen-
like moeity from host serum, Biochem. J. 305, 549-556.
Mason, R. W. (1989) Interaction of lysosomal cysteine proteinases with
a;-macroglobulin: conclusive evidence for the endopeptidase activi-
ties of cathepsins B and H. Arch. Biochem. Biophys. 273, 367 —
374.
Mbawa, Z. R., Webster, P. & Lonsdale-Eccles, J. D. (1991) Immunolo-
calisation of a cysteine protease within the lysosomal system of Try-
panosoma congolense. Eur. J. Cell Biol. 56, 243 — 250.
Mbawa, Z. R.. Guram, I. D.. Shaw, E. & Lonsdale-Eccles, J. D. (1992)
Characterisation of a cysteine protease from bloodstream forms of
Trypanosoma congolense. Eur. J. Biochem. 204, 371—379.
Mottram. J. C . North. M. J., Barry. J. D. & Coombs, G. H. (1989) A
cysteine protease cDNA from Trypanosoma brucei predicts an en-
zyme with an unusual C-terminal extension. FEBS Lett. 258, 2 1 1 -
2*15.
Murta. A. C. M., Persechini, P. M.. de Souto Padron. T, de Souza. W..
Guimaraes, J. A. & Scharfstein, J. (1990) Structural and functional
identification of GP57/51 antigen of Trypanosoma cruzi as a cysteine
proteinase, Mol. Biochem. Parasitol. 43, 27-38.
736 Troebera et al. (Eur. J. Biochem. 238)
Nwagwu. M, Okenu. D. M. N.. Olusi. T. A. & Molokwu. R. I. (1988)
Trypanosoma brucei releases proteases extracellularly. Trans. R. Sac.
Trop. Med. Hyg. 82, 577.
Pamer, E. G., So, M. & Davis, C. E. (1989) Identification of a develop-
mentally regulated cysteine protease of Trypanosoma brucei. Mol.
Biochem. Parasitol. 33, 27-32 .
Pamer, E. G., Davis, C. E., Eakin, A. & So, M. (1990) Cloning and
sequencing of the cysteine protease cDNA from Trypanosoma brucei
rhodesiense, Nucleic Acids Res. 18, 6164.
Pamer, E. G., Davis, C. E. & So, M. (1991) Expression and deletion
analysis of the Trypanosoma brucei rhodesiense cysteine proteinase
in Escherkhia coli. Infect. Immun. 59, 1074-1078.
Pike, R. N. & Dennison, C. (1989) Protein fractionation by three-phase
partitioning (TPP) in aqueous//-butanol mixtures, Biotech. Bioeng.
55,221-228.
Pike, R. N., Coetzer, T. H. T. & Dennison. C. (1992) Proteolytically
active complexes of cathepsin L and a cysteine proteinase inhibitor;
purification and demonstration of their formation in vitro. Arch. Bio-
chem. Biophys. 294, 623-629.
Potempa, J., Watorek, W. & Travis, J. (1986) The inactivation of human
plasma alpha-1-proteinase inhibitor by proteinases from Staphylo-
coccus aureus, J. Biol. Chem. 261, 14330-14334.
Read. S. M. & Northcote. D. H. (1981) Minimization of variation in the
response to different proteins of the Coomassie Blue dye-binding
assay for protein. Anal. Biochem. 116, 53 -64 .
Russo, D. C. W., Williams, D. J. L. & Grab, D. J. (1994) Directional
movement of variable surface glycoprotein-antibody complexes in
Trypanosoma brucei, Parasitol. Res. 80, 487-492.
Salvesen, G. & Nagase. H. (1992) Inhibition of proteolytic enzymes, in
Proteolytic enzymes: a practical approach (Benyon, R. J. & Bond,
J. S., eds) pp. 83-104, IRL Press, Oxford.
Shagger, H. & von Jagow, G. (1987) Tricine-sodium dodecyl sulfate-
polyacrylamide gel electrophoresis for the separation of proteins in
the range from 1 to 100 kDa, Anal. Biochem. 166, 368-379.
Smith, P. K., Krohn. R. I., Hermanson, G. T.. Mallia, A. K., Gartner. F.
H., Provenzano. M. D.. Fujimoto, E. K., Goeke, N. M., Olson, B.
J. & Klenk, D. C. (1985) Measurement of protein using bicincho-
nonic acid. Anal. Biochem. 150, 76 -85 .
Tizard, I., Nielsen, K. H.. Seed, J. R. & Hall, J. E. (1978) Biologically
active products from African trypanosomes, Microbiol. Rev. 42,
661-681.
Walgate, R. (1994) Sleeping sickness on the boil in Zaire, TDR News
46, 6.
FEBS 20676 FEBS Letters 433 (1998) 251-256
A trypanosome oligopeptidase as a target for the trypanocidal agents
pentamidine, diminazene and suramin
Rory E. Mortya, Linda Troeberga, Robert N. Pike'\ Roy Jonesc, Peter Nickeld,
John D. Lonsdale-Ecclese, Theresa H.T. Coetzera>*
"Department of Biochemistry. University of Natal, Private Bag X01, Scottsville 3209, South Africa
''Department of Biochemistry and Molecular Biology, Monash University, Clayton, Vic. 3168, Australia
'Department of Development ami Genetics, The Babraham Institute, Cambridge CB2 4 AT, UK
''Pharmazeutisches Institut, Universitdt Bonn, D-53121 Bonn. Germanv
'•'Department of Biochemistry and Molecular Genetics, University of Alabama. Birmingham, AL, USA
Received 27 April 1998; revised version received 13 July 1998
Abstract African trypanosomes contain a cytosolic serine
oligopeptidase, called OP-Tb, that is reversibly inhibited by the
active principles of three of the five most commonly used
trypanocidal drugs: pentamidine, diminazene and suramin. OP-
Tb was inhibited by pentamidine in a competitive manner, and by
suramin in a partial, non-competitive manner. The inhibition of
OP-Tb by a variety of suramin analogues correlated with the
trypanocidal efficacy of these analogues (P = 0.03; by paired
Student's /-test). Since intracellular (therapeutic) concentrations
of pentamidine and suramin are reported to reach approximately
206A"i and 15/fi respectively, we suggest that these drugs may
exert part of their trypanocidal activity through the inhibition of
OP-Tb.
© 1998 Federation of European Biochemical Societies.
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1. Introduction
African trypanosomes are protozoan parasites that cause
widespread disease in livestock (e.g. cattle) as well as in hu-
mans. Collectively, the diseases are referred to as African
trypanosomiasis. A number of drugs are available for the
chemotherapy of African trypanosomiasis, including sulfo-
nated naphthylamines such as suramin [1]; aromatic diami-
dines, including pentamidine [2] and diminazene [3]; the tri-
valent arsenical, melarsoprol [4]; and a-DL-difluoromethyl-
ornithine (DFMO), a suicide inhibitor of ornithine decarbox-
ylase [5]. With the exception of DFMO, the in vivo targets of
the drugs have not been unequivocally identified. Conse-
quently, the biochemical basis of their trypanocidal action is
unclear [6]. During the course of our studies on the peptidases
of African trypanosomes, we have identified and purified a
cytosolic [7] oligopeptidase from the African trypanosome
Trypanosoma brucei brucei, which we called OP-Tb [8,9].
The substrate specificity of OP-Tb, which preferentially
cleaves peptides after pairs of basic amino acid residues
[8,9], suggested that the aromatic diamidines (pentamidine
and diminazene), would act as competitive inhibitors of OP-
Tb. Similarly, previous reports of the inhibition of trypsin-like
"Corresponding author. Fax: (27) (331) 260 5462.
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Abbreviations: AMC, 7-amino-4-methylcoumarin: Cbz, carbobenz-
oxy; DFMO, a-DL-difluoromethylornithine: PGK. phosphoglycerate
kinase; Sue, succinyl
serine peptidases by suramin [10-12] raised the possibility that
suramin might inhibit OP-Tb. Furthermore, OP-Tb activity is
abolished in the presence of thiol-reactive compounds [9], and
since melarsoprol forms adducts with thiol-containing pro-
teins via disulfide bonds [13,14], it was also possible that mel-
arsoprol could inactivate OP-Tb. Here we report that penta-
midine, diminazene and suramin are indeed inhibitors of OP-
Tb, and that, in the case of pentamidine and suramin, the
inhibition of OP-Tb by these inhibitors is likely to be of in
vivo significance. This represents the first report where pep-
tidases have been identified as possible targets of trypanocidal
drugs and we suggest that serine peptidase inhibitors may
represent a class of lead compounds for the development of
new chemotherapeutic agents that are active against OP-Tb.
Recent reports of drug resistance by African trypanosomes
[15-17] underscore the importance of developing new and
improved therapeutic strategies.
2. Materials and methods
2.1. Materials
Melarsoprol and melarsen oxide were from Dr. Alan Fairlamb,
Biomedical Sciences Institute, University of Dundee. DFMO was
from Dr. Andrew Peregrine, International Livestock Research Insti-
tute, Nairobi, Kenya. Suramin was from Bayer (Leverkusen, Ger-
many). Berenil was from Hoechst Veterinar (Munich, Germany). Pen-
tamidine and diminazene aceturate (minimum 90% purity) were from
Sigma (St. Louis. MO, USA). The structure of suramin (Fig. I) illus-
trates that it is a symmetrical molecule and that each half, connected
by a central urea group, can be sub-divided into three regions; an
acidic naphthalene moiety (Ri), a methylbenzoyl moiety (R^) and a
benzoyl (R:J) moiety. Analogues were synthesized as described previ-
ously [18] with various substitutions at Ri, Rj and R:i (Tables 1 and
2). Analogue nomenclature is adapted from that described in [19].
Fig. I. Chemical formula of suramin and designated nomenclature
for suramin analogues (modified from [18.19]).
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2.2. Isolation of OP-Tb
OP-Tb was purified from T. b. brucei clone ILTat 1.1 [9] and active
enzyme concentration determined using 4-methylumbelliferyl-/?-guani-
dobenzoate as described [20].
2.3. Diagnosis of inhibition mechanism
Inhibition mechanisms were diagnosed from the effect of a drug on
the Km and Vnmx. OP-Tb (1.5 ng, 18.75 fmol active concentration) was
pre-incubated in assay buffer (50 mM Tris-HCl, 10 mM dithiothreitol,
pH 8) for 10 min at 37°C, with or without drug, followed by the
addition of substrate. The initial steady-state velocity was determined
by continuous assay for a range of substrate concentrations (45 nM-
75 (iM). While the kinetic data are represented graphically as Line-
weaver-Burk plots (Fig. 2), due to the inherent error in the determi-
nation of these parameters graphically [21], actual values for Km and
^max were determined by hyperbolic regression using the software
package Hyper 1.01 (obtained from Dr. J.S. Easterby, University of
Liverpool, UK). The kcM was determined from kCM = Ku«x/[E]u. where
[E]o represents the active enzyme concentration. Dithiothreitol was
omitted from assays involving organo-arsenicals to prevent potential
complex formation of arsenic with free thiols [22]. Organo-arsenicals
were made up as stock solutions in dimethylformamide, and diluted
with assay buffer, while the other inhibitors were made up as aqueous
stock solutions. In the case of melarsoprol and melarsen oxide, the Km
and Vmax values were determined in the presence of residual concen-
trations of dimethylformamide, in order to negate the effect of this
solvent on these parameters. Non-competitive inhibition was distin-
guished from irreversible inhibition by diluting out the inhibitory
effect of compounds exhibiting either mode of inhibition. This was
achieved with a succession of four dilution/concentration cycles where
enzyme-inhibitor samples were diluted with assay buffer and concen-
trated to the original volume in 3 ml polysulfone concentrators
(7000 Xg, 10°C). Trypsin and chymotrypsin were assayed as described
previously [12].
2.4. Calculation of inhibition constant
For competitive inhibitors, the apparent K\ (KiUm>)) was determined
in the presence of Cbz-Arg-Arg-AMC as previously described [23],
and corrected for the presence of substrate (A",,,=245 nM) by dividing
the Ari(«pP) by the factor l+[S]/#m to give the true Kt [23]. For partial
non-competitive inhibitors, the K, was determined from the complex
steady-state rate equation of Baici [24] as modified by Szedlacsek et al.
[25],
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(1)
where c = [S]IKm, v. = P kM [E]0[S]/[S]+aA:,,,. The parameters a and P
are dimensionless factors representing the change in the Km and kmi,
respectively, in the presence of an inhibitor and v» is the rate extrapo-
lated at infinite inhibitor concentration, [I]. Once Km, kvM, a and p
had been determined separately, the K\ was calculated by non-linear
regression analysis, fitting (v,, [I]) pairs to Eq. I, in which all other
parameters were fixed.
2.5. Cylotoxicily assays
Trypanosomes were cultured [26] and cytotoxicity assays performed
as previously described [27]. Cultures were maintained in 24-well cell-
culture plates (1 ml culture volume). Drugs were dissolved in dime-
thylsulfoxide, and added at various concentrations to trypanosome
cultures. The final dimethylsulfoxide concentration was maintained
at 1% (v/v). Control cultures (without drugs, but containing 1% (v7
v) dimethylsulfoxide) were incubated under the same conditions. Cell
numbers were determined (in triplicate) with a hemocytometer. and
data analyzed graphically, plotting growth inhibition versus drug con-
centration, from which the effective concentration inhibiting the
growth of trypanosome populations by 50% (ECr,o) was calculated.
3. Results and discussion
The trivalent arsenicals, melarsoprol or melarsen oxide, and
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Fig. 2. Diagnosis of inhibition mechanisms by trypanocidal drugs.
Lineweaver-Burk plots of kinetic data obtained for the inhibition of
Cbz-Arg-Arg-AMC hydrolysis by OP-Tb over a range of inhibitor
concentrations for (A) pentamidine, (B) Berenil and (C) suramin.
the ornithine analogue DFMO had no effect on the hydrolysis
of Cbz-Arg-Arg-AMC by OP-Tb relative to uninhibited con-
trols (data not shown). However, OP-Tb activity is enhanced
in the presence of reducing agents and polyamines [8], Since
melarsoprol therapy depletes intracellular reducing agents
(namely trypanothione) and since DFMO therapy depletes
intracellular polyamihe levels [28] either drug may down-reg-
ulate OP-Tb activity within trypanosomes through the deple-
tion of intracellular OP-Tb activators.
OP-Tb was competitively inhibited by pentamidine with a
^ of 3.4 uM (Fig. 2A), which compares well with the K-,
observed for bovine (3-trypsin (2.3 |aM) [29], bovine mast-
cell tryptase (1.2 uM) [30] and human plasmin (3.3 (iM)
[31]. Pentamidine isethionate is the active principle of the
trypanocidal drug Pentacarinate. The mechanism of its trypa-
nocidal activity is not understood, although it has previously
been attributed to inhibition of trypanosome S-adenosyl-L-
methionine decarboxylase [32] or to the intercalation with
trypanosome DNA [33]. Structurally, the pentamidine mole-
cule represents two benzamidine molecules joined together,
resembling a pair of basic amino acid (arginine) residues in
R.E. Many a al.lFEBS Lelter.s 4i) (IWN) 25! -256
1.2






Fig. 3. Effect of suramin on substrate hydrolysis by serine proteases.
A: Effect of increasing concentrations of suramin on the activity of
OP-Tb (20 nM) against Cbz-Arg-Arg-AMC (c). chymotrypsin (25
nM) against Suc-Leu-Tyr-AMC (•) and trypsin (25 nM) against
Cbz-Arg-AMC (O). Ordinates (r,/vo), initial rale in the presence of
suramin/initial rate in the absence of suramin. B: Effect of NaCl on
the inhibition of OP-Tb (20 nM) activity against Cbz-Arg-Arg-
AMC by suramin (•). Error bars represent the mean \'-,h\, ±S.D.
(« = 3). All substrates at 5 uM.
a dipeptide. During therapeutic regimens, pentamidine typi-
cally reaches concentrations of up to 13 |iM in the host blood-
stream [34] where it has a plasma half-life of 47 h [35]. Fur-
thermore, pentamidine is actively concentrated by
trypanosomes which possess pentamidine transporters [36].
reaching intracellular concentrations of between 700 uM and
1 mM in 3 h [37]. For an inhibitor to be considered physio-
logically relevant, its in vivo concentration must be > lOA",
[38]. As the intracellular concentration of pentamidine within
trypanosomes is likely to reach at least 700 \\M (-2Q6K\)
during therapeutic regimes, it is possible that pentamidine
may exert its trypanocidal activity through the inhibition of
OP-Tb, which is a cytosolic enzyme.
Commercially available preparations of the trypanocidal
drug Berenil contain 45% (m/m) diminazene aceturate, and
55% (m/m) phenyldimethyl pyrazolone [39]. Diminazene ace-
turate is the active principle of this drug and is known to
inhibit S-adenosyl-L-methionine decarboxylase [32] and extra-
nuclear DNA synthesis in trypanosomes [40]. However, the
mechanism of the trypanocidal activity of diminazene has
not been unequivocally determined. Diminazene is like pen-
tamidine in that it resembles two benzamidine molecules
joined together, albeit with a shorter spacer region. Thus,
like pentamidine, it also mimics potential substrates for OP-
Tb. This structural similarity to pentamidine suggests that
diminazene molecules may behave similarly with respect to
OP-Tb, within the parasites. Berenil exhibited mixed inhibi-
tion of OP-Tb (Fig. 2B). This raises the possibility that the
diminazene aceturate competitively inhibits OP-Tb activity,
while the phenyldimethyl pyrazolone contributes to the inhib-
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ition of OP-Tb by Berenil in a non-competitive manner. How-
ever, similar data were obtained using a 90% pure preparation
of diminanizene aceturate (results not shown), suggesting that
diminazene aceturate itself is entirely responsible for the
mixed inhibition observed.
Suramin is known to inhibit a number of serine peptidases.
These include kallikrein, thrombin and plasmin [10], Cl ester-
ase [11] and trypsin [41]. However, the mechanism is un-
known. Kinetic analysis of kallikrein inhibition by suramin
revealed that it was not competitive. More detailed analysis
of the suramin interaction with neutrophil elastase, cathepsin
G and proteinase 3 indicated that suramin was a non-com-
petitive inhibitor of these enzymes [12]. Here we show that the
suramin inhibition of OP-Tb activity against Cbz-Arg-Arg-
AMC resulted in a 4.5-fold reduction in Vlmx with no appar-
ent effect on Km (Fig. 2C). As it was possible to dilute out the
effect of suramin with a series of four dilution/concentration
cycles (results not shown), the inhibition by suramin was re-
versible, and therefore non-competitive. The clustering of the
n̂mx values at high suramin concentrations (ordinate. Fig.
2C) suggested that a partial inhibition mechanism was oper-
ating [12,24.25]. and this did indeed prove to be the case (Fig.
3A). The [E]n/A ĵ ratio for the inhibition of OP-Tb by suramin
was < 0.01, indicating that there was no tight binding of
inhibitor to enzyme [38]. A similar situation was observed
for the inhibition of neutrophil proteinase 3 by suramin.
which also exhibited partial, non-competitive inhibition by
suramin with an [E]nIKi ratio <0.0I [12].
In general there is a good relationship between the basicity
of an enzyme and its affinity for suramin [12], but this rule
appears to break down with OP-Tb which has a p/ of 5.1 [7].
However, despite its low p/, OP-Tb has 24 lysine residues and
59 arginine residues (unpublished data). We suspect that the
sulfonic acid groups of suramin electrostatically interact with
these basic residues, a conclusion supported by the observa-
tion that NaCl abolished the inhibition of OP-Tb by suramin
(Fig. 3B). However, additional specific interactions appear to
be involved, as polysulfonated glycosaminoglycans such as
heparin do not inhibit OP-Tb (unpublished data), suggesting
that the inhibition is not due to a non-specific electrostatic
effect with polysulfonated compounds.
Both suramin and its demethylated analogue (NF037, Table
1) were potent inhibitors of OP-Tb activity, and were equally
trypanocidal. These findings contrast with those of Forneau et
al. [42], who reported that demethylation of suramin resulted
in complete loss of trypanocidal activity. However, the EQo
values reported here were determined in vitro, whereas For-
neau et al. [42] investigated the ability of suramin analogues
to cure trypanosome infection in vivo, in mice. Taken togeth-
er, these data suggest that, while the methyl groups are un-
important for OP-Tb-inhibitory activity and trypanocidal
efficacy, they may be essential for the metabolism and/or
transport of suramin in mice.
Both the number and spatial arrangement of the sulfonic
acid groups on the aminonaphthyl (R|) moiety were impor-
tant for inhibitory and trypanocidal activity. Replacing each
of the l-naphthy!amino-4,6,8-trisu!fonic acid moieties of sur-
amin with aniline-2.4-disulfonic acid (NF065: Table 1) re-
sulted in a 12-fold increase in K,. but only a 15% increase
in ECr,o. Removal of a second sulfonate group from each of
the aniline moieties in NF065 (NF078: Table 1) elevated the
Ki 25-fold when compared with suramin. This weak inhibitor
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Table 1
Inhibition constants and ECr,n values for symmetrical suramin analogues
Analogue Structural substituents


































Analogue nomenclature is detailed in [19].
possessed no trypanocidal activity at the concentrations
tested.
It is apparent from Tables 1 and 2 that the length of the
molecule is also important for both inhibitory potency and
trypanocidal activity. Removal of the benzoyl (R() group of
suramin (NF058; Table 1) increased the K, 24-fold and the
ECr,n two-fold. Demethylation of the methylbenzoyl (R^) moi-
ety of this shortened molecule (to generate NF023 from
NF058; Table 1) had little effect on A'; or EC.-,,, when com-
pared with NF058. This is in agreement with our findings that
these methyl groups are not important for inhibitory or tryp-
anocidal activity.
Replacement of both the methylbenzoyl (R_>) and benzoyl
(R;t) groups of suramin with 4-C-benzoyl groups (NF031;
Table 1) elevated the K, nine-fold, with a 10% increase in
ECflo. Subsequent removal of two of these 4-C-benzoyl groups
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Table 2
Inhibition constants and EC,-,II values for asymmetrical and half-suramin analogues
















n.m. denotes that no inhibitory activity was observed at the concentrations tested. Analogue nomenclature is detailed in [19].
(NF013; Table 1) increased the K{ 19-fold and the EC50 by
31% when compared with suramin. This indicated that a re-
duction in the length of the molecule was accompanied by a
reduction in both inhibitory and trypanocidal activity.
The importance of the length and symmetry of the molecule
is also illustrated by the lack of inhibitory or trypanocidal
activity of the 'half-suramin' analogue NF036 (Table 2). Nei-
ther the rearrangement of one of the sulfonate groups on the
naphthylene ring (NF035; Table 2), nor the attachment of the
4,6,8-substituted aminonaphthylsulfonate to a 5-nitro-2-furyl
group (NF226; Table 2) improved the inhibitory or trypano-
cidal activity.
In the absence of a three-dimensional structure of OP-Tb, it
is difficult to predict how suramin may interact, in such a
specific fashion, with OP-Tb. Hart et at. [43] examined the
interactions of suramin and trypanosome phosphoglycerate
kinase (PGK). Computer modelling of a putative PGK-sur-
amin complex illustrated that electrostatic interactions
between PGK and suramin would bridge the PGK active
site and block the mechanism of action of the enzyme. How-
ever, it is premature to speculate whether or not suramin may
somehow occlude the active-site 'pit' proposed to exist in
oligopeptidases [44].
There was a significant correlation (/> = 0.03; by paired Stu-
dent's Mest; Table 1) between the inhibitory potency and
trypanocidal efficacy of suramin analogues, which strongly
suggests that OP-Tb represents an important intracellular tar-
get for suramin. During treatment regimens, suramin reaches
concentrations of approximately 100 uM within the host
bloodstream [45] and, although not actively concentrated in
the parasite, it reaches intracellular concentrations of approx-
imately 100 u.M [6]. Since suramin has a K, of 6.7 u.M for OP-
Tb, the inhibition of OP-Tb by suramin may be physiologi-
cally relevant and this may explain, at least in part, the try-
panocidal action of suramin, which remains unelucidated [6].
The trypanocidal action of suramin has previously been
attributed to the inhibition of trypanosome glycolytic en-
zymes, and while K\ values for the inhibition of these enzymes
by suramin have not been determined, IC50 values of 10-100
uM have been reported [46]. Additionally, a ^ of 15 u,M has
been reported for the inhibition of trypanosome 6-phospho-
gluconate dehydrogenase by suramin [47]. However, Wang [6]
pointed out that all nine glycolytic enzymes are protected
from cytosolic suramin by compartmentalization in a glyco-
some, which is unlikely to take up suramin by diffusion or
endocytosis. Suramin has been used for over 70 years [6] and
appears still to be effective against the parasite as there are
few reports of T. b. brucei resistance [48]. As trypanosomes do
not readily develop resistance to suramin, it seems likely that
the drug may act on multiple targets in the parasite. Given
that the K\ for the inhibition of OP-Tb by suramin is lower
than that reported for other enzymes, as well as the significant
correlation between trypanocidal efficacy and OP-Tb inhibi-
tion, and the cytosolic location of OP-Tb, we propose that
OP-Tb is one of these targets.
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